Laboratory Guide 2022

Laboratory
Guide 2022
Valid from 1st January 2022
Cover: Alistair Lam, BMS, performing an agglutation test
for anti streptolysin antibodies.
TAP4942B/14-03-22/V3
Laboratory
Guide 2022
Valid from 1st January 2022
TDL Customer Charter
We are committed to being the most helpful pathology service in the UK. Our goal is
always to provide a high level of service to our customers, who request pathology services,
for their patients. This is a philosophy shared by all Sonic Healthcare Pathology practices.
We are medically led, and patients are our first concern. We always try to look to improve our
operational expertise, and we strive to provide professional leadership within our specialities.
We promise to provide easy access to our pathology services

• We will always provide a friendly, helpful service.
• Our automated laboratory departments operate 24 hours a day, 7 days a week,
and we aim to achieve, or improve, our published turnaround times.
• Our medical consultants and laboratory teams are available to provide additional
clarification, advice or information for tests or results.
We promise to help you

• We invest in technical and operational excellence, with an extensive test repertoire,
to ensure access to a leading-edge laboratory service.
• We return results using the reporting method choice, in an as organised
and safe way as possible.
We promise to support the communities we work in

• We do our utmost to provide a service, even during extreme external disruptions
beyond our control.
• We are committed to our staff’s continued professional development.
• We have an organised programme to provide young people with work experience.
• We support our local community.
We promise to listen
• We acknowledge customer issues, and try to resolve them promptly and consistently.
• If our delivery has been adversely affected, we will address and review our procedures
so that our service reaches the highest standards.
• We actively ask for feedback so that we can continue to improve our service.
Complaints policy
It is the aim of the company to maintain its core values. Two of these core values are:
• Commit to service excellence.
• Be enthusiastic about continuous improvement.
Where a doctor or patient needs to raise a complaint about service levels they should contact
Cyril Taylor, Director of Laboratory Compliance, or Annette Wilkinson, Director of Service at
[email protected] giving details of the complaint.
The information forwarded will be treated as confidential and investigated by the above persons.
This process will link into Quality Management procedure for incident investigation.
Corrective and preventative actions will be introduced where indicated.
Contents
PAGE
Index of TDL Profiles 2-3

Location maps for TDL London and TDL Manchester 4-5
Helpful information for using The Doctors Laboratory 7-13
Quality assurance 14-22
Special instructions for samples 23
TDL Screening Profiles DL1 – DL12 24-25
Testing for COVID-19 (SARS-CoV-2) 26-27
Biochemistry 29-37
Haematology 38-41
Microbiology 42-50
Endocrinology 51-57
Reproductive health 58-61
TDL Andrology 62-66
Sexual Health: Tests, profiles and detection information 67-78
Immunology: General / Infectious immunology / Serology 79-87
Tropical and travel-related immunology 88-90
Virology: Immune status testing 91
Hepatitis testing and hepatitis profiles 92-95
HIV testing 96-97
General 98-100
Tumour markers 101-102
Genetics – Cytogenetics / Molecular genetics 103-132
In-Vivo Tests: Glucose Tolerance Tests /Extended Tests / Antibiotic Assays 133
Therapeutic drug assays 134-135
Allergy 137-145
Vitamins, Nutrition and Lifestyle, Omega 3/6 147-149
TDL Tinies™ and Self-collection samples 150-155
Screening for Drugs of Abuse / Alcohol 157-158
Occupational Health 159-160
Cervical Screening 161-169
Histopathology 170-174
Alphabetical test index 176-209
TDL Referral Laboratories 210-212
Terms and Conditions of Business from 1st Jan 2022 213-220
Forms 221
Downs risk profile (1st & 2nd trimester)
Leukaemic studies request form (Cytogenetics / Molecular genetics)
Genetic request form
Supplies order
TDL request form
1
Index of TDL Profiles
TDL SCREENING PROFILES PAGE
DL1/DL1L Biochemistry Profile 24
DL2/DL2L Haematology and Biochemistry Profile (24 parameters) 24
DL3 Haematology Profile 24
DL4/DL4L Haematology and Biochemistry Profile (16 parameters) 24
DL5/DL5L Postal Haematology and Biochemistry Profile 24
DL6/DL6L General Well Person Profile 24
DL7/DL7L Well Man Profile 25
DL8/DL8L Well Person Profile 25
DL9M Senior Male Profile 25
DL9F Senior Female Profile 25
DL10 Cardiovascular Risk Evaluation Profile 25
DL11 Cardiovascular Risk Plus Profile 25
DL12 Sexual Health Screen / 7 STI’s by PCR 25
TDL SPECIFIC PROFILES

Alcohol Profiles 157-158
Allergy Screens 137-140
Amenorrhoea Profile 51, 57
Anaemia Profile 38, 41
Andropause Profile 51, 56
Antenatal Profile 38, 41
Ashkenazi Jewish Carrier Screen 110, 112, 128,132
Autoantibody Profiles 79, 87
Azoospermia Profile 110
Bone Screens 30, 37
Calprotectin / Elastase Profile 79, 87
Cardiovascular Risk Profiles 30, 37
Chest Pain Profile 30, 37
Chlamydia (Species Specific) Antibody Profile 80, 87
Chronic Fatigue Syndrome Profile 80, 87
Clotting Profiles 38, 41
Coeliac Profiles 80-81
COVID-19 (PCR and Antibody testing) 26-27, 80, 98
Deep Vein Thrombosis (DVT) Profile (Pre-travel screen) 38, 41, 88-89, 132
Diabetic Profiles 31-32, 37
Drugs of Abuse / Alcohol Screens 157-158
Enteric Organism Rapid Antigen Detection 88-89
Epstein-Barr Virus Profile 98
Erectile Dysfunction Profile 51, 56
Female Hormone Profile 51, 56
First Trimester Antenatal Screening Bloods 51, 57
Genetic Profiles 132
Haematology Profile 38, 41
2
PAGE
Hepatitis Profiles 92
Hirsutism Profile 51, 57
HIV Profiles 67, 77-78, 96-97
HRT Profile 51, 57
Impotence Profile 52, 56
Infertility Male Profile 52, 56
Iron Overload Profile 33, 36, 119, 132
Iron Status Profile 33, 36
Lipid Profile 33, 36
Liver Function Tests 33, 36
Male Genetic Reproductive Profile 116, 120, 132
Menopause Profile 52, 57
Metabolic Syndrome Profile 52, 57
Mineral Screen 147-148
Myeloma Screen 34, 36
Natural Killer Profile 38, 41
Needle Stick Injury Profile 91
Neurological Viral Screen 99-100
Osteoporosis Screen
34, 37
Pituitary Function Profile 52, 57
Pneumonia (Atypical) Screen 99-100
Polycystic Ovary Syndrome Profile 52, 57
Post-Travel Screens 88-89
Pre-Travel Screen 38, 41, 88-89, 123,132
Prostate Profile 101
NEW Prostatitis Screening Panel 43-44
Recurrent Miscarriage Profile 124, 132
Respiratory Viral Screen 99-100
Rheumatology Profiles 82, 86
Rickettsial Species Antibodies 82, 88
Sports/Performance Profile 147-148
STI / Sexual Health Profiles 67-68, 76-78
Thrombotic Risk/Miscarriage Profile 39, 41, 125, 132
Thyroid Profiles 53, 56
Torch Screen 99-100
Trace Metal Screen 148, 159
Tropical Screen 88-89
Urea and Electrolytes 35-36
Viral Profiles 100
Vitamin Screens 147-149
Von Willebrand Profile 39, 41

Personal Profiles (Doctor’s own) are available on request.
3
St Pancras King’s
Pancr as R o a d
Eve
Hampstead
Cross
York
Francis Crick International
rsh
Institute
olt
W ay
Mid
S
A40 Westway
tree
la n
King’s
dR
t
M40 THE DOCTORS LABORATORY British Cross
o ad
Gray’
Paddington HALO BUILDING Library
1 MABLEDON PLACE
s I nn
Judd
M ab
oad
Road
Road
Euston
on R
Eus t
ledo
Albany
Street
ma n
Madame Tussauds F la x r ac e uth St
n Pl
Sidmo
Wo
Ter
e
ac e
Plac
bur
Euston
St
Regent’s ck
ad isto
Gor
nP
o
Baker Park Euston R Square Tav
Marylebone Road
don
lac
Street
M a r ch
Hunter
e
Warren
H er b
St
Marylebone W a r re
n St Street Sq
m o nt S
on
Gow
Great
r a nd
ay d
Grafton W Gor
Street
M
Portland
a r yl
er S
T ot
Gloucester
St
re St Street Maple St
t
Devonshi Russell
Baker Str
ten
t
t
ebone High Street
S
St Square Guilford
Great
ham
Paddington
R us
Wh
St St
eymouth land
itfie
Portland
sel
W How
h St
ld S
l Sq
Place
ee
New Cavendis
Fitz
Harley
Wimpo
Goodge
Cle
t
t
oyr
Street
v el
Sou
Place
St
and
t
ge S
Portland
S
le S t
th
Cou
Blo
d
G oo
t
am
St
ne St
PATIENT RECEPTION Queen An
om
rt R
d
pto
r St Roa
76 WIMPOLE STREET alds
Cha
sbu
rt i m e
nR
d
t ob
cy S
New
Mo The
Per
rlot
ow
ry S
man
te S
Cavendi
Wigmore St
Regent S
t
St
t
St
sh
James St
Holborn
Orchard St
Tottenham
Sq
Henrietta Pl
A40
Holles St
Court Road
Vere St
Oxford St
t
Marble
Arch
Oxford St
Take Exit 4: Regent St
Davies St
New
Oxford
Bond Circus (North), Oxford St (West)
Bon
Street
dS
t
Selfridges John Lewis
THE DOCTORS LABORATORY Out-of-hours samples

The Halo Building, 1 Mabledon Place, London WC1H 9AX can be dropped at:
Tel: 020 7307 7373 Patient Reception
Email: [email protected] 76 Wimpole Street
Web: www.tdlpathology.com London W1G 9RT
Or at any time at
PATIENT RECEPTION/PHLEBOTOMY SERVICES the main laboratory:
76 Wimpole Street, London W1G 9RT The Halo Building
Telephone: 020 7307 7383 1 Mabledon Place
Email: [email protected] London WC1H 9AX
OPENING TIMES Phlebotomy Services

Monday to Friday 7.00am – 7.00pm are only available at
Saturday 7.00am – 1.00pm Patient Reception,
76 Wimpole Street.
Samples cannot be taken
at The Halo Building.
4
a ne
ss L
Cro
3
06
A5
G r ay t L i ve r p
o ol S
y
hor pe t ree t
Wa
Walk
M6 02 on
lbi
t
S t ree
A
et
S t re
er t on
ds or
W Eg
W in
A 57
E c cle s THE DOCTORS LABORATORY
N ew R (MANCHESTER)
d
St
Howard
063
St
Rege
o ebe
nt Rd
d A5
A57
N Ph
G ood
Trafford R
ier s D
r
W Cr
own
Ph o e b
Av
e
e St
THE DOCTORS LABORATORY

(MANCHESTER)
Regents Place, 4 Windsor Street
Salford M5 4HB
Tel: 0161 332 7181
Web: www.tdlpathology.com
Samples can be dropped

at the laboratory at any time.
COURIER COLLECTIONS
Tel: 0161 332 7187
5
N21
N14
N20 N9 E4
NW7 N13
N12 N11 N18
N3 N22 N17
E18
N10
N2 E17
NW4 N8
NW9 N15
NW11
N6 E11
N4
N19 E10
N16
E5
NW2 NW3 N5 E12
NW5 N7 E7
E20
E8 E9
NW6 N1 E15
NW10
NW8 NW1 E2 E3 E13
W9 E6
W10 EC
WC E1
W1
W7 W13 W5 W3 W12 W11 W2 E16
E14 SE28
W8 SE1
W14 SW1 SE16
SW7 SE10
W6 SW5 SE2
SW3 SE11 SE17 SE8 SE7
W4 SE18
SW
10
SW8 SE14
SW13 SW6 SE5 SE15 SE3
SW11 SW9
SW14 SE4
SW4 SE13
SE24 SE22
SW15
SW18 SW2 SE12 SE9
SW12
SE23
SE21 SE6
SW17 SE27 SE26
SW19
SW16 SE19
SE20
SW20
SE25
TDL COLLECT: SPECIMEN COLLECTION SERVICES BY COURIER

TDL COLLECT provides a dedicated medical sample collection service (vans by arrangement) on
a scheduled or ad hoc basis.
No charge is made for collections from practices within the M25. Collections from patients’ or doctors’
private addresses are by special arrangement only.
The courier collection service for Inner London postcodes operates on a 24/7 basis, as shown.
Postcodes extending beyond to the M25 operate from 9.00am to 8.00pm. Outside the M25,
and throughout the UK, sample collections are by arrangement and may incur courier charges.
TDL Collect Online Courier Booking is a time-saving option for arranging couriers for sample collection:
www.tdlpathology.com/couriers
Please contact [email protected] for your practice’s secure login and password.
High-risk samples should be clearly labelled and packed separately from other samples.
TDL’s couriers cannot transport samples containing Hazard Group 4 Pathogens such as Ebola Fever
or Viral Haemorrhagic Fever.
TDL COLLECT UK: 020 7307 7373
6
Helpful information
The Laboratory Guide is designed to give you an easy-to-use reference for the most regularly requested
services, pathology profiles and tests. If you are not able to find details for tests and services, please
contact the laboratory on 020 7307 7373. We continue to develop a wide range of test and patient
services and our aim is to offer commitment to customer service, strong working relationships and
help and support for referring doctors and their practices.
For details about all services, please contact the laboratory on 020 7307 7373,
or for more information visit www.tdlpathology.com.
LONDON LABORATORY TIMES: 24 HOURS

A wide range of analytical services are run 24/7 but not all tests or departments operate
through the night, weekends or bank holidays.
No surcharges are made unless there are special arrangements for services requiring additional resources.
Outside of Patient Reception hours, samples may be dropped off at 76 Wimpole Street, London W1G 9RT,
or at The Halo Building, 1 Mabledon Place, London WC1H 9AX (see map on page 4).
MANCHESTER LABORATORY TIMES: 24 HOURS

Samples can be dropped off at Regents Place, 4 Windsor Street, Salford M5 4HB (see page 5) at any time.
MANCHESTER TURNAROUND TIMES

Tests not processed at our laboratory in Manchester will be referred to the TDL Main laboratory.
If you need information about turnaround times, please contact the laboratory.
PATIENT RECEPTION TIMES

Patient Reception is at:
76 Wimpole Street, London W1G 9RT
Monday to Friday 7.00am – 7.00pm, Saturday 7.00am – 1.00pm
Direct line tel: 020 7307 7383 Email: [email protected]
Appointments are only necessary if a patient needs specialised investigations or care. Patients should
always bring a request form or referral letter with them. Instructions can be telephoned ahead of the
patient’s attendance, if this is more convenient.
Sample-taking is undertaken by qualified phlebotomy staff for which a standard sample-taking fee of
£45.00 is charged to patients. Doctors and clinics are charged £25.00 for each patient. Sample-taking
services for Extended Tests (see page 133) and Drugs of Abuse with Chain of Custody (see page 157)
are routinely available.
Cervical cytology, HVS and cervical swabs are not taken at 76 Wimpole Street.
Patient Reception sample-taking services are not available in Manchester.
Ensure all specimens and forms are labelled with given Forename, Surname, DOB, Date and Time
of collection. Turnaround times are quoted as working days. 7
Helpful information
SEMEN ANALYSIS
Semen samples need specialist handling within the laboratory. For this reason all requests for
Semen Analysis must be made by appointment. Practices or patients can make an online appointment
at www.tdlpathology.com/andrologybooking or call 020 7025 7940 to make appointments and
confirm instructions for sample collection. There is an attendance fee of £45.00.
1 Patients must abstain from ejaculation for at least 2 days but not longer than 5 days
before the test.
2 Ideally semen samples should be produced at The Doctors Laboratory, 76 Wimpole Street,
unless there are exceptional circumstances. In these exceptional circumstances please
contact TDL Andrology on 020 7025 7940 for special arrangements and instructions.
Refer to Andrology, see page 62.
Semen Analysis services are not provided in Manchester.
PATIENT REQUEST FORM

To comply with good clinical practice it is important that there is one request form for each patient’s
request, and specimens and form are correctly and fully labelled, to include three unique patient identifiers:
• First name, Surname, Date of birth, Hospital/ • Relevant details of medication
Clinic number, Medical Record Number (MRN) • High-Risk Samples should be clearly identified
are examples of patient identifiers on the form and individually packed separately
• Time and Date of collection of samples from other samples
• Type of sample and Anatomical site, • Hazard Group 4 pathogens (such as Ebola or
where appropriate (e.g. swabs) Viral Haemorrhagic Fever) must not be sent to
• Relevant clinical information the laboratory – please contact the National
Fever Service on 0844 778 8990 for advice
before sending samples to the laboratory.
If additional tests are required for a sample already received please contact the laboratory on 020 7307
7373 with your request for specific further analysis. Samples are stored within timeframes according to
their discipline. Laboratory staff will advise on the ability to undertake further testing from samples already
received in the laboratory.
8 of collection. Turnaround times are quoted as working days.
Helpful information
EMAILED REQUESTS FOR ADD ONS
The majority of samples received in the laboratory are kept for one week. If sample type and
volume allow, further testing can be requested by telephone on 020 7307 7373 or by email to
[email protected]. Please specify the details of the test(s) details to be added;
Patient details and LABORATORY NUMBER also need to be given with emailed requests.
HOME VISITS
This service is available for patients who, for whatever reason, prefer samples to be taken at home
or at locations other than a doctor’s practice or TDL’s Patient Reception at 76 Wimpole Street, London.
This is a service that is used regularly to save time for both doctors and patients and ensures that
results can be made available before consultation is undertaken.
There is a visit fee from £120.00 to patients within the M25, and from £160.00 for children when two
nurses are needed. Home visits outside the M25, for weekends, bank holidays and night fees are by
special arrangement. To arrange a Home Visit please telephone Patient Reception on 020 7307 7383
or email [email protected].
SAMPLE PACKING
Samples need to be transported for subsequent processing and testing. Transport systems will be various
and cover both long or short distances.
Samples need to be collected and packed into appropriate sample containers provided by the laboratory in
order to maintain integrity of the sample(s). Attention needs to be given to temperature, special transport
containers and time limitations.
Clinics, practices and laboratories who are posting or transporting samples by air, sea, rail and road
between local, regional and reference laboratories, or between laboratories in other countries,
must adhere to a number of regulations. These regulations are designed to deal with transportation
accidents and spills, reduce biohazards and keep samples intact for testing.
Regulations are given by several sources including
• National transport regulations • IATA
• Rail and road traffic agencies • Postal services
Compliance is mandatory in order to reduce risk to couriers, carrier, laboratory staff and passengers.
Sample transport requirements are based on the category of samples being transported.
Infectious substances are classified as Category A or Category B.
TDL does not arrange for transport of Category A samples (infectious substances capable of causing
permanent disability or life-threatening or fatal disease to humans or animals).
Instruction and packaging for Category B is provided, covering Biological Substances, UN number UN 3373.
Helpful information
PACKAGING REQUIREMENTS
There are specific packaging instructions and labelling requirements requiring triple packaging.
1 Primary leak-proof container – tube or vial containing the sample must be placed
inside a ziplock specimen bag with absorbent material
2 Secondary watertight container, with absorbent material, intended to protect the primary container
3 Outer container protects the secondary container.
There are specific packaging instructions for frozen samples requiring shipment using BioFreeze bottles,
or Dry Ice.
For information please contact the Referrals Dept ([email protected])
POSTAL PATHOLOGY
Postal pathology services should be considered by all practices in the UK who need a rapid
delivery service to the laboratory. Changes with Royal Mail mean that ALL pathology postal packs
are now made up with Tracked 24 returns. This provides a particularly suitable method of transport
for any healthcare organisation. Postal pathology with Tracked 24 returns provides:
• Simple and convenient sample handling throughout the UK for most tests.
It is not suitable for microbiology or coagulation samples
• Scope for large and small numbers of samples
• Next morning delivery
• Allows patients and practices to track samples through the Royal Mail system
• Samples can be posted from any Royal Mail post box, including COVID-19 antibodies
• Designated Priority boxes for COVID-19 PCR (swab) kits
• There is a charge of £2.26 for each Royal Mail Tracked 24 pack. This charge
will be itemised in monthly invoices to the practice or patient, as requested.
DX SYSTEM
DX is a well known next-day courier of Category B specimens – transporting biological samples
in compliance with the industry’s highest regulations. DX is compliant to IATA regulations,
is audited independently by Dangerous Goods Safety Advisors. They work with a combination
of large health organisations and smaller, independent laboratories to ensure the safe delivery
of specimens every year.
TDL’s DX Address is DX 340201, St Pancras 90 WC.
PATHOLOGY CONSUMABLES / REQUEST FORMS / POSTAL PACKS

Our Stores Department provides all appropriate sample collection consumables required for sample
collection. Orders will be sent same or next day and can be made by telephone (020 7307 7373)
or email ([email protected]). There is a Supplies Order Form at the back of this
Laboratory Guide.
Helpful information
REQUESTING AND REPORTING OPTIONS
We continually review and update our IT Services for receiving requests and reporting results
electronically between practices and the laboratory. A number of innovative report formats
are now available.
• Encrypted Email
Results will be sent in encrypted format to any number of predetermined email addresses.
Copy reports will be emailed automatically to email addresses on the system.
• Link to Practice Management System
Bidirectional requests and results can be delivered electronically to a number of integrated practice
systems. Practice software that accepts data in an HL7 format can be linked to receive results
from the laboratory.
All TDL systems are accredited to the latest International Standard for Information Security
ISO/IEC 27001:2013.
• TDL e-View
Registered users can view all their results online. This is a secure Login/Password protected
look-up system, with a cumulative results reporting function. Results can be accessed any time,
from anywhere, through the internet.
• Printed Copy
Results are posted out on the day they are reported.
• TDL Portal
This provides the most accurate option for clinics without a practice management system.
For information about this option please contact [email protected].
EMAILED RESULTS INCORPORATING YOUR LOGO

If your practice or company receives results by email, and would like these personalised with
your logo, simply email your company details and logo in GIF format to [email protected].
TDL WEBSITE
The TDL website at www.tdlpathology.com gives updated details of our tests – sample types,
turnaround times and special instructions. The Specialities section provides a new way to find tests
you need, and a Services section has additional information for TDL Collect, Postal Pathology
and TestGuide app. Reference Ranges are given on the website or can be requested by emailing
[email protected]. Full details of our tests and profiles are also available in the
TDL TestGuide app (see page 12).
TDL PATHOLOGY HANDBOOK

With more than 1000 entries and 1100 pages covering pathology tests, methods and disease conditions,
the Handbook provides comprehensive detail about the range of tests and services offered by the
laboratory. Email [email protected] for more information. The Handbook is also available
in the TDL TestGuide app (see page 12).
Helpful information
TDL TESTGUIDE APP
Available for iOS and Android, the TDL TestGuide app offers:
• Full details of TDL’s tests and profiles
• The TDL Pathology Handbook, which provides information on more than 1000 pathology topics,
reflecting our deep collective knowledge across all areas of pathology
The app can be downloaded from the Apple App Store or Google Play Store. To register for the app, you
will just need your TDL Source Code and an email address. Please contact [email protected]
if you need help with finding your Source Code.
Feedback for the TestGuide app and Pathology Handbook and is always welcome; please send
suggestions and comments to [email protected].
FEES FOR PATHOLOGY

Fees can be paid directly by patients or by the practice, clinic or requesting organisation. A payment
instruction clearly identifying to whom invoices need to be sent must be given with each patient’s request.
Patients are normally invoiced within 7 days to the address provided by the patient or practice.
Their pathology fees include a standard credit/administration charge.
Receipts for insurance purposes are sent, if requested. Patients visiting Wimpole Street for sample-
taking have the opportunity to settle their pathology fees at the time of their visit. A credit/administration fee
is raised for invoices sent to patients. All normal credit, debit or chargecards are accepted and payment can
be made by following the telephone payment instructions given with each invoice.
The Terms and Conditions of Business appearing on pages 213-20 of this Laboratory Guide shall apply
to the services we provide to you, unless otherwise agreed.
PROTECTION OF PERSONALLY IDENTIFIABLE INFORMATION

The General Data Protection Regulation (GDPR) came in to force in May 2018 and has had a significant
impact upon the way that personal data is managed; placing legal requirements upon data processors
and controllers to manage that information securely, maintain records of the processing that is carried
out, and report when breaches of the regulation do occur. This has impacted the way many businesses
operate, and is not restricted to the healthcare sector.
The GDPR requirements have been implemented within the context of a mature ISO 27001 Information
Security Management System – the globally accepted standard by which information is secured.
This ensures that senior management have regular visibility of the threats to the confidentiality,
availability and integrity of the information that we process, and are able to steer the efforts of their
teams to provide an efficient service that places the confidentiality of our customers and their patients
at the heart of everything we do.
In order to support our customers compliance with the regulation and as a part of a wider GDPR
compliance project TDL has updated its standard terms and conditions to include revised data processing
clauses, which are mandatory when providing personal data to another organisation.
Helpful information
WHO TO ASK FOR HELP
24 hour Telephone (main switchboard / all services): 020 7307 7373
CEO David Byrne [email protected]
Group Commercial Director Brian Madden [email protected]
Group Laboratory Director Tim Herriman [email protected]
Director of Sales / Service Annette Wilkinson [email protected]
Director of Genetics Dr Lisa Levett [email protected]
& Molecular Pathology
Chief Information Officer (IT) John Matthews [email protected]
HEADS OF SUPPORT DEPARTMENTS
Group Laboratory Operations Manager Lisa Manze [email protected]

Director of Governance Emer Nestor [email protected]
Patient / Doctor Invoices Lauren Burgess [email protected]
Logistics / Couriers Steve Kettle [email protected]
Patient Reception / Home Visits Abdulrhman Joumah [email protected]
Call Centre Chris Tanalega [email protected]
IT Operations / Customer Service Rochelle Fakhri [email protected]
Sample Reception Aileen Francis [email protected]
Referrals Department Maulik Trivedi [email protected]
Human Resources Matthew Gibbins [email protected]
HEADS OF LABORATORY DEPARTMENTS (LONDON)
Haem / Bio / Automated Pathology Naina Chavda [email protected]

Microbiology Alan Spratt [email protected]
Andrology Andrew Dawkins [email protected]
Cervical Screening Margaret Morgan [email protected]
Immunology/Virology Kushen Ramessur [email protected]
Cytogenetics Rebecca Watts [email protected]
Molecular Genetics Dr Stuart Liddle [email protected]
TDL Trials Abraham Roodt [email protected]
TDL MANCHESTER
Operational Site Lead Diane Benson [email protected]

Systems Manager Andy Leeson [email protected]
SRA Manager Georgina Arnold [email protected]
Quality Manager Eamonn Donnellan [email protected]
Courier Control Marc Rennard [email protected]
Quality assurance
8169 8860 8059 8812 10199 8511 9706
The Doctors Laboratory is committed to providing doctors with pathology of the highest quality.
The quality of results is of fundamental importance and the laboratory operates to stringent technical
and administrative standards.
Internal quality assurance is achieved by strict adherence to standard operating procedures for all
analytical processes. TDL participates in recognised National External Quality Assessment Schemes.
These schemes are subscribed to by NHS and private laboratories. Results are subjected to strict
internal and external quality control. Details of the laboratories to whom TDL refers specialist testing are
available from TDL Referrals. These laboratories are UKAS accredited or of equal accreditation status.
Details of the tests that are referred are given on the TDL website. QA is administered by TDL’s Quality
Management Group (QMG) who also adhere to regulatory and accreditation requirements.
BIOCHEMISTRY: UKNEQAS, WEQAS, RIQAS, BIORAD for Hepatitis A (with B and C)

ACE Hepatitis B Serology
AFP / CEA & HCG Hepatitis C Serology
Antibiotics (Gentamicin, Vancomycin and Amikacin) HIV Serology
Anti-Hbs Detection Homocysteine
Ammonia HTLV
Autoimmune (RF and TPO) IGF-1
B2 Microglobulin Immunity Screen
Cardiac Markers Lipase
Clinical Chemistry Lipid Investigations
CMV IgG / IgM NT-Pro BNP
CRP & Ultra-Sensitive CRP Paediatric Bilirubins
CSF Parasitology
Cyclosporin and Tacrolimus Peptide Hormones
DEQAS PSA, Free PSA
Diagnostic Serology Exanthem PTH, ACTH and hCT
Diagnostic Serology Hepatitis Rubella IgG Serology
Drugs of Abuse Salicylate and Paracetamol
Ethanol Specific Proteins
Faecal Markers for Inflammation (Calprotectin) Steroid Hormones
Free Beta HCG and PAPP-A Syphilis Serology
GFR Thyroglobulin Surveys
Glucose / Glucometer Thyroid Hormones
Glycated Haemoglobins Total IgE
Guildford Peptides Toxoplasma IgG / M Serology
Haematinics Tumour Markers
Healthcontrol Therapeutic Drugs Screen (TDM) Toxoplasma IgM Serology
Quality assurance
Toxoplasma IgG Serology Cystic Fibrosis
Trace Elements Duchenne / Becker Muscular Dystrophy
Urine Chemistry Hereditary Haemochromotosis (C282Y+H63D)
Vitamin D (25 OH) genotyping + reporting
HLA Class I (HLA-A, HLA-B, HLA-C)
HAEMATOLOGY: UKNEQAS for Tissue Typing (low resolution)
Automated Differential Leucocyte Count HLA Class II (HLA-DRB1, HLA-DQB1)
Blood Film Morphology Tissue Typing (low resolution)
Coagulation (Including PoCT Coagulation) HLA-B27 Genotyping
EBV Mononucleosis HLA-B57*01 Genotyping
ESR and NRBC (nucleated Rbc) HLA+ Disease Typing
Flow Cytometry Cytochrome P450 2D6 / 2C19 genotyping
Leukaemia immunophenotyping Human Papillomavirus DNA
Myeloperoxidase Mature B & T cell Neoplasms –
Iron stain FISH for CLL and Lymphoma
Full Blood Count Mature B & T cell Lymphoma – G-banding
Haematology Myeloid (AML/MDS/CML) – G-banding and FISH
Haematology Analysis Myeloma – sample FISH set up
Malaria and analysis plus online
Parasite Films NGS AML gene panel
Reticulocyte NIPT for aneuploidies
Sickle Screening NIPT for sexing
Thrombophilia Screening Paternity Testing
Blood Transfusion Laboratory Practice Scheme (BTLP) Prader-Willi and Angelman Syndromes
QF-PCR Aneuploidy Detection
Factors assays: Sexually Transmitted Diseases (CT/NG/MGEN/TV)
Von Willebrand (vWD) screen
Spinal Muscular Atrophy
Anti-Xa assays
Thrombophilia (Factor II, V, MTHFR)
Plasma viscosities
Y Microdeletion PCR Assay
ADAMTS-13 activity
ADAMTS-13 antibody MOLECULAR VIROLOGY
Heparin / Platelet Factor 4 Induced Antibodies Atypical Mycobacterium
Platelet function analysis (RCPA) Adenovirus DNA Viral load
Lupus anticoagulant: Bacterial 16S
Taipan Venom Time B19 virus DNA Viral load
DRVVT assay BK virus DNA Viral load
CMV DBS (dried blood spots)
GENETICS AND MOLECULAR VIROLOGY
CMV DNA Plasma Viral load
MOLECULAR GENETICS
CMV DNA Whole Blood Viral load
Acquired array (CLL/MDS)
CMV Resistance
Acute Leukaemia FISH pilot
EBV DNA Plasma Viral load
Acute Lymphoblastic Leukaemia (ALL)
EBV DNA Whole Blood Viral load
– G banding and FISH
Enterovirus RNA
BoBs Rapid Aneuploidy detection
Gastroenteritis Virus Panel
Chlamydia & Gonorrhoea detection by PCR
Hepatitis B Genotyping
Constitutional Clinical Cytogenetics
Hepatitis B Drug Resistance Typing
(Rounds for Amniocentesis, CVS,
Solid Tissue, Blood, Array CGH) Hepatitis B Viral Load
Quality assurance
Hepatitis C genotyping Cryptococcal antigen
Hepatitis C Resistance genome detection (NS5a & b) Fungal culture
Hepatitis C Resistance Typing (NS3 & NS5a) Fungal biomarkers
Hepatitis C Viral Load Urinary antigen
Hepatitis D Virus Viral load and Qualitative PCR
WEQAS POCT:
Hepatitis E Virus Viral load and Qualitative PCR
Urinalysis
HIV-1 Drug Resistance (Pol)
HIV-1 Drug Resistance (Integrase) QCMD:
HIV-1 RNA Viral load Dermatophyte PCR
HIV-1 RNA Qualitative PCR PCP PCR
HIV-1 Tropism Genome Detection Atypical pneumoniae PCR
HIV-2 Viral load and Qualitative PCR
HSV 1&2 DNA IMMUNOLOGY
HSV Drug Resistance UKNEQAS – General Immunology for:
Human Herpes virus 6 DNA Allergen Component Testing
Influenza Haemagglutinin typing Autoimmune Serology ANCA/GBM Antibodies
JC virus DNA Bullous Dermatosis Antibodies
Measles and Mumps PCR Allergen Specific IgE Antibodies
MERS Coronavirus General Autoimmune Serology
Parechovirus RNA Anti-Phospholipid Antibodies (ACAB)
Respiratory panel I Nuclear and Related Antigens
Respiratory panel II IGRA TBQ
SARS-CoV-2 (COVID-19) PCR/NAAT Intrinsic factor
SARS-CoV-2 (COVID-19) antibodies Islet Cell Antibodies (Diabetic Marker)
Syphilis PCR Myositis Antibodies
Transplantation Virus Panel Specific Microbial Antibodies
VZV DNA C1 Esterase inhibitor and functional complement
Syphilis (TPPA and RPR)
MICROBIOLOGY Lyme (IgG and IgM)
Laboratory Quality Scheme: Hepatitis C
Helicobacter pylori antigen from faeces Hepatitis E (IgG and IgM)
Polarising crystal microscopy from synovial fluid Coeliac Disease (Endomysium, Tissue transglutaminase)
Streptococcus pyogenes (Group A) detection
in pharyngeal samples EUROQAS:
Surveillance for multi drug resistant bacteria Liver Blot
UKNEQAS: UKNEQAS – Infectious Immunology for:

Clostridium difficile detection and toxin testing HIV Serology / POCT
Faecal parasites Immunity Screen – VZV, Parvo Viruse, EBV
General bacteriology Chlamydia Detect
Genital pathogens Varicella Zoster (IgG) Serology
MRSA screening Parasite Serology
Microbial susceptibilities Chlamydia & Gonorrhoea (NAAT / PCR)
Mycobacterial microscopy Hepatitis E
Mycobacterial culture and molecular detection
Antifungal assays RIQAS Scheme:
Antifungal susceptibilities Procalcitonin
Quality assurance
RCPAQAP Scheme: CERVICAL SCREENING:
Brucella Serology PHE:
Legionella (IgG) Serology Gynaecological Cytopathology EQA Scheme (GEQA)
Scleroderma Antibodies National EQA Scheme for the Preparation and Staining
Striated Muscle Antibodies of Cervical Liquid Based Cytology Samples (TEQA)
Chlamydia Serology
HOLOGIC:
INSTAND Scheme:
ThinPrep Stain EQA
Adrenal Antibodies
Hepatitis E Serology UKNEQAS for Microbiology
RNAP Antibodies
Molecular Detection of HPV
CSCQ Scheme:
DIAGNOSTIC CYTOLOGY
Lyme Serology
UKNEQAS for CPT:
Laboratory Quality Scheme: Stained Non-Gynaecological Cytology Module.
Herpes Simplex Virus All non-gynaecological (diagnostic cytology),
Cytomegalovirus including Urine Cytology, are referred to a UKAS
Antistreptolysin O Titre accredited laboratory for reporting.
Helicobacter Pylori IgG Antibodies
RNA Polymerase III ANDROLOGY: UKNEQAS for
Euroimmun ifW-Lubeck Liver Autoimmune Disease Scheme Semen Analysis Scheme
ENDOCRINOLOGY: UKNEQAS for Information security:

Steroid Hormones Accredited by British Standards Institute
Peptide Schemes 1 to 4 ISO/IEC 27001:2013
Thyroid Scheme
Allergens Scheme
SHBG
Prostate Specific Antigen
Tumour Markers
PTH
Specific IgE / Total IgE
AFP / CEA
Quality assurance
LINKS TO THE UKAS SCHEDULES OF ACCREDITATION
(Certain UKAS accreditations can be found under Health Services Laboratories (HSL),
which is part of the TDL Group of Laboratories.)
HSL Blood Sciences (8169)
https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/8169%20Medical%20Single.pdf
HSL Infection Sciences (8860)
HSL Molecular Pathology and Genetics (8059)
TDL Manchester (8812)
https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/8812%20Medical%20Multiple.pdf
TDL Andrology (10199)
HSL Cytology (8511)
TDL Urine Cytology (9706)
https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/9706-Medical-Multiple.pdf
Quality assurance
MEASUREMENT UNCERTAINTY
Medical laboratories are responsible for ensuring that test results are fit for clinical application by
defining analytical performance goals and selecting appropriate measurement procedures. All types
of measurement have some inaccuracy due to bias and imprecision; therefore measurement results
can only be estimates of the values of the quantities being measured. To properly use such results,
medical laboratories and their clinical users need some knowledge of the accuracy of such estimates.
The complete result of a measurement is a value, a unit and an estimate of uncertainty. This estimate
of uncertainty is conventionally referred to as Measurement Uncertainty (MU) and incorporates the
cumulative range of factors involved in the testing procedure itself in addition to consideration of the
inter-individual and intra-individual biological variation which will potentially influence the overall test
result. Evaluating measurement uncertainty is an ISO 15189:2012 accreditation requirement.
In terms of MU determined by the TDL / HSL group of laboratories, it should be noted all assays are
performed in strict accordance with the manufacturers’ instructions. MU, which has been estimated for
each assay during the verification procedure, is reviewed at regular intervals to ensure that MU values do
not exceed the pre-defined maximum allowable uncertainty for each assay. Overall assay performance
is also regularly monitored through internal quality control (IQC) and external quality assessment (EQA)
schemes and incorporated in test result interpretation. MU for individual assays is available upon request.
SAMPLE REJECTION CRITERIA

Sometimes tests cannot be performed in the laboratory if samples fall short of the quality, volume or
other eligibility criteria. In these cases, the laboratory may need to reject the samples, and not carry
out processing. Sometimes the laboratory is able to rectify a situation – and although turnaround times
may be affected, it avoids having to arrange for samples to be taken again.
Summary List for Sample Rejection

• Incorrect sample types received:
• Basic incorrect blood tube / other sample.
• Samples without the appropriate preservative (e.g. acidified urine samples).
• Samples that are received ambient, when a frozen sample is required.
• Samples that are received unprotected from light, when they are required to be covered
at the point of venepuncture.
• Samples in incorrect containers (e.g. cervical cytology must be a ThinPrep vial;
urine cytology must be in a uricyte container).
• Insufficient sample received.
• No sample received.
• Labelling or form issues (mislabelled / unlabelled / no forms / no clinical information).
• Clotted / haemolysed / lipaemic / icteric samples.
• Sample is broken or has leaked in transit.
• Stability time has been exceeded. Stability time is test dependant,
and also refers to tests that can only be carried out on certain days of the week.
Quality assurance
• Sample contamination (e.g. being in the same bag as a leaking sample).
• Samples are high risk or infectious.
• Samples that are received in expired tubes.
Department Specific
• Sample Reception will not accept samples packaged with needles of any kind.
• Haematology cannot accept frozen whole blood for testing.
• Coagulation cannot accept over or under filled samples for testing.
• Coagulation cannot accept previously frozen samples that have thawed in transit.
• Biochemistry cannot accept previously frozen samples that have thawed in transit.
• Biochemistry cannot accept samples that display antibody interference.
• Biochemistry cannot accept samples that have had separation delays/un-centrifuged
samples that have been stored in the fridge.
• Biochemistry cannot accept paraprotein resulting in viscous samples.
• Biochemistry cannot accept CSF protein that is blood stained.
• Immunology cannot accept TBQ kits that:
• Do not contain all of the appropriate tubes.
• Are incubated for more than the specified 16 hours.
• Have passed the incubation time period.
• Are over or under filled.
• Microbiology cannot accept samples in non-sterile containers or in formalin.
• Referrals cannot accept samples without three points of identification for DRP testing.
• Referrals cannot accept samples that are not labelled by hand for blood group testing.
• Molecular Pathology cannot accept samples for Haemophilia testing without informed consent.
• Cervical Cytology cannot accept over or under filled samples for testing.
• Cervical Cytology cannot accept samples received within three months of the previous test
in order to allow epithelial cells to regenerate.
• Urine cytology cannot accept delayed samples unless they have been refrigerated.
Samples deemed to be PRECIOUS (e.g. CSF, fluid, tissue, bone marrow and paediatric samples) will not
be discarded by the laboratory. Results will include a comment relating to the condition of the sample
(e.g. sample unlabelled).
Quality assurance
CONSULTANT ADVICE AND OPINION
Each department in the laboratory is consultant led. The TDL doctors Consultants listed below
have defined areas of cover and so for doctors wanting clinical advice or professional support,
TDL consultants can be contacted via the laboratory.
TDL LEAD CONSULTANTS

GROUP MEDICAL DIRECTOR BLOOD TRANSFUSION HAEMATOLOGY
Dr Rachael Liebmann OBE Dr Vivienne Andrews Dr Nick Jackson
BSc Hons, MB, BCh, BAO, FRCPath, FRCPath MA, MBBS, MD, MRCP(UK), FRCPath
FAcadMed, SFFMLM
CERVICAL CYTOLOGY MEDICAL MICROBIOLOGY
ALLERGY AND IMMUNOLOGY Dr Geraldine Soosay Dr Robin Smith
Dr Scott Pereira MB, BS, FRCPath FRCPath
MA, MB, B Chir, PhD, FRCPath
Dr Mary Falzon POINT OF CARE TESTING
Professor Suranjith MRCS, LRCP, FRCPath
Dr Gilbert Wieringa
Seneviratne
DIAGNOSTIC MSc, FRCPath, EuSpLM
DPhil (Oxon), FRCP, FRCPath
(NON-CERVICAL) CYTOLOGY
SPECIAL COAGULATION
ANDROLOGY Dr Geraldine Soosay
Professor Marie Scully
Dr Sheryl Homa MB, BS, FRCPath
MRCP, FRCPath
PhD, ARCS, FIBMS
Dr Mary Falzon
MRCS, LRCP, FRCPath VIROLOGY
BIOCHEMISTRY
Dr Mark Atkins
Dr Frank Geoghegan GENETICS
BSc (Hons), MSc, MBBS, FRCPath
FRCPath
Professor Michael Patton
FRCP, FRCPCH
TDL CONSULTANTS
ALLERGY AND IMMUNOLOGY Dr Bernie Croal Dr Mayur Patel
Dr Scott Pereira MB, ChB, BSc Hons, MSc, MD, MB, BS, FRCPath
MA, MB, B Chir, PhD, FRCPath FRCP, FRCPath, CSci, EuSpLM
Dr Michael Thomas
Professor Suranjith Dr Denise Darby BSc, PhD, MSc, FRCPath,
Seneviratne MRCP, FRCPath EuSpLM, SRCS, CSci
DPhil (Oxon), FRCP, FRCPath Professor Carel le Roux Prof Pankaj Vadgama
FRCPath MB, BS, FRCPath
ANDROLOGY
Mr Craig Webster Dr Paul Holloway
Dr Sheryl Homa
FRCPath FRCPath
PhD, ARCS, FIBMS
Mr Ed Kearney Dr Paul Masters
BIOCHEMISTRY AND MSc, MCB, FRCPath MRCP, FRCPath
POINT OF CARE TESTING
Dr Jamie Alaghband-Zadeh Dr Peter Galloway
Dr Frank Geoghegan
FRCPath BSc, MB, ChB, MRCP, DCH, FRCPath
FRCPath
Mr Jim Allison Dr Rachel Webster
Dr Gilbert Wieringa
BSc Hons, FRCPath, CSci, EuSpLM PhD, FRCPath
MSc, FRCPath, EuSpLM
Quality assurance
Dr Rajeev Srivastava Dr Mamta Sohail MEDICAL MICROBIOLOGY
MBBS, MS, FRCS, FRCPath, EuSpLm BM, BS, FRCPath Dr Robin Smith
Dr Mansour Ceesay FRCPath
BLOOD TRANSFUSION
AND HAEMATOLOGY FRCPath Dr Alistair Leanord
Dr Vivienne Andrews Professor Marie Scully FRCPath
FRCPath MRCP, FRCPath Dr Antonia Scobie
Dr Nick Jackson Dr Mark Vickers MBBS, BSc MSc, DTM&H,
MA, MBBS, MD, MRCP(UK), FRCPath MBChB, MCRP, DM, FRCPath MRCP(ID), FRCPath
Dr Abdel-Razek Abu-Sitta Dr Norbert Blesing Professor Brian Jones

FRCPath FRCPath MB, ChB, FRCPath
Dr Adrian Bloor Dr Philip Robson Dr Damien Mack

MA, PhD, FRCP, FRCPath FRCPath MB, BS, MRCP, MSc, FRCPath
Dr Alex Sternberg Dr Salim Shafeek Dr Emmanuel Wey

MB, ChB, FRCPath MB, BS, FRCPath MB, BS, FRCPath
Prof Atul Mehta Dr Sreetharan Munisamy Dr Indran Balakrishnan

B Chir, FRCPath MB, BChir, BA (Hons), MA, MRCP BSc, MSc, MRCP, FRCPath
FRCPath, PGCert, MedEd Dr Jonathon Lambourne
Dr Chris McNamara
MB, BS, FRCPath Dr Taku Sugai MB, BS, FRCPath
MB, BS, FRCPath Dr Rajeev Rajendran
Dr Clare Barnes
MRCP, FRCPath Dr Will Lester MB, BS, FRCPath
BSc Hons, FRCP, FRCPath, PhD Dr Rajesh Rajendran
Dr Faris Al-Refaie
MB, ChB, FRCPath FRCPath
CERVICAL CYTOLOGY
Dr Gerard Dolan Dr Geraldine Soosay Dr Simon Warren
MBChB, FRCP, FRCPath MB, BS, FRCPath FRCPath
Dr Gillian Evans Dr Mary Falzon Dr Sophie Collier

MB, ChB, FRCPath MRCS, LRCP, FRCPath FRCPath
Dr Glenn Rainey Dr Stephen Mepham

DIAGNOSTIC
FRCPath MB, ChB, FRCPath
(NON-CERVICAL) CYTOLOGY
Dr Jindriska Lindsay Dr Vanya Gant
Dr Geraldine Soosay
FRCPath FRCPath
MB, BS, FRCPath
Dr John Paul Westwood Dr Mary Falzon SPECIAL COAGULATION
MD, FRCPath MRCS, LRCP, FRCPath Professor Marie Scully
Dr Josh Wright MRCP, FRCPath
GENETICS: MOLECULAR/
B Med Sci, MB, ChB, MRCP,
CYTOGENETICS VIROLOGY
FRCPath, MD
Professor Michael Patton Dr Mark Atkins
Dr Kenneth Douglas FRCP, FRCPCH BSc (Hons), MSc, MBBS, FRCPath
MB, ChB, FRCPath
Dr Dragana Josif Josifova Dr Colin Graham Fink
Dr Kim Eliott MD, FRCPath MB, ChB, FRCPath
MB, ChB, FRCPath
Dr Maadh Aldouri
MB, BCh, FRCPath
Special instructions for samples
1 Contact the laboratory for special sample tubes/ 20 Sample types: FCRU or PCR swab or TPV
containers/instructions. or Semen.
2 Confirmation of not negative drug screens by 21 Urine cytology container, ideally first catch,
LCMS/MS may take up to 5 days. mid-morning specimen.
3 Clinical history essential and protect from light. 22 Must be fresh.
4 Send to the laboratory without delay. 30 Collect sample at end of exposure.
5 Do not send sample to the laboratory between 33 Sample must be labelled by hand with first
Friday noon and Monday morning. name, family name, gender and date of birth
6 Contact the Referrals Department before taking detailed on sample and form. Do not use labels
and sending sample to the laboratory. other than the tube label.
7 Sample should be separated and frozen if 34 Samples must arrive in the laboratory on the same
sending overnight. day of sample taking or contact the laboratory.
8 DRP Form required. DRP Form can be found 35 Patient should be fasting and resting for 30 mins
at the back of the guide. before sample taking. Samples need handling
urgently.
9 Clinical history must be provided.
36 Renin: Sample collected either upright /active
10 Contact the laboratory for special stability tubes or resting /supine (3 hours lying).
for lymphocyte subsets – or take an EDTA sample
and ensure same day delivery to the laboratory, 37 Provide sample time and date of collection.
Monday to Friday noon (do not send sample 38 EDTA sample should not be separated:
between Friday noon and Monday morning). send whole blood.
11 Patient consent required. Consent Form can 39 Urgent samples have a 3 day TAT if genotype is
be found at the back of this guide. required for prenatal diagnosis or two weeks TAT
12 Please provide one sample for each person if urgent for other factors.
being tested. 40 Informed Consent is required for these tests.
13 Protect from light. 41 Recommendation for patient to attend
14 Provide details of travel history. Patient Reception for sample taking.
15 Ammonia 42 LGV can be added to a positive chlamydia sample
using the same swab if requested within 4 days
Sample: EDTA plasma only. Full tubes and tightly
of receipt of result.
stoppered. On ice, centrifuged and analysed
20-30 mins post venepuncture (or plasma can 43 Please contact [email protected]
be frozen). If haemolysed gives falsely high results. for details for referring samples to the laboratory
Patient: Fasting. Avoid smoking. for sequencing testing.
16 Lactate
Example of profile panel information
Sample: Fluoride oxalate plasma only.
On ice and separate from cells 15-30 mins,
analyse promptly. Handle with care as sweat Profile PRE-TRAVEL SCREEN (DVT)
contains large amounts of lactate. No tourniquet. name
Patient: Rest 30 mins prior to test. FBC
17 Homocysteine Profile Factor II Prothrombin Gene
content Factor V Leiden
Should be spun and separated with 1 hour
Anticardiolipin TAT
of venepuncture.
Turnaround
Antibodies 5
18 Citrate Samples DAYS
time
Samples should be double spun and separated
and frozen within 4-8 hours of sample taking, DVT1
if a delay is expected with transportation to Sample
AAB9 Code
the laboratory, samples must be transported requirements
as frozen. Reference to sample taking and
special handling instructions (see above)
19 Must include patient’s age, height and weight.
TDL Screening Profiles DL1–DL12
BIOCHEMISTRY
HAEMATOLOGY
DL1
BIOCHEMISTRY
DL2
(24 PARAMETERS) DL3 PROFILE
PROFILE & HAEMATOLOGY
PROFILE FBC with 5-part Diff TAT
Urea and Electrolytes HAEMATOLOGY ESR 4

HOURS
Sodium, Potassium, Chloride, FBC with 5-part Diff
Bicarbonate, Urea, Creatinine, ESR DL3
eGFR
Liver Function Tests BIOCHEMISTRY
Urea and Electrolytes A
Bilirubin, Alk Phos, AST, ALT,
Gamma GT, Total Protein, Sodium, Potassium, Chloride,
BIOCHEMISTRY
Albumin, Globulin Bicarbonate, Urea, Creatinine,
(16 PARAMETERS)
Cardiac/Muscle Enzymes eGFR DL4 & HAEMATOLOGY
LDH, CK Liver Function Tests
PROFILE
Bone Markers Bilirubin, Alk Phos, AST, ALT,
Gamma GT, Total Protein, HAEMATOLOGY
Calcium, Phosphate, Uric Acid
Albumin, Globulin FBC with 5-part Diff
Glucose Cardiac/Muscle Enzymes ESR
Triglycerides LDH, CK
BIOCHEMISTRY
Cholesterol Bone Markers
Renal Function
Iron Calcium, Phosphate, Uric Acid
Urea, Creatinine, eGFR
Total Iron Binding
Glucose Liver Function Tests
Triglycerides Bilirubin, Alk Phos, AST, ALT,
Cholesterol Gamma GT, Total Protein,
Iron/TIBC Albumin, Globulin
TAT TAT Bone Markers
4 4 Calcium, Phosphate, Uric Acid
HOURS HOURS
Glucose
DL1 DL2 Triglycerides
Cholesterol
plus plus
TAT
HDL Cholesterol HDL Cholesterol
DL1L LDL Cholesterol DL2L LDL Cholesterol 4
Non-HDL Cholesterol Non-HDL Cholesterol HOURS
BG ABG DL4
BIOCHEMISTRY plus
GENERAL WELL
DL5 & HAEMATOLOGY DL6 PERSON PROFILE DL4L HDL Cholesterol
LDL Cholesterol
POSTAL PROFILE Non-HDL Cholesterol
DL2
As DL4 FT4/TSH ABG
DL5/DL5L do not include ESR and Ferritin
Phosphate as these results
may be more affected by TAT TAT
overnight transit times. 4 4
HOURS HOURS
DL5 DL6
plus plus
DL5L LDL Cholesterol DL6L LDL Cholesterol
Non-HDL Cholesterol Non-HDL Cholesterol
ABG ABG
TDL Screening Profiles DL1–DL12
WELL MAN WELL PERSON SENIOR MALE
DL7 PROFILE DL8 PROFILE DL9M PROFILE 60+
DL2 DL2 DL2

FT4/TSH FT4/TSH HDL/LDL Cholesterol
Ferritin Ferritin HbA1C
Prostate Profile Vitamin D FT4/TSH
Prostate Profile
TAT TAT CRP
4 4 Ferritin
HOURS HOURS
QFIT
DL7 DL8 MSU
TAT
Vitamin D (25 OH)
plus plus Lp-PLA2 (PLAC) Test
2
DAYS
DL7L LDL Cholesterol DL8L LDL Cholesterol DL9M
ABG ABG ABBG RU QFIT 4
SENIOR FEMALE CARDIOVASCULAR CARDIOVASCULAR

DL9F PROFILE 60+ DL10 RISK PROFILE 1 DL11 RISK PROFILE 2
DL2 Cholesterol Cholesterol

HDL/LDL Cholesterol Triglycerides Triglycerides
HbA1C HDL Cholesterol HDL Cholesterol
FT4/TSH LDL Cholesterol LDL Cholesterol
CRP Non-HDL Cholesterol Non-HDL Cholesterol
Ferritin Apolipoprotein A Apolipoprotein A
QFIT Apolipoprotein B Apolipoprotein B
MSU Lipoprotein (a) Lipoprotein (a)
Vitamin D (25 OH) hsCRP Fibrinogen
HE4 Lp-PLA2 (PLAC) Test hsCRP
Lp-PLA2 (PLAC) Test TAT TAT Lp-PLA2 (PLAC) Test TAT
2 3 Homocysteine 3
DAYS DAYS DAYS
DL9F DL10 DL11
ABBG RU QFIT 4
BB B B B C34
7 STI PROFILE BY PCR

DL12 (7 PCR TESTS FROM 1 SAMPLE)
Chlamydia trachomatis Trichomonas vaginalis

N. gonorrhoea Gardnerella vaginalis
Mycoplasma genitalium Herpes Simplex I/II
Ureaplasma
TAT
2
DAYS
DL12
FCRU OR PCR Swab OR TPV
Key: See page 23 for sample-taking and special handling instructions. 25

Testing for COVID-19 (SARS-CoV-2)
CDC/ Alissa Eckert, MSMI; Dan Higgins, MAMS
There are six human coronaviruses that can infect people:

Common Cold – coronaviruses 229E, NL63, OC43, and HKU1 (these four are included in TDL’s
COVID-19 / FLU / RSV Screen, details on page 100).
The other two human coronaviruses are MERS-CoV and SARS-CoV-2 – the coronavirus that causes coronavirus
disease 2019, or COVID-19.
TDL will continue to update on COVID-19 testing developments as they become available but is currently offering:
• COVID-19 by PCR: For General Testing, Travel Testing with the most recent DHSC and UKHSA requirements,
and Viral Genetic Sequencing of positive Day2 samples.
• COVID-19 Antibodies: Total Spike (Vaccine) Antibody Status, Total Antibody status, and IgG and IgM serology.
COVID-19 (SARS-CoV-2) RNA by PCR

Results are reported as Positive, Not Detected, Indeterminate, or Invalid.
Test Code: NCOV
Sample Type PCR swab in CE Marked COVID-19 sample pack
Turnaround time Within 24 hours of receipt of sample
COVID-19 (SARS-CoV-2) T-SPOT®.COVID NEW

The T-SPOT®.COVID test is intended for qualitative detection of a cell mediated (T cell) immune response to SARS
CoV-2 in human whole blood. The T-SPOT®.COVID test is intended for use as an aid in identifying individuals with
an adaptive, or acquired, immune response to SARS-CoV-2, specifically the T cell response.
TEST CODE SAMPLE REQS TAT

NEW T-SPOT®.COVID TCEL H *** 3 days
*** Do not refrigerate samples at any time. Samples must be received by TDL within 24 hours of taking the sample.
Please do not send samples to the laboratory on Saturdays. T-SPOT®.COVID test is CE marked.
Testing for COVID-19 (SARS-CoV-2)
Roche Elecsys Roche Elecsys Abbott Architect Abbott Architect
Anti-SARS-CoV-2 S Anti-SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgM
(Spike – detects Total antibody (does not detect (does not detect
vaccine) Total (does not detect antibodies from antibodies from
antibody antibodies from vaccine) vaccine)
vaccine)
Platform Roche e801 Roche e801 Abbott Architect Abbott Architect
Assay Electro- Electro- Chemiluminescent Chemiluminescent

type chemiluminescence chemiluminescence Microparticle Microparticle
immunoassay (ECLIA) immunoassay Immunoassay Immunoassay
(ECLIA) (CMIA) (CMIA)
Reporting QUANTITATIVE Qualitative Qualitative Qualitative

format
Reporting Positive with value Positive / Negative Positive / Negative Positive / Negative
ranges reported in U/ml /
Negative
Antigen Receptor binding Nucleocapsid Nucleocapsid Spike protein

used domain (RBD)
of Spike antigen
Analyte SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 SARS-CoV-2

target Antibodies (IgG/IgM) Antibodies (IgG/IgM) Antibodies (IgG) Antibodies (IgM)
Total antibodies Total antibodies
Sample Serum – venous Serum – venous Serum – venous Serum – venous

type or capillary self- or capillary self-
verified collection collection
Sensitivity 98.8% 97.4% 97.5% 96.67% in samples

taken more than
14 days post
symptoms onset
Specificity 99.98% in samples 100% 99.1% 99.0%

taken 14 days or later
after positive PCR
Seasonal 24/24 Negative 26/26 Negative 26/26 Negative N/A

Corona
Virus
panel
TDL reports all Antibody and PCR activity daily to the UK Health Security Agency (UKHSA). It is a statutory
requirement that laboratories notify this information and it is therefore essential that the patient’s address
and postcode are provided so that positive results can be followed by Test and Trace.

Biochemistry
5 HIAA RU5H PU 1 5 days

5’ Nucleotidase 5NT B 5 days
6-Thioguanine Nucleotides TGN AA 2 weeks
21 Hydroxylase Ab’s 21HA B (Frozen) 10 days
Acetylcholine Receptor Autoantibodies ACRA B4 5 days
Acetylcholinesterase Isoenzymes ACEI AF 7 days
Acid Phosphatase – Total APT B 5 days
Adenosine Deaminase AD A / B / Fluid 3 weeks
Adiponectin ADIP B 2 weeks
Albumin ALB B 4 hours
Alcohol (Medical) [Do not use alcohol
ALCO G1 4 hours
swab prior to sample taking]
Alcohol (Urine) UALC RU 4 hours
Aldolase ALDO B 5 days
Alk Phosphatase lsoenzymes APIE B 5 days
Alkaline Phosphatase ALP B 4 hours
Alpha 1 Antitrypsin (Serum) A1AT B 1 day
Alpha 1 Antitrypsin (Stool) A1AF RF 10 days
Alpha 1 Antitrypsin Genotype Requires patient informed consent
– PI*M, PI*S, PI*Z GENE A9 4 weeks
Alpha 1 Glycoprotein OROS B (Frozen) 5 days
Alpha 1 Microglobulin A1MG RU 1,22 10 days
Alpha 2 Macroglobulins A2MG B 5 days
Alpha Feto Protein (Maternal) AFPM B 4 hours
ALT (Alanine Aminotransferase) (SGPT) ALT B 4 hours
Aluminium (Blood) ALUM K 7 days
Amino Acid (Serum/Plasma) AMIN B 7 days
Amino Acid Quantitative (Urine) UAAQ RU 7 days
Amino-Laevulinic Acid (Urine) RUAL 100mls PU 5 days
Ammonia AMMO A (Frozen) 15 4 hours
Amylase AMY B 4 hours
Amylase (Urine) UAMY CU 4 hours
Amylase lsoenzymes AMYI B 5 days
Amyloidosis (Amyloid A Protein) SAA B 5 days
Androstanediolglucoronide ANDG B 3 weeks
Angiotensin II ANG2 A (Frozen) 2 weeks
Angiotensin Converting Enzyme ACE B 4 hours
Angiotensin Converting Enzyme – CSF ACEF CSF (Frozen) 2 weeks
Antimony (Urine) ANTI RU 30 10 days
Antimullerian Hormone (AMH Plus) AMH B 4 hours
AP50 Alternative Hemolytic Complement AP50 B (Frozen) 2 weeks
Apolipoprotein A1 APOA B 3 days
Apolipoprotein B APOB B 3 days
Apolipoprotein C APOC B 3 months

Biochemistry
Apolipoprotein E (12 hours fasting) APOE B (fasting) 5 days

Arsenic (Blood) ARS A or H 5 days
Arsenic (Urine) ARSE RU 30 5 days
Arylsulphatase A ARYL H 5,6 8 weeks
Aspartate Transaminase (AST) (SGOT) AST B 4 hours
Bence-Jones Protein RBJP 1 x 30mls (RU) 5 days
Beta 2 Microglobulin (Serum) B2MG B 2 days
Beta 2 Microglobulin (Urine) UB2M RU 3 days
Beta-Glucuronidase (Sly Disease) BGLU H H 9,4 8 weeks
Bicarbonate HCO3 B 4 hours
Bile Acids – Serum BILE B 4 hours
Bilirubin (Direct/Indirect) DBIL B 4 hours
Bilirubin (Total) BILI B 4 hours
Bilirubin (Urine) UBIL RU 1 day
Biotinidase BIOT H (Frozen plasma) 4 3 weeks
Bismuth BISM B 5 days
BNP (NT-pro BNP) BNP B 4 hours
Bone Alkaline Phosphatase BALP B (Frozen) 2 weeks
Bone Screen BONE B CU 4 hours
Bone Screen (Bloods only) BON2 B 4 hours
BUN (Blood Urea Nitrogen) BUN B 4 hours
C Reactive Protein CRP B 4 hours
C Reactive Protein (High Sensitivity) HCRP B 4 hours
C1 Esterase: Function & Total FC1E C C (Plasma Frozen) 4,18 10 days
C1q Binding Immune Complex IMCP B 5 days
Cadmium (Blood) CADM A or H 5 days
Cadmium (Urine) URCD RU 30 5 days
Calcium CA B 4 hours
Calcium (24 hour Urine) UCA PU 4 hours
Calcium/Creatinine Ratio CACR RU B 4 hours
Carbohydrate Deficient Glycoprotein CDG B 2 weeks
Carbohydrate Deficient Transferrin (CDT) CDT B4 3 days
Cardiac Enzymes (not chest pain) CENZ B 4 hours
Cardiovascular Risk Profile 1 PP10 BB 3 days
Cardiovascular Risk Profile 2 PP11 B B B C 34 3 days
Carnitine – Free & Total CARN H H (Frozen Plasma) 10 days
Ceruloplasmin CERU B 1 day
Chest Pain Profile CPP B STAT
Chloride CL B 4 hours
Cholesterol CHO B 4 hours
Cholesterol (Familial Requires patient informed consent
Hypercholesterolaemia) GENE AA 9 7 weeks
Cholinesterase (Serum/Pseudo) CHPS B 4 hours
Biochemistry
Chromium (Blood) CHRO A 5 days

Chromium (Urine) URCR RU 30 10 days
Chromogranin A CGA B 5 days
Chromogranin A & B MTAB J1 3 weeks
Citrate (Blood) CITR B 5 days
Citrate (Urine) UCIT CU (Frozen) 5 days
CK (MB Fraction) CKMB B 4 hours
CK Isoenzymes CKIE B 5 days
Cobalt (Blood) COB A 5 days
Cobalt (Serum) COBB B 5 days
Cobalt (Urine) COBA RU 30 5 days
Coenzyme Q10 CQ10 B 2 weeks
Cold Agglutinin CAGG J1 5 days
Collagen (Type I, II, IV) Antibodies COAB B 10 days
Collagen Type 1 Cross-Linked
NTX 2nd EMU 2 weeks
N-Telopeptide – NTX
Complement C1q C1Q B 5 days
Complement C2 C2 B 10 days
Complement C5 C5A B 2 weeks
Complement C6 C6 B (Frozen)* 5 weeks
Complement Factor H FACH B 3 weeks
Copper (Serum) COPP B 5 days
Copper (Urine) URCU CU 5 days
Cortisol Binding Globulin CBG B (Frozen) 1 month
Cotinine (Urine) COTT RU 2 days
Creatine Kinase (CK, CPK) CKNA B 4 hours
Creatinine CREA B 4 hours
Creatinine (Urine) UCR CU 4 hours
Creatinine Clearance CRCL B CU 4 hours
B (Freeze within
Crosslaps (Serum DPD) SDPD 4 days
24 hours)
Cryoglobulins CRYO J6 10 days
Cyclic Amp (Urine) CAMP CU (Frozen) 5 days
Cyclosporin (Monoclonal) CYCL A 1 day
Cystatin C CYCC B 5 days
Cystine – Quantitative (Beta-CTX) QCYS PU 5 days
B (Freeze within
Deoxypyridinoline (DPD) – Serum SDPD 4 days
24 hours)
Deoxypyridinoline (DPD) – Urine DPD EMU 4 days
Diabetic Profile 1 DIAB AG 8 hours
* Separate and freeze within 2 hours after collection.

Biochemistry
Diabetic Profile 2 DIA2 A G RU 2 days

Diamine Oxidase Activity DIAM B 2 weeks
Elastase (Faecal) ELAS RF 5 days
Electrolytes ELEC B 4 hours
Electrolytes (Urine) UELE CU 4 hours
ELF/Enhanced Liver Fibrosis ELF B 5-7 days
Eosinophil Cationic Protein ECP B 7 days
Faecal Elastase ELAS RF 5 days
Faecal Fat (1 Day Collection) TFFA LF 6 5 days
Faecal Fat (3 day) FFAT LF 6 5 days
Faecal Lactoferrin FLAC RF 5 days
Faecal Sugar Chromatography FCRO RF (Frozen) 3 weeks
Faecal Urobilinogen FURO RF 5 days
Fat Globules in Faeces FGLO RF 1 week
Ferritin FERR B 4 hours
Fibrotest (Liver Fibrosis) FIBT B 2 weeks
Fluoride (Urine) UFL RU 5 days
Folate (Red Cell) RBCF A 2 days
Folate (Serum) FOLA B 1 day
Free Fatty Acids FFA B (Frozen) 1 10 days
Fructosamine FRUC B 1 day
Galactose-1-Phosphate Uridyltransferase GAL1 H 5,6 2 weeks
Galactosidase – Alpha* GALA J* 6 weeks
Gall Stone Analysis RSTA STONE 10 days
Gamma GT GGT B 4 hours
Gastrin GAST B (Frozen) 5 days
Globulin GLOB B 4 hours
Glucagon GLUG J1 10 days
Glucose RBG G 4 hours
Glucose Tolerance Test see page 133
Haemochromatosis – HFE common
HMD A9 3 days
mutations C282Y + H63D
Haemosiderin (Urine) HSID EMU 2 weeks
Haptoglobin HAPT B 5 days
HbA1c GHB A 6 hours
HDL Cholesterol HDL B 4 hours
Homocysteine (Quantitative) HOMO B 17 1 day
Homocysteine (Urine) HCYS CU 2 weeks
Homovanillic Acid (HVA) HVA PU 5 days
Hyaluronic Acid AHT B 1 week
Hydroxybutyrate Dehydrogenase HBD B (Frozen) 1 week
Hydroxyprolene UHYD CU 2 weeks
* Sample must reach TDL Referrals Dept. urgently, to be tested within 24 hours of collection.
Monday–Thursday only. Referrals to send immediately
Biochemistry
IgG Subclasses IGSC B 4 days

Immunoglobulin A IGA B 4 hours
Immunoglobulin D IGD B 5 days
Immunoglobulin E – Total IGE B 1 day
Immunoglobulin G IGG B 4 hours
Immunoglobulin M IGM B 4 hours
Immunoglobulins (IgG, IgM, IgA) IMM B 4 hours
Insulin-Like Growth Factor 2 IGF2 B6 1 month
Iodide – Urine UIOD RU 1 week
Iodine – Serum IODI B 1 week
Ionised Calcium ICPA B 5 days
Iron (TIBC included) FE B 4 hours
Iron Overload Profile IOP AB 9 3 days
Iron Status Profile ISP B 4 hours
Lactate (Plasma) LACT G 16 1 day
Lactate Dehydrogenase (LDH) LDH B 4 hours
Lactate Pyurvate Ratio LPR J1 4-6 weeks
Lactose Tolerance Test see page 133
LDH lsoenzymes ISOL B 5 days
LDL7 Subfractions LDL7 B 10 days
Lead (Blood) LEAD A 5 days
Lead (Urine) URPB RU 5 days
Leptin LEPT B 19 5 days
Leucine Amino Peptidase LAP B 5 days
Lipase LIPA B 4 hours
Lipid Profile LIPP B 4 hours
Lipoprotein (a) LPOA B 4 hours
Lipoprotein Electrophoresis LEL B 5 days
Lithium (take 12 hours after dose) LITH B 4 hours
Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF B 5-7 days
Liver Fibrosis Fibrotest FIBT B 2 weeks
Liver Function Tests LFT B 4 hours
Lp-PLA2 (PLAC) Test PLA2 B 2 days
Lysosomal Enzyme Screen LE HH 6 2 months
Lysozyme LYSO B 5 days
Magnesium (Serum) MG B 4 hours
Magnesium (Urine) URMG PU 1 day
Manganese (Serum) MANG B 5 days
Mannose Binding Lectin MBL B 3 weeks
Mercury (Blood) MERC A or H 5 days
Mercury (Urine) URHG RU 1 5 days
Methaemoglobin METH A 3 days
Methaqualone METQ RU 5 days
Methylmalonic Acid – Serum MMAS B 5 days

Biochemistry
Methylmalonic Acid – Urine MMA CU 2 weeks

Microalbumin (Urine) UMA RU 4 hours
Mucopolysaccharides MPS RU (Frozen) 3 weeks
Myeloma Screen MYEL A B G RU 5 days
Myoglobin (Serum) SMYO B 4 hours
Myoglobin (Urine) UMYO RU 5-10 days
Newborn Screening Panel GUTH J1 2 weeks
Nickel (Serum) NICK B 5 days
Nickel (Urine) NICU RU 10 days
NMP22 (Bladder tumour) NMP J1 4 days
Oligosaccharides UOLI RU 6 weeks
Orosomucoid (A1AG – Alpha 1 Glycoprotein) OROS B (Frozen) 5 days
Osmolality (Serum) OSMO B 1 day
Osmolality (Urine) ROSM RU 1 day
Osteoporosis Screen OPS BB 4 days
Oxalate (Plasma) POXA A (Frozen) 7 days
Oxalate (Urine) UOXA PU 5 days
Pancreatic Peptide PP J 4 weeks
2ml A Plasma frozen
Parathyroid Related Peptide PTRP 2 weeks
(Freeze immediately) 1
PEth (Phosphatidylethanol) PETH A 38 5-7 days
Phencyclidine (PCP) DUST RU 5 days
Phosphate PHOS B 4 hours
Phosphate (24 hour Urine) UPH PU 4 hours
PLAC Test (Lp-PLA2) PLA2 B 2 days
Plasminogen PLAS C (Frozen plasma) 4 5 days
Plasminogen Activator Inhibitor – 1 PAI1 C (Frozen plasma) 2 weeks
Porphyrin (Blood) PORP A3 15 days
Porphyrins (Faeces) FPOR RF 3 3 weeks
Porphyrins Full Screen (Total:
PORS A RU, RF 3 3 weeks
Urine, Stool, Blood)
Porphyrins Screen (Urine) RPOR RU 3 3 weeks
Potassium K B 4 hours
Pregnancy (Serum) [Quantitative] QHCG B 4 hours
Pregnancy Test (Urine) PREG RU 4 hours
Procalcitonin PCAL B (Frozen) 4,7 1 day
Procollagen 1 Peptide N-Terminal (NTX) P1NP B 5 days
Procollagen III Peptide PRCO B 5 days
Propoxyphene DPRO RU 5 days
Prostatic Acid Phosphatase PACP B (Frozen) 3 days
Protein (Urine) UPRT CU 4 hours
Protein 14.3.3 (Creutzfeldt–Jakob Disease) CJD CSF (Frozen) 5 weeks
Protein Electrophoresis incl. immunoglobin PRTE B 2-4 days
Protein Total (Blood) PROT B 4 hours
Biochemistry
Protein/Creatinine Ratio (Urine) UCPR RU 4 hours

Renal Calculi Screen (Metabolic) RSPR J6 5 days
Renal Stone Analysis RSTA STONE 10 days
Retinol Binding Protein RBP B 3 days
Salicylates SALI B 4 hours
Selenium (Serum) SELE B 4 days
Selenium (Whole Blood) SELR A or H 4 days
Serum Free Light Chains SLC B 1 week
Silver (Blood) SILV B 5 days
Silver (Urine) USIL RU 5 days
Sodium NA B 4 hours
Superoxide Dismutase Inhibitor SODI A/ H 5 days
Thiopurine Methyl Transferase TPMT A5 5 days
Tissue Polypeptide Antigen TPA B 1 week
Total Acid Phosphatase APT B 5 days
Total Bile Acid/Bile Salts BILS B 1 week
Total IgE IGE B 1 day
Transferrin TRAN B 1 day
Transferrin Electrophoresis TREL B 2 weeks
Triglycerides TRI B 4 hours
Trimethylaminuria (Fish Odour Syndrome) FOS PU 6 weeks
Troponin T (High sensitive) TROT B 4 hours
Tryptase STRY B 2 days
Tumour Necrosis Factor – Alpha TNF B (Frozen) 4 2 weeks
Urate (Uric acid) UA B 4 hours
Urea UREA B 4 hours
Urea (Urine) UURE CU 4 hours
Urea and Electrolytes U/E B 4 hours
Urea Electrolytes (Urine) UELE CU 4 hours
Uric Acid (Serum) UA B 4 hours
Uric Acid (Urine) UURI CU 4 hours
Urine Free Light Chains UFLC RU 1 week
Urine Organic Acids UORG RU (Frozen) 3 weeks
Urine Steroid Screen (Steroid Hormones) USTE CU or RU 9 2 weeks
Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks
Urobilinogen (Urine) UURO RU 1 day
Very Long Chain Fatty Acids VLCF A or H (Frozen) 9 4-6 weeks
Vitamin B12 (Active) B12 B 1 day
Vitamin B12 (Active)/Red Cell Folate B12F AB 2 days
Vitamin B12 (Total) TB12 B 1 day
Vitamin D (25-OH) VITD B 4 hours
VLDL Cholesterol VLDL B 13 1 week
VMA UVMA PU 1 5 days

Biochemistry
LIPID PROFILE UREA AND ELECTROLYTES LIVER FUNCTION TESTS
Triglycerides Sodium Bilirubin

Cholesterol Potassium ALT
HDL Cholesterol Chloride AST
LDL Cholesterol Bicarbonate Total Protein
Non-HDL Cholesterol Urea Alkaline Phos
Creatinine Albumin
TAT TAT TAT
Globulin
4 4 Gamma-GT 4
HOURS HOURS HOURS
LIPP U/E LFT
B B B
IRON STATUS PROFILE IRON OVERLOAD PROFILE MYELOMA SCREEN
Iron Iron FBC and ESR

Total Iron Binding Capacity Total Iron Binding Capacity Biochemistry Profile
Ferritin Ferritin TAT Protein Electrophoresis
Transferrin Saturation Transferrin Saturation 4 Immunoglobulins
TAT HOURS
TAT TAT
Haemochromatosis (IgA, lgG, IgM)
4 C282Y, H63D 3 Bence-Jones Protein 5
HOURS DAYS DAYS
ISP IOP MYEL
B AB9 ABG RU
AMI
B A: Myoglobin
20
Multiples of the AMI
B: Cardiac Troponin T (high sensitive)

10
cutoff limit
C: CK-MB
5 C
2 A
1 AMI Decision Limit
D
URL (Upper Reference limit)
0
0 1 2 3 4 5 6 7 14
4 12 16
hrs hrs hrs Days after onset of AMI
Kinetic Characteristics for Chest Pain Markers
Beginning Peak Duration
Myoglobin 0.5–2 hours 5–12 hours 12–24 hours
Troponin T (hs) 3–4 hours 12–24 hours 14 days
CKMB 3–8 hours 10–18 hours 24–36 hours
Troponin T (high sensitive)

This assay can be used to aid in the differential diagnosis of acute coronary syndrome to identify
necrosis, e.g. acute myocardial infarction. As a result of its high tissue‑specificity, cardiac troponin T
is a cardio‑specific, highly sensitive marker for myocardial damage. Cardiac Troponin T (hs) increases
approximately 3‑4 hours after myocardial infarction and may persist for up to 2 weeks.
Biochemistry
BONE SCREEN
BONE SCREEN OSTEOPOROSIS SCREEN
(BLOODS ONLY)
24 hour Urinary Calcium Urea and Electrolytes Alkaline Phosphatase

24 hour Urinary Phosphate LFT’s Calcium
Urea and Electrolytes Calcium Albumin
Alkaline Phosphatase Phosphate Phosphate
Total Protein Vitamin D (25 OH) Serum Crosslaps (DPD)
Albumin Vitamin D (25 OH)
Globulin
TAT TAT TAT
Calcium
4 4 4
HOURS HOURS DAYS
BONE BON2 OPS
B CU B BB
CARDIOVASCULAR RISK PROFILE 1 CARDIOVASCULAR RISK PROFILE 2
Cholesterol Cholesterol
Triglycerides Triglycerides
LDL Cholesterol LDL Cholesterol
Apolipoprotein A Apolipoprotein A
Apolipoprotein B Apolipoprotein B
Lipoprotein (a) Lipoprotein (a)
hsCRP Fibrinogen
Lp-PLA2 (PLAC) Test hsCRP
TAT Lp-PLA2 (PLAC) Test TAT
3 Homocysteine 3
DAYS DAYS
PP10 PP11
BB B B B C 34
CHEST PAIN PROFILE DIABETIC PROFILE 1 DIABETIC PROFILE 2
Myoglobin Glucose Glucose

CK MB Fraction HbA1c HbA1c
Troponin T Microalbumin
TAT TAT
STAT 8 2
HOURS DAYS
CPP DIAB DIA2
B AG AG RU

Haematology
All citrate samples C sent by post or with an overnight delay must be double spun and sent frozen.
Anaemia Profile ANAE AAB 2 days

Antenatal Profile ANTE A A 33 B B B G 3 days
APTT/KCCT KCCT C 18 4 hours
Atypical Antibody Screen
AASC A 22,33 2 days
(handwritten tube label)
Blood Film Examination FILM A 1 day
Blood Group † ABO A 22,33 2 days
Carboxyhaemoglobin CBHB A 1 week
Coagulation Profile 1 CLPF C 18 4 hours
Coagulation Profile 2 CLOT A C 18 4 hours
D-Dimers (Fibrinogen Degradation Products) DDIT C4 4 hours
DVT/Pre-travel Screen DVT1 AAB 9 5 days
ESR ESR A 4 hours
Fibrinogen FIB C 4,18 4 hours
Full Blood Count FBC A 4 hours
Haematology Profile PP3 A 4 hours
Haemoglobin HB A 4 hours
Immune Function Evaluation (Total) TIE A + B 5,10 7 days
INR PTIM C 18 4 hours
Lymphocyte Subsets (CD3/CD4/CD8) LYSS A 10 1 day
Malarial Parasites MALP A 4,9,14 STAT
Mean Cell Volume (MCV) MCV A 4 hours
Microfilaria Blood Film MICF A STAT
Natural Killer Profile 2 NKP2 A 2 days
PAI1 4G/5G Polymorphism PAIP A 10 days
Paul Bunnell (Monospot) PAUL A or B 8 hours
Pre-Travel Screen (DVT) DVT1 AAB 9 5 days
Prothrombin Time PTIM C 18 4 hours
Prothrombin Time + Dose PT+D C 18 4 hours
Reticulocyte Count RETC A 4 hours
Thrombin Time THRO C 18 4 hours
Vitamin K (With PIVKA II) VITK B 13 10 days
†
The tube’s own label must be completed by hand. This must correspond with same name and date of birth
details as given on the request form. Do not affix additional computerised or hand written labels.
Haematology
SPECIAL HAEMOSTASIS
Activated Protein C Resistance APCR C (Frozen) 4,18 3 days

ADAMTS-13 Activity CP13 C (Frozen) 3 days
ADAMTS-13 Antibody A13A C (Frozen) 1 month
Anti-Xa Apixaban monitoring APIX C (Frozen)* 3 days
Anti-Xa Fondapariux Monitoring FOND C (Frozen)* 3 days
Anti-Xa LMWH monitoring LMWX C (Frozen)* 3 days
Anti-Xa Rivaroxaban monitoring RIVA C (Frozen)* 3 days
Antithrombin Ill A111 C (Frozen) 4,9,18 3 days
Factor II Assay FAC2 C (Frozen) 9,18 5 days
Factor V Assay FAC5 C (Frozen) 9,18 5 days
Factor VII Assay FAC7 C (Frozen) 9,18 5 days
Factor VIII Assay FAC8 C (Frozen) 9,18 5 days
Factor VIII Inhibiting Antibody F8IA C C 18 2 weeks
Factor IX Assay F1X C (Frozen) 9,18 5 days
Factor IX Inhibiting Antibody F9IA C C 18 2 weeks
Factor X Assay FX C (Frozen) 9,18 5 days
Factor XI Assay FX1 C (Frozen) 9,18 5 days
Factor XII Assay FX11 C (Frozen) 9,18 5 days
Factor XIII Assay FA13 C (Frozen) 9,18 5 days
Hughes Syndrome LUPA B C 4,18 2 days
Lupus Anticoagulant and Anticardiolipin Abs LUPA B C 4,18 2 days
Lupus Anticoagulant only LUPC C 18 2 days
Miscarriage/Thrombotic Risk Profile PROP A A B C C C 18 5 days
P2Y12 Receptor Platelet Function
P2Y C (Whole blood)** 1 day
Analysis (Clopidogrel Resistance)
Platelet Aggregation Studies PLAG J 5,6 3 days
Protein C PRC C (Frozen) 4,9,18 3 days
Protein S Activity PS1 C (Frozen) 4,9,18 5 days
Protein S Free Ag FPRS C (Frozen) 4,9,18 3 days
Taipan Snake Venom Time TTVT C 18 1 week
Thrombotic Risk Profile PROP A A B C C C 18 5 days
Viscosity (Plasma) VISC A4 3 days
Von Willebrand Profile FVWF C C C 4,12 5 days
Von Willebrands Multimers VWM C C C 18 3 months
* Please state drug and time of dose on request.

** Deliver directly to 60 Whitfield Street, Haemostasis Laboratory

Haematology
SPECIAL HAEMATOLOGY
Coombs (Direct Antiglobulin Test) COOM A 2 days

Erythropoietin ERY B 4 days
G6PD G6PD A 3 days
Haemoglobin Electrophoresis HBEL A 4 days
HFE gene (Haemochromatosis) –
HMD A9 3 days
common mutations C282Y + H63D
Sickle Solubility SSOL A 4 days
Thalassaemia Screen HBEL A 4 days
FLOW CYTOMETRY
Bone Marrow (Aspirate) BMAS J1 14 days

Bone Marrow (Trephine Biopsy) BMI J1 3 days
CD3/CD4/CD8 LYSS A 10 1 day
CD16 CD16 A4 1 day
CD19 B Cells CD19 A4 1 day
CD20 CD20 A 10 2 days
CD25 CD25 A 10 2 days
CD56 CD56 A4 1 day
CD57 CD57 A 1 day
Hams Test for PNH (CD59) HAMS J 34,5 5 days
Leukaemia Immunophenotyping LYPT A 4,5 5 days
Haematology
HAEMATOLOGY PROFILE COAGULATION PROFILE 1 COAGULATION PROFILE 2
FBC + 5 part Diff Prothrombin Time FBC + 5 part Diff

ESR APTT Prothrombin Time
Fibrinogen APTT
Fibrinogen
TAT TAT TAT
4 4 4
HOURS HOURS HOURS
PP3 CLPF CLOT
A C 18 A C 18
ANAEMIA PROFILE PRE-TRAVEL SCREEN (DVT) VON WILLEBRAND PROFILE
FBC + 5 part Diff FBC Von Willebrand Factor

ESR Factor II Prothrombin Gene Von Willebrand Activity
Iron, TIBC Factor V Leiden (Ristocetin Cofactor)
Ferritin Anticardiolipin Factor VIII Assay
B12 (Active) TAT Antibodies TAT TAT
Folate (RBC) 2 5 5
DAYS DAYS DAYS
ANAE DVT1 FVWF
AAB AAB9 C C C 4,12
THROMBOTIC RISK PROFILE ANTENATAL PROFILE NATURAL KILLER PROFILE 2
FBC FBC + 5 part Diff CD3

Coagulation Profile Blood Group and Rh Type CD4
Antithrombin III Atypical Antibody Screen CD8
Factor V Leiden Haemoglobin Electrophoresis CD16/CD56
Common Mutation Syphilis IgG/IgM CD19
Factor II Prothrombin Glucose
TAT
Common Mutation FT4/TSH
MTHFR Common Variants Rubella Antibodies (IgG) 2
DAYS
Lupus Anticoagulant Toxoplasma (IgG/IgM)
Protein C Hepatitis B sAg NKP2
Free Protein S Ag Hep C Abs
Anticardiolipin Abs Varicella Zoster IgG (Immunity) A
HIV 1 & 2 Abs
TAT
3
DAYS
Please ensure the blood
TAT
group (EDTA) tube label is
HANDWRITTEN. Do not affix
5 a secondary label.
DAYS
PROP ANTE
A A B C C C 18 A A 33 B B B G

Microbiology
16S rRNA Bacterial Gene 16S J 1 week

18S rRNA Fungal Gene 18S J 1 week
Aspergillus Precipitins ASPP B 5 days
Beta D Glucan XBDG B 3 days
Blood Culture# BCUL 2 x BC 4 6 days +
Campylobacter Jejuni Antibodies CJAB B 5 days
Candida (Culture) CANC STM / CS 2-4 days
Candida Antibodies CANA B 5 days
Candida Antigen CCAG B 5 days
Carbapenemase producing
MDR STM (rectal) 4-5 days ‡
organism screen
Clostridium Difficile Toxin by PCR CLOS RF* 2 days
Cryptococcal Antigen CRYC Serum or CSF 1 day
Cryptosporidium CRPO RF 2 days
CSF for Microscopy and Culture CSF CSF 1-3 days
Culture (Any site) CULT up to 5 days
Faecal Occult Blood/FOB
QFIT QFIT 1 day
(immunochemical/FIT)
Fluid Culture FLUD SC 2-7 days
Fluid for Crystals FLU2 SC 1 day
Fungal ID + Sens FUID Fungal sample / STM 14 days
Fungal investigations
(superficial/dermatophyte DERM Skin, Hair, Nails 3-7 days
PCR test) – see page 48
Fungal investigations
All specimens other than
(non-superficial extended FUN From 3 days
Skin, Hair and Nails
culture) – see page 48
Galactomanan
SGAL B 2 weeks
(Aspergillus Antigen)
Gonorrhoea (Culture) GONN CS ‡‡‡ 2-3 days
Group B Strep GBSX 2 x STM 3-4 days
H. pylori Antigen (Stool) HBAG RF 3 days
H. pylori Culture HPCU J 3 weeks
HVS HVS STM / CS ‡‡‡‡ 2-4 days
IUCD for Culture IUCD Send Device 11-12 days
Legionella Urine Antigen LEGA RU 1 day
# Please contact the Phlebotomy at Patient Reception 020 7307 7383 for further details, as needed.
Blood cultures must be taken prior to any other blood samples.
The aerobic bottle must be collected first, followed by the anaerobic bottle.
Each bottle should be filled with 8-10 ml of blood, use the markings on the bottles to achieve this.
• Other bloods can be collected but must be collected after the blood cultures.
• Bottles must be labelled with the patient’s identification details.
• Bottles and Request Form need to give the time taken and the body site that the blood was taken from.
Ensure that the bottle barcodes are not obscured when adding patient labels.
• Send the blood cultures to the laboratory without delay.
Microbiology
MRSA (Rapid PCR) one

MRSA Blue Micro Swab 4 hours
swab per site
MRSA Culture one swab per site MRSW Blue Micro Swab 2 days
Mycology/Skin Scrapings by PCR DERM Submit Sample 3-7 days
Nail Clippings DERM Nail clippings 3-7 days
Pleural Fluid for Culture FLUP SC 7 days
Pneumococcal Antigen PNAG RU 1 day
Pneumocystis Jiroveci
PCYS BAL ‡‡ 2-3 days
(PCP) Examination
Prostatitis Screening Panel VB1U + VB2U + EPS
NEW PROS 4-5 days
– see page 44 for sample details or EPSW + VB3U
Rapid Strep (incl. m/c/s) RAPS STM** 1-3 days**
Mid-morning terminal urine
Schistosoma (Urine) USCH 1-2 days
following exercise 14
Sellotape Test SELL Send Sample*** 1 day
Semen Culture SPCU Semen 2-4 days
Skin Scrapings/Mycology by PCR DERM Send Sample 3-7 days
Specific Gravity (Urine) USG RU 24 hours
Sputum for Routine Culture SPU1 SC 2-4 days
Sputum for TB Culture (AFB) SPU2 SC up to 8 weeks
Stool for OCP and Culture PENT RF 2-3 days
Stool for OVA Cysts &
OCP RF 1 day
Parasites by PCR
Stool Reducing Substances STRS RF 7 5 days
Swab (Cervical) CERS STM / CS 2-4 days
2-4 days (Culture)
Swab (Ear) EARS STM 8-9 days (Fungal) –
same swab
Swab (Eye) EYES STM 2-4 days
* Not performed on formed stool specimens.

** Do not use a black swab for RAPS. Use Blue only. Rapid antigen is reported within 4 hours with full culture to follow.
*** Use clear Sellotape only and attach to slide.
**** Culture techniques have been discontinued, please send PCR (see Sexual Health section for full details).
‡
Presumptive positive isolates will be sent to the PHE reference laboratory for confirmation.
‡‡
BAL: Induced sputum or bronchoalveolar larage.
‡‡‡
The optimal sample type from the female genital tract is an endocervical swab. Gonorrhoea does not survive
well outside the endocervical epithelium; a negative gonorrhoea culture result from a vaginal swab is not reliable
for excluding infection.
‡‡‡‡
Culture for Mycoplasma, Ureaplasma and Trichomonas vaginalis has been discontinued due to the superiority of molecular
methods. If investigations for Mycoplasma genitalium, Ureaplasma or Trichomonas vaginalis are required please request
PCR testing (see Sexual Health section).
†
Please state site of swab collection on both request form and swab label.
††
Please provide relevant travel history. If travel history is not provided, stool will be investigated for endemic pathogens
only [Campylobacter, Salmonella, Shigella, Shigatoxin-producing E coli (VTEC), Cryptosporidium and Giardia].
†††
If prosthetic joint is present please state in clinical details to ensure that enrichment culture is prolonged for 14 days.
††††
Optimal sample type for urine culture is a mid-stream clean catch urine sent in a sterile pot containing boric
acid preservative.

Microbiology
Swab (Nasal) NASS STM 2-4 days

Swab (Oral) ORSW STM / CS 2-4 days
Swab (Penile) PENS STM / CS 2-4 days
Swab (Rectal) RECG STM / CS 2-4 days
Swab (Skin) SKIS STM 2-4 days
Swab (Throat) THRS STM 2-4 days
Swab (Urethral) URES STM / CS 2-4 days
Swab (Vaginal) VAGS STM / CS 2-4 days
Swab (Vulval) VULV STM / CS 2-4 days
Swab (Wound) WOUS STM 2-4 days
Synovial Fluid (for microscopy
FLU2 SC ††† 14 days
and culture)
TB (pleuralfluid) TBCU SC up to 8 weeks
TB Culture SPU2 SC up to 8 weeks
TB Culture (Urine) TBUR 3 x EMU up to 8 weeks
TB Slopes – Confirmation
TBSL TB slope (LJ medium-green) 6 up to 8 weeks
and Sensitivity
Tissue for culture TISS Tissue sample up to 14 days
Urine (Microscopy Only) UMIC RU 1 day
Urine for Extended Culture
NEW – Request from outset, UCXD MSU up to 7 days
not as an add on
Urine for Microscopy and Culture UCEM MSU †††† 1-2 days
PROSTATITIS SCREENING PANEL
Sample types:
VB1U: first-pass urine (pre-prostatic massage)
VB2U: mid-stream urine (pre-prostatic massage)
EPS: expressed prostatic secretion fluid
or
EPSW: expressed prostatic secretion fluid swab
VB3U: first-pass urine (post-prostatic massage)
Please clearly label each sample individually

BY CODE – send to the laboratory
in one sample bag TAT
NEW
2022 4-5
DAYS
PROS
VB1U + VB2U + EPS or EPSW + VB3U
Microbiology
URINE CULTURE PROCESSING AND RESULTS
All urine culture testing is performed using manual methods. The culture pathway adheres to national guidance
and is a fully UKAS-accredited method.
Manual testing allows a larger amount of urine to be tested than previous automated method, which enables the
laboratory to detect lower bacterial counts (as low as 103 cfu/mL) and also facilitates the follow up of significant
organisms grown from mixed cultures.
If the culture result is indicative of urinary tract infection, antibiotic susceptibilities will be tested from the
culture growth and will be available 24 hours after the culture result. ‘Direct sensitivities’ are no longer performed.
Direct susceptibility testing is not inoculum-controlled, produces inaccurate results and is not UKAS-accredited.
Culture results should be interpreted alongside the microscopy WBC count and clinical signs and symptoms.
Significant growth on culture in the absence of pyuria may be suggestive of contamination with regional flora
rather than true infection. It should be noted, however, that WBC degrade in urine quite rapidly and delays between
sample collection and microscopy may lead to falsely low WBC readings which may account for these findings.
What does the result ‘No significant growth’ mean?

The amount of growth falls below the threshold for urinary tract infection (< 103 cfu/mL).
There is no laboratory evidence of urinary tract infection.
Occasionally, this may be seen in very early stages of infection or in a partially treated urinary tract infection.
Therefore, please send a repeat specimen if symptoms persist.
What does the result ‘mixed growth doubtful significance’ mean?

This means that the culture revealed a heavy growth of at least 3 organisms with no predominating organism;
this represents contamination of the urine with the patient’s flora during collection.
This result does not exclude urinary tract infection but it is not possible to determine the causative organism
among the mixture of organisms.
If symptoms persist, please send a repeat urine specimen and ensure that patient understands optimal
collection technique.
If you are receiving a lot of ‘mixed growth of doubtful significance’ results, please consider the following:
• The instructions that patients are given to collect their urine sample
Poor collection technique is the most common reason for a heavily mixed growth in a urine sample.
It is almost impossible to collect a urine sample without any contamination from the normal bacterial flora
which inhabits the area surrounding the urethral opening, but optimal collection technique will minimise
this contamination and allow the true infective cause to stand out and be identified (a patient instruction
leaflet is available).
• Delays between sample collection and laboratory processing
The time between sample collection and laboratory processing can allow small amounts of contaminating
bacterial flora to multiply up to higher amounts prior to laboratory testing, which can result in heavy mixed
growth of bacteria on culture. Using a red topped specimen pot containing boric acid preservative will
minimise this.

Microbiology
RED TOPPED BORIC ACID CONTAINERS
The preservative reduces the overgrowth of organisms and, to a lesser extent, reduces the degradation
of white cells during transit leading to a more accurate laboratory result for both microscopy and culture.
UKAS recommends the use of boric acid containers for all urine sample for microscopy and culture
(Urine M,C&S) to improve the quality of microbiological results.
Red topped boric acid containers are for requests for urine microscopy and culture
(MC&S) ONLY. Boric acid container should NOT be used for:
• Other urine microbiology tests (e.g. investigations for Chlamydia, Mycobacterium,
Schistosomiasis, urinary antigen testing)
• Urine samples being analysed by PCR methodology
• Urine samples for non-microbiology tests (e.g. biochemistry, virology, pregnancy testing)
• Very small urine volumes (<20ml) e.g. neonates
Use of urinary dipsticks: boric acid may inhibit leukocyte esterase dipstick readings; dipstick testing
performed on a sample in a boric acid container should be interpreted with caution.
If additional tests are required in addition to urine microscopy and culture, an additional sample in
a white-topped universal container should be sent. In this case, it is advised that the mid-stream
clean catch urine is collected in a sterile bowl and then transferred to the necessary specimen containers.
If, despite these measures, a patient has recurrent mixed growth reports from multiple urines, it may suggest that
your patient has abnormal urinary tract architecture, immunosuppression or other non-infective cause that requires
different laboratory investigations or referral to a specialist. If further information is required, please telephone the
laboratory and ask to discuss the case with one of our consultant Microbiologists.
Microbiology
Swabs: Types and Codes
Patient Request Forms AND Swabs should be labelled with the body site from which the sample
was taken. This is important. The swab site determines the appropriate culture media required
to target the most likely pathogens.
SITE CODE SAMPLE TYPE
Culture Swabs
Candida Only Swab CANC Black or Blue Micro Swab
Cervical Swab CERS Black or Blue Micro Swab
Blue Micro/Transwab
Ear Swab EARS Blue or Orange Micro Swab are multipurpose, culture
Eye Swab EYES Blue or Orange Micro Swab swabs in transport medium
Gonorrhoea GONN Black Charcoal Swab
Orange Micro/Transwab
High Vaginal Swab HVS Black or Blue Micro Swab are small, thin wire culture
Nasal Swab NASS Blue or Orange Micro Swab swabs in transport medium
Oral Swab ORSW Black or Blue Micro Swab Black Charcoal
Penile Swab PENS Black or Orange Micro Swab Micro/Transwab
Rectal Swab RECG Black or Blue Micro Swab Wound, skin and urogenital.
Skin Swab SKIS Blue Micro Swab
Throat Swab THRS Blue Micro Swab
Urethral Swab URES Black or Orange Micro Swab
Vaginal Swab VAGS Black or Blue Micro Swab
Vulval Swab VULV Black or Blue Micro Swab
Wound Swab WOUS Black or Blue Micro Swab
MRSA by Culture MRSW Blue Micro Swab x 1 – state site

MRW2 Blue Micro Swab x 2 – state sites
RAPIDThis
Note: MRSAPCRby PCR MRSA Blue Micro Swab x 1 – state site
methodology uses MRS2 Blue Micro Swab x 2 – state sites
Blue Micro Swabs MRS3 Blue Micro Swab x 3 – state sites
MRS4 Blue Micro Swab x 4 – state sites
MRS5 Blue Micro Swab x 5 – state sites

Microbiology
PCR METHODS FOR THE DETECTION OF DERMATOPHYTE FUNGAL CULTURES
The detection of Dermatophyte fungal cultures uses High Sensitivity PCR testing. This reduces the overall
turnaround time by up to three weeks, and increases the detection of fungal infection compared to combined
microscopy and culture. Furthermore the specific targeting pathogens associated with superficial fungal infection
is increased which assists in preventing the over reporting of insignificant fungi that are contaminants.
FUNGAL TEST CODES
Investigation of Investigation of
Superficial Fungal Infection Non-Superficial Fungal Infection
Test Code DERM* FUN*
Sample type Nail, Hair, Skin. All specimens other than Skin, Hair and Nail.
72 hours for interim PCR report, and 7 days 7 days (non-sterile e.g. ear swab)
Turnaround
for final culture (unless the fungal culture and 3 weeks (sterile i.e. CSF).
time
needs to be extended for significant growth).
• Dermatophyte PCR is replacing microscopy • Non-sterile specimen fungal cultures

for Nails, Hair and Skin (72 hour TAT). are performed on Sabouraud’s agar
• Non-dermatophyte culture will take plates for 7 days with no microscopy.
Notes 7 days rather than 3 weeks. • Sterile specimen fungal cultures have
• Microscopy will be used to confirm significance microscopy (Calcafluor) reported on
of rare fungi that may cause infections. the day of processing and culture on a
Sabouraud’s agar slope, incubated for
• There is no change in the price of this test. 21 days.
STOOL TEST CODES

Traditional culture methods have been replaced by Real Time PCR for enteric pathogen testing.
The benefits are increased sensitivity and a higher detection rate. Once received and processed in
the microbiology lab, negative results will be available within 24 hours. Positive results will be followed
up with culture and sensitivities for final reporting.
STOOL OCP AND CULTURE

Sample Please request as PENT Comments
Type
Stool Serosep EntericBio PCR All stool samples will be tested for UK Pathogens.
Bacteria/Bacterial Toxins Overseas pathogens will only be tested if specifically requested
• Salmonella • Campylobacter and travel history and clinical details are provided. Samples that
are positive for the bacterial pathogens will be cultured to provide
• Shigella • VTEC
sensitivities and, if indicated, for PHE referral.
Parasites
Samples will be kept for 7 days after receipt to allow
• Cryptosporidium • Giardia
for additional testing if required.
Microbiology
STOOL FOR OCP
Sample Please request as OCP Comments
Type
Stool Requests for OCP only will include Overseas pathogens will only be tested if requested
testing for cryptosporidium and and travel history and clinical details are provided.
giardia by PCR
C. DIFFICILE DETECTION
Sample Please request as CLOS Comments
Type
Stool Serosep Enteric Bio PCR Change to PCR and Elisa methods.
Alere Techlab EIA (Toxin) Two tier PCR & Toxin c. diff screening based on PHE guidance.
Improved sensitivity and specificity for both targets tested.
Primary c. diff gene screening using Enteric Bio PCR.
Secondary sequential testing using Alere EIA to confirm Toxin.
GASTRO VIRUS DETECTION (INCLUDING ROTAVIRUS) SEE VIROLOGY
ENTERIC ORGANISM RAPID DETECTION SEE VIROLOGY

Microbiology
GROUP B STREPTOCOCCUS (GBS)
Group B Streptococcus (GBS or group B Strep) is the most common cause of severe infection
in newborn babies, and of meningitis in babies under age 3 months. On average in the UK:
• 2 babies a day develop group B Strep infection
• 1 baby a week dies from group B Strep infection
• 1 baby a week survives group B Strep infection with long term disability
Most GBS infection is of early onset, presenting in babies within the first 6 days of life, and usually
within the first 12 hours after birth. Between age 7 days and 3 months, these infections are rare,
and in babies over 3 months they are very rare indeed.
Most early-onset GBS infections (in babies aged 0-6 days) can be prevented by giving intravenous
antibiotics in labour to women whose babies are at raised risk of developing GBS infection.
In the UK, women are offered IV antibiotics in labour based on specific risk factors.
GBS is normal flora of the distal GI tract. Up to 30% of women carry it harmlessly in their vaginal tract.
Vaginal carriage at the time of vaginal delivery can result in transmission of GBS to baby. Babies are
more vulnerable to infection as their immature immune systems cannot fight off the multiplying bacteria.
If untreated, GBS can cause serious infections, such as meningitis and septicaemia, which may lead
to stillbirths, and newborn and infant deaths. If they survive, babies can develop permanent problems
including hearing or vision loss, or cerebral palsy.
Current GBS prevention focuses on giving intravenous antibiotics to women in labour, aiming to reduce
disease in infants at delivery. 2 x Blue culture swabs (lower vaginal and lower rectal) should ideally
be taken from 35 weeks. Swabs will be placed in enrichment culture in the microbiology laboratory
to ensure maximal detection.
Endocrinology
11 Deoxycorticosterone DEOX B 10 days

11 Deoxycortisol 11DC B (Frozen) 10 days
17 Hydroxyprogesterone 17OH B 5 days
ACTH (Adreno Corticotrophic Hormone) ACTH A (Plasma Frozen) 41 1 day
Aldosterone ALDN A or B 5 days
Aldosterone (Urine) UALD PU 5 days
Alpha Feto Protein AFP B 4 hours
Amenorrhoea Profile AMEN B 4 hours
Andropause Profile ANDP BB 8 hours
Androstenedione ANDR B (Frozen) 4 days
Antidiuretic Hormone ADH A A (Plasma Frozen) 4 10 days
Antimullerian Hormone (AMH Plus) AMH B 4 hours
Beta HCG (Quantitative) QHCG B 4 hours
BNP (NT-pro BNP) BNP B 4 hours
C Peptide CPEP B 3 days
Calcitonin CATO B (Frozen) 4 1 day
Catecholamines (Plasma) CATE A A (Plasma Frozen) 4 5 days
Catecholamines (Urine) UCAT PU 1 5 days
Cortisol CORT B 4 hours
Cortisol (Urine) UCOR CU 5 days
DHEA DHEX B 7-10 days
DHEA – Urine (Dehydroepiandrosterone) UDHE CU 3 weeks
DHEA Sulphate DHEA B 4 hours
Dihydrotestosterone DHT BB 7 days
Down Syndrome Risk Bloods only HCGF/
B 4 hours
(Risk to be calculated by clinician) PAPA
Down Syndrome Risk Profile
DRP B DRP form 7,8 2 days
(2nd trimester) Quad
Down Syndrome Risk Profile with B DRP form +
DRP 2 days
risk calculation first trimester image of scan 7,8
Erectile Dysfunction Profile IMPO ABBG 3 days
Female Hormone Profile FIP B 4 hours
First Trimester Antenatal Screen (Risk HCGF/
B 4 hours
to be calculated by requesting clinician) PAPA
Free Cortisol (Urine) UCOR CU 5 days
Free T3 FT3 B 4 hours
Free T4 FT4 B 4 hours
FSH FSH B 4 hours
Growth Hormone (Fasting) GH B 7,35 4 hours
A A (Frozen within
Gut Hormone Profile GUTP 3 weeks
15 minutes) 41
Hirsutism Profile HIRP B 4 hours
HRT Profile 1 HRT B 4 hours
HRT Profile 2 HRT2 BG 4 hours

Endocrinology
IGF-1 (Somatomedin) SOMA B (Frozen) 4 1 day

IGF-BP3 IGF3 B (Frozen) 4 5 days
Impotence Profile IMPO ABBG 3 days
Inhibin A INIA B 1 month
Inhibin B INIB B (Day 3 of cycle, frozen) 5 days
Insulin INSU B 4 hours
Insulin Resistance (Fasting) FIRI BG 4 hours
Luteinising Hormone (LH) LH B 4 hours
Macroprolactin PRLD B 4 days
Male Hormone Profile MIPR B 4 hours
Melanin MELA RU 13 5 days
Melatonin (Serum) MEL B (Frozen) 5 days
Melatonin (Urine) UMEL CU 13 2 weeks
Menopause Profile MENO B 4 hours
Metabolic Syndrome Profile METS ABBG 9 days
Metanephrines (Plasma) PMET A (Frozen plasma) 7 days
Metanephrines (Urine) UMEX PU 1 5 days
Oestradiol (E2) OEST B 4 hours
Oestriol (Estriol) E3 BB 4 days
Oestrone E1 BB 4 days
Osteocalcin OST B (Frozen) 4 4 days
Parathyroid Hormone (Whole) PTHI B4 1 day
Pituitary Function Profile PITF BB 1 day
Polycystic Ovary Syndrome Profile PCOP ABBBG 7 5 days
Polycystic Ovary Syndrome SHORT PCOS BG 4 hours
Pregnancy (Serum) [Quantitative] QHCG B 4 hours
Pregnanetriol (Urine) UPTR CU (Frozen) 5 days
Pregnenolone PREN B 15 days
Progesterone PROG B 4 hours
Proinsulin PROI A (Frozen plasma) 4 5 days
Prolactin PROL B 4 hours
Prolactin (Macro) PRLD B 4 days
Renin RENI A (Frozen plasma) 36 5 days
Reverse T3 RT3 B 7,37 10 days
Serotonin SERT H (Frozen whole blood) 1 10 days
Serotonin (Urine) USER PU 50mls (Frozen) 1 5 days
Sex Hormone Binding Globulin SHBG B 4 hours
Somatomedin (IGF-1) SOMA B (Frozen) 4 1 day
T3 T3 B 4 hours
T3 (Reverse) RT3 B 7,37 10 days
Testosterone TEST B 4 hours
Testosterone (Bioavailable) BTES B 5 days
Testosterone (Free) FTES B 3 days
Endocrinology
Thyroglobulin Abs TGAB B 1 day

Thyroglobulin Assay TGA B 1 day
Thyroid Abs (incl. Thyroglobulin
THAB B 1 day
+ Thyroid Peroxidase Abs)
Thyroid Peroxidase Antibodies/Anti TPO TPEX B 1 day
Thyroid Profile 1 TF B 4 hours
Thyroid Profile 2 TF2 B 2 days
Thyroid Profile 3 TF3 B 4 hours
Thyroxine (T4) T4 B 4 hours
Thyroxine Binding Globulin TBG B (Frozen) 10 days
TSH TSH B 4 hours
TSH-Receptor Antibodies TSI B 4 days

Endocrinology
REPRODUCTIVE IMMUNOLOGY AT
ROSALIND FRANKLIN LABORATORIES, CHICAGO, USA
Endometrial Biopsy Immune Profiling 23RF J (Contact Referrals) 2 weeks

Reproductive Immunophenotype Panel 3RF HHH 1 week
NK Assay/Cytotoxicity Panel 4RF HHH 1 week
NK Assay Follow-Up Panel 5RF HHH 1 week
TH1/TH2 Cytokine Ratio 6RF HHH 5 1 week
Leucocyte Antibody Detection Panel MALE 7RF H H H 3,4,6 1 week
Leucocyte Antibody Detection Panel FEMALE 8RF B 1 week
HLA DR Antigens 9RF AA 2 weeks
HLA DQ Alpha Antigens 10RF AA 2 weeks
HLA DQ Beta Antigens 11RF AA 2 weeks
NK Assay Panel + Intralipids 16RF HHH 1 week
KIR (Killer-like Immunoglobulin-
17RF AAA 2-3 weeks
like Receptors) Genotyping
TH1/TH2 Intracellular Cytokine
20RF HHH 5 1 week
Ratios with IVIG, Prednisolone
TH1/TH2 Intracellular Cytokine Ratios with IVIG 21RF HHH 5 1 week
22RF HHH 5 1 week
Ratios with Prednisolone
T Regulatory Cells 25RF H 3 days
Patients who have samples taken at TDL’s Patient Reception at 76 Wimpole Street may attend any time
during hours of opening on Mondays or Tuesdays, and by NOON on Wednesdays to allow for same day
shipping to Chicago by Fed Ex. Samples for Rosalind Franklin are not accepted on Thursdays, Fridays
or Saturdays. Fed Ex charges are included in these charges.
Endocrinology
REPRODUCTIVE IMMUNOLOGY AT
ST HELIER, CARSHALTON
NK (CD69) Cell Assay CD69 H* Send Mon-Thurs only

NK Cytotoxicity Assay HSNK HHH* Send Mon-Thurs only
NK (CD69) and NK Cytotoxicity 69C HHH* Send Mon-Thurs only
NK Cytotoxicity with suppression,
NKCY HHH* Send Mon-Thurs only
steroid, IVIg & Intralipin
NK Cytotoxicity with suppression
with steroid, IVIg and intralipin, 69CI HHH* Send Mon-Thurs only
and NK (CD69) cell assay
TH1/TH2 Cytokine Profile 1TH2 HHH* Send Mon-Thurs only
Suppression with steroid, IVIg and intralipin,
NCIT HHH* Send Mon-Thurs only
NK (CD69) cell assay, TH1/TH2 cytokines
* Patients need to attend Patient Reception at 76 Wimpole Street by 11.00am latest Mondays –
Thursdays. Samples cannot be accepted on Fridays, Saturdays or Sundays. Allow 2 days for results.

Endocrinology
THYROID PROFILE 1 THYROID PROFILE 2 THYROID PROFILE 3
FT4 T4 FT3
TSH TSH FT4
Free T3 TSH
Free T4
TAT Thyroglobulin Abs TAT TAT
4 Thyroid Peroxidase 2 4
HOURS DAYS HOURS
TF TF2 TF3
B B B
FEMALE HORMONE PROFILE MALE HORMONE PROFILE ANDROPAUSE PROFILE
LH FSH DHEAs
FSH LH FSH
Prolactin Testosterone Testosterone
Oestradiol (17-Beta) Free Androgen Index Free Androgen Index
TAT TAT TAT
Prolactin LH
4 SHBG 4 SHBG 8
HOURS HOURS HOURS
FIP MIPR ANDP
B B BB
ERECTILE DYSFUNCTION/
ANTIMULLERIAN HORMONE (AMH PLUS)
IMPOTENCE PROFILE
Lipid Profile Age related reference Age Range Elecsys AMH
Glucose intervals in women (pmol/L)
HbA1C The reference intervals below
TSH 20 – 29 years 13.1 – 53.8
are derived from a population
Prolactin 30 – 34 years 6.8 – 47.8
of apparently healthy women
Total Testosterone not taking any contraceptive 35 – 39 years 5.5 – 37.4
Free Testosterone medication. The reference 40 – 44 years 0.7 – 21.2
PSA intervals represent the 10th –
SHBG 45 – 50 years 0.3 – 14.7
90th percentile values for the
Free Androgen Index women in each age bracket.
TAT TAT
3 4
DAYS HOURS
IMPO AMH
ABBG B Samples can be taken, at any time during a patient’s monthly cycle. Ambient, unspun
sample stability has been validated for up to 5 days. Postal samples are therefore
acceptable, and samples can also be collected and posted using TDL TINIES.
More Hormone Profiles
are shown on page 52
Endocrinology
HRT PROFILE 1 HRT PROFILE 2 AMENORRHOEA PROFILE
FSH Lipid Profile FSH LH

Oestradiol (17-Beta) Glucose OEST FSH
Progesterone TAT
FT4 TAT
Prolactin TAT
TSH Oestradiol (17-Beta)
4 4 4
HOURS HOURS HOURS
HRT HRT2 AMEN
B BG B
POLYCYSTIC OVARY
METABOLIC SYNDROME PROFILE PITUITARY FUNCTION PROFILE
SYNDROME: SHORT
Lipid Profile TSH Testosterone
Glucose FSH SHBG
HbA1C LH FAI
Insulin Prolactin FSH
hsCRP TAT Growth Hormone LH
Adiponectin 9 Cortisol Glucose
DAYS
Please provide details of time Insulin
METS of day sample is taken. Lipid Profile
TAT
Patient should be FT4/TSH
resting for 30 mins 4
ABBG before sample taking. TAT
HOURS
1 PCOS
DAY
MENOPAUSE PROFILE
PITF BG
FSH
LH
BB POLYCYSTIC OVARY
Oestradiol (17-Beta) SYNDROME PROFILE
TSH TAT FIRST TRIMESTER Testosterone A fasting
FT4 4 SCREENING BLOODS ONLY TSH 9.00am sample
HOURS (Risk to be calculated is recommended.
by requesting clinician) Glucose
MENO HbA1C
Free β-hCG FSH
B PAPP-A DHEAs
Free β-hCG and PAPP-A in serum and
Insulin
sonographic determination of nuchal LH
HIRSUTISM PROFILE translucency (NT) are markers of 17 Hydroxyprogesterone
choice to identify women at increased Lipid Profile
FSH risk of Down Syndrome during the first
Prolactin
LH trimester (week 11-13) of pregnancy.
Cortisol
Testosterone Antimullerian Hormone
DHEAs Androstenedione
TAT TAT TAT
SHBG
4 4 SHBG 5
HOURS HOURS DAYS
HIRP HCGF / PAPA PCOP
B B ABBBG7

Reproductive health
The tests in this section are drawn from all disciplines of diagnostic pathology and are listed in other
appropriate sections in the Laboratory Guide.
PUBERTY
The beginning of the reproductive

cycle of life – diagnosis tests
may include: LH
• Oestradiol Oestradiol
• FSH FSH
• LH Progesterone
• Progesterone
• Androstenedione
• DHEA sulphate
• Testosterone
• SHBG Day1 Day 14 Day 28
Menstruation Ovulation Menstruation
• Prolactin
Follicular Phase Luteal Phase
THE MENSTRUAL CYCLE/PREGNANCY
This cycle controls female fertility and is influenced by hormone levels which impact bone health and
many other aspects of female physiology. Pregnancy lasts 40 weeks and is divided into trimesters.
First Trimester (week 0–13): confirmation of pregnancy and associated tests may include:
• Pregnancy test (urine)
• Quantitated Beta HCG (serum)
• Ectopic Pregnancy assessment (Beta HCG and Progesterone)
• Recurrent Miscarriage Profile
• Antenatal Screen
• Nuchal Scan with Free Beta HCG and PAPP-A or Non-Invasive Prenatal Test (Harmony)
for risk assessment of Downs Risk (a DRP request form must be enclosed with samples,
see back of guide, and an image of the scan attached to the request form).
Contact TDL Genetics for details of Non-Invasive Prenatal Testing (NIPT)
• Chorionic Villus Sampling (CVS) for chromosomal analysis
(PCR for Rapid Trisomy and karyotyping for the rarer abnormalities)
• Toxoplasma/Varicella Zoster/Parvovirus/CMV
Reproductive health
Second Trimester (week 14–26): Third Trimester (week 27–40):
testing is primarily directed at evaluating the testing for foetal wellbeing and the health
actual and potential development of the baby of the mother may include:
and may include: • Glucose and Protein (urine or serum)
• Downs Risk Profile (Triple Test +) • Toxoplasma
• Amniocentesis for chromosomal analysis • Atypical antibody screening
(AmnioPCR for Rapid Trisomy and karyotyping
• Group B Strep (From 35 weeks –
for the rarer abnormalities)
rectal and low vaginal swabs)
• Glucose and Protein (urine or serum)
• Chlamydia
INFERTILITY
Infertility and its management is increasingly implicated in growing numbers of clinical disciplines.
More recently, greater emphasis is being given to male infertility. Recent data suggests that approximately
40% of all infertility is ascribed entirely, or in part, to male factors, 40% to female factors with an
additional 20% unexplained. Testing at the outset of infertility treatment can reduce some of the
emotional and financial costs, as well as allowing couples to pursue other possible options.
• Hormones • Infection
• Lifestyle/Environmental • Chromosomes/Genetics
• Ovarian Reserve • Polycystic Ovary Syndrome
• Unexplained Infertility/Implantation failure • Recurrent/Spontaneous miscarriage
• Male Factors
AGEING
Reaching menopause and andropause is a gradual process with modulating hormones as ovarian
function declines in women, and the more gradual, less defined and highly variable effect in men.
Testing may include:
• Hormones (Menopause/Andropause Profile)
General patterns of age-related decline
• Testosterone/Free testosterone/
in estradiol levels in women (left)
Bioavailable Testosterone and total testosterone levels in men (right)
• SHBG
• DHEAs
• Thyroid function
• Osteoporosis/Bone Markers

Reproductive health
INFERTILITY
HORMONES
FEMALE MALE
FSH – day 2/3 Testosterone/Prolactin/FSH/LH
LH Sex Hormone Binding Globulin
Oestradiol Inhibin B (male)
Antimullerian Hormone (AMH) Male Hormone Profile
Progesterone – day 21 Andropause Profile
Female Hormone Profile Insulin Resistance
Prolactin Erectile Dysfunction
Impotence Profile
INFECTION
FEMALE MALE
High Vaginal swab Investigations for prostatitis/urethritis
Cervical swab Mycoplasma Genitalium
Bacterial Vaginosis screen Ureaplasma
Toxoplasma Chlamydia/Gonorrhoea
Chlamydia/Gonorrhoea Chlamydia in Semen
CMV Hep B sAg/Hep B Core Abs/Hep C/HIV 1&2
Syphilis Herpes Simplex I/II by PCR
Hep B sAg/Hep B Core Abs/Hep C/HIV 1&2 Semen culture
Herpes Simplex I/II by PCR Syphilis
STI Profiles STI Profiles
Infection screening by PCR Infection screening by PCR
LIFESTYLE /ENVIRONMENT
FEMALE MALE
Well Person Profile DL6 Fit for Fertility Male Profile
Zinc, Lead Well Person Profile DL6
Trace Metal Profile (blood) Trace Metal Profile (blood)
Antioxidant Activity Antioxidant Activity
Thyroid Profiles Thyroid Profiles
Vitamin Profiles Vitamin Profiles
Vitamin D (25 OH) Vitamin D (25 OH)
Folate Folate
Selenium Selenium
Omega 3/Omega 6 Zinc
Omega 3/Omega 6
Oxidative Stress (ROS) in Semen
Reproductive health
CHROMOSOMES/GENETICS
FEMALE MALE
Chromosome/Karyotype (parental) Chromosome/Karyotype (parental)
Fragile X (female) Male Hormone Profile
Cystic Fibrosis Screen Y-Chromosome microdeletion
Tay Sachs Fragile X Male
Carrier Screen (Ashkenazi Jewish) Screen Cystic Fibrosis Screen
Inherited disorders (specific) Tay Sachs
Carrier Screen (Ashkenazi Jewish) Screen
Inherited disorders (specific)
OVARIAN TUMOUR
FEMALE
Antimullerian Hormone (AMH) CA 125 / HE4
POLYCYSTIC OVARY SYNDROME

FEMALE
Polycystic Ovary Profile
UNEXPLAINED INFERTILITY/IMPLANTATION FAILURE

/RECURRENT MISCARRIAGE
FEMALE MALE
Recurrent Miscarriage Profile Chromosome/Karyotype (parental)
Reproductive Immunophenotyping Y-Chromosome microdeletion
(CD 3/4/8, CD 5/19, CD 16/56/69) Sperm DNA Fragmentation
NK Cell Profile Sperm aneuploidy
Antiphosholipid Antibodies Infection screening (See Infection)
Lupus anticoagulant and Anticardiolipin Antibodies Heavy Metals (Blood)
Thrombotic Profile Male Recurrent Miscarriage Profile
Antinuclear antibodies Oxidative Stress in Semen (Reactive Oxygen Species)
Anti-Thyroglobulin Antibodies
Chromosome/Karyotype (parental)
Infection screening (See Infection)
SPERM HEALTH
MALE
See TDL Andrology on page 62.

TDL Andrology
The single most important factor determining Andrology booking can now be done online at
a man’s fertility potential is the production www.tdlpathology.com/andrologybooking
of healthy sperm. A semen analysis has
classically been used as the marker of this
potential, by providing information about
the sperm count, motility and morphology.
However, there are other parameters given
in a semen analysis that are often neglected
or overlooked, which may indicate important
pathologies – such as infection, prostatic
disease, immunological infertility, retrograde
ejaculation, malformation or obstruction
of the genital tract, tumour, and congenital
or endocrine disorders.
Early diagnosis of the male factor is important in order to detect any underlying pathology, determine
the extent of infertility and ensure appropriate treatment. It may also avoid unnecessary investigations
for the female partner, particularly if her age is a limiting factor.
For men who have had a vasectomy, clearance should only be given when there is no evidence of
presence of sperm in two consecutive semen samples. It is therefore vital to ensure that results are
reported according to best practice guidelines. Special clearance may be given at the doctor’s discretion
when there are persistent non-motile sperm present.
Guidelines for Producing Samples

Ideally semen samples should be produced on-site at TDL’s Patient Reception at 76 Wimpole Street.
Ideally patients must abstain from ejaculation for 2-3 days prior to the test, but no less than 2 days
and no longer than 5 days before the test. This requirement is important for semen analyses and
post vasectomy analyses to ensure reliability of results. It is possible that samples that do not comply
with guidelines for abstinence and collection may not be able to be processed. All semen samples
must be produced directly into the sterile containers provided by The Doctors Laboratory.
All containers are weighed and batch tested for sperm cytotoxicity. In exceptional circumstances
when semen samples are produced off-site, they can only be accepted by the Andrology Department
in sample containers provided by TDL.
WHO 2010 guidelines state that two semen analyses should be performed before any diagnosis
is confirmed. This may require requests for two (separate) semen analyses.
Appointments
It is important to make an appointment for all semen samples (on or off site) whether for
a comprehensive semen analysis or post vasectomy analysis. It may be necessary to give
patients who attend without an appointment a specific time to re-attend. The first appointments
for post vasectomy samples should usually be 12 weeks and 20 ejaculations after surgery.
Appointments can be made by calling 020 7025 7940. There is an attendance fee of £45.00
in addition to pathology charges.
Please complete a Pathology Request Form for your patient. If you would like to request other
pathology, you can use the same form or complete a second additional form. Results will usually
be reported to you within 48 hours.
If you would like to discuss these tests, or any aspect of this service including clinical interpretation by
the consultant please contact TDL Andrology on 020 7025 7940 or email [email protected]
for further information.
TDL Andrology
SEMEN
Individual Semen Parameters*** SPOD Semen 1

1 day
Oxidative Stress in Semen (ROS + MIOXSYS) SROS Semen 1 1 day
Retrograde Ejaculation RTRO Contact lab 2 days
Semen Analysis, Comprehensive* SPER Semen 1 2 days*
Semen Analysis, Post-Vasectomy** PVAS Semen 1 2 days
Semen Analysis, Vasectomy Reversal* SPER Semen 1 2 days*
Semen Culture SPCU Semen 2-4 days
Semen Fructose SPCF Semen 2 days
Semen Leucocytes PMNS Semen 2 days
Semen Zinc SPCZ Semen up to 10 days
Sperm Aneuploidy SPPL Semen 1 4 weeks
Sperm Antibodies (Serum) ASAB B 5 days
Sperm Antibodies/MAR Test (Semen)† ASPA Semen 1 day
Sperm Comet® CMET Semen 1-2 weeks
Sperm Count (Post-Vasectomy) PVAS Semen 1 2 days
Sperm DNA Fragmentation (SCSA) SEXT Semen 1 1-2 weeks
Sperm Morphology (Kruger strict criteria) MRPH Semen 1 2 days
Semen parameters
may be requested INDIVIDUALLY (eg count only, vitality only, etc).
Please request as SPOD and indicate on the request form which parameter is required.
Semen Parameters SPOD Semen 1 1 day
* If required, comprehensive semen analysis can be reported within 4 hours, with morphology to follow.
** For men who have had a vasectomy, clearance should only be given when there is no evidence of presence
of sperm in a single ejaculate when recommendations are met. It is rare that a ‘diagnosis’ is made without
confirmation, therefore patients/clinicians should be able to freely request a second confirmatory sample.
Special clearance may be given at the doctor’s discretion, when there are <100 000/ml non-motile sperm
present after the assessment of two specimens in full accordance with recommendations. Recommendations,
as given by the Association of Biomedical Andrologists, the British Andrology Society and the British Association
of Urological Surgeons 2016, are as follows:
1 Analysis of post vasectomy semen samples should not occur until 12 weeks post-surgery
and after a minimum of 20 ejaculates
2 Semen samples must be analysed within 4 hours of production, and in cases where sperm
is found a repeat analysis must be performed within 1 hour of production
3 Semen should be provided in weighed specimen containers provided by TDL Andrology
4 Sexual abstinence should be between 2 and 7 days
*** Semen parameters may be requested individually (e.g. count only, vitality only, motility etc.).
Please request as SPOD and indicate on the request form which parameter is required.
†
Sperm antibodies in semen are measured as part of the routine semen analysis.

TDL Andrology
BY SPECIAL ARRANGEMENT
Sperm swim test

Sperm preparation for overnight survival
Sperm motility and vitality testing for epididymal toxicity
Sperm retrieval procedures (biopsy, PESA, MESA)
Sperm cryopreservation and storage (undertaken by Andrology Solutions – HFEA licensed)
All men who store sperm must be screened for HIV 1&2, Hepatitis B, Hepatitis C and HTLV. Under HFEA
regulations, sperm can be stored for an initial period of 10 years with formal consent. All patients are offered
counselling prior to sperm cryopreservation.
These arrangements, and details for other specialist semen tests, are available on request. Please contact
TDL Andrology on 020 7025 7940 or email [email protected] for further information.
Sperm DNA fragmentation

High sperm DNA fragmentation is associated with reduced natural pregnancy rates and assisted
conception pregnancy rates as well as live birth rates. In addition, DNA fragmentation leads
to higher miscarriage rates as published in the ESHRE Recurrent Pregnancy Loss 2017 Guideline.
High levels of DNA fragmentation may be reduced by considering varicocele repair, treatment of
underlying infections or inflammation, changes in lifestyle or with antioxidant supplements.
When requesting Sperm DNA Fragmentation there are two options. Please specify whether the
request is for sperm DNA fragmentation by SCSA or COMET.
• Sperm Chromatin Structure Assay (SCSA®) [SEXT]

This test has the ability to measure large numbers of cells (between 5,000 and 10,000 sperm),
rapidly in an ejaculate. The SCSA® test monitors the changes in fluorescence of a probe,
acridine orange, to detect both single and double DNA strand breaks using flow cytometry.
It has been developed using human and animal models over the last 35 years and is one of
the most statistically robust tests available for sperm DNA fragmentation. It is a standardised,
validated CLIA approved test with high reproducibility and low variability. The test requires
a minimum sperm count of approximately 0.1 million/ml.
• Sperm COMET® Assay [CMET]
Exact® tests, powered by SpermComet ® technology measure sperm DNA damage. The Exact
range of tests are available via healthcare professionals only. Sperm DNA can be damaged when
sperm are being made in the testes or as they mature before ejaculation. This damage breaks
the DNA into fragments, so sperm DNA tests are also known as sperm DNA fragmentation tests.
Men with high levels of sperm DNA damage are less likely to get their partner pregnant and have
increased risk of miscarriage. Even if semen analysis results are ‘normal’, the sperm DNA could
be damaged and therefore poor quality. Sperm DNA damage can reduce your chances of having
a baby. The Comet® assay can measure both single and double strand breaks. Only a small
number of sperm (a minimum of 5,000) sperm are required to perform the assay.
Sperm Aneuploidy
Chromosomal abnormalities may be somatic cell in origin, in which case they can be detected by
a simple blood karyotype analysis. However, most sperm chromosome anomalies arise as a result
of errors during meiosis, which cannot be detected by a blood karyotype analysis. These anomalies
TDL Andrology
can only be detected by looking at the sperm chromosomes directly. Studies have shown that sperm
with a high rate of aneuploidy have a negative impact on pregnancy rate and are associated with
recurrent pregnancy loss.
This test uses fluorescent in situ hybridisation (FISH) to label individual chromosomes with specific
probes. Hundreds of sperm are assessed from one ejaculate. There are limitations to the test as only
5 probes are currently used routinely for analysis (three of the 22 autosomes: chromosomes 13, 18
and 21, and the sex chromosomes, X and Y), although others are available upon specific request.
The results are reported showing incidence of disomy or nullisomy for each of the autosomes and
for both sex chromosomes. A sex chromosome ratio is also reported. It is CE marked.
Instructions for collection of Sperm DNA and Aneuploidy specimens

Sperm DNA Fragmentation or Sperm Aneuploidy testing are not part of the Comprehensive Semen
Analysis and need to be requested as a separate test, test code SEXT and SPPL, respectively.
Semen samples ideally need to be frozen as soon as possible after liquefaction, but not longer
than 60 minutes post ejaculation. Samples must be snap-frozen for Sperm DNA Fragmentation
and cryopreserved in TYB for Sperm Aneuploidy. If samples are prepared by another laboratory.
Two cryovials containing not less than 0.25 mls of semen is required. Frozen samples can be sent
to, or collected by TDL, by arrangement, and must be accompanied with relevant patient details,
the sperm count and GDPR consent form. A count of a minimum 0.1 million/ml is required for
accurate DNA and aneuploidy reporting.
Oxidative Stress in Semen (ROS + MIOXSYS) and Male infertility

There is now growing evidence to support a link between oxidative stress and male infertility.
It is the underlying cause of sperm DNA damage and impairs semen parameters and fertilisation,
adversely affects embryo development and is associated with reduced pregnancy rates. It may
also increase the risk of miscarriage. High levels of ROS may be reduced by considering varicocele
repair, treatment of underlying infections or inflammation, changes in lifestyle or with antioxidant
supplements.
TDL provides a comprehensive assessment of oxidative stress by combined measurement of
Reactive Oxygen Species and Redox Potential. Please request as oxidative stress test (code ROS).
The test includes combined testing for:
• Chemiluminescence Assay for Reactive Oxygen Species
Reactive Oxidative stress may be measured by a simple chemiluminescence test in semen,
which measures the level of reactive oxygen species.
• MIOXSYS Electrochemical Assay for Redox Potential
Oxidative stress may be determined by an electrochemical assay which measures the redox
potential in semen. This test measures the overall difference between total oxidants and
antioxidants in the system.
References
Vassiliou A, Martin CH, Homa ST, Stone J, Dawkins A, Genkova MN, Skyla Dela Roca H, Parikh S, Patel J, Yap T, Killeen AP.
Redox potential in human semen: Validation and qualification of the MiOXsys assay. Andrologia. 2021 Mar;53(2):e13938.
doi: 10.1111/and.13938. Epub 2020 Dec 30. PMID: 33377541.
If you would like to discuss these tests, or any aspect of this service, please contact TDL Andrology
on 020 7025 7940 or 020 7307 7373, or email [email protected].

TDL Andrology
Effects of ROS-induced Oxidative Stress Causes of Elevated ROS Levels
on Sperm • Genito-urinary tract infection
• Lipid peroxidation which damages the • Prostatitis
sperm surface causing an abnormal • Vasectomy reversal
morphology and impaired motility.
• Varicocoele
• Damage to proteins on cell surface
responsible for cell signalling and may • Cryptorchidism
affect enzyme function inside the cell. • Chronic disease
• Increased semen viscosity. • Xenobiotics
• Peroxidation of DNA and subsequent • Chemical pollutants and
unravelling or fragmentation. occupational hazards
• Possible mutagenic effects. • Heavy metal exposure
• Damage to seminiferous epithelium, • Removal of seminal plasma during sperm
damage to tubules, testicular atrophy, preparation for assisted conception
reduced spermatogenesis. • Drugs – cyclophosphamide, aspirin,
• Decrease in sperm vitality, motility. paracetamol
• Impaired fertilization by affecting sperm • Smoking
capacitation and the acrosome reaction. • Excessive exercise
• Heat exposure
• Obesity
• Age
Semen samples need specialist handling – for this reason all requests for semen analyses should be
made by appointment. Practices or patients should contact TDL Andrology on 020 7025 7940 to make
appointments and to confirm instructions for sample collection.
Sexual Health
7 STI Profile by PCR (7 tests from 1 Sample) PP12 FCRU / PCR / TPV 2 days
Chlamydia (PCR swab) SPCR PCR 2 days
Chlamydia (Thin Prep) TPCR TPV 2 days
Chlamydia (Urine) CPCR FCRU 2 days
Chlamydia/Gonorrhoea (PCR Swab) SCG PCR 2 days
Chlamydia/Gonorrhoea (Rectal) RSCG PCR 2 days
Chlamydia/Gonorrhoea (Thin Prep) TCG TPV 5 days
Chlamydia/Gonorrhoea (Throat) TSCG PCR 2 days
Chlamydia/Gonorrhoea (Urine) CCG FCRU 2 days
Chlamydia/Gonorrhoea/Trichomonas by PCR CCGT FCRU / PCR / TPV 2 days
CT/GC/Trichomonas/Mgen (PCR Swab) SGTM PCR Swab 2 days
CT/GC/Trichomonas/Mgen (Urine) CGTM FCRU 2 days
A 10mls or 2 x 4mls
Early Detection Screen PCR/NAAT STDX 3 days
(Vacutainer only)
Early Detection Screen PCR/
STXX B A 10mls or 2 x 4mls 3 days
NAAT with Syphilis
FASTest Sexual Health Screening Tests See page 71
Gardnerella vaginalis by PCR GVPC FCRU / PCR / TPV 2 days
Gonorrhoea (Culture) GONN CS ‡ ‡ ‡ 2-3 days
Gonorrhoea (PCR swab) SGON PCR 2 days
Gonorrhoea (Thin Prep) TGON TPV 2 days
Gonorrhoea (Urine) CGON FCRU 2 days
Haemophilus ducreyi by PCR DUCR PCR 7 days
Hepatitis A Profile HEPA B 4 hours
Hepatitis B Surface Antigen AUAG B 4 hours
Hepatitis C Antibodies HEPC B 4 hours
Herpes Simplex I/II by PCR (Swab) HERS PCR 5 days
Herpes Simplex I/II by PCR (Urine) HERD FCRU / PCR / TPV 5 days
HIV 1 & 2/p24Ag HDUO B 4 hours
HIV/HBV/HCV (Early detection by
STXX B A 10mls or 2 x 4mls 3 days
PCR/NAAT) with Syphilis
HIV/HBV/HCV Screen by PCR/ A 10mls or 2 x 4mls
STDX 3 days
NAAT (10 days post exposure) (Vacutainer only)
HIV Rapid RNA HIV-1 QUALITATIVE LHIV A (Vacutainer only) 4 hours
HIV Rapid RNA HIV-1 QUANTITATIVE RHIV A (Vacutainer only) 4 hours
HPV (DNA and reflexed mRNA) HPVT TPV 3 days
HPV (HR mRNA types 16, 18 + others) HPVH TPV 3 days
HPV (Individual low & high
HP20 TPV / PCR 3 days
risk DNA subtypes)
Lymphogranuloma Venerium (LGV) LGVP PCR* 42 1-2 weeks
Macrolide Resistance Test (Mgen) MGR FCRU / PCR 1-2 weeks
Mycoplasma genitalium by PCR MGEN FCRU / PCR / TPV 2 days
Mycoplasma genitalium/Ureaplasma by PCR MUPC FCRU / PCR / TPV 2 days
* LGV can be added to a positive chlamydia sample using the same swab if requested within 4 days of receipt of result.

Sexual Health
Rapid Xpert HIV-1 RNA Qualitative –

LHIV A (Vacutainer only) 4 hours
Early Detection from 10 days
Rapid Xpert HIV-1 RNS Viral Load – Rapid
Testing for HIV-Positive Patient Prognosis RHIV A (Vacutainer only) 4 hours
and Response To Antiretroviral Therapy
RPR (VDRL) RPR B 2 days
STD1 M/F STD Quad (Urine and Serology) STD1 B FCRU 2 days
B FCRU (If culture
STD2 M/F STI Profile Plus
STD2 swabs are needed please 4 days
(Urine and Serology)
request separately)
STD3 Female STD Quad (PCR
STD3 B PCR 2 days
Swab and Serology)
B PCR (If culture swabs
STD4 Female STI Profile Plus
STD4 are needed please 4 days
(PCR Swab and Serology)
request separately)
STD5 Serology only STD5 B 4 hours
STD6 Serology only without HIV STD6 B 4 hours
STD8 Vaginitis/BV Profile using
STD8 PCR / STM 3 days
Culture & PCR Swab
STD9 Symptomatic lesion sample using
STD9 2 x PCR Swab 7 days
PCR Swab from lesion & PCR Swab
B / FCRU / PCR Swab
STI Profile: MSM1 MSM1 2 days
Throat / PCR Swab Rectal
B / FCRU / PCR Swab
STI Profile: MSM2 MSM2 3 days
Syphilis by PCR (chancre) SYPS PCR 5 days
Syphilis IgG/IgM SERJ B 4 hours
TPPA TPPA B 2 days
Trichomonas vaginalis by PCR TVPC FCRU / PCR / TPV 2 days
Ureaplasma urealyticum by PCR UGEN FCRU / PCR / TPV 2 days
Vaginitis/BV Profile using
STD8 PCR / STM 3 days
Culture & PCR Swab
Sexual Health
Chlamydia
Chlamydia is the most common curable STI diagnosed in the UK. Often asymptomatic, anyone who is sexually
active is considered to be at increased risk of chlamydia infection. It is the most commonly recognised,
screened and treated of all STI’s. Allow 6 weeks before re-testing to avoid picking up the DNA from
a previous infection.
Gonorrhoea
Gonorrhoea is caused by the bacterium Neisseria gonorrhea, which multiplies easily in the mucous membranes
of the male and female reproductive tract. It can cause serious and permanent health conditions if not treated.
Symptoms of gonorrhoea are usually overt in men with white, yellow, or green discharge from the penis.
Gonorrhoea can also infect the throat and rectum – individual PCR swabs from each site should be taken to
screen for gonorrhoea. Resistance to antibiotics is increasing and treatment is now combined oral and injectable
antibiotics. Partners should be treated at the same time with retesting after two weeks to confirm
clearance – test of cure is recommended following treatment for gonococcal infections.
Mycoplasma Genitalium (M.Gen)

M.gen is an important sexually transmitted pathogen detectable only by NAAT. M.gen lacks a cell wall and has
limited treatment options. It spontaneously develops resistance to antimicrobials. BASHH recommends treatment
with Resistance Guided Therapy – testing for M.gen with macrolide resistance determination. M.gen cannot be
cultured for diagnostic testing. M.gen prevalence is higher than GC, and in some populations can be similar to
CT. M.gen risk factors are similar to CT and consider testing M.gen in all males with non-GC urethritis and all
individuals with signs or symptoms of PID, cervicitis, endometritis, associated infertility, ano-rectal condition or
epididymo-orchitis. Partner testing is advised for current partners only. Rectal infections are common, and appear
to be an important reservoir for resistance. BASHH guidance – all patients must return for test of cure at 3-5 weeks.
Macrolide Resistance Testing (M.gen)

Prevalence of M.gen in men and women in the general population is 1-2%. Mycoplasma genitalium has been
implicated as a cause of acute and chronic non-chlamydial non-gonococcal urethritis in males and post coital
bleeding, cervicitis, endrometritis and pelvic inflammatory disease in females. It is a sexually transmitted, fastidious
microorganism that is extremely difficult to culture – with nucleic acid amplification testing (NAAT urine or swab)
being the only method available for routine M. genitalium detection. Macrolides are generally considered the first-
line treatment for M. genitalium infections. However, resistance to macrolides seems to be increasing worldwide
typically exceeding > 40% in male patients who are detected positive for M.gen at screening.
M.gen can be requested as a single PCR test or with CT/GC, with or without other testing options. Important
updates to the UK BASHH M. genitalium management guidelines are taking the issue of antimicrobial resistance
seriously. The draft guidelines have been posted for consultation and include a grade 1B recommendation to
test for antimicrobial resistance, stating the importance of knowing the macrolide resistance status to determine
whether azithromycin should be prescribed. The guidelines aim to support laboratories in making a case
for increased funding to bring in the necessary testing to manage M. genitalium infections and associated
antimicrobial resistance.
Ureaplasma
U. Urealyticum and parvum are strains of bacteria that can lead to urinary tract infection and pelvic inflammation.
Usually asymptomatic, it is part of the normal genital flora of both men and women. It is found in about 70% of
sexually active humans. In males with lower sperm quality, ureaplasma infection could lead to a more pronounced
decreased in some seminal parameters and compromise sperm motility.

Sexual Health
Trichomoniasis
Trichomoniasis is caused by a tiny parasite called Trichomonas vaginalis – and is one of the most common
STI’s worldwide. Frequency of coinfection with other STI’s is well recognised, and notably, infection increases
the risk of HIV transmission in both men and women. It is associated with adverse pregnancy outcomes,
infertility, and cervical neoplasia. Some women may mistake this infection for a yeast infection or bacterial
vaginosis since the symptoms are similar: frothy discharge, strong vaginal odour, pain on intercourse, irritation
and itching. Men can get trichomoniasis too, but they don’t tend to have symptoms. It seems to be linked
to male factor infertility. Partners (male or female) need to be treated to avoid ongoing re-infection. Infected
women who are sexually active have a high rate of reinfection, thus re-screening at 3 month post treatment
could be considered.
Gardnerella vaginalis
‘Gardnerella vaginalis is a bacterium rather than a sexually transmitted infection. It is part of the normal vaginal
flora but, when the normal balance of bacteria in the vagina is disrupted, it can flourish and overgrow leading
to bacterial vaginosis. Does it matter if it not an STI? Yes, because it can be characterised by a fishy smelling,
white vaginal discharge, itching, burning, and irritation, and there are some known pregnancy and pelvic
inflammatory conditions associated with Gardnerella as well as a higher risk of getting other STI’s.
In a patient with signs and symptoms suggestive of bacterial vaginosis detection of Gardnerella vaginalis
provides supportive evidence of bacterial vaginosis. It can, however, be detected in asymptomatic individuals
and it can also be absent in patients with bacterial vaginosis which has been caused by overgrowth of other
similar organisms such as Mobiluncus and Atopobium species. Results should be interpreted in line with
patient’s clinical symptoms and microscopy.
Herpes/Herpes Simplex Virus I/II

Genital herpes caused by the herpes simplex virus (HSV). The virus lives in the nerves and when active it travels
to the surface of the infected area and makes copies of itself – called shedding, because new virus cells can
at this time rub off onto another person. The virus travels back down the nerve to a ganglion usually at the base
of the spine where it lies dormant for a while. It causes painful blisters on the genitalia and surrounding areas.
It can be passed through intimate sexual contact and for this reason is referred to as an STI. Once infected,
it remains a chronic long term condition with the virus remaining with recurrent activity with variable frequency.
There are two types of herpes simplex virus: Type I and Type 2. Both are highly contagious and can be passed
easily from one person to another. There is no cure for genital herpes, the symptoms can usually be controlled
by antiviral medication. Although using a condom can reduce the risk of herpes transmission, condoms are
not 100% effective since herpes can be spread from skin-to-skin.
Lymphogranuloma venereum (LGV)

LGV is a type of chlamydia bacteria that attacks the lymph nodes. It is seen predominantly in gay and bisexual
men, and very rarely seen in the UK in heterosexual men and women.
Nearly all LGV infections seen in the UK in recent years have been in the rectum. Within a few weeks of
becoming infected, most people get painful inflammation in the rectum with bleeding, pus, constipation or
ulcers, sometimes with fever, rash and groin, armpit or neck swelling. Left untreated, LGV can cause lasting
damage to the rectum that may require surgery. LGV in the penis might cause a discharge and pain when
urinating, with swollen glands in the groin. LGV in the mouth or throat is rare but can cause swollen glands
in the neck.
Investigation for possible LGV symptoms is by PCR swab taken from the rectum and penis. If LGV infection
is suspected in female patients, cervical and vaginal PCR swabs should be taken. Samples are first tested
for chlamydia and if chlamydia is detected, if LGV is suspected, swabs can be further tested, if requested,
for LGV as an additional tests, using the same swab samples. Sexual contact partners should also be checked.
Sexual Health
FASTest Test Now

Sexual Health Screening – ahead of expected time
FAST SSC FAST USC

Fast Screen SHORT Fast Screen with URINE
HIV 1&2/p24 Ag HIV 1&2/p24 Ag
Syphilis IgM/IgG Hep B sAg
FAST Urine CT/GC Hep C Abs
Syphilis IgG/IgM
TAT FAST Urine CT/GC TAT
4 4
HOURS HOURS
FSSC FUSC
B FCRU B FCRU
FAST SSS FAST SSC

Fast Screen SHORT with SWAB Fast Screen with SWAB
HIV 1&2/p24 Ag HIV 1&2/p24 Ag
Syphilis IgM/IgG Hep B sAg
FAST Swab CT/GC Hep C Abs
Syphilis IgG/IgM
TAT FAST Swab CT/GC TAT
4 4
HOURS HOURS
FSSS FSWS
B PCR B PCR
FAST SINGLE TESTS Sample type
FCT FAST Chlamydia Urine FCRU

FGN FAST Gonorrhoea Urine FCRU
FCG FAST CT/GC Urine FCRU
FSCT FAST Chlamydia PCR Swab PCR Swab
FSGN FAST Gonorrhoea PCR Swab PCR Swab
FSCG FAST CT/GC PCR Swab PCR Swab
FTCG FAST CT/GC Throat PCR Swab PCR Swab
FRCG FAST CT/GC Rectal PCR Swab PCR Swab

Sexual Health
STI’s can be caused by virus, fungus, parasite or bacteria. Anyone who is sexually active may be at risk
of acquiring an STI. The risk is higher for those with increased numbers of sexual partners, or who have
had sex with someone who has/had many partners, or have had unprotected sex.
STI INCUBATION PERIOD SAMPLE SITE

Chlamydia CT Bacterial 1 – 3 weeks, up to 6 weeks Urine
Cervix / Vagina
Cervix / Vagina
Gonorrhoea GC Bacterial 2 – 7 days, up to 1 month Urine

Cervix / Vagina
Cervix / Vagina
Cervix / Vagina
CT/GC Combined Bacterial 1 – 3 weeks, up to 6 weeks Urine

Cervix / Vagina
Cervix / Vagina
Rectum
Throat
Mycoplasma Bacterial Symptoms develop at Urine

genitalium 1 – 3 weeks GU Site
Cervix / Vagina
Ureaplasma Bacterial Symptoms develop at Urine

urealyticum 1 – 3 weeks GU Site
Cervix / Vagina
Trichomonas Parasitic 4 – 28 days, many patients are Urine

vaginalis asymptomatic carriers GU Site
Cervix / Vagina
Gardnerella Bacterial Imbalance of normal flora Urine

vaginalis GU Site
Cervix / Vagina
Bacterial Bacterial Imbalance of normal flora Cervix / Vagina

Vaginosis (BV)
Herpes Simplex Viral 2 – 14 days, testing is most appropriate Herpes lesion

Viral I/II for patients with symptomatic lesion(s)
Human Viral HPV is the most common sexually Cervical cells

Papillomavirus transmitted infection – usually Cells / papilloma from site
asymptomatic (throat /penile/anal)
Genital Viral Weeks / months after exposure GU Warts

warts
Syphilis/Herpes Bacterial / Whenever active lesions are present Symptomatic lesion

Viral
Sexual Health
TEST TEST CODE SAMPLE TYPE TAT

Chlamydia CPCR First catch Urine 2 days
Chlamydia SPCR PCR Swab 2 days
Chlamydia TPCR Thin Prep Vial 2 days
Gonorrhoea by PCR CGON First Catch Urine 2 days
Gonorrhoea by PCR SGON PCR Swab 2 days
Gonorrhoea by PCR TGON Thin Prep Vial 2 days
Gonorrhoea by CULTURE GONN Black Charcoal swab 2-3 days
CT/GC CCG First Catch Urine 2 days
CT/GC SCG PCR Swab 2 days
CT/GC TCG Thin Prep Vial 5 days
CT/GC RSCG PCR Swab 2 days
CT/GC TSCG PCR Swab 2 days
Mycoplasma genitalium by PCR MGEN First Catch Urine 2 days
Mycoplasma genitalium by PCR MGEN PCR Swab 2 days
Mycoplasma genitalium by PCR MGEN Thin Prep Vial 2 days
Ureaplasma by PCR UGEN First Catch Urine 2 days
Ureaplasma by PCR UGEN PCR Swab 2 days
Ureaplasma by PCR UGEN Thin Prep Vial 2 days
Trichomonas vaginalis by PCR TVPC First Catch Urine 2 days
Trichomonas vaginalis by PCR TVPC PCR Swab 2 days
Trichomonas vaginalis by PCR TVPC Thin Prep Vial 2 days
Gardnerella vaginalis by PCR GVPC First Catch Urine 2 days
Gardnerella vaginalis by PCR GVPC PCR Swab 2 days
Gardnerella vaginalis by PCR GVPC Thin Prep Vial 2 days
Bacterial Vaginosis (BV) Profile STD8 Both Microscopy 3 days
by both MICROSCOPY and PCR & PCR swab
Herpes by PCR HERS PCR Swab 5 days

Herpes by PCR HERD First Catch Urine 5 days
PV (DNA and reflexed mRNA) HPVT Thin Prep Vial 3 days

HPV (Individual low & high risk DNA subtypes) HP20 PCR Swab 3 days
HPV (Individual low & high risk DNA subtypes) HP20 Cells / Papilloma 3 days
PV (DNA and reflexed mRNA) HPVT Thin Prep Vial 3 days
HPV (Individual low & high risk DNA subtypes) HP20 PCR Swab 3 days
HPV (Individual low & high risk DNA subtypes) HP20 Cells / Papilloma 3 days
Syphilis/Herpes Lesion Profile STD9 PCR Swab 7 days

Sexual Health
BLOOD INCUBATION PERIOD SAMPLE SITE
Syphilis Bacterial 9 – 21 days, but up to 90 days Blood
Herpes Simplex Viral IgG 4 – 6 weeks after exposure Blood

Virus I/II IgM 5 – 35 days after exposure, Blood
after which test IgG
HIV Viral Usually 10 – 90 days, Blood
but up to 180 days Blood
Hep B Viral Usually 45 – 180 days, Blood
average of 60 – 90 days Blood
Hep C Ab Viral Usually 9 – 180 days, Blood
average of 45 – 65 days Blood
EARLY DETECTION
INCUBATION PERIOD SAMPLE SITE
PROFILES BY PCR
7 STIs by PCR One sample for 7 STI Tests Urine
Cervix
Vagina
HIV / HBV / HCV Early Detection Screen by PCR Multiplex Blood

(HIV from 10 days)
Sexual Health
Syphilis IgG / IgM SERJ B 4 hours
Herpes IgG (past infection) HERP B 2 days

Herpes IgM (current / recent) HERM B 2 days
HIV I&II / p24 antigen (screening from HDUO B 4 hours

45 days post exposure (BHIVA))
Hep B surface antigen AUAG B 4 hours
Hep C Antibodies HEPC B 4 hours
Chlamydia PP12 Thin Prep Vial 2 days

Gonorrhoea or
Mycoplasma genitalium PP12 First Catch Urine 2 days
Ureaplasma genitalium or
Trichomonas vaginalis PP12 PCR Swab 2 days
Herpes Simplex I/II
HIV 1&2 RNA STDX A 10mls or 2 x 4mls 3 days
Hepatitis B (HBV DNA) (Vacutainer only)
Hepatitis C (HCV RNA)

Sexual Health
M/F STD QUAD M/F STI PROFILE PLUS
STD1 (Urine and Serology) STD2 (Urine and Serology)
Serology Urine Serology Urine

HIV 1&2/p24 Antigen Chlamydia HIV 1&2/p24 Antigen Chlamydia/Gonorrhoea
Syphilis IgG/IgM Gonorrhoea Hep B Surface Antigen Mycoplasma genitalium
Hep C Abs Ureaplasma
Syphilis IgG/IgM Trichomonas vaginalis
Herpes Simplex I/II
TAT TAT
2 4
DAYS DAYS
STD1 STD2
If culture swabs are needed please
B FCRU B FCRU request separately
FEMALE STD QUAD FEMALE STI PROFILE PLUS

STD3 (PCR Swab
swab and
and Serology)
Serology) STD4 (PCR Swab
swab and
and Serology)
Serology)
Serology Vaginal PCR Swab Serology Vaginal PCR Swab

HIV 1&2/p24 Antigen Chlamydia HIV 1&2/p24 Antigen Chlamydia/Gonorrhoea
Syphilis IgG/IgM Gonorrhoea Hep B Surface Antigen Mycoplasma genitalium
Hep C Abs Ureaplasma
Syphilis IgG/IgM Trichomonas vaginalis
Herpes Simplex I/II
TAT TAT
2 4
DAYS DAYS
STD3 STD4
If culture swabs are needed please

B PCR B PCR request separately
STD5 SEROLOGY ONLY STD6 SEROLOGY ONLY WITHOUT HIV
HIV 1&2/p24 Antigen Hepatitis B Surface Antigen

Hepatitis B Surface Antigen Hep C Abs
Hep C Abs Syphilis IgG/IgM
Syphilis IgG/IgM
TAT TAT
4 4
HOURS HOURS
STD5 STD6
B B
Sexual Health
VAGINITIS / BV PROFILE SYMPTOMATIC LESION SAMPLE
STD8 USING CULTURE & PCR SWAB STD9 USING PCR SWAB FROM LESION
Candida species Syphilis by PCR

Gardnerella vaginalis by PCR Herpes Simplex I/II by PCR
Trichomonas vaginalis by PCR (from single swab)
swab)
TAT TAT
3 7
DAYS DAYS
STD8 STD9
PCR STM PCR PCR
HIV / HBV / HCV SCREEN EARLY DETECTION SCREEN WITH SYPHILIS

(HIV1/HIV2/HBV/HCV by PCR/NAAT) (HIV1/HIV2/HBV/HCV by PCR/NAAT)
HIV1 and HIV2 (RNA) HIV1 and HIV2 (RNA)

Hepatitis B Virus (HBV DNA) Hepatitis B Virus (HBV DNA)
Hepatitis C Virus (HCV RNA) Hepatitis C Virus (HCV RNA)
Samples must be received in the Syphilis IgG/IgM
laboratory within 2 days of sample taking TAT TAT
Samples must be received in the
3 laboratory within 2 days of sample taking 3
DAYS DAYS
STDX STXX
A 10mls or 2 x 4mls (Vacutainer only) B A 10mls or 2 x 4mls
7 STI PROFILE BY PCR (7 TESTS FROM 1 SAMPLE)

CT/GC/TRICHOMONAS/MGEN
(Urine, Swab, Thin Prep or Semen)
Chlamydia Chlamydia trachomatis

Gonorrhoea N. gonorrhoea
Trichomonas vaginalis Mycoplasma genitalium
Mycoplasma genitalium Ureaplasma
All tests can be requested individually Trichomonas vaginalis
Herpes Simplex I/II
All tests can be requested individually
TAT TAT
2 2
DAYS DAYS
CGTM (Urine) / SGTM (Swab) PP12
FCRU OR PCR Swab FCRU OR PCR Swab OR TPV

Sexual Health
M/F STI PROFILE PLUS M/F STI PROFILE PLUS
STI Profile:
(UrineMSM1
and Serology) STI Profile:
(UrineMSM2
and Serology)
HIV 1&2/p24 Ag HIV 1&2/p24 Ag Hep B sAg

Syphilis IgG/IgM Syphilis IgG/IgM Hep C Abs
Urine for CT/GC 7 STI by PCR Screen
Throat Swab CT/GC Throat Swab CT/GC
Rectal Swab CT/GC TAT Rectal Swab CT/GC TAT
2 3
DAYS DAYS
MSM1 MSM2
B FCRU PCR Swab Throat PCR Swab Rectal B FCRU PCR Swab Throat PCR Swab Rectal
RAPID XPERT HIV-1

For some patients earlier diagnosis of HIV infection is important. Xpert HIV-1 Qual is a qualitative test that provides
on-demand molecular testing for early diagnosis (from 10 days).
FOR PATIENT ON TREATMENT FOR HIV

Xpert HIV-1 Viral Load accommodates on demand testing and measurement of blood plasma HIV-1 RNA
concentration (HIV viral load/40 copies/ml) which has been established as the standard of care in assessing HIV-
positive patient prognosis and response to antiretroviral therapy. Assessment of viral load levels is a strong predictor
of the rate of disease progression and, by itself or in combination with CD4 T-cell counts, has great prognostic value.
• Improve Patient Care: Same day results support better clinical decisions
• Increase Efficiency: Rapid results enable earlier adjustments to appropriate therapy
• Strengthen Communities: Quick decisions can help reduce drug resistance
RAPID XPERT HIV-1 RNA VIRAL LOAD

RAPID XPERT HIV-1 RNA QUALITATIVE RAPID TESTING FOR HIV-POSITIVE
EARLY DETECTION FROM 10 DAYS PATIENT PROGNOSIS AND RESPONSE TO
ANTIRETROVIRAL THERAPY
HIV-1 RNA HIV-1 RNA VIRAL LOAD (40 copies/ml)
Sample must be received in the laboratory Sample must be received in the laboratory
within 24 hours of sample taking TAT within 24 hours of sample taking TAT
4 4
HOURS HOURS
LHIV RHIV
A (Vacutainer only) A (Vacutainer only)
Immunology
Acute Viral Hepatitis Screen AHSC B 4 hours

Adrenal Cortex Antibodies ACTX B 2 days
ANCA (Anti-Neutrophil Cytoplasmic Abs) ANCA B 2 days
Anti-Actin Antibodies AAA B 5 days
Anti-Basal Ganglia Antibodies ABGA B 3 weeks
Anti-CCP Antibodies (RF) CCP B 2 days
Anti-Liver Cytosol Antibodies ALCA B 5 days
Anti-MOG [Myelin Oligodendrocyte
AMOG B 3 weeks
Glycoprotein] Antibodies
Anti-MUSK Antibodies MUSK B 2 weeks
Anti-Phosphatidylserine Antibodies PHTS B 5 days
Anti-Phospholipase A2 Receptor AA2R B 3 weeks
Anti-Ri Antibodies RIAB B 3 days
Anti-SLA (Soluble Liver Antigen) Abs LSA B 10 days
Antinuclear Antibodies (titre & pattern) ANAB B 2 days
Antistaphylolysin Titre (SGOT) ASTT B 3 days
Antistreptolysin Titre/ASOT ASLT B 2 days
Antisulfatide Antibodies ASA B 5 weeks
Aquaporin 4 Antibodies (Neuromyelitis Optica) AQUA B 2 weeks
Ascariasis Serology ASC B 5 days
Autoantibody Profile I AUTO B 2 days
Autoantibody Profile II ENDO B 2 days
Avian Precipitins (11 Species) AVIA B 5 days
Babesia Antibodies BABE B 3 weeks
Beta 2 Glycoprotein 1 Abs B2GP B 5 days
Borrelia Antibodies (Lyme Disease)
BORR B 9,14 2 days
IgG, IgM – see page 90
BORM B 2 days
IgM – see page 90
Borrelia Confirmation (Immunoblot)
BORC B 9,14 10 days
– see page 90
Brucella Serology BRUC B9 2-3 weeks
C1 Esterase Inhibitor C1EI B 5 days
C3 Complement C3 B 4 hours
C3/C4 Complement COMP B 4 hours
C4 Complement C4 B 4 hours
Calprotectin CALP RF 5 days
Calprotectin/Elastase Profile CEP RF 5 days
Cardiolipin Antibodies (IgG+IgM) ACAB B 2 days
Cartilage Antibodies ACA B 5 days
CCP Antibodies (RF) CCP B 2 days
Centromere Autoantibodies CENT B 2 days
CH50 (Classical pathway) CH50 B (Frozen) 4 4 days
Chagas Disease Serology (S.American
CHGA B 9,14 10 days
Trypanosomiasis) T. Cruzi

Immunology
Chlamydia Species Specific (MIF) Ab Screen CHAB B 2 days

Chronic Fatigue Syndrome Profile VIP1 A + B 10 5 days
Coeliac Disease – HLA DQ2/DQ8 Genotype Q2Q8 A9 10 days
Coeliac/Gluten Profile 2 GSA2 AB 10 days
Coeliac/Gluten Sensitivity Profile GSA B 2 days
Colloid Antigen-2 Antibodies CA2A B 2 weeks
Cotinine (Serum) COT B 4 days
SST / Serum B *
COVID-19 (SARS-CoV-2) Abbott IgG Antibody GCOV 24 hours
(Venous only)
SST / Serum B *
COVID-19 (SARS-CoV-2) Abbott IgM Antibody MCOV 24 hours
(Venous only)
SST/Serum
COVID-19 (SARS-CoV-2) Roche Elecsys
NEW SCOV B (Venous/Capillary 24 hours
Anti-SARS-CoV-2 S (SPIKE)
self-collection*)
SST / Serum B *
COVID-19 (SARS-CoV-2) Roche Elecsys
TCOV (Venous and Capillary 24 hours
Anti-SARS-CoV-2 Total Antibody
self-collection)
NEW COVID-19 (SARS-CoV-2) T-SPOT®.COVID TCEL H *** 3 days
Diphtheria Antibodies DIPH B 5 days
DNA (Double Stranded) Antibodies IgG DNAA B 2 days
DNA (Single Stranded) Antibodies DNAS B 5 days
Echinococcus (Hydatid) Antibodies EFAT B 9,14 5 days
Ehrlichiosis Antibodies EHRL B 9,14 10 days
Elastase/Calprotectin Profile CEP RF 5 days
Endomysial Antibodies (IgA) AEAB B 2 days
Extractable Nuclear Antibodies (nRNP,
ENA B 2 days
Sm, Ro, La, Jo1, Scl70) CENP-B
Farmers Lung Precipitins FARM B 5 days
Fasciola Hepatica Antibodies (Liver Fluke) FASC B 2 weeks
Ganglionic Acetylcholine Receptor Antibodies GACA B 1 month
Ganglioside GM1, GD1B, GQ1B Abs GANG B 5 days
Gastric Parietal Autoantibodies GASP B 2 days
Giardia Serology GIAR B 5 days
Gliadin Antibodies (IgG) (deamidated) AGAB B 2 days
Glomerular Basement Membrane Abs AGBM B 2 days
Glutamic Acid Decarboxylase
GAD B 5 days
Antibodies (GAD 65)
Gluten Allergy Profile GLUT ABB 10 days
Gluten Sensitivity Evaluation GSA B 2 days
Gluten/Coeliac Profile 2 GSA2 AB 10 days
Granulocyte Immunology GRIM AA 2 weeks
H. pylori Antibodies (IgG) HBPA B 2 days
H. pylori Antigen (Breath) HBQT J 5 days
Haemophilus B Influenzae Antibodies HINF B 5 days
Immunology
Histamine (Blood) HITT A (Frozen plasma) 5 days

Histamine (Urine) HITU RU 5 days
Histamine Releasing Urticaria Test CURT B 3 weeks
Histone Antibodies HISA B 5 days
Histoplasmosis HISP B 10 days
HLA B27 HLAB A9 3 days
Human Anti-Mouse Antibodies HAMA B (Frozen) 6 weeks
IgE (Total) IGE B 1 day
Immune-Complexes IMCP B 5 days
Immunoglobulins (IgG, IgM, IgA) IMM B 4 hours
Inner Ear Antigen (Ottoblot) IEA B 3 weeks
Insulin Antibodies INAB B 5 days
Interferon – Alpha IFA B (frozen) 9 3 weeks
Interferon – Gamma IFG A (frozen) 3 weeks
Interleukin 1 Beta ILB B (Frozen) 4,7 1-2 weeks
Interleukin 2 IL2 B (Frozen) 4,7 1-2 weeks
Interleukin 4 IL4A B (Frozen) 4,7 1-2 weeks
Interleukin 28b Genotype IL28 A 2 weeks
Intrinsic Factor Antibodies IFAB B 2 days
Islet Cell Antibodies ICAB B 2 days
Legionella Antibodies LEGO B 2 days
Legionella Urine Antigen LEGA RU 1 day
Leptospirosis (Weil’s Disease) Abs (IgM) LEP B 5 days
Leukotriene E4 LTE4 CU (Frozen) 3 weeks
Listeria IgG/IgM Antibody LIST B 1 week
Liver Immunoblot LIVI B 3 days
Liver Kidney Microsomal Antibodies LKM B 2 days
Lupus Anticoagulant and Anticardiolipin Abs LUPA B C 4,18 2 days
Lyme Disease (Borrelia Abs) IgG, IgM BORR B 9,14 2 days
Lyme Disease (Borrelia Abs) IgM BORM B 2 days
Meningococcal Abs MENI B 2-4 weeks
Mitochondrial Antibodies AMIT B 3 days
Mitochondrial Antibodies M2 MAM2 B 2 days
Myasthenia Gravis Evaluation MGE B 5 days
Myelin Associated Glycoprotein Antibodies MAG B 5 days
Myelin Basic Protein Antibodies MBPA B 2 weeks
Myeloperoxidase Antibodies MPO B 2 days
Myocardial Antibodies MYO B 1 week
Myositis Panel MYOS B 3 days
Neuronal Antibody (Hu, Ri, Yo, Cv2, Ma2) NEUR B 10 days
NMDA Receptor Antibodies NMDA B 3 weeks

Immunology
Nucleic Acid Antigen Antibodies DNA B 2 days

Oligoclonal Bands CSFO CSF + B 5 days
Ovarian Autoantibodies OVAB B 2 days
Paragomius Serology PRGM B 2 weeks
Parathyroid Antibodies PTHA B 1 week
Pemphigus/Pemphigoid Autoantibodies SKAB B 2 days
Pertussis (Whooping Cough) Antibodies PERS B 5 days
Pituitary Antibodies PITU B4 1 month
Pneumococcal Antibodies – Serotype Specific PASS B 5 weeks
Pneumococcal Antibody Screen PNEU B 5 days
Proteinase 3 Ab PR3 B 2 days
Purkinje Cell Antibody (Hu and Yo) PURK B 10 days
Q Fever (C Burnetti) Antibodies QFEV B9 10 days
Rheumatoid Factor (Latex Test) RF B 1 day
Rheumatology Profile 1 (Screen) RH AB 2 days
Rheumatology Profile 2 (Connective tissue) RH2 AABB 3 days
Rheumatology Profile 3 (Rheumatoid/Basic) RH3 AB 2 days
Rheumatology Profile 4 (Systemic Lupus) RH4 ABB 2 days
Rheumatology Profile 5 (Mono Arthritis) RH5 AABB 3 days
Rheumatology Profile 6 (Rheumatoid Plus) RH6 B 2 days
Rheumatology Profile 7 (Sjogren’s Syndrome) RH7 B 10 days
Rickettsial Species Antibody Profile RICK B 7 days
NEW RNA Polymerase Antibodies RNAP B 3 days
RPR (VDRL) RPR B 2 days
Saccharomyces Cerevisiae Antibodies ASCA B 2 weeks
Salivary Duct Antibodies SAB B 12 days
Scleroderma Immunoblot SCLI B 3 days
Sjogren’s Syndrome RH7 B 10 days
Skin (Pemphigus/Pemphigoid) Autoantibodies SKAB B 2 days
Skin Antibodies by Immunofluorescence STSK B 1 month
Sleeping Sickness Serology
TRYP B9 10 days
(African Trypanosomiasis)
Smooth Muscle Antibodies ASMO B 2 days
Sperm Antibodies (Serum) ASAB B 5 days
Steroid Cell Antibody SCA B 2 days
Striated/Skeletal Muscle Antibody STRA B 2 days
Strongyloides Antibodies STGA B 10 days
Syphilis IgG/IgM SERJ B 4 hours
NEW T-SPOT®.COVID TCEL H *** 3 days
TB Quantiferon®-TB Gold* TBQ4 Special tubes or H 1 3 days
Testicular Autoantibodies TAB B 2 days
Tetanus Antibody TETA B 5 days
THAB B 1 day
Immunology
Thyroid Peroxidase Antibodies/Anti TPO TPEX B 1 day

Tissue Transglutaminase IgA (Coeliac)** TAA B 2 days
Tissue Transglutaminase IgG TAAG B 5 days
Total Immune Function Evaluation TIE A + B 5,10 7 days
Total Immunoglobulin E IGE B 1 day
Toxocara Antibodies (IgG) TFAT B9 5 days
Toxoplasma Antibodies (IgG+IgM) TFAM B9 4 hours
Toxoplasma Antibody Full Evaluation
TDYE B9 10 days
(IgM, Dye Test, IgG Avidity)
Toxoplasma by PCR TXAG A 5 days
TPPA TPPA B 2 days
Trichinella Serology TRIC B 5 days
Trypanosome (Chagas) Antibodies CHGA B 9,14 10 days
TSH-Receptor Antibodies TSI B 4 days
Tularaemia Antibodies TULA B 14 5 days
Urinary Methyl Histamine UHIT RU (Frozen) 2 weeks
Urticaria Test (Histamine Releasing) CURT B 3 weeks
Vascular Endothelial Growth Factor VEGF B 14 days
VDRL (RPR) RPR B 2 days
Voltage Gated Calcium Channel Antibodies CCAB B 3 weeks
Voltage Gated Potassium Channel Antibodies VPCA B 3 weeks
Whooping Cough (Pertussis) Antibodies PERS B 5 days
Prenasal (posterior
Whooping Cough (Pertussis) by PCR PERP 5 days
nasopharynx) swab
Yellow Fever Antibodies YELL B 9,14 10 days
Yersinia Antibodies YERS B 4 days
Zika Abs IgM and IgG –
ZKAB B Up to 14 days
Antibody detection from 15 days
Zika RNA by PCR in Semen ZIKS Semen Up to 14 days
Zika RT PCR – Window of detection from
ZIKU RU Up to 14 days
1-14 days from onset of symptoms
ZIKA B Up to 14 days
* Please indicate clearly if samples have / have not been incubated prior to sending to the laboratory. If Lith Hep (green top)
tube is used, please request as TBQ4 and ensure sample is received in the laboratory within 16 hours of sample taking.
** If Tissue Transglutaminase (TAA) is regulated and is LOW (<0.2U/ml) total IgA will be reflexed. If total IgA is low (<0.1g/L)
deamidated gliadin IgG will be reflexed. If Tissue Transglutaminase (TAA) is HIGH (>10 U/ml), endomysial IgA will be reflexed
as confirmatory test.
*** Do not refrigerate samples at any time. Samples must be received by TDL within 24 hours of taking the sample. Please do
not send samples to the laboratory on Saturdays. T-SPOT®.COVID test is CE marked

Immunology
HLA DQ2/DQ8

Coeliac/Gluten Profile 2 GSA2 AB 10 days
Coeliac/Gluten Sensitivity Profile GSA B 2 days
GLUTEN SENSITIVITY
EVALUATION COELIAC DISEASE PROFILE 2 GLUTEN ALLERGY PROFILE
(COELIAC DISEASE ANTIBODY)
Endomysial IgA Endomysial IgA Gluten single IgE Allergen

Gliadin deamidated lgG Gliadin deamidated lgG Endomysial Antibodies IgA
Total IgA* Total IgA* Deamidated Gliadin IgG
Tissue Transglutaminase (IgA) Tissue Transglutaminase (IgA) Antibodies
HLA DQ2/DQ8 Tissue Transglutaminase IgA
HLA DQ2/DQ8
TAT TAT TAT
Total IgA*
2 10 10
DAYS DAYS DAYS
GSA GSA2 GLUT
B AB ABB
* To reduce the risk of missing IgA deficient patients, a Total IgA will be run for all low Tissue
Transglutaminase IgA results.
If IgA deficiency is identified, a reflex deaminated Gliadin IgG will be carried out to determine whether
the patient is likely to have coeliac disease.
Coeliac pathway:
1 Initial TTG IgA samples are received and tested
2 If TTG IgA is LOW <0.2 U/ml reflex testing for Total IgA will be undertaken
3 If Total IgA is LOW <0.1 g/L then reflex testing for Gliadin IgG test will be undertaken
4 If TTG IgA is HIGH (>/= 10 U/ml then reflex testing for Endomesial IgA will be undertaken
as a confirmatory test.
Endomysial IgA
• This is no longer available as a stand-alone test. If requested the request will default to TTG IgA.
• However if TTG IgA is positive endomysial IgA will be carried out as a confirmatory test.
This only needs to be done once in the patients history.
Endomysial IgG requests
• No longer available as a single test request.
Immunology
Deamidated gliadin IgA requests
• This is no longer available. If requested the request will default to TTG IgA.
Deamidated gliadin IgG requests
• This can be requested as an individual standalone test as well as being incorporated
into the coeliac pathway. This may be useful when testing children’s samples.
Appropriate clinical comments will be added to results automatically – as follows:
TTG IgA Total IgA result Deamidated gliadin Comment

result U/ml for new assay g/L IgG result U/ml
0.2 to 10 N/A N/A Coeliac disease unlikely (please note
that if the patient has no dietary gluten
results may appear false negative)
>/= 10 N/A N/A Suggestive of coeliac disease
<0.2 >/= 0.1 N/A Coeliac disease unlikely (please note
that if the patient has no dietary gluten,
<0.2 <0.1 >/=10 Consistent with coeliac disease in
a patient with selective IgA deficiency
<0.2 <0.1 <7 Coeliac disease unlikely (please note
that if the patient has no dietary gluten,
<0.2 <0.1 7-10 Result equivocal suggest referral to
a gastroenterologist for consideration
of duodenal biopsy
Coeliac Disease (CD) is an immune-mediated disease of the intestines that is triggered by the ingestion
of gluten in genetically susceptible individuals. Gluten is the major protein component of wheat, rye,
and barley. Genetic predisposition does play a key role in CD, and it is well known that CD is strongly
associated with specific HLA class II genes known as HLA-DQ2 and HLA-DQ8. Approximately 95% of
CD patients express HLA-DQ2, and the remaining patients are usually HLA-DQ8 positive. The negative
predictive value for both tests is higher than 99%. However, the HLA-DQ2 allele is common and is carried
by approximately 30% of Caucasian individuals. Thus, HLA-DQ2 or HLA-DQ8 is necessary for disease
development but is not sufficient for disease development; its estimated risk effect is only 36-53%.
Note: History taking is important if a patient has been on a gluten-free diet for 6-12 months,
approximately 80% will lose their antibody response. After 5 years this increases to >90%.

Immunology
RHEUMATOLOGY RHEUMATOLOGY
RHEUMATOLOGY
PROFILE 3 PROFILE 5
PROFILE 1
Rheumatoid Disease Mono Arthritis
FBC FBC FBC

ESR ESR ESR
Uric Acid Uric Acid Uric Acid
RF RF RF
Anti CCP Antibodies (RF) Anti CCP Antibodies (RF) Anti CCP Antibodies (RF)
C Reactive Protein Antinuclear Autoantibodies Antinuclear Autoantibodies
C Reactive Protein C Reactive Protein
HLA B27
TAT TAT TAT

2 2 3
DAYS DAYS DAYS
RH RH3 RH5
AB AB AABB
RHEUMATOLOGY RHEUMATOLOGY
PROFILE 2 PROFILE 4 RHEUMATOLOGY
PROFILE 6
General screen for Systematic Lupus
Rheumatoid Factor
Connective Tissue Disorders Erythematosus
FBC FBC RF
ESR ESR Anti CCP Antibodies (RF)
Uric Acid Antinuclear Autoantibodies C Reactive Protein
Antinuclear Autoantibodies Anti-dsDNA IgG
Anti-dsDNA IgG Antibodies to Extractable TAT
Antibodies to Extractable Nuclear Antigens (ENA) 2
Nuclear Antigens (ENA) Anti nRNP DAYS
Anti nRNP Anti Sm
Anti Sm Anti Ro (SS-A) RH6
Anti Ro (SS-A) Anti La (SS-B)
Anti La (SS-B) Anti Jo-1 B
Anti Jo-1 Anti Scl 70
Anti Scl 70 Anti CENP
RHEUMATOLOGY
Anti CENP RF PROFILE 7
RF Anti CCP Antibodies Sjogren’s Syndrome
Anti CCP Antibodies Anti Cardiolipin Autoantibodies
HLA B27 Complement 3,4 Anti RO (SS-A)
C Reactive Protein C Reactive Protein Anti La (SS-B)
CENP-B Salivary Antibodies (SAB)
C Reactive Protein
TAT TAT TAT
3 2 10
DAYS DAYS DAYS
RH2 RH4 RH7
AABB ABB B
Patients with Irritable Bowel Syndrome (IBS) may benefit by testing for Calprotectin, see page 79 for details.
Immunology
CHLAMYDIA SPECIES SPECIFIC
AUTOANTIBODY PROFILE I AUTOANTIBODY PROFILE II
(MIF) ANTIBODY SCREEN
Thyroid Peroxidase Antibodies Thyroid Peroxidase Antibodies Chlamydia trachomatis
Antinuclear Antibodies Islet Cell Antibodies (serovar A-K & L1-L3)
Mitochondrial Antibodies Adrenal Antibodies Chlamydia pneumoniae
Smooth Muscle Antibodies Gastric Parietal Cell Antibodies Chlamydia psittaci
Gastric Parietal Cell Gonadal (Ovarian/
Antibodies Testicular) abs
LKM TAT TAT TAT
2 2 2
DAYS DAYS DAYS
AUTO ENDO CHAB
B B B
FAECAL CALPROTECTIN CHRONIC FATIGUE
ELASTASE PROFILE SYNDROME PROFILE
Faecal Calprotectin Epstein-Barr Virus
Faecal Elastase Antibody Profile
Lymphocyte Subsets (CD4/CD8)*
CRP
Vitamin D (25 OH)
TAT TAT
5 5
DAYS DAYS
CEP VIP1
RF A + B 10

Tropical and travel-related immunology
Amoebic (E. histolytica) Antibodies AFAT B 2 days

Amoebic (E. histolytica) PCR AMAG RF 2 days
Bilharzia (Schistosome) Antibody Screen BILH B 14 10 days
Mid-morning terminal
Bilharzia (Urine) USCH 1-2 days
urine following exercise 14
BORR B 9,14 2 days
IgG, IgM – see page 90
Borrelia Antibodies (Lyme
BORM B 2 days
Disease) IgM – see page 90
Borrelia Confirmation
BORC B 9,14 10 days
(Immunoblot) – see page 90
Cryptosporidium Detection by PCR CRPA RF 2 days
Dengue Virus Serology DENG B 9,14 5 days
Echinococcus (Hydatid) Antibodies EFAT B 9,14 5 days
Enteric Organism Rapid Detection EORD RF 2 days
Filaria (Lymphatic and Non-
FIFA B 9,14 10 days
Lymphatic) Antibodies
Insect/Worm/Ova/Cysts FLEA Send Specimen 9,14 5 days
Leishmania Antibodies LEIS B 5 days
Malarial Antibodies (Pl. falciparum) MALA B 9,14 5 days
Malarial Antibodies (species specific) MALS B 9,14 10 days
Post-Travel Screen 1 (Prior to 6 weeks) PTS A A B G 14 10 days
Post-Travel Screen 2 (Prior to 6 weeks) PTS2 A A B B B G 14 10 days
Rickettsial Species Antibody Profile RICK B 7 days
Schistosome (Bilharzia) Antibodies BILH B 14 10 days
Toxoplasma Antibodies (IgG+IgM) TFAM B9 4 hours
Tropical Screen (from 6 weeks post-travel) TROP B B 9,14 10 days
ZIKU RU Up to 14 days
ZIKA B Up to 14 days
TROPICAL SCREEN POST-TRAVEL SCREEN 1 POST-TRAVEL SCREEN 2
(from 6 weeks post-travel) (Prior to 6 weeks) (Prior to 6 weeks)
Amoebic Antibodies Haematology Profile Haematology Profile
Schistosomal Antibodies Biochemistry Profile Biochemistry Profile
(Bilharzia) Schistosome Abs Schistosome Abs
Echinococcus Antibodies (Hydatid) Malarial Abs Malarial Abs
Leishmania Antibodies Hep A IgM Abs
Malarial Antibodies (IFA) Hep B sAg
Toxoplasma Antibodies IgG Hep C Abs
Toxoplasma HIV Duo
TAT TAT TAT
Antibodies IgM
10 10 10
DAYS DAYS DAYS
TROP PTS PTS2
B B 9,14 A A B G14 A A B B B G14
DVT/PRE-TRAVEL SCREEN ENTERIC ORGANISM RAPID DETECTION
FBC Detection of Bacterial, Viral and Parasitic Infection by Multiplex

Factor II Prothrombin Gene Real-Time PCR
Factor V Leiden Bacteria and Bacterial Toxins
Anticardiolipin Antibodies C. difficile Toxin A/B gene, Campylobacter spp., Enteroaggregative E.coli
(EAEC), Enteroinvasive E.coli (EIEC)/Shigella, Enterotoxigenic E.coli (ETEC),
Enteropathogenic E.coli (EPEC), Plesiomonas shigelloides, Salmonella,
Shiga-toxin producing E.coli (STEC) stx1/stx2, Shiga-toxin producing E.coli
(STEC) O157:H7, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus,
Yersinia enterocolitica
Viruses
TAT Adenovirus 40/41, Astrovirus, Norovirus GI, Norovirus GII,
5 Rotavirus A, Sapovirus (I, II, IV, V)
DAYS
Parasites
DVT1 Cyclospora cayetanensis, Cryptosporidium spp.,
Entamoeba histolytica, Gardia lamblia
AAB9 This does NOT include stool for m/c/s – this needs to be requested as TAT
a separate test. Please provide two samples if this is required.
2
DAYS
EORD
RF

Borrelia Antibodies (Lyme Disease) Borrelia burgdorferi

   
Presence of antibodies confirms infection with the Lyme Disease
 spiral bacterium (spirochaete) known

 
as Borrelia burgdorferi by a bite from an infected tick. Patients bitten

by an infected tick which is not
 
removed within a day or so may develop Lyme  disease. An expanding rash would usually appear at
 
the site of the bite within 3 to 30 days in a
large proportion of
 
 those infected. The rash spreads and
often develops a ‘bulls-eye’ appearance. Many also develop flu-like symptoms with aching joints
 and
 
  
muscles. The disease can later affect the nervous
 system, joints and other body systems.  
  
   
Borrelia Antibodies IgM (BORM):
detectable after 2-3 weeks 
increasing up to 6 weeks.  


Borrelia Antibodies IgG/IgM 

(BORR): detectable after several 


weeks increasing to maximum at 

4-6 months and may remain at 

high levels for many years. 



Borrelia Confirmation 

(Immunoblot) (BORC): 

The ELISA test is sensitive but 

has a well-documented high 


false positive rate giving positive 

results in cases of glandular 
 
fever, rheumatoid arthritis and 

other autoimmune conditions. 

If the ELISA is positive testing by 


Immunoblot confirms a diagnosis 

by Lyme disease. IgM and IgG 
antibodies are tested separately.

It is essential that details of the
IgG +IgM Elisa are provided for
this test.
   
Virology
IMMUNE STATUS
Hepatitis A Immunity (IgG/IgM) HAIM B 4 hours

Hepatitis B Immunity HBIM B 4 hours
Measles Antibodies (IgG) Immunity MEAS B 1 day
Measles Antibodies (IgM) MEAM B9 2 days
Measles, Mumps, Rubella (MMR) MMR B 1 day
Mumps Antibodies (IgG) MUMP B 1 day
Mumps Antibodies (IgM) MUMM B 1 day
Pertussis (Whooping Cough) Antibodies PERS B 5 days
Pneumococcal Antibody Screen PNEU B 5 days
Polio Virus 1, 2, 3 Antibodies POLO B9 15 days
Rabies Antibody RABI B 10 days
Rubella Antibody (IgG) RUBE B 4 hours
Rubella Antibody (IgM) RUBM B 4 hours
Rubella PCR RUBP A / Amniotic Fluid 5 days
Tetanus Antibody TETA B 5 days
Varicella Zoster Antibodies (IgG) VZOS B 1 day
Varicella Zoster Antibodies (IgM) VZOM B 1 day
Hepatitis B Immunity/Vaccination
NEEDLE STICK INJURY PROFILE
Anti HBs
(Donor – Not recipient)
less than 10 mIU/ml Non-immune to Hepatitis B Hep B sAg
Hep C Abs
10 – 50 mIU/ml borderline – Booster indicated HIV 1+2 Abs/p24 Antigen
TAT
Serum saved for 2 years
50 – 100 mIU/ml low level immunity – Booster suggested
4
HOURS
100 and over Immune to Hepatitis B NSI
BB
HEPATITIS VIRAL LOAD SAMPLE INSTRUCTIONS
Whole blood can be stored at 2°C to 30°C and must be centrifuged within 24 hours of specimen collection.
Separate the plasma or serum from the pelleted red blood cells following the manufacturer’s instructions
for the tube used. Plasma or serum can be tested on the Panther system in the primary tube or transferred
to a secondary Aptima Specimen Aliquot Tube (SAT) for testing on the Panther system. If not tested
immediately, plasma and serum can be stored in accordance with the specifications below. If transferred
to the SAT, plasma may be frozen at -20°C or -70°C, and serum may be frozen at -20°C. Do not freeze
specimens in EDTA, ACD, or serum primary collection tubes.
After centrifugation: In the primary collection tube at 2°C to 8°C for up to 3 days
In the Aliquoted Tubes: at 2°C to 8°C for up to 5 days
In the Aliquoted Tubes: at -20°C or -70°C for up to 90 days

Virology
HEPATITIS TESTING
Hepatitis (Acute) Screen AHSC B 4 hours

Hepatitis A (IgM) HAVM B 4 hours
Hepatitis A Immunity (IgG/IgM) HAIM B 4 hours
Hepatitis A Profile HEPA B 4 hours
Hepatitis A RNA by PCR HAVR A or B 3 weeks
Hepatitis A, B & C Profile ABC B 4 hours
Hepatitis B (PCR) Genotype BGEN A 7 days
Hepatitis B ‘e’ Antigen and Antibody HEPE B 4 hours
Hepatitis B Core Antibody – IgM HBCM B 4 hours
Hepatitis B Core Antibody – Total HBC B 4 hours
Hepatitis B DNA (Viral load) – see page 91 DNAB A 5 days
Hepatitis B Immunity HBIM B 4 hours
Hepatitis B Profile HEPB B 4 hours
Hepatitis B Resistant Mutation HBRM A or B 7 days
Hepatitis B Surface Antigen AUAG B 4 hours
Hepatitis C Abs Confirmation (RIBA) RIBA B 5 days
Hepatitis C Antibodies HEPC B 4 hours
Hepatitis C Antigen (Early detection) HCAG B 4 hours
Hepatitis C Genotype CGEN A 5 days
Hepatitis C Quantification (Viral Load) – see page 91 QPCR A or B 5 days
Hepatitis Delta Antibody HEPD B 5 days
Hepatitis Delta Antigen HDAG B 5 days
Hepatitis Delta RNA DRNA A (Frozen plasma) 5 days
Hepatitis E (PCR) EHEP A 2 weeks
Hepatitis E IgG/IgM HBE B 5 days
Hepatitis G (PCR) HEPG A (Frozen plasma) 2 weeks
HEPATITIS ACUTE VIRAL HEPATITIS

B PROFILE HEPATITIS SCREEN A, B & C PROFILE
Hep B Surface Antigen Hepatitis A IgM Abs Hepatitis A Profile
Hep B Surface Antibodies Hepatitis B Surface Antigen Hepatitis B Profile
Hep B Core IgG/IgM Hepatitis C Abs Hepatitis C Abs
LFT’s
TAT TAT TAT

4 4 4
HOURS HOURS HOURS
HEPB AHSC ABC
B B B
Virology
All virology samples are processed as per HBV Viral Load (DNAB)
manufacturers sample requirements and guidelines. This assay measures the concentration of Hepatitis B
viral DNA in patient serum. The test enables the viral
Hepatitis virus is named in order of their discovery
load at the beginning of treatment to be established
A, B, C, D, E and G.
and, thereafter, monitored to indicate treatment
Hepatitis A success.
Hepatitis A is spread through food and water that
have been contaminated with the virus derived from HBV Genotyping (BGEN)
human faeces and urine. Hepatitis A is an acute Identifies the hepatitis B genotype (A to H) in a patient’s
infection, not a chronic form of the disease. serum/plasma. This is critical for determining treatment
and monitoring response.
HBV Drug Resistance Detection (HBRM)
HBV Assays Detects hepatitis B virus wild-type and drug-induced
Hepatitis B surface antigen (HBsAg) (AUAG) mutations, associated with lamivudine, entecavir
A protein on the surface of HBV; it can be detected and tenofovir.
in high levels in serum during acute or chronic HBV
infection. The presence of HBsAg indicates that the
person is infectious. The body normally produces HCV Assays
antibodies to HBsAg as part of the normal immune HCV Antibody (HEPC)
response to infection. HBsAg is the antigen used to The test indicates exposure to virus but does not
make Hepatitis B vaccine. necessarily signify current infection. The HCV antibody
test may therefore be used to screen patients for
Hepatitis B surface antibody (anti-HBs) (HBIM)
possible HCV infection to detect the presence of
The presence of anti-HBs is generally interpreted as
antibodies to the virus, indicating exposure to HCV.
indicating recovery and immunity from HBV infection.
This test cannot tell if the viral infection is active,
Anti-HBs also develops in a person who has been
only that you were exposed to the virus in the past.
successfully vaccinated against Hepatitis B.
HCV Viral Load (QPCR)
Total Hepatitis B core antibody (anti-HBc) (HBC)
Measures the concentration of hepatitis C viral RNA in
Appears at the onset of symptoms in acute Hepatitis B
patient serum. This state-of-the-art assay enables the
and persists for life. The presence of anti-HBc indicates
viral load at the beginning of treatment to be established
previous or ongoing infection with HBV in an undefined
and, thereafter, monitored to indicate treatment success.
time frame.
HCV Genotype for Treatment (CGEN)
IgM antibody to Hepatitis B core antigen
Determines the HCV genotype in a patient’s serum.
(IgM anti-HBc) (HBCM)
The result is presented as being of either Genotype
Positivity indicates recent infection with HBV
[1, 5, 6], [4] or [2, 3]. This grouping reflects required
(≤6 months). Its presence indicates acute infection.
treatment duration of the different genotypes.
Hepatitis B e antigen and antibody (HEPE)
HCV Drug Resistance
Hepatitis B e antigen (HbeAg): A secreted product of
Detects hepatitis C wild-type or drug-induced mutations
the nucleocapsid gene of HBV that is found in serum
associated with resistance to HCV drugs including
during acute and chronic Hepatitis B. Its presence
NS5A inhibitors, NS5B inhibitors or NS3 inhibitors.
indicates that the virus is replicating and the infected
person has high levels of HBV.
Hepatitis B e antibody (HBeAb or anti-HBe): Produced
by the immune system temporarily during acute HBV
infection or consistently during or after a burst in viral
replication. Spontaneous conversion from e antigen
to e antibody (a change known as seroconversion) is
a predictor of long-term clearance of HBV in patients
undergoing antiviral therapy and indicates lower
levels of HBV.

Virology
Hepatitis B Surface Antigen
HEPATITIS B
• Transmission: • Development of chronic form:
Sexual, parenteral, perinatal, direct contact Yes (5% of adult cases).
between individuals. • Prevention:
• Clinical Signs: Vaccination ++++; specific IgG.
Asymptomatic in 90% of cases.
• Main Marker:
• Cure: 95% of cases (adults). HBS Ag, anti HBc IgM, total anti HBc Ab,
• Complications: How to request for Hepatitis B Surface Antigen / A
Cirrhosis and hepatocellular carcinoma.
Anti-HBs Ab, HBe Ag, Anti-HBe Ab, HBV DNA.
Not detected Weakly Reactive or

Total anti-HBc Ab
Positive
Proceed to Full Hep B Profile

Incubation (undertaken byphase
Acute TDL as routine reflex Cure
4-7 weeks testing to identify
4-12 weeksactive information) years
Anti-HCV Ab
Not detectedHCV Ag Positive

HepB e Antigen
HCV RNA
HepB e Antigen
HepB core Specific IgM HepB core Specific IgM
contact clinical signs

HCV RNA
HBs Ag
HCV Ag
HepB
Anti-HCV AbDNA Quantitative (reports viral load)
Increase in transaminase levels
20 – 4656 IU/ml low viraemia
4656 – 4.4 million IU/ml moderate viraemia
> 4.4 million IU/ml high viraemia
Incubation Acute phase Convalescence Cure

4-12 weeks 2-12 weeks 2-16 months years
Total anti-HBc Ab
Anti-HBs Ab
HBs Ag
Anti-HBe Ab
Anti-HBc IgM
HBe Ag
clinical signs immunity

contact infectivity
HBV DNA
HBe Ag
HBs Ag
Anti-HBc IgM
Total Anti-HBc Ab
Anti-HBe Ab
Anti-HBs Ab
Virology
Hepatitis C Antibodies
HEPATITIS C
• Transmission: • Complications: • Prevention:
Parenteral, nosocomial, sexual. Cirrhosis and hepatocellular Hygiene, no vaccination.
• Clinical Signs: carcinoma. • Main Marker:
Asymptomatic in 90% of cases. • Development of chronic form: Anti HCV Ab, HCV RNA.
• Cure: Yes (80% of adult cases).
How to request for Hepatitis C Antibodies

95% of cases (adults).
Not detected Weakly Positive

Reactive
mial.
Positive
0% of cases. The prognostic value
of HCV genotyping
lts). Chronic hepatitis; cirrhosis
may, ultimately develop in
HCV RNA Quantitative (reports viral load)
tocellular up to 20% of HCV cases.
< 4,000 IU/ml considered low levels Genotype 1b is more
ronic form: 4,000 – 40,000 IU/ml considered moderate levels frequent (~70%)
cases). > 40,000 IU/ml considered high levels Genotype 1a, 2a and 2b
are less frequent (~10%)
ation.
Patient / treatment
management
Confirmation by HCV
Viral Load (Quantitative)
Positive Not detected Total anti-HBc Ab

(Proceed to Hep C RNA (No further investigation)
Viral Load)
Incubation Acute phase Cure

4-7 weeks 4-12 weeks years
Anti-HCV Ab
HCV Ag
HCV RNA
contact clinical signs

HCV RNA
HBs Ag
HCV Ag
Anti-HCV Ab

Incubation Acute phase Convalescence Cure
Virology
HIV TESTING
HIV-1 Proviral DNA HIVP A Whole blood 7 days

HIV Confirmation of Positive Screens
HIVC B 1 day
(Using 3 methodologies)
HIV/HBV/HCV Screen by PCR/NAAT A 10mls or 2 x 4mls
STDX 3 days
(10 days post exposure) (Vacutainer only)
HIV Rapid RNA HIV-1 QUALITATIVE LHIV A (Vacutainer only) 4 hours
HIV Screening: HIV1 & 2 Abs/p24 Ag (4th Gen) HDUO B 4 hours
HTLV 1 & 2 Abs. (Human T
HTLV B 8 hours
Lymphotropic Virus Type I-II)
HTLV by PCR HTLP A Whole blood 21 days
TDL TINY™ SELF-COLLECTION HIV TESTS

(please refer to page 150 for information about self-collection tests)
4th Generation HIV1 & 2 Abs/p24

THIV B Tiny™ 4 hours
Ag (45 days post-contact)*
*Reactive 4th Gen HIV Results require confirmation with a follow up venous blood sample.
HIV POSITIVE PATIENT MONITORING


HIV Therapeutic Drug Monitoring TDM J 21 days
HIV-1 RNA Viral Load by PCR HIV1 A A (2 x 6ml whole blood) 3 days
HIV-2 RNA by PCR HIV2 A 21 days
HIV-1 GENOTYPIC RESISTANCE TESTING

HIV-1 Genotypic Resistance (Integrase) INTE A A (2 x 6ml whole blood) 21 days

HIV-1 Genotypic Resistance (RT & Protease) HIVD A A (2 x 6ml whole blood) 21 days
HIV-1 Tropism TRPM A A (2 x 6ml whole blood) 28 days
HLA B*57:01 HL57 A9 10 days
HLA-B*57:01 should be tested before starting patients on an Abacavir (ABC) containing regimen to reduce the risk
of hypersensitivity reaction. HLA-B*57:01-positive patients should not be prescribed ABC and a positive status
should be recorded as an ABC allergy in the patient’s medical record.
Virology
RAPID XPERT HIV-1 RNA VIRAL LOAD
RAPID XPERT HIV-1 RNA QUALITATIVE RAPID TESTING FOR HIV-POSITIVE
EARLY DETECTION FROM 10 DAYS PATIENT PROGNOSIS AND RESPONSE TO
ANTIRETROVIRAL THERAPY
HIV-1 RNA HIV-1 RNA VIRAL LOAD (40 copies/ml)
Sample must be received in the laboratory Sample must be received in the laboratory
within 24 hours of sample taking TAT within 24 hours of sample taking TAT
4 4
HOURS HOURS
LHIV RHIV
A (Vacutainer only) A (Vacutainer only)
HIV / HBV / HCV SCREEN

(SIMULTANEOUS TESTING FOR
HIV1/HIV2/HBV/HCV BY PCR/NAAT)
Positive findings will be reflexed for individual qualitative

confirmatory testing using the Roche Cobas Ampliscreen
HIV1 and HIV2 (RNA)

Hepatitis B Virus (HBV DNA)
Hepatitis C Virus (HCV RNA)
Samples must be received in the laboratory TAT
within 2 days of sample taking 3
DAYS
STDX
A 10mls or 2 x 4mls (Vacutainer only)

Virology
Adenovirus by PCR ADV A / PCR / VS / SC 7 days

Arbovirus Antibodies/Abs ARBO B 9,14 3 weeks
Atypical Pneumonia Screen APS B 2 days
Bancroftia/Oncerciasis/Filarial Antibodies TFIF B 14 2 weeks
BK Polyoma Virus by PCR BKPV A /B /RU 5 days
Cat Scratch Fever (Bartonella IgG+IgM) CAT B 5 days
Chikungunya Virus Abs CHIK B 9,14 10 days
COVID-19 (SARS-CoV-2) Rapid RNA
NEW Sequencing – Contact Lisa Levett for test COSQ RNA or PCR swab 43 48 hours
requirements: [email protected]
PCR Swab (nasal/
COVID-19 (SARS-CoV-2) RNA by PCR NCOV 24 hours
pharyngeal)
COVID-19 / FLU / RSV Screen FLU4 PCR nasopharyngeal 2 days
Coxsackie Antibodies (IgM) COXM B 10 days
CSF Screen by PCR VPCR CSF 2 days
Cytomegalovirus (CMV-DNA) Amnio CMVD AF 5 days
Cytomegalovirus (IgG/IgM) Antibodies CMV B 4 hours
Cytomegalovirus (PCR) Semen SCVM Semen 7 days
Cytomegalovirus (PCR) Urine CMVU RU 5 days
Cytomegalovirus Avidity CMAV B 10 days
Cytomegalovirus DNA (PCR) CMVP A 5 days
Cytomegalovirus Resistance CMVR A A (2 x 6mls) 21 days
Dengue Fever PCR DPCR A or B 9,14 2 weeks
Epstein-Barr Virus Antibodies IgG/IgM EBVA A or B 2 days
Epstein-Barr Virus PCR EBVQ A 5 days
Hantavirus Serology HANV B9 10 days
Herpes Simplex I/II Antibody Profile (IgG) HERP B 2 days
Herpes Simplex I/II by PCR (Swab) HERS PCR 5 days
Herpes Simplex I/II by PCR (Urine) HERD FCRU / PCR / TPV 5 days
Herpes Simplex I/II IgM HERM B 2 days
HIV/HBV/HCV Screen by PCR/NAAT A 10mls or 2 x 4mls
STDX 3 days
(10 days post exposure) (Vacutainer only)
Human Herpes Virus – 6 by PCR HHV6 A 5 days
Human Herpes Virus – 8 (IgG) HHV8 B 10 days
Human Herpes Virus – 8 by PCR HV8D A 5 days
Human Parvovirus B19 – DNA PCRP A 2 weeks
JC Polyoma Virus by PCR JCPV A /B /CSF 5 days
Measles Antibodies (IgG) Immunity MEAS B 1 day
Measles Antibodies (IgM) MEAM B9 2 days
Measles PCR MEAP Buccal swab 48 hours
MERS Coronavirus Test MERS J 1 day
* Contact the laboratory for patient self-collection sample kits.

** CE marked IVD capillary kits must be used for self-collection samples and can be ordered through TDL Supplies.
Virology
Mumps Antibodies (IgM) MUMM B 1 day

Mycoplasma species – DNA MPCR A 5 days
Needle Stick Injury Profile NSI BB 4 hours
Neurological Viral Screen NVIR BB 2 days
Parvovirus Antibodies (IgM) PARV B 2 days
Parvovirus IgG Antibodies PARG B 2 days
Parvovirus IgG/IgM Abs PARP B 2 days
Pneumonia (Atypical) Screen APS B 2 days
Rotavirus in Stool by PCR ROTA RF 1 day
Rubella Antibody (IgG) RUBE B 4 hours
Rubella Antibody (IgM) RUBM B 4 hours
Rubella Avidity RUAV B 1 week
Torch Screen TORC B 2 days
Varicella Zoster – DNA VZPC A 5 days
Varicella Zoster Antibodies (IgG) VZOS B 1 day
Varicella Zoster Antibodies (IgM) VZOM B 1 day
Viral Antibody Screen VIRA BB 2 days
Viral Eye by PCR VPE PCR 3 days
PCR or as specified
Viral Respiratory RNA screen by PCR VPR 2 days
on the form
Viral Skin/Mucosa by PCR VPSK PCR 2 days
West Nile Virus Abs WNV B 2 weeks

Virology
VIROLOGY BY BLOOD
VIRAL ANTIBODY SCREEN NEUROLOGICAL VIRAL SCREEN TORCH SCREEN
Measles IgG Measles IgG Toxoplasma Antibodies

Measles IgM Measles IgM (IgG, IgM)
Mumps IgG Mumps IgG Rubella Antibody (IgG, IgM)
Mumps IgM Mumps IgM CMV Antibody (lgG, IgM)
Mycoplasma pneumonia CMV IgG Herpes Antibody TAT
CMV HSV 1 + 2 IgG (HSV1/HSV2 IgG) 2

DAYS
HSV 1 HSV 1 + 2 IgM
HSV 2 VZV IgG TORC
ATYPICAL PNEUMONIA SCREEN
Mycoplasma pneumonia Abs

Chlamydia pneumoniae (MIF)
TAT TAT Legionella TAT
2 2 pneumophila (IF) 2
DAYS DAYS DAYS
VIRA NVIR APS
BB BB B
VIROLOGY BY PCR
VIRAL RESPIRATORY VIRAL EYE BY PCR

COVID-19 / FLU / RSV SCREEN RNA SCREEN BY PCR
Respiratory Syncytal Virus (RSV) Throat swabs, Herpes Simplex virus

Flu A nasopharyngeal aspirates Varicella Zoster virus
Flu B TAT Adenovirus
Adenovirus
COVID-19 2 Parainfluenza 1,2,3,4
TAT
3
DAYS
DAYS
Influenza A and B
FLU4 Seasonal Coronavirus
VPE
(not COVID-19)
PCR nasopharyngeal Parechovirus
PCR
Rhinovirus
Enterovirus
VIRAL SKIN / MUCOSA BY PCR
Respiratory Syncytial virus CSF SCREEN BY PCR
A and B
If chicken pox or shingles
Human metapneumovirus Herpes Simplex virus
suspected, please indicate
Varicella Zoster virus
clearly on request form
TAT TAT
Enterovirus TAT
Herpes Simplex virus
Varicella Zoster virus 2 2 2
DAYS DAYS DAYS
VPSK VPR VPCR
PCR PCR or as specified on the form CSF
Tumour markers/sites
Alpha Feto Protein AFP B 4 hours

Beta HCG (Oncology) HCGQ B 4 hours
Requires patient informed consent
Breast Cancer NGS Panel – full gene sequencing
GENE A A 9,11 4 weeks
CA 15-3 C153 B 4 hours
CA 19-9 C199 B 4 hours
CA 50 CA50 B 5 days
CA 72-4 C724 B 5 days
CA 125 C125 B 4 hours
Carcino Embryonic Antigen CEA B 4 hours
Complex PSA (Prostate Specific Ag) CPSA B 3 days
Cyfra 21-1 CY21 B 4 days
Early CDT-Lung CDTL B 10 days
HE4 + ROMA (Earlier Detection of Ovarian Tumour) HE4 B 1 day
Neurone Specific Enolase NSE B 5 days
NMP22 (Bladder tumour) NMP J1 4 days
Osteocalcin OST B (Frozen) 4 4 days
Prostate Profile (Total & Free PSA) PR2 B 4 hours
Prostate Specific Antigen (Total)* PSPA B 4 hours
Pyruvate Kinase (M2-PK) M2ST RF 4 5 days
Pyruvate Kinase (M2-PK) M2PK A 5 days
S100 Malignant Melanoma S100 B 4 days
Squamous Cell Carcinoma SCC B 4 days
Testicular Tumour Profile TTP B 4 hours
* Results that fall between 4.00 ug/L and 10.00 ug/L will
automatically reflex to a Free PSA with a calculated ratio. HE4
Earlier Detection of Ovarian Tumour
The ratio of Free to Total PSA may help discriminate between
prostate cancer and benign prostatic hyperplasia. HE4 / CA 125 / ROMA
Calculated Algorithm for pre
TAT
TUMOUR MARKERS/SITES and post menopausal risk
of malignant disease 1
DAY
AFP: Liver, Testes Cyfra 21-1: Oesophagus,
BHCG: Testes Lung, Bladder HE4
BRCA1/2: Breast HE4: Ovary
CA 125: Ovary NMP22: Bladder B

CA 15-3: Breast NSE: Lung, Brain, Thyroid
PROSTATE PROFILE
CA 19-9: Stomach, Colorectal, PSA: Prostate
Total and Free PSA
Gastrointestinal, Pancreas S100: Melanoma
CA 50: Bladder, Colon SCC: Oesophagus, Bronchus, Total PSA
TAT
Free PSA
CDTL: Lung Lung, Cervix
Calculated Ratio 4
HOURS
CEA: Stomach, Liver, Breast,
Ovary, Gastrointestinal, Lung
PR2
Tumour markers/sites
Site Tumour Sample Turnaround Site Tumour Sample Turnaround

marker type time marker type time
Oesophagus CA 19-9 serum 4 hours Thyroid
CEA serum 4 hours
CEA serum 4 hours Thyroglobulin serum 1 day
SCC serum 4 days Calcitonin 1ml 1 day
Frozen serum
Site Tumour Sample Turnaround

marker type time Site Tumour Sample Turnaround
marker type time
Bronchial/ NSE* serum 5 days
Lung SCC* serum 4 days Breast Breast Cancer EDTA 4 weeks
NGS Panel
CDTL serum 7 days
CA 15-3 serum 4 hours
CEA serum 4 hours
CEA serum 4 hours
Cyfra 21-1 serum 4 days

Site Tumour Sample Turnaround marker type time
marker type time Liver AFP serum 4 hours
Bile duct CA 19-9 serum 4 hours CEA serum 4 hours
CEA serum 4 hours Ferritin serum 4 hours

Pancreas CA 19-9 serum 4 hours Gastro- CEA serum 4 hours
CEA serum 4 hours intestine CA 19-9 serum 4 hours

Carcinoid 5-HIAA 24 hour 5 days Ovary Ovarian Cancer EDTA 4 weeks
urine/ NGS Panel
acidified CA 125 serum 4 hours
HE4 serum 1 day
marker type time AFP serum 4 hours
Bladder/ CEA serum 4 hours
Chorion CA 50 serum 5 days Site Tumour Sample Turnaround
NMP22 urine 4 days marker type time
Colon CEA serum 4 hours
Site Tumour Sample Turnaround CA 50 serum 5 days
marker type time
Cervix/ SCC serum 4 days
Uterus CEA serum 4 hours Site Tumour Sample Turnaround
marker type time
Testes AFP serum 4 hours
Site Tumour Sample Turnaround Beta HCG serum 4 hours
marker type time (quantitative)
Prostate Prostate serum 4 hours
Profile (Total + Free PSA) Site Tumour Sample Turnaround
marker type time
Osteocalcin serum 4 days
Site Tumour Sample Turnaround (frozen)
marker type time
Melanoma S-100 serum 4 days
* NSE: Neurone Specific Enolase
SCC: Squamous Cell Carcinoma
TDL Genetics
TDL Genetics is a consultant-led service which is
able to provide extensive expertise in the testing,
diagnosis and genetic counselling of inherited
disorders. Genetic tests are performed on DNA
for molecular genetic analysis and on whole chromosomes for cytogenetic analysis. Some tests are part of profiles
that can be linked with assays from other TDL disciplines, such as biochemistry and haematology, to give more
comprehensive results for the patient.
Genetic tests are available for:
• Prenatal diagnosis and rapid trisomy • Genetic variation that influences risk of disease
screening by Amnio-PCR • Identity studies (paternity, zygosity, tissue typing)
• Carrier screening • Fertility studies
• Newborn chromosome analysis • Products of conception
• Confirmation of symptomatic individuals • Cancer
and pre-symptomatic testing
Genetic testing is sometimes complex and tests will vary in their ability
to detect mutations or to detect all patients who have, or will develop, the
disease. Some tests are diagnostic for a condition, others are indicative
or are associated with an altered risk for a condition. Results can affect DNA peaks from
the lives of individuals and have implications for their family, for insurance normal fetus
and employment. Where testing will predict the inheritance of a disease in
a healthy person, counselling and consent are mandatory. For these tests,
please complete the Genetic Request form at the back of the guide (including
informed consent). Our service provides result interpretation and risk
assessment to patients and their family members. Genetic counselling
can be arranged by TDL’s Consultant Clinical Geneticist.
DNA peaks from
To meet the increasing range and complexity of genetic testing we have Down Syndrome fetus
developed an excellent collaboration with other specialist laboratories.
Tests marked GENE are sent to these laboratories within our network and have a fixed price.
GENE panel composition may change throughout the year to reflect new and improved developments.
Turnaround times may be longer if follow-up studies are required.
Specimen Receipt at The Doctors Laboratory is 24 hours a day. Specifically, TDL Genetics results service is
available Monday to Friday 8.30am – 5.30pm with the laboratory also open for processing of samples on
Saturdays from 9.00am – 1.00pm.
Test codes, sample requirement codes, turnaround times, and prices may be found on the following pages.
All samples must be collected in the specified containers, as shown in the key at the back of this guide.
Samples should be fresh and in good condition (e.g. not clotted if EDTA or heparinised whole blood is required)
otherwise testing may be adversely affected and another sample may be required. Small DNA samples are
stored routinely for one year, larger DNA samples can be stored by special arrangement.
Instructions for transportation, sample labelling, and the completion of request forms can be found on the
reverse of the TDL Genetics Request Form.
The locations of the Laboratory and Patient Reception are indicated on the map on the reverse of each request
form. If you do not find the test you require in this directory or need more information and advice please
telephone the laboratory on 020 7307 7409.
Always provide Clinical Details and Family History with requests for Genetic Tests.
TDL Genetics
Sending samples to the laboratory
Essential information on sample container label:
Transport arrangements
• Patients surname and forename (not initials)
All specimens should be kept at room temperature
and despatched to the laboratory as soon as possible, • Date of birth
by TDL/international courier, first class post, guaranteed • Hospital number or reference number
next day delivery or a reliable alternative.
If a delay in sending the sample is unavoidable, please Consent forms
refrigerate overnight – DO NOT FREEZE. Specimens must Consent forms (at the back of this guide) are available
not be allowed to come in contact with request forms, for genetic testing. As genetic testing may have
but should be kept separate by using dual – pocketed implications for other family members and is regarded
plastic bags. Specimens for inland postage must be as personal data, it is recommended that written
packed in a rigid crush-proof container according to consent is obtained wherever possible. In cases with
current Post Office guidelines. IATA guidelines should predictive testing for severe disorders, as indicated
be followed for international transport (Advice is available in the laboratory guide, it is essential that patients
from the laboratory). should also be offered formal genetic counselling.
It is the responsibility of the referring clinician to
Labelling of high risk samples obtain appropriate consent from the patient.
Please note that it is the responsibility of the referring
clinician to ensure that high-risk samples are clearly Unlabelled samples
identified to reduce the risk of infection to staff Unlabelled samples will ONLY be processed if the
and others. individual who took the sample can confirm the sample
is from the patient in question. In the absence of
Patient details on request forms this assurance, the sample will be discarded and
and samples a repeat required.
Request and consent forms are available directly
from TDL Genetics.
In order to avoid unnecessary time spent in obtaining
details please provide the following information:
Information for request forms:
• Surname, forename (not initials), date of birth
and biological sex of patient for postnatal referrals
• Full name (not initials) and location of
referring clinician
• Full address of clinician to whom the result
should be sent
• Legible clinical summary, including details
of any relevant family history
• Address for billing – Doctor, patient or other
• Gestation on prenatal samples
• Hospital or reference number
• Test required
104 Key: See page 23 for sample-taking and special handling instructions.
TDL Genetics
Genetic Testing
THE IMPORTANCE OF CLINICAL DETAILS
Clinical details are very important when providing genetic analysis. The more clinical information that is available
(e.g. details of ultrasound information, phenotypic features or family history) the better the service we can provide.
Failure to provide this information for cytogenetic studies may result in an inaccurate analysis.
MOLECULAR GENETICS
Clinical details can be extremely important for clinical interpretation of a molecular genetic test.
For example, the clinical comments accompanying a cystic fibrosis screening report will vary depending
on whether the patient is a potential gamete donor or a person exhibiting a cystic fibrosis phenotype.
It may also be crucial, where a mutation has already been shown to be segregating in a family, to be provided
with information concerning the mutation and a family pedigree to ensure the correct analysis is performed
and reliable risk figures calculated.
CYTOGENETICS
Cytogenetic analysis is performed according to the Professional Guidelines for the Association of Clinical Genetic
Science and the recommendations provided are dependent on the clinical indications given for each case.
Clinical details inform the investigation at all stages:
• Prior to analysis, clinical details may indicate, for example, that procedures such as chromosome
breakage or leukaemic studies are required, which must be referred to the oncogenomic department
or specialist centre.
• During analysis they may indicate that extra cells should be screened to investigate the possibility of
mosaicism, for example in a diagnosis of suspected Turner syndrome, or that particular chromosomes must
be targeted for high-resolution study, for example chromosome 4 in suspected Wolf-Hirschhorn syndrome.
• When the analysis has been completed they may help to provide an accurate interpretation of the findings
and in some instances prompt further investigations, for example FISH or molecular genetic studies.
When clinical details are not available a routine analysis will be performed and a conditional report issued.
SAMPLE STABILITY
Molecular Genetic Samples
Whole blood collected in EDTA should be sent to the laboratory between 4˚C-28˚C within 48 hours.
Long term storage should be at 2-8°C.
Extracted DNA samples should be sent to the laboratory between 4˚C-28˚C.
Cytogenetic Samples
Cytogenetic studies require living cells, please ensure that samples reach the laboratory as soon
as possible. If a delay before dispatch is unavoidable, samples may be stored in a refrigerator (4°C)
but they must not be frozen.
Samples sent more than 48 hours after sampling, or kept at temperatures below 4˚C
and greater than 38˚C may have inhibited growth.
Information concerning packaging, transportation, and labelling of samples is provided
on the reverse of our TDL Genetics Request Form.
TDL Genetics
Requesting additional tests
Any further tests not requested at the time of sample receipt must be requested within:
• 1 week for tests requiring prenatal culture or cultured cells
• 2 weeks for DNA testing
• 2 weeks for cell culture testing
• 3 months for FISH testing
Samples can be stored for longer periods if specifically requested at the time of sample receipt.
POSTNATAL DIAGNOSIS (BLOOD CULTURE)

Reasons for analysis: Chromosome studies are requested where problems that may have a cytogenetic basis are
suspected, e.g. babies with birth defects; children with developmental delay and physical handicaps, or adults with fertility
problems. Additionally, prospective gamete donors are screened to detect carriers of balanced chromosome rearrangements.
Sample requirements: Lithium heparin whole blood specimens are required – gently mixed to prevent clotting and
must not be frozen, See sample stability section for cytogenetic samples. Sample volumes may be reduced for children
(2-4ml) and neonates (1-2ml).
Turnaround time: The usual turnaround time is 2-3 weeks however the laboratory will endeavour to respond to urgent
requests. Where a major trisomy is suspected, a rapid PCR screen may be performed to provide an urgent provisional result.
Notes
a) Rarely, blood samples fail to culture (<1%);
b) The culture may yield chromosomes of insufficient quality. This will be indicated on the report
and a repeat study suggested;
c) The laboratory should be informed if the patient has recently received a blood transfusion.
d) The laboratory should be informed if the patient has EVER had a bone marrow transplant.
e) The patient’s biological sex should be included on the request form.
PRENATAL DIAGNOSIS
Reasons for analysis: Chromosome studies are requested where pregnancies are identified as being at risk of
a cytogenetic abnormality e.g. positive maternal serum screening combined NT test; fetal abnormalities found
on ultrasound; or where a parent is a known carrier of a chromosome anomaly, or where a high risk trisomy
has been found by NIPT.
Sample requirements:
a) amniotic fluid – 10ml+ in a plain sterile, leak-proof container. Suitable containers can be provided
by the laboratory. The specimen must not be frozen. See sample stability section for cytogenetic samples.
b) chorionic villus – 5mg+ in sterile transport medium. Suitable containers containing medium can be provided
by the laboratory. The specimen must not be frozen. See sample stability section for cytogenetic samples.
c) fetal blood – 1-2ml LITHIUM HEPARIN whole blood, gently mixed to prevent clotting.
The specimen must not be frozen. See sample stability section for cytogenetic samples.
Turnaround time: This is dependent on the rate of cell growth, however, the usual turnaround time
is approximately 2 weeks. A number of circumstances now occur more frequently, as invasive prenatal
diagnosis becomes less common, that may result in delayed reporting time. These include:
a) A delay in transportation in order to collect a batch of samples to reduce courier costs.
Even when couriered promptly, sample growth may be slower than that seen in samples sent immediately.
b) Sampling at early or late gestations, for example to confirm non-invasive tests or follow up anomaly scans.
c) A tendency to take smaller quantities of sample or to take insufficient sample for multiple techniques.
d) The request for karyotyping as an add-on after an initial PCR test.
Fetal blood results will usually be reported by 10 calendar days. For all other prenatal tests,
please contact the laboratory prior to taking samples.
TDL Genetics
Notes
a) Maternal contamination, and mosaicism may complicate the analysis and may lead
to the suggestion that a second invasive test is performed.
b) Rarely, cultures fail to grow (overall <1%)
c) Very small chromosome abnormalities may not be detected (this is why the phrase
‘No trisomies or major chromosome abnormalities detected…’ is used in our reports).
d) for TTTs or heavily blood stained amniocentesis samples, please provide a maternal
EDTA blood sample for comparison studies.
SOLID TISSUE
Reasons for analysis: Fibroblast cultures may be used in addition to blood cultures, for example where tissue
specific mosaicism is suspected, or where blood samples cannot be obtained. POC samples may be requested
for early spontaneous miscarriages, stillbirths, or to confirm a prenatal diagnosis.
Sample requirements: All specimens should be placed in a sterile container, preferably containing transport medium.
This can be supplied by the laboratory. Sterile normal saline can be used if transport medium is not available.
Samples must not be placed in formaldehyde or other preservative and must not be frozen. See sample stability
section for cytogenetic samples.
Turnaround time: This is dependent on the rate of cell growth, however, the usual turnaround time
is approximately 4 weeks.
Notes
a) Material from miscarriages has a relatively high culture failure rate (around 20%). Where failure occurs,
alternative molecular methods may be attempted, usually a KaryoLite Bacs-on-Beads assay that can detect
whole monosomy or trisomy of any chromosome, if possible.
b) If no villus or fetal parts are identified in supposedly POC material and a normal female chromosome result
is found, this may indicate that maternal tissue has been cultured (this will be noted on our report).
c) Material from miscarriages can be returned for sensitive disposal if requested at the time of receipt.
If no special request is made, fetal material will be sent for incineration separate from general clinical waste.
Placental and other POC material will be disposed of in general clinical waste for incineration.
FLUORESCENCE IN SITU HYBRIDISATION (FISH)

Where FISH studies for specific microdeletion syndromes are required this must be indicated on the request form.
Note: FISH studies for a rapid pre or postnatal aneuploidy screen have now been superseded in our laboratory by
multiplex-PCR technology. Subtelomeric screens are now performed by Array CGH as part of developmental delay
investigations. Common microdeletion syndrome testing is now performed by BOBs analysis.
CELL LINE KARYOLOGY

The cytogenetics laboratory can perform cell line karyology on live cultures or fixed cells suspensions
(recommended) on a research basis. Please note: a laboratory processing charge of £100+VAT is applicable
to those cases wherein a successful analysis cannot be obtained. Please contact the laboratory for further details.
STATEMENT REGARDING MEASUREMENT UNCERTAINTY (MU)

Measurement Uncertainty is determined for each measurement procedure in the examination phase used to report
measured quantity values on patients’ samples. This is determined during verification of this assay for service
introduction; creation of laboratory standard operating procedures (SOP) and interpretation of the results.
Where examinations include a measurement step but do not report a measured quantity value, the laboratory
calculates the uncertainty of the measurement step where it has utility in assessing the reliability of the
examination procedure or has influence on the reported result.
Estimates of measurement uncertainty are regularly reviewed and are available upon request to laboratory users.
TDL Genetics
KEY PERSONNEL
Consultant Clinical Geneticist Prof. Michael Patton 020 7307 7409 [email protected]
Consultant Clinical Scientist Elaine Holgado 020 7307 7409 [email protected]
Head of Cytogenetics Rebecca Watts 020 7460 4787 [email protected]
Senior Cytogeneticist Kath Masters 020 7307 7409 [email protected]
Cytogenetics Operations Manager Emma Wilcock 020 7307 7409 [email protected]
Postnatal Lab Manager Allison Daffern 020 7307 7409 [email protected]
Director of Genetics & Molecular Pathology Dr Lisa Levett 020 7307 7409 [email protected]
Head of Genetics & Molecular Pathology Dr Stuart Liddle 020 7307 7409 [email protected]
Operations Manager Andrew Levett 020 3908 1282 [email protected]
Molecular Cytogenetics Manager Alessandra Callegari 020 7307 7409 [email protected]
TDL Genetics
1p36 Deletion Syndrome KARY,

CVS / AF / H 9 12-17 days
– karyotype + FISH FISH
21-Hydroxylase Deficiency Requires patient informed consent
(Congenital Adrenal Hyperplasia) GENE A 9,11 9 weeks
22q11 & 10p14 deletion (Di George
DGB CVS / AF / A 9 5 days
Syndrome) – BOBs only
22q11 & 10p14 deletion (Di George
Syndrome) – BOBs (5 days) DGB, KARY CVS / AF / A H 9 5-15 days
+ karyotype (15 days)
Achromatopsia NGS Panel Requires patient informed consent
– full gene sequencing GENE AA 9 5 weeks
Aicardi-Goutières Syndrome NGS Requires patient informed consent
Panel – full gene sequencing GENE AA 9 7 weeks
Alagille Syndrome NGS Panel – Requires patient informed consent
full sequencing JAG1 + NOTCH2 genes GENE AA 9 6 weeks
Alpha Fetoprotein on Amniotic fluid AFPA AF 9 5-10 days
Alpha Thalassaemia – multiplex Requires patient informed consent
PCR for common large deletions GENE A9 4 weeks
Alpha-1 Antitrypsin Genotype Requires patient informed consent
Alport Syndrome NGS Panel –
full sequencing COL4A3 + COL4A4
GENE AA 9 9 weeks
+ COL4A5 + MYH9 genes
Amelogenesis/Dentinogenesis
Imperfecta NGS Panel –
GENE AA 9 6 weeks
full gene sequencing
AML/ALL Molecular MRD – NPM1,
PML-RARA, CBFB-MYH11, RUNX1- Requires patient informed consent
RUNX1T1, ETV6-RUNX1 – Contact GENE Bone Marrow / A 5 days
lab for further information
AmnioBOBs only – rapid aneuploidy
diagnosis for all chromosomes + ABOB AF 9 5 days
common microdeletion syndromes
Amniocentesis – rapid BOBs aneuploidy
diagnosis for all chromosomes (5 days) ABK AF 9 5-15 days
+ culture (10-15 days) – see profiles
Amniocentesis – rapid PCR diagnosis
for common aneuploidies (2 days) APCC AF 9 2-15 days
+ culture (10-15 days)
Amniocentesis culture (karyotype) only ACUL AF 9 10-15 days
AmnioPCR only – rapid common
APC AF 9 2 days
aneuploidy diagnosis by QF-PCR
Amylotrophic Lateral Sclerosis
(Motor Neurone Disease) NGS Panel
GENE AA 9 8 weeks
– full gene sequencing
TDL Genetics
Androgen Insensitivity – Requires patient informed consent

AR gene sequencing GENE A9 9 weeks
Aneurysm/Connective Tissue
Disorders/Ehlers-Danlos Syndrome Requires patient informed consent
NGS Panel – full gene sequencing GENE AA 9 7 weeks
+ deletions/duplications
Angelman Syndrome (Primary
PWAM A9 10 days
Screen) – methylation PCR
Angelman/Rett Syndromes NGS Requires patient informed consent
Aniridia, Isolated – PAX6 gene Requires patient informed consent
sequencing + deletions/duplications GENE A9 8 weeks
Anophthalmia/Microphthalmia NGS Requires patient informed consent
Antithrombin Deficiency – SERPINC1 AA
ATMA 6 weeks
Gene Variant Analysis (Known Genotype) (Whole Blood 10ml) 40
Antithrombin Deficiency –
AA
SERPINC1 Gene Variant Analysis ATMA 12 weeks
(Whole Blood 10ml) 40
(Unknown Genotype)
Aortopathy/Marfan Syndrome/
Loeys-Dietz Syndrome NGS
GENE AA 9 9 weeks
Panel – full gene sequencing
Apert Syndrome – Requires patient informed consent
common FGFR2 mutations GENE A9 9 weeks
Apolipoprotein E genotype – E2, E3, E4 APEG A9 5 days
Array CGH (Comparative
CGH CVS / AF / A H 9 10 days
Genomic Hybridisation)
Arrhythmogenic Right Ventricular
Cardiomyopathy (ARVC) NGS Panel
GENE AA 9 4 weeks
– sequencing + deletions/duplications
Ashkenazi Breast Cancer Screen Requires patient informed consent
– common mutations GENE A 9,11 4 weeks
Ashkenazi Jewish Carrier Screen – see Requires patient informed consent
Carrier Screen on page 132 for details GENE A9 4 weeks
Ataxia/Episodic Ataxia Disorders Requires patient informed consent
Autoinflammation/Periodic Fever Requires patient informed consent
Azoospermia – karyotype + cystic fibrosis
GRP AH 9 10-15 days
screen + polyT(5T) + Y deletions
B cell clonality assay (IgH and IgK) IGHA A or FFPE 2 weeks
Bardet-Biedl Syndrome NGS Requires patient informed consent
110 Turnaround times are quoted as working days.
TDL Genetics
Batten Disease (Neuronal

Ceroid Lipofuscinosis) NGS
GENE AA 9 9 weeks
BCR-ABL Diagnostic Assay BCRD A 2 weeks
BCR/ABL Quantitative – fusion
gene sizes p190 + p210 – MUST
BCRA AA 9 10 days
arrive in the laboratory within 48
hours, before 12pm on Fridays
Becker Muscular Dystrophy
DMD A9 10 days
– deletions/duplications
Beckwith-Wiedemann Syndrome
– methylation studies on 11p15
GENE A9 4 weeks
imprinting domains KvDMR + H19
Behcet’s Disease –
B51 A9 10 days
HLA Tissue Typing B*51
Beta Thalassaemia – Requires patient informed consent
beta-globin gene sequencing GENE A9 5 weeks
Bleeding and Platelet Gene Panel Requires patient informed consent
(known familial variants) – Contact lab GENE AA 6 weeks
Bleeding and Platelet Gene
Panel (unknown familial
GENE AA 12 weeks
variants) – Contact lab
Blood PCR for Chromosome 21 BPCR A 5 days
BRAF V600E mutation by PCR Requires patient informed consent
for Hairy Cell Leukaemia GENE Bone Marrow / A 5 days
Breast Cancer Ashkenazi Requires patient informed consent
Screen – common mutations GENE A 9,11 4 weeks
Breast Cancer – BRCA1 + BRCA2 only Requires patient informed consent
gene sequencing + deletions/duplications GENE A 4 weeks
Breast Cancer NGS Panel – Requires patient informed consent
full gene sequencing GENE A A 9,11 4 weeks
Brugada Syndrome/Long-QT NGS Requires patient informed consent
C-KIT D816V mutation by Requires patient informed consent
PCR for Mastocytosis GENE Bone Marrow / A 5 days
CADASIL – NOTCH3 gene sequencing
GENE A9 6 weeks
CAKUT (Congenital Anomalies
of Kidney & Urinary Tract) NGS Panel
GENE AA 9 9 weeks
Calreticulin –
CALR A9 2 weeks
CALR exon 9 mutation screen
Cancer, Comprehensive NGS Panel – full Requires patient informed consent
gene sequencing + deletions/duplications GENE A A 9,11 6 weeks
TDL Genetics
Carbohydrate Metabolism Deficiency

NGS Panel – full gene sequencing Requires patient informed consent
+ deletions/duplications + GENE AA 9 9 weeks
mitochondrial DNA
Cardio-Facio-Cutaneous/Noonan/
LEOPARD/Costello Syndromes
GENE AA 9 6 weeks
NGS Panel – full gene sequencing
Cardiomyopathy, Arrhythmogenic
Right Ventricular NGS Panel –
GENE AA 9 4 weeks
sequencing + deletions/duplications
Cardiomyopathy, Comprehensive
GENE AA 9 6 weeks
Cardiomyopathy, Dilated NGS Panel – full Requires patient informed consent
gene sequencing + deletions/duplications GENE AA 9 6 weeks
Cardiomyopathy, Hypertrophic
GENE AA 9 6 weeks
Carrier Screen (Ashkenazi Jewish)
GENE A9 4 weeks
Carrier Screen (Ashkenazi
Jewish) – Partnered Report – Requires patient informed consent
Please contact the lab for special GENE A9 4 weeks
requirements before sending
Carrier Screen (Pan-Ethnic)
GENE A9 4 weeks
Carrier Screen (Pan-Ethnic) – Partnered
Report – Please contact the lab for
GENE A9 4 weeks
special requirements before sending
Charcot-Marie-Tooth Syndrome
NGS Panel – full gene sequencing. Requires patient informed consent
Evidence of neurology counselling and GENE AA 9 6 weeks
genetic consent form is required.
Charcot-Marie-Tooth Type 1A –
PMP22 duplications – Evidence of Requires patient informed consent
neurology counselling and genetic GENE A9 7 weeks
consent form is required.
CHARGE Syndrome – Requires patient informed consent
CHD7 gene sequencing GENE A9 8 weeks
Chediak-Higashi Syndrome – Requires patient informed consent
LYST gene sequencing GENE A9 6 weeks
Cholestasis, Intrahepatic NGS Requires patient informed consent
Chromosome Analysis
ACUL AF 9 10-15 days
(Amniocentesis) – culture only
TDL Genetics
Chromosome Analysis (Amniocentesis)

– rapid BOBs aneuploidy diagnosis
ABK AF 9 5-15 days
for all chromosomes (5 days) +
culture (10-15 days) – see profiles
Chromosome Analysis (Amniocentesis) –
rapid PCR diagnosis for common
APCC AF 9 2-15 days
aneuploidies (2 days) +
culture (10-15 days)
Chromosome Analysis (Blood) KARY H9 2-3 weeks
Chromosome Analysis (Chorionic
Villus) – rapid BOBs aneuploidy
CBK CVS 9 5-15 days
diagnosis for all chromosomes (5 days)
+ culture (10-15 days) – see profiles
Chromosome Analysis
(Chorionic Villus) – rapid PCR
CVPC CVS 1,9 2-15 days
diagnosis for common aneuploidies
(2 days) + culture (10-15 days)
Chromosome Analysis
CVSC CVS 1,9 10-15 days
(Chorionic Villus) – culture only
Chromosome Analysis (Products of
Conception) – reflex to BOBs testing
PROC Placental Sample 1,9 20-25 days
if culture fails to grow – reflex to
BOBs testing if culture fails to grow
Conception) – BOBs rapid aneuploidy
PBK Placental Sample 1,9 5-25 days
diagnosis for all chromosomes
(5 days) + culture (25 days)
Chromosome Analysis (Solid Tissue) PROC Fetal tissue 1,9 4-5 weeks
STEM/
Chromosome Analysis (Stem Cells) Culture/Fixed cells Contact lab
SUSP
Chromosome Y Deletion –
YDEL A9 5 days
AZFa, AZFb, AZFc + SRY
Cockayne Syndrome NGS Panel – Requires patient informed consent
full sequencing ERCC6 + ERCC8 GENE AA 9 6 weeks
Colorectal Cancer NGS Panel – full gene Requires patient informed consent
sequencing + deletions/duplications GENE A A 9,11 4 weeks
Comparative Genomic
CGH CVS / AF / A H 9 10 days
Hybridisation (Array CGH)
Congenital Absence of Vas Deferens
– karyotype + cystic fibrosis screen GRP AH 9 10-15 days
+ polyT(5T) + Y deletions
Congenital Muscular Dystrophy NGS Requires patient informed consent
Connective Tissue Disorders/
Ehlers-Danlos Syndrome/ Requires patient informed consent
Aneurysm NGS Panel – full gene GENE AA 9 7 weeks
TDL Genetics
Connexin-26 Associated Deafness Requires patient informed consent

– full sequencing of GJB2 gene GENE A9 8 weeks
Connexin-30 Associated Deafness Requires patient informed consent
– full sequence of the GJB6 gene GENE A9 8 weeks
Cornelia de Lange Syndrome NGS Requires patient informed consent
Costello/Noonan/LEOPARD/Cardio-
Facio-Cutaneous Syndromes NGS
GENE AA 9 6 weeks
Craniosynostosis and related Requires patient informed consent
disorders NGS Panel GENE AA 6 weeks
Cri du Chat Syndrome – PBOB,
CVS / AF / A H 9 5-15 days
BOBs (5 days) + karyotype (15 days) KARY
Cri du Chat Syndrome – BOBs only PBOB CVS / AF / A 9 5 days
CVS PCR for common aneuploidies
CVPC CVS 1,9 2-15 days
CVSBOBs – rapid BOBs aneuploidy
diagnosis for all chromosomes CBK CVS 9 5-15 days
(3-5 days) + culture (10-15 days)
CVSBOBs only – rapid aneuploidy
diagnosis for all chromosomes + CBOB CVS 9 5 days
CYP450 2D6 Genotyping TGEN A9 10 days
Cystic Fibrosis (139 common mutations)
CFS A 9 5-7 days
– reflex to Poly T when required
Deafness NGS Panel – Requires patient informed consent
full gene sequencing GENE AA 9 6 weeks
Dentinogenesis/Amelogenesis
Imperfecta NGS Panel –
GENE AA 9 6 weeks
NEW Diabetes – Obesity NGS Panel
GENE A 6 weeks
Diabetes Panel – MODY + Neonatal
GENE A 7 weeks
DiGeorge Syndrome (22q11 & 10p14
deletion) – BOBs (5 days) DGB, KARY CVS / AF / A H 9 5-15 days
DiGeorge Syndrome (22q11
DGB CVS / AF / A 9 5 days
& 10p14) – BOBs only
Dihydropyrimidine Dehydrogenase
deficiency screening 5FU A9 1-2 weeks
(Fluoropyrimidine Toxicity)
Dilated Cardiomyopathy NGS Panel – full Requires patient informed consent
DNA Extraction & Storage –
XDNA A9 20 days
3 years (longer upon request)
TDL Genetics
DNA Identity Profile – 15 STR markers DNAF A 9,11 10 days

Duchenne Muscular Dystrophy
DMD A9 10 days
– deletions/duplications only
Duchenne Muscular Dystrophy Requires patient informed consent
– full sequencing DMD1 gene GENE A9 6 weeks
Ehlers-Danlos Syndrome/Aneurysm/
Connective Tissue Disorders Requires patient informed consent
Endometrial Cancer NGS Panel – full gene Requires patient informed consent
Epidermolysis Bullosa, Comprehensive Requires patient informed consent
NGS Panel – full sequencing GENE AA 9 8 weeks
Epidermolysis Bullosa, Simplex Panel – Requires patient informed consent
full sequencing of KRT5 + KRT14 genes GENE AA 9 8 weeks
Epilepsy, Adolescent/Adult Onset Panel Requires patient informed consent
– sequencing + deletions/duplications GENE A 6 weeks
Epilepsy, Comprehensive NGS Panel – Requires patient informed consent
full sequencing + deletions/duplications GENE AA 9 6 weeks
Epileptic Encephalopathy NGS Panel
GENE A 6 weeks
Exudative Vitreoretinopathy, Familial Requires patient informed consent
(FEVR) NGS Panel – full gene sequencing GENE AA 9 8 weeks
Eye Developmental Disease NGS Requires patient informed consent
Fabry Disease, X-linked –
FABM A9 6 weeks
GLA gene sequencing
Facioscapulohumeral Muscular
Dystropy (FSHD) – D4Z4 repeat
deletion – Contact lab prior to sending.
GENE AAA 9 9 weeks
Evidence of neurology counselling and
genetic consent form is required.
Factor II Prothrombin –
FX2 A9 5 days
G20210A mutation
Factor V Leiden – G1691A mutation FX5 A 9 5 days
Factor VII Deficiency – F7 Gene AA
7MA 6 weeks
Variant Analysis (Known Genotype) (Whole blood 10ml) 40
Factor VII Deficiency – F7 Gene Variant AA
7MA 12 weeks
Analysis (Unknown Genotype) (Whole blood 10ml) 40
Factor X Deficiency – F10 Gene AA
10MA 6 weeks
Factor X Deficiency – F10 Gene Variant AA
10MA 12 weeks
TDL Genetics
Factor XI Deficiency – F11 Gene AA

11MA 6 weeks
Factor XI Deficiency – F11 Gene Variant AA
11MA 12 weeks
Familial Adenomatous Polyposis
(FAP) – full gene sequencing
Familial Exudative Vitreoretinopathy Requires patient informed consent
(FEVR) NGS Panel – full gene sequencing GENE AA 9 8 weeks
Familial Hypercholesterolaemia – LDLR Requires patient informed consent
+ APOB + PCSK9 + LDLRAP1 screening GENE AA 9 7 weeks
Familial Hypocalciuric Hypercalcaemia
(FHH) Panel – full sequencing
GENE AA 9 9 weeks
CASR + AP2S1 + GNA11 genes
Familial Mediterranean Fever – Requires patient informed consent
hotspot sequencing MEFV gene GENE A9 6 weeks
Familial Medullary Thyroid Carcinoma Requires patient informed consent
– hotspot sequencing RET gene GENE A 9,11 8 weeks
Fatty Acid Oxidation Deficiency NGS Requires patient informed consent
Fever (Recurrent) Screening
GENE AA 10 weeks
FLT3-ITD and FLT3-TKD screening assay FLT3 A 24 hours
Fragile X Syndrome screen – Requires patient informed consent
FMR1 repeat analysis PCR GENE AAA 9 3-8 weeks
Friedreich Ataxia – Requires patient informed consent
frataxin gene repeat analysis GENE A9 6 weeks
Gastric Cancer NGS Panel – full gene Requires patient informed consent
Gaucher Disease
GENE A9 5 weeks
Gaucher Disease full gene sequencing GDMA A 40 4 weeks
Genetic Reproductive Profile
GRP AH 9 10-15 days
(Male) – see profiles
Gilbert Syndrome Requires patient informed consent
– common UGT1A1 repeat variation GENE A9 6 weeks
Glaucoma NGS Panel Requires patient informed consent
Glucose-6-Phosphate Dehydrogenase
(G6PD) Deficiency – full G6PD
GENE A9 4 weeks
gene sequencing
Glycogen storage disease type 2
POMP A 4 weeks
(Pompe) mutation analysis
TDL Genetics

HMD A9 3 days
Haemolytic–Uremic Syndrome NGS Requires patient informed consent
Haemophilia A CVS Variant Analysis
(Known Genotype) – F8 Intron 22
8CVS CVS 40 3 days
Inversion, F8 Intron 1 Inversion, Sequence
analysis of known variants for F8 gene
Haemophilia A Variant Analysis (Known
Genotype) – F8 Intron 22 Inversion, AA
HACD 6 weeks
F8 Intron 1 Inversion, Sequence analysis (Whole blood 10ml) 40
of known variants for F8 gene
Haemophilia A Variant Analysis
(Unknown Genotype) – F8 Intron 22
Inversion, F8 Intron 1 Inversion, Sequence GENE AA 12 weeks
analysis of unknown variants for F8 gene (Whole blood 10ml) 40
Haemophilia B CVS Variant Analysis
(Known Genotype) – Sequence 9CVS CVS 40 3 days
analysis of known variants for F9
Haemophilia B Variant Analysis
AA
(Known Genotype) – Sequence HBCD 6 weeks
(Whole blood 10ml) 40
analysis of known variants for F9
Haemophilia B Variant Analysis
AA
(Unknown Genotype) – Sequence HBMA 12 weeks
analysis of unknown variants for F9
Harmony® Prenatal Test (Non-Invasive
Prenatal Testing) – common aneuploidy NIPT J/Special tubes 1 3-5 days
screening from maternal blood
Hearing Loss NGS Panel – Requires patient informed consent
Hemiplegic Migraine, Familial NGS Requires patient informed consent
Panel – full gene sequencing + mtDNA GENE AA 9 9 weeks
Hereditary Cancer NGS Panel,
Comprehensive – full gene
Hereditary Hemorrhagic Telangiectasia
– ACVRL1 + ENG full sequencing
GENE AA 9 9 weeks
Hereditary Neuropathy NGS Panel
– full gene sequencing. Evidence of Requires patient informed consent
neurology counselling and genetic GENE AA 9 6 weeks
Hereditary Neuropathy with Liability
to Pressure Palsy – PMP22
deletion analysis. Evidence of
GENE A9 7 weeks
neurology counselling and genetic
TDL Genetics
Hereditary Colon Cancer (Lynch

Syndrome) NGS Panel – full gene
Hereditary Spastic Paraplegia NGS
Panel – full gene sequencing + deletions/
GENE AA 9 9 weeks
duplications + mitochondrial DNA
Hermansky-Pudlak Syndrome/
Oculocutaneous Albinism/ Requires patient informed consent
Pigmentation NGS Panel GENE AA 9 5 weeks
HMD A9 3 days
Hirschprung Disease NGS Panel
– full sequencing across 6 genes
GENE AA 9 6 weeks
+ copy number variant
HLA Tissue Typing A HLA A9 10 days
HLA Tissue Typing A+B HLBA A9 10 days
HLA Tissue Typing A+B+C (Class I) HABC A9 10 days
HLA Tissue Typing A/B/DRB1/3/4/5 HLAF A9 10 days
HLA Tissue Typing A/B/
HLF A9 10 days
DRB1/3/4/5/DQB1
HLA Tissue Typing A/B/C/
HLFC A9 10 days
DRB1/3/4/5/DQB1 (Class I & II)
HLA Tissue Typing B HLB A9 10 days
HLA Tissue Typing B*27 only HLAB A9 3 days
B51 A9 10 days
(Behcet’s Disease)
HLA Tissue Typing B*57:01
HL57 A9 10 days
high resolution
HLA Tissue Typing C HLC A9 10 days
HLA Tissue Typing Coeliac
Q2Q8 A9 10 days
Disease – DQ2/DQ8
HLA Tissue Typing DRB1/3/4/5 DRB1 A9 10 days
HLA Tissue Typing DRB1/3/4/5/
HLDQ A9 10 days
DQB1 (Class II)
HLA Tissue Typing Narcolepsy Requires patient informed consent
– DQB1*06:02 GENE A9 4 weeks
Huntington Disease – HD gene
repeat analysis PCR. Evidence of Requires patient informed consent
neurology counselling and genetic GENE A A 9,11 6 weeks
Hyperinsulinism NGS Panel Requires patient informed consent
Hyperparathyroidism – CASR sequencing
GENE A9 8 weeks
Identity Profile (DNA) – 15 STR markers DNAF A 9,11 10 days
TDL Genetics

NEW IDH1/2 screening assay
GENE A 48 hours
IgVH mutation analysis for CLL IGMU A 4 weeks
Incontinentia Pigmenti, X-linked – Requires patient informed consent
IKBKG/NEMO common mutation GENE A9 4 weeks
Intellectual Disability NGS Panel – full Requires patient informed consent
Intrahepatic Cholestasis NGS Panel – full Requires patient informed consent
sequencing ABCB11 + ABCB4 + ATP8P1 GENE AA 9 9 weeks
JAK2 – exon 12 sequencing (rare
mutations) – MUST arrive in the Requires patient informed consent
laboratory within 48 hours, GENE A9 4 weeks
before 12pm on Fridays
JAK2 V617F genotyping assay JAK2 A 2 weeks
Jervell and Lange-Nielsen Syndrome – Requires patient informed consent
full sequencing KCNE1 + KCNQ1 genes GENE AA 9 9 weeks
Joubert/Meckel-Gruber Syndrome Requires patient informed consent
NGS Panel – full gene sequencing GENE A 6 weeks
Kallmann Syndrome NGS Panel Requires patient informed consent
Kennedy Disease (Spinal
Bulbar Muscular Atrophy)
GENE A9 9 weeks
– AR repeat expansion
Ketolysis Disorders NGS Panel Requires patient informed consent
Kidney/Urinary Tract Cancer NGS
Krabbe Disease – GALC sequencing Requires patient informed consent
+ 502T/del common deletion GENE A9 6 weeks
NEW KRAS/NRAS screening assay
GENE A 48 hours
Lactose Intolerance Gene LACG A 2 weeks
Langer-Giedion Syndrome – PBOB,
Langer-Giedion Syndrome – BOBs only PBOB CVS / AF / A 9 5 days
Leber’s Congenital Amaurosis NGS Requires patient informed consent
Leber’s Hereditary Optic Neuropathy
– m.3460G>A + m.11778G>A +
GENE A9 8 weeks
m.14484T>C common mutations
Leigh Syndrome NGS Panel –
full gene sequencing + deletions/
GENE AA 9 4 weeks
TDL Genetics
LEOPARD/Noonan/Cardio-Facio-
Cutaneous/Costello Syndromes
GENE AA 9 6 weeks
Leukaemia Fusion Gene
LMPX A 24 hours
Screening Assay (Q30)
Li-Fraumeni Syndrome (p53-
related cancer predisposition)
GENE A 9,11 6 weeks
– TP53 sequencing + MLPA
Limb-Girdle Muscular Dystrophy (LGMD) Requires patient informed consent
Lissencephaly NGS Panel – Requires patient informed consent
Loeys-Dietz Syndrome/Marfan
Syndrome/Aortopathy NGS
GENE AA 9 9 weeks
Long-QT Syndrome/Brugada Requires patient informed consent
Syndrome – full gene sequencing GENE AA 9 4 weeks
Lowe (Oculocerebrorenal) Requires patient informed consent
Syndrome – OCRL sequencing GENE A9 6 weeks
Lung Disorders NGS Panel Requires patient informed consent
Lynch Syndrome (HNPCC) NGS
Lysosomal Disorders NGS Panel Requires patient informed consent
Male Genetic Reproductive Profile GRP AH 9 10-15 days
Marfan Syndrome – FBN1 sequencing Requires patient informed consent
+ deletions/duplications GENE A9 5 weeks
Marfan Syndrome/Loeys-Dietz
Syndrome/Aortopathy NGS
GENE AA 9 9 weeks
Maturity-Onset Diabetes of the Requires patient informed consent
Young (MODY) Diabetes GENE A 7 weeks
Meckel-Gruber/Joubert Syndrome Requires patient informed consent
NGS Panel – full gene sequencing GENE A 6 weeks
Medium-Chain Acyl-CoA Dehydrogenase Requires patient informed consent
Deficiency – ACADM sequencing GENE A9 5 weeks
Melanoma NGS Panel – full gene Requires patient informed consent
Microdeletion (common)
PBOB CVS / AF / A 9 5 days
Syndromes – BOBs only
Microphthalmia/Anophthalmia/
Coloboma NGS Panel –
GENE AA 9 9 weeks
TDL Genetics
Miller-Dieker Syndrome – PBOB,

Miller-Dieker Syndrome – BOBs only PBOB CVS / AF / A 9 5 days
Mitochondrial genome – full mitochondrial Requires patient informed consent
DNA sequencing + deletions GENE A9 6 weeks
Mitochondrial genome sequencing
GENE A9 6 weeks
Motor Neurone Disease (Amylotrophic
Lateral Sclerosis) NGS Panel
GENE AA 9 8 weeks
MPL exon 10 analysis MPL A 2 weeks
MTHFR – common C677T +
MTHF A 9 5 days
A1298C mutations
Mucopolysaccharidosis NGS Requires patient informed consent
Multiple Endocrine Neoplasia Requires patient informed consent
Type 1 – full MEN1 sequencing GENE A 9,11 9 weeks
Multiple Endocrine Neoplasia Type 2 Requires patient informed consent
– RET gene hotspot sequencing GENE A 9,11 8 weeks
Myotonic Dystrophy Type 1 Requires patient informed consent
– DMPK repeat PCR GENE A9 6 weeks
Myotonic Dystrophy Type 2 Requires patient informed consent
(PROMM) – ZNF9 repeat PCR GENE A9 6 weeks
Narcolepsy (HLA DQB1*06:02)
GENE A9 4 weeks
Nephrotic Syndrome, Steroid-Resistant Requires patient informed consent
Nervous System/Brain Cancer
Neurofibromatosis Type 1 –
NF1 + SPRED1 sequencing + deletions/
duplications – Contact lab prior to sending
Neurofibromatosis Type 2 (Bilateral
Acoustic) – NF2 sequencing
GENE A9 8 weeks
Neuronal Ceroid Lipofuscinosis
(Batten Disease) NGS Panel
GENE AA 9 9 weeks
Non-Invasive Prenatal Testing – common
NIPT J / Special tubes 1 3-5 days
aneuploidy screening from maternal blood
Noonan Syndrome Prenatal Screening Requires patient informed consent
– PTPN11 exons 3 & 8 only GENE CVS / AF 2 weeks
TDL Genetics
Noonan/LEOPARD/Cardio-Facio-
Cutaneous/Costello Syndromes
GENE AA 9 6 weeks
NPM1 mutascreen assay NPM1 A 24 hours
Nystagmus, X-linked Infantile Requires patient informed consent
– FRMD7 gene sequencing GENE A9 7 weeks
Oculocutaneous Albinism/Hermansky-
Pudlak Syndrome/Pigmentation
GENE AA 9 5 weeks
Oculopharyngeal Muscular Dystrophy Requires patient informed consent
– PABPN1 repeat analysis GENE A9 5 weeks
Optic Atrophy NGS Panel – Requires patient informed consent
full sequencing OPA1 + OPA3 genes GENE AA 9 6 weeks
Osteogenesis Imperfecta NGS Requires patient informed consent
Ovarian Cancer NGS Panel – full gene Requires patient informed consent
p53-related cancer predisposition
(Li-Fraumeni Syndrome) –
GENE A 9,11 6 weeks
TP53 sequencing + MLPA
Pancreatic Cancer NGS Panel – full gene Requires patient informed consent
Paraganglioma/Pheochromocytoma
Paternity Testing (postnatal and
A / AF / CVS 9,11,12
prenatal) – sample required from PATT 5 days
Contact lab
each person being tested (3 people)
Pelizaeus-Merzbacher Disease – Requires patient informed consent
PLP1 sequencing + deletions/duplications GENE A9 8 weeks
Pendred Syndrome – SLC26A4 Requires patient informed consent
gene sequencing GENE A9 6 weeks
Periodic Fever/Autoinflammation Requires patient informed consent
Peutz-Jegher Syndrome – STK11 Requires patient informed consent
sequencing + deletions/duplications GENE A9 5 weeks
Phelan-McDermid Syndrome KARY,
CVS / AF / H 9 12-17 days
– karyotype + FISH FISH
Pheochromocytoma/Paraganglioma
Pigmentation/Oculocutaneous Albinism/
Hermansky-Pudlak Syndrome
GENE AA 9 5 weeks
TDL Genetics
POLG-Related Disorders – full POLG Requires patient informed consent

sequencing + copy number variant GENE A9 6 weeks
Polycystic Kidney/NGS Panel Requires patient informed consent
Pontocerebellar Hypoplasia NGS Requires patient informed consent
Postnatal array CGH CGH AH 9 10 days
Prader-Willi Syndrome
PWAM A9 10 days
(Primary Screen) – methylation PCR
Prenatal array CGH CGH Amniotic fluid or CVS 9 10 days
ABK or
Prenatal Diagnosis (BOBs + Culture) AF / CVS 9 3-5 days, 15 days
CBK
Prenatal Diagnosis for CVS / Amniocentesis
PND 3 days
haemoglobinopathies / fetal blood
Primary Ciliary Dyskinesia (PCD) Requires patient informed consent
Primary Hyperoxaluria Panel Requires patient informed consent
– full gene sequencing + CNV GENE A 6 weeks
Products of Conception – rapid BOBs
aneuploidy diagnosis for all chromosomes PBK Placental Sample 1,9 5-25 days
Products of Conception (BOBs + Culture) PBK Placental Sample 1,9 5-25 days
Products of Conception BOBs only
Placental Sample
– rapid aneuploidy diagnosis KBOB 3-6 days
or Solid Tissue 1,9
for all chromosomes
Prostate Cancer NGS Panel – full Requires patient informed consent
Protein C Deficiency – PROC Gene AA
PCMA 6 weeks
Protein C Deficiency – PROC Gene AA
PCMA 12 weeks
Variant Analysis (Unknown Genotype) (Whole blood 10ml) 40
Pseudoachondroplasia (Multiple
Epiphyseal Dysplasia) –
GENE A9 9 weeks
COMP hotspot sequencing
PTEN-related disorders (including
Bannayan-Riley-Ruvalcaba, Requires patient informed consent
Cowden & Proteus Syndromes) – GENE A A 9,11 8 weeks
QF-PCR rapid common
APC AF / A 9 1-2 days
aneuploidy screen
Recurrent Fever Screening
GENE AA 10 weeks
Recurrent Miscarriage Profile (female) RMP A A B C C C H 9,18 10-15 days
TDL Genetics
Renal Cysts and Diabetes (RCAD)

– HNF-1β sequencing +
GENE A9 9 weeks
deletions/duplications
Renal/Urinary Tract Cancer NGS
Retinal Dystrophy/NGS Panel Requires patient informed consent
Retinoblastoma – RB1 sequencing Requires patient informed consent
+ deletions/duplications GENE A A 9,11 9 weeks
Rett Syndrome (MECP2 gene only) – Requires patient informed consent
full sequencing + deletions/duplications GENE A 9,11 9 weeks
Rett/Angelman Syndromes NGS Requires patient informed consent
Sarcoma NGS Panel – full gene Requires patient informed consent
Short-Chain Acyl-CoA Dehydrogenase Requires patient informed consent
Deficiency – ACADS sequencing GENE A9 5 weeks
Short Stature – SHOX mutation Requires patient informed consent
screening + deletions/duplications GENE A9 9 weeks
Silver-Russell Syndrome –
methylation studies on 11p15
GENE A9 9 weeks
imprinting domains KvDMR + H19
Skeletal Dysplasia NGS Panel Requires patient informed consent
Smith-Lemli-Opitz Syndrome Requires patient informed consent
– DHCR7 sequencing GENE A9 9 weeks
Smith-Magenis Syndrome – PBOB,
Smith-Magenis Syndrome – BoBs only PBOB CVS / AF / A 9 5 days
Sotos Syndrome (Cerebral Gigantism) – Requires patient informed consent
NSD1 sequencing + deletions/duplications GENE A9 5 weeks
Spastic Paraplegia NGS Panel –
full gene sequencing + deletions/
GENE AA 9 9 weeks
Spinal Bulbar Muscular Atrophy Requires patient informed consent
(Kennedy Disease) – AR repeat analysis GENE A9 9 weeks
SMA A9 10 days
– SMN1 deletions/duplications
Spinocerebellar Ataxia
– multiplex SCA1+2+3+6+7+17
GENE A9 9 weeks
common repeat expansions
SRY (Sex-determining Region Y) SRY A9 2 days
Stargardt/Macular Dystrophy NGS Panel Requires patient informed consent
TDL Genetics
Stickler Syndrome NGS Panel Requires patient informed consent

Systemic mastocystosis – Requires patient informed consent
C-Kit common mutation (KIT D816V) GENE A9 4 weeks
T cell clonality assay (TCR
TCRA A or FFPE 2 weeks
beta and TCR gamma)
Tay Sachs Screen – common
mutations. See also Carrier Screen
GENE A9 5 weeks
(Ashkenazi Jewish/Pan-Ethnic)
Thrombosis Gene Panel Requires patient informed consent
NEW
(known familial variants) GENE A A 6 weeks
Thrombosis Gene Panel Requires patient informed consent
NEW
(unknown familial variants) GENE A A 12 weeks
Thyroid Cancer NGS Panel – full gene Requires patient informed consent
Torsion Dystonia (DYT1) – TOR1A Requires patient informed consent
common mutation c.904-906delGAG GENE A9 7 weeks
Treacher-Collins Syndrome
NGS Panel – full sequencing
GENE AA 9 9 weeks
POLR1C + POLR1D + TCOF1
Tuberous Sclerosis – Requires patient informed consent
full TSC1 + TSC2 gene sequencing GENE AA 9 5 weeks
Uni Parental Disomy (UPD) – Specify
A 9,12 5 days
parents and child – Specify chromosome type
Urinary Tract/Renal Cancer NGS
Usher Syndrome NGS Panel Requires patient informed consent
Very Long-Chain Acyl-CoA
Dehydrogenase Deficiency
GENE A9 6 weeks
– ACADVL sequencing
Von Hippel-Lindau Syndrome – Requires patient informed consent
VHL sequencing + deletions/duplications GENE A9 9 weeks
Von Willebrands Disease – Type 2 (Ex28) AA
VW2A 6 weeks
Variant Analysis (VWF) (Known Genotype) (Whole blood 10ml) 40
Von Willebrands Disease –
AA
Type 2 (Ex28) Variant Analysis VW2A 12 weeks
(VWF) (Unknown Genotype)
Von Willebrands Disease – Type 2 VWD AA
2AVW 6 weeks
AA
Type 2 VWD Variant Analysis 2AVW 12 weeks
(VWF) (Unknown Genotype)
TDL Genetics
Von Willebrands Disease – Type 2N AA

VW2N 6 weeks
AA
Type 2N Variant Analysis (VWF) VW2N 12 weeks
(Unknown Genotype)
Wolf-Hirschhorn Syndrome – BOBs PBOB,
(5 days) + karyotype (15 days) KARY
Wolf-Hirschhorn Syndrome – BOBs only PBOB CVS / AF / A 9 5 days
Y chromosome microdeletions –
YDEL A9 5 days
AZFa + AZFb + AZFc + SRY
Zellweger Syndrome NGS Panel Requires patient informed consent
A (From each twin
Zygosity testing – comparative DNA profile DNAC 5 days
and both parents) 9
TDL Genetics
ARRAY CGH TESTING
Chromosome abnormalities can be associated with developmental delay, autism spectrum disorder,
learning difficulties, dysmorphic features and other congenital abnormalities.
Array CGH can detect smaller genetic changes than is possible by conventional karyotyping, and can
provide accurate information on the size and possible consequences of the gains (duplications) or losses
(deletions) identified. Multiple studies have shown that Array CGH, when applied to appropriate patients,
will detect up to three times more pathogenic chromosome imbalances than karyotyping due to its
greater precision and sensitivity.
Array CGH testing is now considered to be the front line test for patients presenting with developmental delay
(motor or growth), autism spectrum disorder, moderate to severe learning difficulties, dysmorphic features,
with or without congenital abnormalities. Consortiums in the USA and many EU countries have adopted
Array CGH as the front line test in this patient cohort.
Array CGH is now more frequently used for prenatal studies as an adjunct or replacement for conventional
cytogenetic studies, particularly where structural fetal abnormalities are seen at ultrasound scan but also at
a patient’s or doctor’s request. The technique may also be utilised as a follow up test to characterise anomalies
detected by a previous study (e.g. an apparently balanced de novo rearrangement or marker chromosome).
When to use Array CGH

In postnatal cases, patients should present with one or more of the following:
• Mental retardation • Autism/autism spectrum disorder • Congenital malformations
• Developmental delay • Dysmorphic features
In prenatal cases, patients may present with:
• Abnormalities or increased nuchal translucency on ultrasound scan
which may be associated with a chromosome imbalance.
Approximately 10-20% of results identify extra or missing DNA which may or may not be relevant
to the clinical phenotype, and will require further family studies to assist with interpretation.
What can Array CGH detect?

Deletions and duplications with greater sensitivity than conventional karyotyping.
What does Array CGH not detect?

• Balanced chromosome rearrangements such as translocations or inversions.
The chromosome location of duplications (this would require additional FISH testing).
• Low frequency mosaicism (<30% abnormal cells), some types of polyploidy like
triploidy, Uniparental disomy (UPD) and Fragile X syndrome, imprinting defects,
genetic diseases caused by point mutations or multifactorial inheritance.
Further information is provided by the UNIQUE website at www.rarechromo.org
Postnatal array CGH CGH AH 9 10 days
Blood from both parents may also be provided in case of follow up studies at no extra charge.

Prenatal array CGH CGH Amniotic fluid or CVS 9 10 days
EDTA and heparin blood from both parents should be provided at the time of prenatal sampling,
if possible, in case of follow up studies at no extra charge.
TDL Genetics
PAN-ETHNIC CARRIER SCREENING
The Fulgent Beacon carrier panel is a comprehensive genetic screen for people of all ethnic backgrounds.
The panel analyses more than 400 genes, in which mutations may cause over 440 different recessive
disorders. Testing includes Cystic Fibrosis, Sickle Cell Disease, Thalassemia and Spinal Muscular Atrophy.
These conditions vary in morbidity, mortality and treatment.
The Beacon carrier screen can also be filtered to report only on diseases common to the Jewish population –
such as Bloom Syndrome, Canavan Disease, Gaucher Syndrome and Tay-Sachs Disease.
Indications for use

• Pre-pregnancy screening for couples that wish to check if they are silent carriers for
a disease that would have serious implications for the future health of any children.
• For patients who are concerned about a family history of a particular disease,
where common mutation detections are very high – such as Tay-Sachs Disease.
The report comes with a synopsis of any diseases for which a mutations was found, including prognosis,
treatment and mode of inheritance. It includes a risk assessment and recommendations for further testing.
A full list of diseases covered by this test is available from the laboratory.
4978 Santa Anita Ave 4978 Santa Anita Ave
Temple City, CA 91780 Temple City, CA 91780
(p) 626-350-0537 (f) 626-454-1667 (p) 626-350-0537 (f) 626-454-1667
[email protected] [email protected]
www.fulgentgenetics.com www.fulgentgenetics.com
Patient Information Partner Information Physician: Laboratory: Patient Information Partner Information Physician: Laboratory:
Patient Last, Patient First Not Tested Physician Last, Physician First Fulgent Genetics Patient Last, Patient First Not Tested Physician Last, Physician First Fulgent Genetics
DOB: Jan 01, 1900 Portal Example Lab [DO NOT USE] CAP#: 8042697 DOB: Jan 01, 1900 Portal Example Lab [DO NOT USE] CAP#: 8042697
Sex: ? CLIA#: 05D2043189 Sex: ? CLIA#: 05D2043189
MR#: 000-000-000 Phone: Laboratory Director: MR#: 000-000-000 Phone: Laboratory Director:
FD Patient#: FT-PT21496 Fax: Dr. Hanlin (Harry) Gao FD Patient#: FT-PT21496 Fax: Dr. Hanlin (Harry) Gao
Report Date: {{DATESIGNED}} Report Date: {{DATESIGNED}}
Accession: Accession: Accession: Accession:
FT-1612508 N/A FT-1612508 N/A
Test#: FT-TS51816 Test#: FT-TS51816
Specimen Type: TBD Specimen Type: TBD
Collection Date: Collection Date:
DRAFT RESULTS TEST PERFORMED DRAFT RESULTS TEST PERFORMED

Beacon Expanded Female Beacon Expanded Female
 Carrier for ONE genetic condition.

Genetic counseling is recommended.
Carrier Screening
(326 Gene Panel; full gene
sequencing with deletion and
 Carrier for ONE genetic condition.
Genetic counseling is recommended.
Carrier Screening
(326 Gene Panel; full gene
sequencing with deletion and
duplication analysis) duplication analysis)
Condition and Gene Inheritance Patient Last, Patient First Partner Condition and Gene Inheritance Patient Last, Patient First Partner
Fragile X syndrome X-linked  Premutation carrier N/A Neuronal ceroid lipofuscinosis, CLN3-related Autosomal Recessive  Carrier N/A
FMR1 (29 repeats and 75 repeats; 2 AGG interruption detected) CLN3 c.906+5G>A (p.?)
INTERPRETATION: INTERPRETATION:
Notes and Recommendations: Notes and Recommendations:
Based on these results, there is increased risk to have a child with an FMR1-related condition. See below for details. A likely pathogenic variant in the CLN3 gene was identified. Based on these results, there is an approximately 1 in 920
chance of having a child affected with Neuronal ceroid lipofuscinosis. Testing for mutations in this gene in the partner is
Testing for copy number changes in the SMN1 gene was performed to screen for your carrier status for Spinal Muscular highly recommended to better understand this risk. Please contact the lab for this service. See page 2 of this report for more
Atrophy. Two copies of the SMN1 gene were detected. These results are within the normal range for non-carriers. See information.
Limitations section for more information.
Testing for a 3 nucleotide (CGG) repeat sequence in the FMR1 gene was performed to screen for your carrier status for
This carrier screening test does not screen for all possible genetics conditions, nor for all possible mutations in every gene Fragile X Syndrome. The repeat sizes detected were: 18 and 22 repeats. These results are within the normal range.
tested. Individuals with negative test results may still have up to a 3-4% risk to have a child with a birth defect due to genetic Therefore, you are not considered a carrier for Fragile X Syndrome.
and/or environmental factors.
Testing for copy number changes in the SMN1 gene was performed to screen for your carrier status for Spinal Muscular
Patients may wish to discuss any carrier results with blood relatives, as there is an increased chance that they are also Atrophy. Two copies of the SMN1 gene were detected. These results are within the normal range for non-carriers. See
carriers. Limitations section for more information.
This carrier screening test does not screen for all possible genetics conditions, nor for all possible mutations in every gene
tested. Individuals with negative test results may still have up to a 3-4% risk to have a child with a birth defect due to genetic
and/or environmental factors.
Patients may wish to discuss any carrier results with blood relatives, as there is an increased chance that they are also
carriers.
Patient: Patient Last, Patient First; Sex: ?; Accession#: FT-1612508; FD Patient#: FT-PT21496; Patient: Patient Last, Patient First; Sex: ?; Accession#: FT-1612508; FD Patient#: FT-PT21496;
DOB: Jan 01, 1900; MR#: 000-000-000 DocID: ; Page 1 of 17 DOB: Jan 01, 1900; MR#: 000-000-000 DocID: ; Page 1 of 17
Male patients will not be screened for X-linked conditions. If an X-linked condition is suspected in a male patient
please contact the laboratory or a genetics specialist about diagnostic testing for that particular condition.
Limitations
A normal result does not rule out the possibility that the patient carries a rare mutation not detectible by
this particular assay. For this reason, this test is also not appropriate to use as a direct prenatal screen
(both parents must be confirmed carriers for a particular disease before we can offer prenatal diagnosis).
Screening is not designed to detect somatic mutations.

Carrier Screen (Ashkenazi Jewish)
GENE A9 4 weeks
Carrier Screen (Ashkenazi Jewish) –
Partnered Report – Please contact the lab
GENE A9 4 weeks
for special requirements before sending
Carrier Screen (Pan-Ethnic)
GENE A9 4 weeks
Carrier Screen (Pan-Ethnic) –
Partnered Report – Please contact the lab
GENE A9 4 weeks
for special requirements before sending
TDL Genetics
• Trisomy 18 (Edwards syndrome) and Trisomy 13
(Patau syndrome) are associated with a high rate
of miscarriage. These babies are born with severe
brain abnormalities and often have congenital heart
performed in the UK
NON-INVASIVE PRENATAL TESTING (NIPT) defects as well as other birth defects. Most affected
The Harmony test is a cell-free DNA-based prenatal individuals die before or soon after birth, and very
blood screen. It is being used in more than 100 few survive beyond the first year of life.
countries around the world, and has been used • Sex chromosome conditions occur when there
to guide clinical care in over 1.4 million pregnancies. is a missing, extra, or incomplete copy of the X
The test can be used in singleton, twin, and egg-donor or Y chromosomes. The Harmony test with sex
pregnancies and has been validated for use in pregnant chromosome aneuploidy panel option can assess risk
women aged 16 to 48. It can be administered as for XXX, XYY, XXYY, XXY (Klinefelter syndrome), and
early as 10 weeks gestation. a missing X chromosome in a girl (Turner syndrome).
The test can screen for: An option is also available to look for Turner syndrome
• Trisomies 21, 18, and 13 only (and not the other sex chromosome conditions).
If the mother is interested in having this optional
• Sex chromosome aneuploidy testing, she should talk with her healthcare provider
• Monosomy X to determine if it is right for her. This option is not
• Fetal sex available for twin pregnancies.
Patient information Risk

Non-invasive prenatal testing (NIPT) analyses The testing is non-invasive: it involves taking a blood
cell-free DNA circulating in a pregnant mother’s blood. sample from the mother. The pregnancy is not put at
It is used screen for Down syndrome (trisomy 21) risk of miscarriage, or from other adverse outcomes
and other common chromosomal conditions (trisomies that are associated with invasive testing procedures
18 and 13). Options are also available to screen for such as amniocentesis.
X and Y chromosome conditions.
Accuracy
About the test A ‘high probability’ result is indicative of a high
DNA from the fetus circulates in the mother’s blood. probability for a trisomy. In singleton pregnancies,
Cell-free DNA (cfDNA) results from the natural the test identifies more than 99% of fetuses with
breakdown of fetal cells (presumed to be mostly trisomy 21, 97% of fetuses with trisomy 18, 94%
placental) and clears from the maternal system of fetuses with trisomy 13, and 96% of fetuses with
within hours of giving birth. Turner syndrome. X and Y analysis provides >99%
accuracy for fetal sex. Accuracy for detecting other
During a pregnancy, cfDNA can be tested to give the
sex chromosome anomalies varies by condition.
most accurate screening approach in estimating the
risk of a fetus having a common chromosome condition After the test, less than 1% of women need to have
sometimes called a trisomy. This occurs when there a CVS or an amniocentesis procedure.
are three copies of a particular chromosome instead The Harmony test is considered a prenatal screening
of the expected two. The test looks to detect the test, not a diagnostic test. So if the test results show
following conditions: there is a high risk of the fetus having trisomy 21, 18,
• Trisomy 21 is the most common trisomy at the time 13 or a sex chromosome condition, it does not mean
of birth. Also called Down syndrome, it is associated that the fetus definitely has one of these conditions –
with moderate to severe intellectual disabilities and although it is highly likely. For this reason, in the event
may also lead to digestive disease, congenital heart of a ‘high risk’ (or positive) result, follow-up testing
defects and other malformations. by an invasive procedure is recommended.
TDL Genetics
In the same way, if the test results show a ‘low
probability’ of the fetus having trisomy 21, 18, 13 or
a sex chromosome condition, it is unlikely that the fetus
has one of these conditions. However, there is a very
small risk that not all trisomic fetuses will be detected.
Who can have this test?

The Harmony test can be ordered by healthcare
professionals for women with pregnancies of at least
10 weeks’ gestational age. This test can be requested
for any singleton or twin pregnancy, including those
conceived naturally or by IVF using the patient’s own
egg or a donor egg. Note that, in twin pregnancies,
sex chromosome (X and Y) analysis can determine fetal Who carries out the analysis of the test?
sex but not sex chromosome conditions. The Harmony Her sample and completed request form need to be sent
test also does not assess risk for mosaicism, partial to TDL Genetics, where the Harmony test is performed
trisomies or translocations. on the DNA extracted from her blood sample.
Results will be ready in approximately 3-5 days.
Women still can have their 12-week scan for a Will the mother need to have any other tests?
detailed examination of the fetal anatomy, including The Harmony test does not provide information on
measurement of nuchal translucency, nasal bone and mosaicism, partial trisomies or translocations, or other
other important factors. In this visit, patients can discuss rare chromosomal abnormalities. If the ultrasound scan
the DNA and ultrasound results with their obstetricians. shows a high nuchal translucency or other major physical
On the basis of the NIPT result and the ultrasound defects such as brain abnormalities, heart abnormalities,
findings, a patient can decide whether or not she the risk for some rare chromosomal defects may be high.
wants to have an invasive procedure (for example, In such cases, the mother may choose to have a CVS
CVS or amniocentesis). or an amniocentesis.
The non-invasive prenatal test does not provide
Repeat samples information on other physical defects such as spina bifida,
There needs to be enough fetal DNA in the maternal or information on fetal growth. It is therefore advisable
blood to be able to provide a result. If there is that the mother has all the usual ultrasound scans during
insufficient fetal DNA in the sample (which occurs her pregnancy.
in 3% of cases), another blood sample from the
mother may be required. This will be processed Sample stability
in the laboratory at no extra charge. Samples must be taken in special tubes provided by the
laboratory. These samples must not be refrigerated, but
What is the process? stored at ambient temperature protected by the gel packs
Once the mother has taken an independent personal provided. The lab must receive the samples within 7 days
decision that she wants to have the NIPT performed, to allow testing to proceed.
she will be asked to sign a consent form and her
blood sample can be taken from a vein in her arm.
Non-Invasive Prenatal Testing Two 10ml tubes of maternal

– common aneuploidy screening NIPT blood – special tubes 3-5 days
from maternal blood provided by the laboratory
TDL Genetics
THE RELIABILITY YOU WANT, AND THE ACCURACY YOU NEED.
TDL Genetics
MALE GENETIC CARRIER SCREEN RECURRENT MISCARRIAGE
REPRODUCTIVE PROFILE (PAN-ETHNIC) PROFILE (FEMALE)
Chromosome Analysis Targets 400+ Autosomal FBC
Y-Chromosome Microdeletions Recessive and X-linked Coagulation Profile
Cystic Fibrosis Carrier Screen Inherited Disorders** Antithrombin III
(139 common mutations) Factor V Leiden
PolyT (5T,7T,9T) if clinically ** Male patients will not Common Mutation
indicated be screened for X-linked Factor II Prothrombin
conditions (e.g., FMR1, etc.). Common Mutation
MTHFR Common Variants
TAT TAT
Fibrinogen
10-15 4 Lupus Anticoagulant
DAYS WEEKS
Protein C
GRP GENE Free Protein S Ag
Anticardiolipin Abs
AH9 A9 Chromosome Analysis
Please request Partner’s TAT
THROMBOTIC RISK PROFILE
CARRIER SCREEN
(ASHKENAZI JEWISH)
Chromosome Analysis using
a separate request form. 10-15
DAYS
FBC This test is optimised for

RMP
Coagulation Profile individuals and couples of
Antithrombin III Ashkenazi Jewish ancestry.**
Factor V Leiden A A B C C C H 9,18
Uses the same technology as
Common Mutation the Carrier Screen (Pan-Ethnic).
Factor II Prothrombin PRENATAL DIAGNOSIS
(BOBS + CULTURE)
Common Mutation ** Male patients will not
MTHFR Common Variants be screened for X-linked Rapid Aneuploidy Diagnosis for
Lupus Anticoagulant conditions (e.g., FMR1, etc.). all Chromosomes + Common
Protein C Microdeletion Syndromes
Free Protein S Ag by BOBs Analysis TAT
Anticardiolipin Abs
TAT
5
TAT
4 3-5
DAYS
DAYS WEEKS
TAT
Chromosome Analysis
PROP GENE (Karyotype) 15
DAYS
AABCCC 18
A 9
ABK or CBK
PRE-TRAVEL (DVT) SCREEN IRON OVERLOAD PROFILE AF / CVS 9
FBC Iron PRODUCTS OF CONCEPTION

Anticardiolipin Antibodies Total Iron Binding Capacity (BOBS + CULTURE)
Factor II Prothrombin Mutation Ferritin Rapid Aneuploidy Diagnosis for
(G20210A) Transferrin Saturation all Chromosomes TAT
Factor V Leiden Mutation Haemochromatosis
(G1691A) C282Y, H63D
by BOBs Analysis 3-5
DAYS
TAT TAT TAT
Chromosome Analysis
5 3 (Karyotype) 25
DAYS DAYS DAYS
DVT1 IOP PBK
AAB9 AAB9 Placental sample1,9
In-vivo tests
These tests, ideally, must be carried out by appointment. Please telephone 020 7307 7383
for details, information for patient preparation, and appointment times. Sample taking fees
for Extended tests are charged at £98.00 per visit.
EXTENDED TESTING
• 50g liquid glucose is consumed for the glucose challenge test/Mini-GTT.
• 75g liquid glucose is consumed for all other glucose tests.
• Each sample tube must be labelled with time of collection.
GLUCOSE TOLERANCE TESTS

TEST CODE SAMPLE REQS COLLECTION TIME TAT
(MINUTES POST-GLUCOSE)
Glucose Challenge 1 at 60 mins
RBGM G 1 day 129
Test / Mini-GTT (50gm glucose)
Glucose Tolerance 1 each at 0, 60 and 120 mins
GTT 3 x G 3 x RU 1 day 129
Test / OGTT (75gm glucose load)
Glucose Tolerance
GTTI 3 x B 3 x G 3 x RU 1 each at 0, 60 and 120 mins 1 day 129
with Insulin
Glucose Tolerance
with Growth GTT + GHDF 3 x B 35 3 x G 3 x RU 1 each at 0, 60 and 120 mins 1 day 129
Hormone
Glucose Tolerance
GTTS 2 x G 2 x RU 1 each at 0 and 120 mins 1 day 129
Test (Short)
Glucose Tolerance 1 each at 0, 30, 60, 90
GTTE 5 x G 5 x RU 1 day 129
Test (Extended) and 120 mins
Glucose Tolerance 1 each at 0, 30, 60, 90,
GTTX 7 x G 7 x RU 1 day 129
Test (Extended Plus) 120, 150 and 180 mins
EXTENDED TESTS
TEST CODE SAMPLE REQS COLLECTION TIME TAT
(MINUTES POST-GLUCOSE)
Contact 020 7025 7997
Lactose Tolerance Test LTT By appointment only 1 day 129
(Phlebotomy)
Synacthen Contact 020 7025 7997
SYNA By appointment only 1 day 129
Stimulation Test (Phlebotomy)
ANTIBIOTIC ASSAYS
Amikacin Level (State dose) AMIK B 4 4 hours

Gentamicin Assay GENT B4 4 hours
Metronidazole Level METR B4 7 days
Teicoplanin Assay TEIC B 5 days
Tobramycin Assay (Provide Clinical Details) TOBR B 3 days
Vancomycin Hydrochloride VANC B 4 hours
Therapeutic drug assays
There are three different collection times for Therapeutic Drug Monitoring:
TROUGH LEVEL Blood should be collected just before the next dose. Trough Levels
check that the appropriate drug concentration is being maintained.
PEAK LEVELS Sample collection time is dependent on specific drug type and method of
administration. Peak levels check that the drug level is not in the toxic range.
SUSPECTED TOXICITY Blood can be collected any time.
All collections should have the following noted on the request form:
• Dosage schedule including the amount and frequency and time of the last dose
• Time of specimen collection
• Clinical status of patient (e.g. routine, suspected toxicity)
• Name(s) of other drugs being taken by the patient
Amitriptyline AMTR A 4 5 days

Anafranil (Clomipramine) CHLO A 7 days
Carbamazepine (Tegretol) CARB B 4 hours
Clobazam CLOB A 5 days
Clomipramine (Anafranil) CHLO A 7 days
Clonazepam CLON A 7 days
Diazepam (Valium) DIAZ A 7 days
Digoxin DIGO B 4 hours
Epanutin (Phenytoin) PHEN B 4 hours
Erythropoietin ERY B 4 days
Ethosuximide ETHO A 7 days
FK506 (Tacrolimus/Prograf) FK5 A4 1-2 days
Flecainide (Tambocor) FLEC A 5 days
Fluoxetine (Prozac) PROZ A4 5 days
Gabapentin GABA B4 5 days
Imipramine IMIP A4 4 days
Lamotrigine LAMO B4 5 days
Levetiracetam (Keppra) LEVE B4 3 days
Lithium (take 12 hours after dose) LITH B 4 hours
Lorazepam LORA A4 10 days
Methotrexate METX B 2 days
Mycophenolic Acid (Cellcept) MYCP A 5 days
Mysoline (Primidone) PRIM B4 3 days
Olanzapine OLAN A4 5 days
Paracetamol PARA B 4 hours
Phenobarbitone PHB B 4 hours
Phenytoin (Epanutin) PHEN B 4 hours
Primidone (Mysoline) PRIM B4 3 days
Therapeutic drug assays
Propanalol PRO B4 7 days

Risperidone RISP A4 7 days
Sinequan (Doxepin) DOXE A 10 days
Sirolimus SIRO A 3 days
Streptomycin Levels STRM F 5 days
Sulpiride SULP B4 4 days
Tacrolimus/Prograf (FK506) FK5 A4 1-2 days
Tegretol (Carbamazepine) CARB B 4 hours
Temazepam TEMA B4 4 days
Theophylline THEO B 4 hours
Topiramate (Topamax) TOPI B4 4 days
Trimipramine TRIM A 5 days
Valium (Diazepam) DIAZ A 7 days
Valproic Acid (Epilim) VALP B 4 hours
Vigabatrin (Sabril) VIGA A 10 days
Allergy
Allergy, Asthma and Autoimmune diseases are increasing around the world, especially in industrialised
countries and affect all ages. Since every country has their own dietary habits there are noteworthy
differences in the allergens causing food allergy.
UK PROFILE MEDITERRANEAN PROFILE MIDDLE EAST PROFILE
Total IgE plus: Total IgE plus: Total IgE plus:

Food Mix inc. A. alternata Food Mix inc.
Cod, Cow’s Milk, Egg White, Cat Epithelium and Dander Cod, Cow’s Milk, Egg White,
Soya Bean, Peanut, Wheat Cow’s Milk Soya Bean, Peanut, Wheat
Grass Mix inc. Egg White Fish: Cod
Cocksfoot, Meadow Fescue, House Dust Mite
Dust Mix inc.
Meadow, Rye, Timothy (Dermatophagoides
House Dust Mite,
pteronyssinus and
Fish: Cod Dermatophagoides
Dermatophagoides farinae)
Cat Dander pteronyssinus,
Olive
Cladosporium Herbarum Dermatophagoides farinae,
Peanut Blatella germanica
Dog Dander Rye-grass
House Dust Mite Timothy Grass
Latex
TAT TAT TAT
2 2 2
DAYS DAYS DAYS
ALUK ALMD ALME
B B B
Allergy
Allergy – Individual Allergens (see list on page 141) ALLE B 2 days

Total IgE IGE B 1 day
Allergy Profile (Mediterranean) ALMD B 2 days
Allergy Profile (Middle East) ALME B 2 days
Allergy Profile (UK) ALUK B 2 days
Allergy Profile 1 (Food & Inhalants) 1A BB 2 days

Allergy Profile 2 (Inhalants) 2A B 2 days
Allergy Profile 3 (Food) 3A B 2 days
Allergy Profile 4 (Nuts & Seeds) 4A B 2 days
Allergy Profile 5 (Children’s Panel) 5A B 2 days
Allergy Profile 6 (Shellfish) 6A B 2 days
Allergy Profile 7 (Finfish) 7A B 2 days
Allergy Profile 8 (Cereal – singles) 8A B 2 days
Allergy Profile 9 (Antibiotics) 9A B 2 days
Allergy Profile 10 (Insects) 10A B 2 days
Allergy Profile 11 (Combined Shellfish/Finfish) 11A B 2 days
Allergy Profile 12 (Milk & Milk Proteins) 12A B 2 days
Allergy Profile 13 (Stone fruit/Rosaceae family) 13A B 2 days
Eczema Provoking Profile ALEC B 2 days
Rhinitis Provoking Profile ALRN B 2 days
Tryptase STRY B 2 days
Allergen Component Profiles (see page 145)

Histamine Releasing Urticaria Test CURT B 3 weeks
ISAC Panel ISAC B 3 days
Prealbumin PALB B 3 days
ECZEMA PROVOKING PROFILE RHINITIS PROVOKING PROFILE

GLUTEN ALLERGY PROFILE
(9 Allergens) (10 Allergens)
Total IgE with Milk Total IgE with Milk Gluten single IgE Allergen
individual IgE Peanut individual IgE Nettle Endomysial Antibodies IgA
allergens for: Soya Bean allergens for: Peanut Deamidated Gliadin IgG
Cat Dander Wheat Birch Timothy Grass Antibodies
Egg White Cat Dander Tissue Transglutaminase IgA
Egg Yolk Dog Dander HLA DQ2/DQ8
Fish Mix Egg White Total IgA
Hazelnut TAT Egg Yolk TAT TAT
House Dust Mite 2 House Dust Mite 2 10
DAYS DAYS DAYS
ALEC ALRN GLUT
B B ABB
Allergy
IgE ALLERGY PROFILE 1 IgE ALLERGY PROFILE 3
(Food and inhalants) (Food)
Total IgE with individual Tree Mix, inc. Total IgE with individual Egg Yolk
IgE allergens for: Box Elder IgE allergens for: Kiwi
Common Silverbirch Codfish Peanut
Grass Mix, inc.
Hazel Cow’s Milk Sesame TAT
Cocksfoot
Meadow Fescue Oak
London Plane
Egg White Soya
Wheat
2
Meadow DAYS
Rye Maple
Timothy Sycamore 3A
Weed Mix, inc. Single Allergens (19)
Common Ragweed Beef B
Giant Ragweed Bermuda Grass
Western Ragweed Cat Dander IgE ALLERGY PROFILE 4
Clam (Nuts and Seeds)
Dust Mix, inc. Common Silver Birch
Blatella germanica Cow’s Milk Total IgE with individual Pecan
Dermatophagoides Crab IgE allergens for: Pine Nut
pteronyssinus Dog Dander Pistachio
Dermatophagoides Egg White Almond
Brazil Nut Poppy Seed
farinae Egg Yolk Pumpkin Seed
Hollister-Stier Labs Cashew
Fish (Cod) Hazel Nut Sesame Seed
Mould Mix, inc. Sunflower Seed TAT
Hazel Nut Macadamia Nut
A. alternata Horse Dander Peanut Walnut 2
DAYS
Aspergillus fumigatus Latex
Candida albicans Nettle 4A
Cladosporium herbarum Peanut
Helminthosporium Shrimp/Prawn
halodes Soya Bean TAT B
Penicillium notatum Wheat 2
DAYS IgE ALLERGY PROFILE 5
(Children’s Panel)
1A
Total IgE with individual Mite, Pteronyssinus
BB IgE allergens for: Peanut
Cat Dander Soya Bean
Cow’s Milk Timothy Grass
IgE ALLERGY PROFILE 2 Wheat Flour TAT
Egg White
(Inhalants)
Egg Yolk 2
DAYS
Total IgE with individual Common Ragweed
IgE allergens for: Derma farinae 5A
Alternaria Dog Dander
Aspergillus House Dust Mite B
Birch Pollen Horse Dander
Timothy Grass TAT
Cat Dander
Cladosporium 2 IMMUNOCAP ISAC PANEL
DAYS
Simultaneous measurement in a single test of specific

2A
antibodies to more than one hundred allergen
TAT
components from more than 50 preselected
B allergen sources. 3
DAYS
ISAC
Allergy
(Shellfish) (Insects)
Total IgE with individual Lobster Total IgE with individual Paper Wasp
IgE allergens for: Octopus IgE allergens for: Yellow Hornet
Clam Prawns/Shrimp Common Wasp – White Faced
Crab Scallop TAT
Yellow Jacket Hornet TAT
Crawfish/Crayfish Squid 2 Bee 2

DAYS DAYS
6A 10A
B B

(Finfish) (Combined Shellfish/Finfish)
Total IgE with individual Sardine/Pilchard Total IgE with individual Salmon
IgE allergens for: Salmon IgE allergens for: Scallop
Codfish Sole Cod Squid TAT
Mackerel Swordfish TAT Prawn/Shrimp Tuna
2
Plaice Tuna
2 DAYS
DAYS
11A
7A
B
B
IgE ALLERGY PROFILE 12
IgE ALLERGY PROFILE 8 (Milk & Milk Proteins)
(Cereal – singles)
Total IgE with individual Cow’s Milk
Total IgE with individual IgE allergens for: Goat’s Milk
IgE allergens for: Alpha-lactalbumin – Mare’s Milk
Barley milk proteins Sheep’s Milk
Oat Beta-lactoglobulin – Whey
Rye TAT milk proteins (cow and ewe) TAT
Wheat 2 Casein – milk proteins 2

DAYS DAYS
8A 12A
B B

(Antibiotics) (Stone Fruit, Rosaceae family)
Total IgE with individual Total IgE with individual Cherry

IgE allergens for: IgE allergens for: Peach
Cefaclor Almond Pear
Pen G TAT Apple Plum TAT
Pen V 2 Apricot Raspberry
Strawberry
2
DAYS DAYS
9A 13A
B B
Allergy
Allergens, when requested individually are priced as single tests, sample 1 x B (up to 5 allergens).
Protein allergens are manufactured by Thermofisher (Phadia) and are IgE specific.
GRASS POLLENS Plantain (English), Ribwort w9 Mountain juniper t6

Bahia grass g17 Rape w203 Mulberry t70
Barley g201 Rough marshelder w16 Oak t7
Bermuda grass g2 Saltwort (prickly), Oil Palm t223
Brome grass g11 Russian thistle w11 Olive t9
Canary grass g71 Scale, Lenscale w15 Paloverde t219
Cocksfoot g3 Sheep sorrel w18 Pecan, Hickory t22
Common reed g7 Sunflower w204 Peppertree t217
Cultivated oat g14 Wall pellitory w19 Pine t213
Cultivated rye g12 Wall pellitory w21 Privet t210
Cultivated wheat g15 Western ragweed w2 Queen palm t72
Johnson grass g10 Wormwood w5 Red cedar t57
Maize, Corn g202 Yellow dock w23 Red mulberry t71
Meadow fescue g4 Scotch broom t55
Meadow foxtail g16 TREE POLLENS Spruce t201
Meadow grass, Acacia t19 Sweet gum t211
Kentucky blue g8 American beech t5 Walnut t10
Redtop, Bentgrass g9 Australian pine t73 White ash t15
Rye-grass g5 Bald cypress t37 White hickory t41
Sweet vernal grass g1 Bayberry t56 White pine t16
Timothy grass g6 Box-elder t1 Willow t12
Velvet grass g13 Cedar t212 Virginia live oak t218
Wild rye grass g70 Cedar elm t45
Chestnut t206 MICROORGANISMS
WEED POLLENS Common silver birch t3 Acremonium kiliense m202
Alfalfa w45 Cottonwood t14 Alternaria alternata m6
Camomile w206 Cypress t222 Aspergillus flavus m228
Careless weed w82 Date t214 Aspergillus fumigatus m3
Cocklebur w13 Douglas fir t207 Aspergillus niger m207
Common pigweed w14 Elder t205 Aspergillus terreus m36
Common ragweed w1 Elm t8 Aureobasidium pullulans m12
Dandelion w8 Eucalyptus, Gum-tree t18 Botrytis cinerea m7
Dog fennel w46 European ash t25 Candida albicans m5
False ragweed w4 Grey alder t2 Chaetomium globosum m208
Firebush (Kochia) w17 Hackberry t44 Cladosporium herbarum m2
Giant ragweed w3 Hazel t4 Curvularia lunata m16
Goldenrod w12 Horn beam t209 Epicoccum purpurascens m14
Goosefoot, Horse chestnut t203 Fusarium proliferatum
Lamb’s quarters w10 Italian/Mediterranean/ (F. moniliforme) m9
Japanese Hop w22 Funeral cypress t23 Setomelanomma rostrata
Lupin w207 Japanese cedar t17 (Helminthosporium halodes) m8
Marguerite, Ox-eye daisy w7 Linden t208 Malassezia spp. m227
Mugwort w6 Maple leaf sycamore, Mucor racemosus m4
Nettle w20 London plane t11 Penicillium chrysogenum
Parietaria officinalis w19 Melaleuca, Cajeput-tree t21 (P. notatum) m1
Parietaria judaica w21 Mesquite t20 Penicillium glabrum m209
Allergy
Phoma betae m13 Mouse serum proteins e76 INSECTS
Rhizopus nigricans m11 Mouse urine proteins e72 Berlin beetle i76
Staphylococcal enterotoxin A m80 Parakeet droppings e197 Blood worm i73
Staphylococcal enterotoxin B m81 Parakeet serum e198 Cockroach, American i206
Staphylococcal enterotoxin C Parrot feathers e213 Cockroach, German i6
m223 Pigeon feathers e215 Fire ant i70
Staphylococcal enterotoxin TSST Rabbit epithelium e82 Grain weevil i202
m226 Rabbit, serum proteins e206 Green nimitti i72
Stemphylium herbarum Rabbit, urine proteins e211 Horse fly i204
(S. botryosum) m10 Rat epithelium e73 Mediterranean flour moth i203
Tilletia tritici m201 Rat epithelium, serum proteins Mosquito i71
Trichoderma viride m15 and urine proteins e87 Moth i8
Trichophyton mentagrophytes var. Rat serum proteins e75
goetzii m210 Rat urine proteins e74 VENOMS
Trichophyton mentagrophytes var. Reindeer epithelium e202 Bumblebee i205
interdigitale m211 Sheep epithelium e81 Common wasp (Yellow jacket i3
Trichophyton rubrum m205 Swine epithelium e83 European Paper Wasp i77
Ulocladium chartarum m204 Turkey feathers e89 European hornet i75
Honey bee i1
EPIDERMALS AND MITES Paper wasp i4
ANIMAL PROTEINS Acarus siro (Storage mite) d70 White-faced hornet i2
Budgerigar droppings e77 Blomia tropicalis Yellow hornet i5
Budgerigar feathers e78 (House dust mite) d201
Camel dander u328 Dermatophagoides farinae DRUGS
Canary bird droppings e200 (House dust mite) d2 Amoxicilloyl c6
Canary bird feathers e201 Dermatophagoides microceras Ampicilloyl c5
Cat dander e1 (House dust mite) d3 Cefaclor c7
Chicken droppings e218 Dermatophagoides pteronyssinus Chlorhexidine c8
Chicken feathers e85 (House dust mite) d1 Gelatin bovine c74
Chicken, serum proteins e219 Euroglyphus maynei Insulin human c73
Chinchilla epithelium e208 (House dust mite) d74 Penicilloyl G c1
Cow dander e4 Glycyphagus domesticus Penicilloyl V c2
Deer epithelium e216 (Storage mite) d73 Pholcodine c261
Dog dander e5 Lepidoglyphus destructor Morphine c260
Duck feathers e86 (Storage mite) d71 Suxamethonium
Ferret epithelium e217 Tyrophagus putrescentiae (succinylcholine) c202
Finch feathers e214 (Storage mite) d72
Fox epithelium e210 OCCUPATIONAL
Gerbil epithelium e209 ALLERGEN COMPONENTS Bougainvillea k214
Goat epithelium e80 See page 145 for Component Cotton seed k83
Goose feathers e70 Testing and Component Ethylene oxide k78
Guinea pig epithelium e6 Allergen Profiles Ficus k81
Hamster epithelium e84 Formaldehyde/Formalin k80
Horse dander e3 HOUSE DUST Green coffee bean k70
Mink epithelium e203 Greer Labs., Inc. h1 Hexahydrophtalic anhydrid k209
Mouse epithelium e71 Hollister-Stier Labs. h2 Isocyanate HDI (Hexamethylene
Mouse epithelium, diisocyanate) k77
serum proteins and urine Isocyanate MDI (Diphenylmethane
proteins e88 diisocyanate) k76
Allergy
Isocyanate TDI (Toluene Jujube f336 Maize, Corn f8
diisocyanate) k75 Kiwi f84 Oat f7
Ispaghula k72 Lemon f208 Pea f12
Latex k82 Lettuce f215 Peanut f13
Methyltetrahydrophtalic Lime f306 Pecan nut f201
anhydrid k211 Mandarin (tangerine, clementine, Pine nut, pignoles f253
Phthalic anhydride k79 satsumas) f302 Pistachio f203
Silk k74 Mango f91 Poppy seed f224
Silk waste k73 Melon f87 Pumpkin seed f226
Sunflower seed k84 Olive (black, fresh) f342 Quinoa f347
Trimellitic anhydride, TMA k86 Onion f48 Rape seed f316
Orange f33 Red kidney bean f287
PARASITES Papaya f293 Rice f9
Anisakis p4 Passion fruit f294 Rye f5
Ascaris p1 Peach f95 Sesame seed f10
Echinococcus p2 Pear f94 Soybean f14
Persimon (kaki fruit, sharon) f301 Spelt wheat f124
MISCELLANEOUS Pineapple f210 Sugar-beet seed f227
Cotton, crude fibers o1 Plum f255 Sweet chestnut f299
Mealworm o211 Potato f35 Walnut f256
MUXF3 CCD, Bromelain o214 Pumpkin f225 Wheat f4
Seminal fluid o70 Raspberry f343 White bean f15
Streptavidin o212 Red currant f322
Spinach f214 FOODS – SPICES
FOODS – FRUITS & VEGETABLES Strawberry f44 Allspice f339
Apple f49 Sweet potato f54 Anise f271
Apricot f237 Tomato f25 Basil f269
Asparagus f261 Watermelon f329 Bay leaf f278
Aubergine, eggplant f262 Black pepper f280
Avocado f96 FOODS – SEED, Caraway f265
Bamboo shoot f51 LEGUMES & NUTS Cardamon f267
Banana f92 Almond f20 Chilipepper f279
Beetroot f319 Barley f6 Clove f268
Blackberry f211 Blue vetch f310 Coriander f317
Blueberry f288 Brazil nut f18 Curry (Santa Maria) f281
Broccoli f260 Buckwheat f11 Dill f277
Brussel sprouts f217 Cashew nut f202 Ginger f270
Cabbage f216 Chick pea f309 Green pepper (unripe seed) f263
Carrot f31 Coconut f36 Lovage f275
Cauliflower f291 Common millet f55 Mace f266
Celery f85 Fenugreek f305 Marjoram f274
Cherry f242 Foxtail millet f56 Mint f332
Cucumber f244 Gluten f79 Mustard f89
Date f289 Green bean f315 Oregano f283
Fennel, fresh f276 Hazel nut f17 Paprika, Sweet pepper f218
Fig f328 Lentil f235 Parsley f86
Garlic f47 Lima bean f182 Tarragon f272
Grape f259 Linseed f333 Thyme f273
Grapefruit f209 Lupin seed f335 Vanilla f234
Guava f292 Macadamia nut f345
Allergy
FOODS – FISH, SHELLFISH Egg f245
& MOLLUSCS Egg white f1
Abalone f346 Egg yolk f75
Anchovy f313 Turkey meat f284
Blue mussel f37
Cat fish f369 FOODS – MEAT
Chub mackerel f50 Beef f27
Clam f207 Elk/moose meat f285
Crab f23 Mutton f88
Crayfish f320 Pork f26
Fish (cod) f3 Rabbit f213
Gulf flounder f147
Haddock f42 FOODS – MILK
Hake f307 Cheese, cheddar type f81
Halibut f303 Cheese, mold type f82
Herring f205 Cow’s whey f236
Jack mackerel, Scad f60 Goat milk f300
Langust (spiny lobster) f304 Mare’s milk f286
Lobster f80 Milk f2
Mackerel f206 Milk, boiled f231
Megrim f311 Sheep milk f325
Octopus f59 Sheep whey f326
Orange roughy f412
Oyster f290 FOODS – ADDITIVES
Pacific squid f58 Carob (E410) f296
Plaice f254 Guar, guar gum (E412) f246
Pollock f413 Gum arabic (E414) f297
Red snapper f381 Tragacanth (E413) f298
Salmon f41 Cochineal extract
Sardine (Pilchard) f308 (Carmine red) (E120) f340
Sardine, Japanese Pilchard f61
Scallop f338 FOODS – MISCELLANEOUS
Shrimp f24 Cacao f93
Snail f314 Coffee f221
Sole f337 Honey f247
Squid f258 Hop (fruit cone) f324
Swordfish f312 Malt f90
Tilapia f414 Mushroom (champignon) f212
Trout f204 Tea f222
Tuna f40 Yeast f45
Walleye pike f415
Whitefish (Inconnu) f384
FOODS – EGG & FOWL

Chicken f83
Allergy
COMPONENT TESTING
Using ImmunoCAP Allergen Components can help refine the understanding of sensitisation, by assessing
a person’s sensitisation pattern at the molecular level. When used in conjunction with traditional extract-
based IgE testing, these provide information at the individual component level.
For more information, please contact the Immunology Department on 020 7025 7917.
Alpha Gal Components (related to red meat) ZZ37 B 2 days

Alternaria Components ZZ1 B 2 days
Apple Components ZZ36 B 2 days
Aspergillus Components ZZ2 B 2 days
Birch Components ZZ3 B 2 days
Brazil Components ZZ4 B 2 days
Cashew Components ZZ35 B 2 days
Cat Components ZZ5 B 2 days
Celery Components ZZ6 B 2 days
Cow’s Milk Components ZZ7 B 2 days
Dog Components ZZ8 B 2 days
Egg Components ZZ9 B 2 days
Fish Components ZZ10 B 2 days
Hazelnut Components ZZ11 B 2 days
House Dust Mite Components ZZ12 B 2 days
Kiwi Components ZZ32 B 2 days
Latex Components ZZ13 B 2 days
Olive Components ZZ14 B 2 days
Peach Components ZZ15 B 2 days
Peanut Components ZZ16 B 2 days
Shrimp Components ZZ17 B 2 days
Soybean Components ZZ18 B 2 days
Timothy Grass Components ZZ19 B 2 days
Venom Components ZZ33 B 2 days
Wall Pellitory Components ZZ20 B 2 days
Walnut Components ZZ34 B 2 days
Wheat Components ZZ21 B 2 days
Glycan Determinants ZZ27 B 2 days

Lipid Transfer Proteins ZZ23 B 2 days
Lipocalins ZZ28 B 2 days
Parvalbumins ZZ29 B 2 days
Polcalcins ZZ25 B 2 days
PR-10 Proteins ZZ22 B 2 days
Profilins ZZ24 B 2 days
Seed Storage Proteins ZZ26 B 2 days
Serum Albumins ZZ30 B 2 days
Tropomyosins ZZ31 B 2 days
* Please quote the ZZ Code when requesting Allergen Component Profiles.
Vitamins, Nutrition and Lifestyle
VITAMIN B PROFILE VITAMIN PROFILE 1 MINERAL SCREEN
Vitamin B1 Vitamin A Calcium

Vitamin B2 Beta Carotene Magnesium
Vitamin B3 Vitamin B1 Zinc
Vitamin B6 Vitamin B2 Iron
Vitamin B9 (red cell) Vitamin B6 Copper
Vitamin B12 (Active) Vitamin C (Frozen) Chromium
TAT Vitamin E TAT Manganese TAT
5 5 5
DAYS DAYS DAYS
VBP VITS MINE
AAB ABB7 BK
MINERAL SCREEN
SPORTS/PERFORMANCE PROFILE VITAMIN PROFILE 2
– WHOLE BLOOD
FBC/ESR Vitamin A Whole Blood Potassium
Biochemistry Profile Beta Carotene Whole Blood Magnesium
HDL/LDL Vitamin B1 Whole Blood Calcium
Ferritin Vitamin B2 Whole Blood Manganese
C-Reactive Protein Vitamin B3 Whole Blood Zinc
Omega 3/Omega 6 Vitamin B6 Whole Blood Copper
Mineral Screen Vitamin B9 (Red Cell Folate) Whole Blood Selenium
Vitamin B9 (Red Cell Folate) Vitamin B12 (Active) Whole Blood Chromium
Vitamin B12 (Active) Vitamin C (Frozen)
Vitamin D (25-OH)
TAT Vitamin E TAT TAT
5 5 5
DAYS DAYS DAYS
SPOR VIT2 RMIN
AAABBBB A A A B B 7,13 HH
GK4
Patients taking supplements may be advised to stop medication prior to testing.
Ceruloplasmin CERU B 1 day

Essential Fatty Acid Profile (Red Cell) EFAR A4 10 days
Folate (Red Cell) RBCF A 2 days
Glutathione (Red Cell) GLUR H5 5 days
Glutathione Peroxidase GLPX H 5 days
Lutein LUTE B 13 2 weeks
Lycopene LYCO B 2 weeks
Magnesium (Whole blood) RCMG A or H 4 days
Mineral Screen MINE BK 5 days
Mineral Screen (Whole blood) RMIN HH 5 days
Mineral Screen and Industrial Heavy
TRAC ABHK 7-10 days
Metal Screen (Trace Metals)
Omega 3/Omega 6 OMG3 A 4 4 days
Selenium (Serum) SELE B 4 days
Selenium (Whole Blood) SELR A or H 4 days
Sports/Performance Profile SPOR AAABBBBGK 4 5 days
Xylose Tolerance Test XTT J1 7 days
Zinc (Serum/Plasma) ZINC K 1 day
Zinc (Urine) URZN CU 5 days
Zinc (Whole Blood) RBCZ A or H 5 days
This provides valuable diagnostic information, which can be assimilated with other diagnostic markers
in the assessment of nutritional status, and compares favourably to semi-quantitative functional assays.
For fertility and lifestyle refer to page 60.
1,25 Vitamin D D3 B 5-8 days

Beta Carotene CARO B 5 days
Biotin BIOS B 5 days
Carotenes CARO B 13 5 days
Vitamin A (Retinol) VITA B 5 days
Vitamin B (Functional) FUNC A A or H 13 5 days
Vitamin B Profile VBP AAB 5 days
Vitamin B1 (Thiamine) VIT1 A 5 days
Vitamin B2 (Riboflavin) VIB2 A 5 days
Vitamin B3 (Nicotinamide) VIB3 B 5 days
Vitamin B5 (Pantothenic Acid) VB5S B 5 days
Vitamin B6 (Pyridoxine) VITB A 5 days
Vitamin B8 (Biotin) BIOS B 5 days
Vitamin B9 (Folic acid) – Red cell RBCF A 2 days
Vitamin B9 (Folic acid) – Serum FOLA B 1 day
Vitamin B12 (Active) B12 B 1 day
Vitamin B12 (Active)/Red Cell Folate B12F AB 2 days
Vitamin C (Active) VITC B (Frozen) 7 5 days

Vitamin D (1, 25 Dihydroxy) D3 B 5-8 days
Vitamin D (25-OH) VITD B 4 hours
Vitamin E (Alpha Tocopherol) VITE B 5 days
Vitamin K (Nutritional) VKN B 13 5 days
Vitamin Profile 1 VITS ABB 7 5 days
Vitamin Profile 2 VIT2 A A A B B 7,13 5 days
Omega3/6
Essential Red Cell Fatty Acids Omega-3/Omega-6
Omega-3 is the name given to a family of polyunsaturated fatty acids, which the body needs but cannot
manufacture itself. Omega-3 fats are used as the building blocks for fat derived hormones such as
prostaglandins and leukotrienes. The hormones with an Omega-3 base tend to reduce inflammation,
while those that have an Omega-6 base increase inflammation. In the cell membrane the competition
between these two essential fats has a direct bearing on the type of local hormone produced and the
level of inflammation in the cell.
The Omega-6 to Omega-3 ratio in the cell membranes is key to the development of inflammatory
disorders such as rheumatoid arthritis and heart disease. Diets low in oily fish and high in grains will
promote inflammation and affect good health. The ratio of Omega-6 to Omega-3 in the West is around
15 to 1, fifteen times more Omega-6 on the cell membrane promoting inflammation. Having twice as
much Omega-6 is considered by most experts to be the optimal amount but a ratio of 2:1 is not easy to
produce by diet alone. Many people are aware of the health benefits of Omega-3 but the supplementation
to achieve optimal health is erratic. Being able to test for Essential Red Cell Fatty Acids (Omega-6/
Omega-3 ratio) identifies a person’s current status and is sufficiently specific to allow an accurate
supplementation recommendation to be made.
Results show the Omega Ratio with a clear recommendation for the required level of Omega
Supplementation (if any) to achieve optimal levels.
Results show the ratio of Omega 3 to Omega 6, against an optimal ratio and provide a supplementation recommendation
to achieve this optimal ratio.
Omega 3/Omega 6 OMG3 A4 4 days
TDL Tinies™ and Self-collection samples
TDL TINIES™ ([email protected])
This list of tests covers some of the range that can be offered to patients for self-collection,
using TDL TINIES™ and Royal Mail postal packs. Orders for TDL TINIES™ (packs with instructions)
can be made up by TDL, by arrangement, and sent individually to patients, or supplied directly to doctors
or healthcare companies. This is not a patient self-referral service and it is not point of care testing.
All testing is undertaken in the laboratory and results are always returned directly to the healthcare
company or doctor, not to the patient.
TDL TINY™ samples can be combined with other self-collected samples types (e.g. urine, stool,
swabs, HPV).
In the case of positive Sexual Health, results will be reported with the recommendation
for a venous sample to undertake confirmatory sample.
The sample volume from one TINY sample, when filled to the upper fill line, is 600 microlitres. These, on
receipt in the laboratory, are centrifuged and provide a volume of approximately 300 microlitres of serum/
plasma (depending on the tube type used). Different tests require varying amounts of sample, and this,
together with analyser dead volumes, means that although certain tests can be carried out from TINY
tubes, many tests simply cannot be successfully processed achieved from these smaller sample volumes.
TDL TINY™ microtainers are manufactured by BD Diagnostics. They are designed for samples
collection from skin puncture. BD Microtainers come with a variety of additives for various tests,
have visible fill lines, and are colour coded as for standard BD Vacutainer tubes. Tubes and Lancets
are CE marked. TDL TINY™ packs are made up by TDL and contain everything needed for a patient
to self-collect their blood sample.
Recommendation: most people are not experienced at self-collection of their own blood. Whilst it
is certainly possible to process a number of tests from one TINY and it is possible to collect blood drops
for two or three microtainers – the most successful outcomes are collected by patients who read the
instructions given in each pack, and who collect enough sample for one microtainer. Instructions for
sample collection are enclosed in each pack. A completed request form must be enclosed with the
returned sample. Results will always be sent to the requesting doctor/healthcare organisation.
There is a TDL TINY™ video to assist patients with sample collection.
Visit http://www.tdlpathology.com/test-information/test-service-updates/tdl-tinies
This can be personalised with logo and details.
For information and packs, please contact Annette Wilkinson 020 7307 7343
or email [email protected].
Tests that can be self-collected using TDL TINIES™

HAEMATOLOGY
TEST CODE SAMPLE REQS
Full Blood Count FBC A
HbA1c GHB A
BIOCHEMISTRY
Amylase AMY B
Calcium CA B
Calcium + Vitamin D CALD B
Carbohydrate Deficient Transferrin CDT B
C Reactive Protein CRP B
C Reactive Protein (High Sensitivity) HCRP B
Ferritin FERR B
HbA1c GHB A
Iron Status Profile (FE/TIBC/FERR) ISP B
Liver Function Tests LFT B
Lipid Profile LIPP B
Lp-PLA2 (PLAC) Test PLA2 B
Uric Acid UA B
Vitamin B12 (Active) B12 B
Vitamin D (25-OH) VITD B
ENDOCRINOLOGY
AFP AFP B
Antimullerian Hormone AMH B
Beta HCG (Quantitative) QHCG B
Cortisol CORT B
DHEA Sulphate DHEA B
Female Hormone (LH/FSH/PROL/OEST) FIP B
FSH FSH B
HRT Profile 1 (FSH/OEST/PROG) HRT B
Oestradiol OEST B
Progesterone PROG B
Prolactin PROL B
SHBG SHBG B
Testosterone TEST B
Thyroid Profile 1 (Free T4/TSH) TF B
Thyroid Profile 3 (Free T3/Free T4/TSH) TF3 B
IMMUNOLOGY
Borrelia Antibodies (IgG/IgM) BORR B
Borrelia Antibodies (IgM) BORM B
Endomysial Antibodies IgA AEAB B
Gliadin Antibodies (IgG) AGAB B
H. pylori Antibodies (IgG) HBPA B
Tissue Transglutaminase IgA TAA B
VIROLOGY / SEXUAL HEALTH
COVID-19 Roche Total Antibody IgG/IgM (SARS-CoV-2) TCOV CE marked self-collection kit*
Hepatitis B Surface Antigen THBA B
Hepatitis B Immunity (IgG) THBI B
Hepatitis C Antibodies THCV B
HIV1&2 Abs/p24 Ag THIV B
HPV mRNA (All High Risk Subtypes) HPVY Self-collection kit
HPV Individually Typed High Risk DNA Subtypes HPVZ Self-collection kit
Syphilis IgG/IgM TSYP B
*See details below – CE marked self-collection kits for COVID must be used.
TUMOUR MARKERS
AFP AFP B
Beta HCG(Oncology) HCGQ B
CA 15-3 C153 B
CA 19-9 C199 B
CA 125 C125 B
CEA CEA B
HE4 + ROMA HE4 B
Prostate Specific Antigen PSPA B
LIFESTYLE
Omega 3/Omega 6 OMG3 A
Vitamin B9 (Folic Acid) Red Cell RBCF A
Vitamin B9 (Folic Acid) Serum FOLA B
Vitamin B12 (Active) B12 B
Vitamin D (25-OH) VITD B
COVID-19 (SARS-CoV-2) Roche Elecsys Anti-SARS-CoV-2 Total Antibody

Roche Elecsys Anti-SARS-CoV-2 reports both IgG and IgM as a TOTAL antibody result. The Roche Antibody test
is CE marked for capillary samples, and one of the UKHSA selected antibody tests.
Test Code: TCOV
Sample Type SST/Serum B Capillary (>14 days after onset of symptoms)
Performance Specificity 100%, Sensitivity 97.4%
Analysers Roche e801
Turnaround time 24 hours from receipt of sample
Self-collection capillary samples must be taken using CE marked IVD for COVID Postal kits
The kits include a Royal Mail Tracked 24 return label. Contact [email protected] for details.
Screening for Drugs of Abuse /Alcohol
Alcohol Profile AP ABBG 5-7 days

Alcohol Profile 2 ALCP A A B B G RU 5-7 days
Amphetamines – Blood AMPB BB 5 days
Cannabinoids (Urine) Screen CANN RU 1 day
Cocaine (Urine) Screen UCOC RU 1 day
Drugs of Abuse from Blood
DOAP B 5 days
without Chain of Custody
Drugs of Abuse Profile – Random 2 days (5 days with
DOA RU
Urine Sample/No Chain of Custody LC-MS/MS confirmation)
Drugs of Abuse Profile – Random
2 days (5 days with
Urine Sample/No Chain of DOA3 RU
LC-MS/MS confirmation)
Custody Plus Alcohol
Drugs of Abuse Profile – With RU/CoC Collection 2 days (5 days with
DOAL
Chain of Custody Containers 1,2 LC-MS/MS confirmation)
Drugs of Abuse Profile – 2 days (5 days with
DOAN RU 2
Without Chain of Custody LC-MS/MS confirmation)
Ketamine Screen KETA RU 7-10 days
LSD LSD RU 5 days
Opiate Screen (Urine) UOPI RU 2 days
PEth (Phosphatidylethanol) PETH A 38 5-7 days
Urine EtG (Ethyl glucuronide) ETG RU 1 week
Chain of custody refers to the system of controls governing the entire urine collection, processing and
storage of sample to ensure that a particular urine specimen originated from a particular individual and that
the reported results relate, beyond doubt, to that specimen. Chain of custody requires attention to detail so
that it is possible to prove that there has been no opportunity for the sample to be accidentally or maliciously
adulterated. Sample collection should be undertaken by collectors who are well versed in the protocols of
chain of custody.
Samples submitted for analysis will undergo initial screening. Urinary creatinine is routinely measured during
testing to verify the validity of the sample submitted. Creatinine levels below normal occur when the urine
has been diluted, either directly or by drinking large amounts of water before providing the urine sample.
Chain of custody containers, forms, seals and barcodes are provided by TDL on request. All Chain
of Custody, and non-chain, samples with positive findings will proceed to identification/confirmation
by Gas Chromotography/Mass Spectrometry.
Screening for Drugs of Abuse /Alcohol
DRUGS OF ABUSE SCREENING
DRUGS OF ABUSE PROFILE – DRUGS OF ABUSE PROFILE – RANDOM

WITH CHAIN OF CUSTODY URINE SAMPLE/NO CHAIN OF CUSTODY
Alcohol LSD Amphetamines MDMA
Amphetamines MDMA Barbiturates Methadone
Barbiturates Methadone Benzodiazepine Morphine – opiate
Benzodiazepine Methaqualone Cannabinoids
Cannabinoids Morphine – opiate Cocaine
Cocaine Phencyclidine Codeine – opiate
Codeine – opiate Propoxyphene Dihydrocodeine – TAT TAT
Dihydrocodeine – opiate
opiate
2 5 WITH LCMS/MS
CONFIRMATION
DAYS DAYS
Ketamine TAT TAT
2 5 WITH LCMS/MS
CONFIRMATION DOA
DAYS DAYS
plus Alcohol
DOAL
DOA3
1,2
RU/CoC collection containers * See page 157 RU
DRUGS OF ABUSE PROFILE – DRUGS OF ABUSE FROM BLOOD –

WITHOUT CHAIN OF CUSTODY WITHOUT CHAIN OF CUSTODY
As above but with Amphetamines Opiates
NO Chain of Custody Barbiturates Cocaine
Tricyclic Antidepressants
Benzodiazepine
TAT TAT Cannabinoids TAT
2 5 WITH LCMS/MS
CONFIRMATION 5
DAYS DAYS DAYS
DOAN DOAP
RU 2
B
ALCOHOL PROFILE ALCOHOL PROFILE 2
LFT Alcohol Level LFT Alcohol Level

CDT MCV CDT MCV
TAT TAT
PEth PEth
5-7 Urine Ethyl Gluconaride (EtG) 5-7
DAYS DAYS
AP ALCP
ABBG A A B B G RU
Occupational health
OCCUPATIONAL HEALTH – TRACE METALS IN BLOOD
Aluminium (Blood) ALUM K 7 days

Arsenic (Blood) ARS A or H 5 days
Cadmium (Blood) CADM A or H 5 days
Chromium (Blood) CHRO A 5 days
Cobalt (Serum) COBB B 5 days
Lead (Blood) LEAD A 5 days
Lead Profile (Hb, ZPP, Lead) LEAZ A 13 3-5 days
Magnesium (Serum) MG B 4 hours
Manganese (Serum) MANG B 5 days
Mercury (Blood) MERC A or H 5 days
Nickel (Serum) NICK B 5 days
Silver (Blood) SILV B 5 days
Trace Metal (Blood) Profile TRAC ABHK 7-10 days
Zinc (Serum/Plasma) ZINC K 1 day
TRACE METAL (BLOOD) PROFILE
Aluminium Iron Zinc Copper Mercury Chromium TAT

Manganese Calcium Magnesium Cadmium Lead 7-10
DAYS
TRAC
ABHK
Occupational health
OCCUPATIONAL HEALTH – TRACE METALS IN URINE
Aluminium (Urine) ALUU RU 1-2 weeks

Arsenic (Urine) ARSE RU 30 5 days
Cadmium (Urine) URCD RU 30 5 days
Chromium (Urine) URCR RU 30 10 days
Cobalt (Urine) COBA RU 30 5 days
Copper (Urine) URCU CU 5 days
Lead (Urine) URPB RU 5 days
Magnesium (Urine) URMG PU 1 day
Mercury (Urine) URHG RU 1 5 days
Nickel (Urine) NICU RU 10 days
Silver (Urine) USIL RU 5 days
Zinc (Urine) URZN CU 5 days
OCCUPATIONAL HEALTH – TESTS FOR SPECIFIC EXPOSURE

2-Butanone GC BUTA RU 7 days

2-Furoic Acid 2FA RU 10 days
Acetone – Blood ACTB A or H 2 weeks
Acetone – Urine ACTU RU 5 days
Benzene BENZ J 1,6 3 days
Beta 2 Microglobulin (Serum) B2MG B 2 days
Beta 2 Microglobulin (Urine) UB2M RU 3 days
Bromide BROM B 3 days
Cholinesterase (Serum/Pseudo) CHPS B 4 hours
Doxepin Level (Sinequan) DOXE A 10 days
MBOCA in Urine MBOC RU 10 days
Molybdenum (Serum) MOLY B 5 days
Pethidine – Urine UPET RU 4 weeks
Thallium (Blood) THAL A/ H 1 week
Thallium (Urine) URTH RU 1 week
Toluene (Blood) TOL J 10 days
Toluene (Urine) UTOL RU 10 days
Trichloracetic Acid (Urine) UTCA RU 5 days
Xanthine – Blood XANB A 2 weeks
Xylene – Urine UXYL RU 30 2 weeks
Zinc Protoporphyrin ZNPR A 13 5 days
Cervical Screening
The Cervical Cytology laboratory provides a rapid service for liquid based cervical samples.
Urine cytology is performed in house while other non-gynaecological cytology samples
are referred to a UKAS accredited laboratory for reporting.
Human papilloma virus (HPV), Chlamydia and Gonorrhoea testing is carried out routinely
from ThinPrep vials and can be requested at the time the cervical sample is taken.
Laboratory hours
The laboratory department is open between 9.00am and 6.00pm.
Out-of-hours results are available on 020 7307 7373.
Urgent samples
It is helpful if requests for urgent samples can be discussed with the Senior Management Team.
Please telephone 020 7307 7323 ext 4761.
Use of service/Information required

Request forms must include 3 identifiers (this can be patient’s full name = 1, date of birth,
hospital number or reference number). Samples will not be processed without a request form.
Appropriate clinical information providing previous treatment/histological diagnosis is

essential to ensure correct management recommendations can be given in the patient
report. Tick boxes are provided to assist you.
The specimen container must be clearly labelled with patient details. Forms and samples which
are mismatched will result in the sample being returned to the sender for correction and will delay
the report turn around time.
Clinical advice
The Consultant Cytopathologists and the Advanced Practitioner work together to provide clinical and
technical advice, including recommendations for follow-up, HPV testing and management of complex
cases. TDL will provide recommendation for patient management, but not undertake to provide a
direct referral. No result will be entered onto the NHS CSP database and will therefore not be part
of an individual’s NHS screening record. Failsafe and management of the patient and their follow
up, including referral for colposcopy where indicated, would need to be arranged by their referring
clinician. To contact the department directly, please 020 7307 7323.
Cervical Screening
RECORD…
…the patient’s 3 identifiers to include date of birth on the vial.
…the patient information and medical history on the cytology
requisition form.
OBTAIN…
…an adequate sample from the cervix using a Cervex Brush
(broom-like device). Insert the central bristles of the brush
into the endocervical canal deep enough to allow the shorter
bristles to fully contact the ectocervix. Push gently and rotate
the brush in a clockwise direction five times.
RINSE…
…the Cervex Brush immediately into the PreservCyt Solution
vial by pushing it into the bottom of the vial 10 times, forcing
the bristles apart. As a final step, swirl the brush vigorously to
further release material. Visually inspect the Cervex Brush to
ensure that no material remains attached. Discard the brush.
Do not leave the head of the Cervex Brush in the vial.
Check the vial is in date before use.
TIGHTEN…
…the cap so that the black torque line on the cap passes
the black torque line on the vial. Do not over-tighten.
PLACE…
…the vial and request form in a specimen bag for
transportation to TDL.
Cervical Screening
ThinPrep® PAP Test Cervex Brush Protocol
PREPARE ALL EQUIPMENT BEFORE STARTING THE PROCEDURE
• Note expiry date on sample collection vial. Do not use expired vials.
• Ensure the entire plastic seal is removed from the lid of the vial and discarded.
• Complete patient details on both the request form and the vial.
Specimens may be returned or discarded if details are missing from the vial.
• Remove the lid from the vial before taking the sample.
• Use of lubricant is NOT recommended.
DO DON’T
• If excessive mucus is present, this should • DO NOT leave the head of
be gently removed before sampling. the Cervex Brush in the vial.
• Use either the Cervex Brush (broom-like • DO NOT routinely clean the cervix
device) on its own or a Plastic spatula or take a cervical swab before taking
and endocervical brush combination. a cervical sample.
• The Cervex Brush should be rotated • An endocervical brush should never
5 times in a clockwise direction. be used in isolation.
The Plastic spatula should be rotated • DO NOT under any circumstances
through 360 degrees and the endocervical use a wooden spatula.
brush rotated through one quarter to
one half turn. • DO NOT leave the collection device sitting
in the vial whilst dealing with the patient.
• Immediately rinse the collected
material into the vial. • DO NOT over-tighten the lid on the vial.
• Replace the lid and tighten so that the • DO NOT place multiple labels
black torque line on the cap passes on the outside of the vial.
the black torque line on the vial to • DO NOT apply barcoded labels
avoid leakage. vertically on the vial.
• Keep the unlabelled portion of the • DO NOT use expired vials.
sample vial free of labels so that the • DO NOT delay the sending of vials to
contents can be seen. the laboratory. The sample needs to be
• If barcoded labels are used these must processed within 3 weeks of collection.
be applied horizontally around the vial. • DO NOT use excessive lubricant –
• Samples should be sent to the please AVOID if possible.
laboratory without delay.
Cervical Screening
Gynaecological Samples
The Cytology department processes cervical samples directly referred from all sectors
of practice – Health Screening, Occupational Health, GP’s, Consultants, Colposcopy Units,
Clinics, Hospitals and other Laboratories.
Liquid Based Cytology (LBC) is processed using the Hologic ThinPrep system.
The Doctors Laboratory uses the Hologic Imaging system as an enhanced Quality Control.
Information for Sample Takers is available by contacting the department. Important: the head
of the cervical broom must NOT be left in the vial. The use of lubricant interferes with LBC sampling
and may result in an inadequate sample. Use of lubricant is NOT recommended as it can affect the
processing quality of the sample. Supplies of Thin prep vials are available from TDL.
STI Screening from Hologic Thin Prep Vial (HPV – see page 166)
Tests are priced individually. Please request tests individually. Thin Prep Vials are kept for 21 days
after receipt of sample. Requests for additional tests from the vial already received in the laboratory
can be made by contacting the Cytology Department.
Infection by PCR (singles)

Chlamydia trachomatis TPCR TPV 2 days

N. gonorrhoea TGON TPV 2 days
Chlamydia/Gonorrhoea TCG TPV 5 days
Mycoplasma genitalium MGEN TPV 2 days
Ureaplasma urealyticum UGEN TPV 2 days
Trichomonas vaginalis TVPC TPV 2 days
Gardnerella vaginalis GVPC TPV 2 days
Herpes Simplex I/II HERD TPV 5 days
7 STI PROFILE BY PCR FROM THIN PREP VIAL
Chlamydia trachomatis All tests can be

N. gonorrhoea requested individually
Mycoplasma genitalium
Ureaplasma
Trichomonas vaginalis
Herpes Simplex I/II TAT
2
DAYS
PP12
TPV
Cervical Screening
Human papillomavirus (HPV) is a common virus transmitted through sexual contact. High Risk sub-
types of HPV (HR-HPV) are linked to the development of abnormal cells and can cause cervical cancer.
HPV is a necessary cause of invasive cervical cancer. Evidence shows HPV testing is a more effective
way to identify women at risk of cervical cancer than by screening microscopically for abnormal cells
from a PAP test.
HR-HPV testing has been used in the UK since 2011 to identify women with low grade cytology
abnormalities and as a follow up test of cure in women who have received treatment. In 2017 the
UK NHSCSP recommended that testing for HPV should replace cytology as the first (primary test)
in cervical screening. Primary HR-HPV testing has higher sensitivity for high grade CIN than primary
cytology. HR-HPV testing also has a lower false negative rate than cytology. Primary HR-HPV testing
was fully implemented in the UK during 2020. Sample-taking remains unchanged: HR-HPV testing
is carried out from Thin Prep samples. Cytology will be undertaken as a triage if HPV is DETECTED.
WHAT DOES THIS CHANGE MEAN?

It means that HPV testing is the FIRST LINE TEST. It will be carried out as a single test,
with a single result reported as DETECTED/NOT DETECTED.
• If HR-HPV is NEGATIVE (NOT DETECTED) – this means no further testing is needed
for your patient: she returns to Routine Recall
• If HR-HPV is POSITIVE (DETECTED) – this means that CYTOLOGY will be processed
from the same Thin Prep Vial. A further specimen is not required.
• If the result from the sample is HR-HPV NOT DETECTED – the patient Recall
will be determined by the screening history and will either be a repeat HR-HPV test in 12 months’
time or, if HR-HPV remains persistent, a referral to colposcopy will be recommended.
• If the CYTOLOGY result from the sample is ABNORMAL the recommendation is to refer
this patient for COLPOSCOPY.
https://www.gov.uk/government/publications/cervical-screening-primary-hpv-screening-
implementation/cervical-screening-implementation-guide-for-primary-hpv-screening
All TDL requests for HPV have been processed as follows:

• If HPV is requested as a single test and the result is Negative/Not Detected, cervical
cytology (PAPT) would only be processed if specifically requested. Should HPV and PAPT
be undertaken, there would be a charge for both the HPV and the PAPT.
• If the HPV result is HR-HPV Detected, cervical cytology (PAPT) will be processed,
even if the PAPT has not been requested. The PAPT will not be charged.
Cervical Screening
UNDERSTANDING THE SIGNIFICANCE OF HPV TESTING
The benefit of a negative HPV result is its negative predictive value – meaning that a negative HPV
result indicates that a patient is at very low risk of developing cervical disease. However, neither HPV
testing nor negative cervical cytology are able to reduce the risk to zero. The negative predictive value
of both DNA and mRNA testing is the same. DNA tests detect presence of virus only. A mRNA test
detects the presence of viral oncogenic expression.
Requests for Cervical Cytology (PAPT) only will no longer be processed without HPV.
HPV testing will be charged.
Requests for PAPT
Cervical Cytology PAPT will include HPVH TPV 3 days

If PAPT is requested as a single test, HR-HPV will be undertaken additionally, and a combined report
will be issued. PAPT and HPVH will be charged.
Requests for PAPT with selected HPV (HPVH or HP20 or HPVT)
PAPT and HPVH PAPT + HPVH TPV 3 days

If PAPT and HPVH are requested together, results will be given as a combined report, PAPT and
selected HPVH test will be charged.
Requests for HPV as the PRIMARY TEST will reflex to PAPT if HR-HPV is DETECTED/POSITIVE.
PAPT will NOT be charged.
HPV mRNA (All High Risk Subtypes) HPVH TPV 3 days

If HR-HPV is DETECTED/POSITIVE, cervical cytology (PAPT) will be processed without charge.
The PAPT will be processed from the same vial.
Requests for HP20 as a single test
HPV (Individual low & high risk DNA subtypes) HP20 TPV / PCR Swab 3 days
HPV low and high risk DNA subtypes will be reported individually (9 low and 19 high risk).
If High Risk DNA subtypes are positive then cervical cytology (PAPT) using the same vial will be
processed without charge.
Requests for HPVT as a single test
HPV (DNA and reflexed mRNA) HPVT TPV 3 days

If one or more of DNA types 16, 18, 31, 33, 45 are DETECTED/POSITIVE, reflex testing for
expression of E6/E7 oncoproteins will be undertaken and cervical cytology (PAPT) will be
processed without charge. The PAPT will be processed from the same vial.
HPV/PAPT Combined Report

Where HPV result is reported with Cervical Cytology, a recommendation for patient management
will be given, based on the combined findings.
Turnaround times are from receipt of sample in the Cervical Cytology laboratory.
Self-collection HPV samples
TDL Self-Collection HPV Test
Human Papillomavirus (HPV) is the primary cause of nearly all cervical cancer. In most cases,
the HPV virus is harmless and causes no symptoms. Most women who acquire HPV are able
to clear the infection through their own immune systems. Persistent presence of high-risk
types of HPV can cause cervical lesions which over time may develop into cancer if untreated.
Testing for HPV determines the presence, or absence, of HPV and will determine whether
the HPV type present is high risk for CIN and cervical cancer.
The Self Collection HPV Test provides women with the option to self-collect a vaginal specimen
that is then sent to the laboratory for testing. There is well documented high level of concordance
between the HPV DNA results from self-collected and clinician-collected specimens.
The Self-Collection HPV Test is validated, using a CE marked sample collection device for vaginal cell
collection. This sample is then sent to the laboratory for processing for 19 high risk HPV DNA subtypes.
A negative result means that these high-risk subtypes HPV were not detected and the patient is at
extremely low risk of developing high-grade cervical disease/CIN2+ before their next routine visit.
A positive HPV result might indicate an increased risk of developing CIN/cervical cancer,
and the report from the laboratory will provide a clear recommendation for follow-up/colposcopy.
The value of HPV DNA testing in cervical cancer screening and disease detection has been proven
over and over again. Self-collection of specimens for HPV testing is not intended to replace existing
patient management pathways but allows for:
• Those who wish to test following a change of sexual partner
• Option for identifying individual high risk DNA subtypes
• Personal preference to self-collect vaginal samples
• An acceptable option for women who avoid having regular cervical smears
• Self-collection for HPV increases acceptability and coverage rate of cervical cancer prevention
Results will always be sent to the requesting clinician, clinic or healthcare organisation.
HPVY Self-Collected HPV DNA incorporating of high risk subtypes
HPVZ Self-Collected HPV DNA with individual reporting of all High Risk subtypes
(16, 18, 31, 33, 45, 35, 39, 51, 52, 56, 58, 59, 66, 68, 26, 53, 69, 73, 82).
For more information, or to order Self-Collection HPV Test Packs, please contact Annette Wilkinson
on 020 7307 7373 or [email protected]
HPV Individually Typed High Risk DNA Subtypes HPVZ Self-collection kit 10 days
HPV mRNA (All High Risk Subtypes) HPVY Self-collection kit 3 days
Self-collection HPV samples
Non-Gynae Cytology
Non-Gynaecological Cytology
Urines
To prevent cell degeneration it is advisable to collect urine samples in a sample pot containing
preservative (available from TDL Supplies). Use of preservative will ensure the cellular material
is preserved up to 48 hours.
Ideally 10 mls (excluding preservative) from a freshly fully voided urine (when the bladder is
emptied) mid-morning sample should be submitted for cytological assessment. If microbiology or
chemistry investigations are also required, please submit separate urine samples and mark the
vials accordingly. A mid-stream urine sample is NOT recommended for cytological assessment is
it could lead to a low cellular yield. If a delay of greater than 24 hours in reaching the laboratory
is anticipated samples should be refrigerated at 4°C.
Sputum
Sputum should be collected on at least three occasions if underlying lung carcinoma is suspected.
A single sputum is sufficient for microbiological assessment. Sputum should be sent to the laboratory
immediately following production, or stored in a universal container containing cytolyt cell fixative
if there is a likely delay. Please note that this is only acceptable if sputum is only for Cytology.
Microbiology cannot be performed on fixed material. Early morning sputum is ideal,
but contamination with food, toothpaste and tobacco should be avoided.
Fluids
All available material should be submitted in a sterile container without fixative as quickly
as possible. If any delay is anticipated, the material should be submitted in cytolyt fixative.
Cerebrospinal fluid (CSF)

Ideally CSF should be submitted fresh or as an air dried cytospin slide, unstained and in a plastic
transport slide box. A minimum of 3mls should be submitted either in fresh form or spun on multiple
slides for cytopathologists’ review and opinion. Please contact TDL Cytology for advice if required
on 020 7307 7323 / 7373.
URINE/SPUTUM/FLUID
Fluid Cytology CATF Fluid 4 3 days

Urine Cytology (Urine cytology containers
URCY Urine (30mls) 21 2 days
available from TDL Supplies)
Histopathology
CATEGORY CODE TISSUE SAMPLE
Breast HIS1 Breast Capsule

Breast HIS4 Breast Reduction (Bilateral)
Breast HIS3 Breast Reduction (Unilateral)
Breast HIS2 Breast Tissue
Breast HIS2 Cavity Shavings
Breast HIS1 Core Biopsy (1 Specimen)
Breast HIS2 Core Biopsy (2 Specimens)
Breast HIS3 Lumpectomy
Breast HIS5 Mastecomy (simple) / Wide Local Excision (WLE)
Breast HIS5+HIS4 Mastectomy + Axillary Clearance
Breast HIS4 Microdochectomy
Breast HIS2 Nipple
Breast HIS5 Sentinal Nodes
Cardiac HIS3 Aorta
Cardiac HIS2 Cardiac Biopsy
Cardiac HIS3 Cardiac Tumour Excision
Cardiac HIS2 Heart Valves
Cardiac HIS2 Mediastinal Tissue
Cardiac HIS2 Pericardium
Cardiac HIS2 Temporal Artery Biopsy
Endocrine HIS5 Adrenal
Endocrine HIS4 Parathyroid
Endocrine HIS4 Thyroid (Lobe)
Endocrine HIS5 Thyroid (Total)
ENT – Biopsy HIS2 Bronchial Biopsy
ENT – Biopsy HIS1 Cholesteatoma
ENT – Biopsy HIS1 Dental Cyst
ENT – Biopsy HIS1 Ear Canal Biopsy
ENT – Biopsy HIS1 Ear Polyp
ENT – Biopsy HIS1 Epiglottis
ENT – Biopsy HIS1 Gingivial Tissue
ENT – Biopsy HIS1 Laryngeal Biopsy
ENT – Biopsy HIS2 Laryngeal Nodule (Bilateral)
ENT – Biopsy HIS1 Laryngeal Nodule (Unilateral)
ENT – Biopsy HIS2 Mandible Biopsy
ENT – Biopsy HIS2 Maxillary Mucosa
ENT – Biopsy HIS2 Mucocele
ENT – Biopsy HIS1 Nasal Biopsy
ENT – Biopsy HIS1 Nasal Polyps
ENT – Biopsy HIS1 Oral Biopsy
ENT – Biopsy HIS1 Palatal Biopsy
Histopathology
ENT – Biopsy HIS1 Pharyngeal Biopsy

ENT – Biopsy HIS2 Pleural Biopsy
ENT – Biopsy HIS1 Thyroid Biopsy
ENT – Biopsy HIS1 Tongue Biopsy
ENT – Biopsy HIS1 Tonsil (1 Specimen)
ENT – Biopsy HIS2 Tonsil Biopsy
ENT – Biopsy HIS2 Tonsils (2 Specimens)
ENT – Biopsy HIS2 Uvelectomy
ENT – Biopsy HIS1 Vocal Chords
ENT – Resections HIS5+HIS2 Glossectomy
ENT – Resections HIS5 Laryngectomy
ENT – Resections HIS5+HIS2 Maxillectomy
ENT – Resections HIS5+HIS2 Neck Dissection
ENT – Resections HIS5+HIS5 Neck Dissection (Bilateral)
ENT – Resections HIS4 Parotidectomy
ENT – Resections HIS4 Partial Thyroidectomy
ENT – Resections HIS5+HIS5 Pharyngectomy
ENT – Resections HIS5+HIS2 Rhinectomy
ENT – Resections HIS3 Submandibular Gland – Excision
ENT – Resections HIS2 Thyroglossal Cyst
GI Endoscopic – Biopsy HIS1 Bile Duct Biopsy
GI Endoscopic – Biopsy HIS1 Colonic Polyp
GI Endoscopic – Biopsy HIS1 Endoscopic Biopsy (1 specimen)
GI Endoscopic – Biopsy 2H1 Endoscopic Biopsy (2 specimens)
GI Endoscopic – Biopsy 10H1 Endoscopic Biopsy (10-15 specimens)
GI Endoscopic – Biopsy HIS5 Liver Biopsy – Medical
GI Endoscopic – Biopsy HIS3 Liver Biopsy – Tumour
GI Endoscopic – Biopsy HIS3 Omental Biopsy
GI Endoscopic – Biopsy HIS1 Pancreatic Biopsy
GI Endoscopic – Biopsy HIS1 Perianal Biopsy
GI-Resection – Small HIS215 Anal Fistula
GI-Resection – Small HIS2 Appendix
GI-Resection – Small HIS3 Endo Mucosal Resection (EMR / ESD)
GI-Resection – Small HIS2 Gallbladder
GI-Resection – Small HIS2 Haemorrhoidectomy
GI-Resection – Small HIS2 Hernia Sac
GI-Resection – Small HIS3 Meckel’s Diverticulum
Histopathology
GI-Resection – Small HIS2 Mesentery

GI-Resection – Small HIS2 Perianal Biopsy / Warts
GI-Resection – Small HIS2 Pilonidal Sinus
GI-Resection – Small HIS2 Polypectomy
GI-Resection – Small HIS2 Umbilical Lesion
GI Resection – Large HIS5 Biliary Resection
GI Resection – Large HIS5+HIS2 Colon
GI Resection – Large HIS5 Distal Pancreatectomy
GI Resection – Large HIS5+HIS2 Gastrectomy
GI Resection – Large HIS5 Gastric Wedge Resection
GI Resection – Large HIS5 Ileoanal Pouch Resection
GI Resection – Large HIS4 Ileostomy
GI Resection – Large HIS3 Ileum
GI Resection – Large HIS5+HIS2 Large Bowel Resection – Benign / Malignant
GI Resection – Large HIS4 Liver Wedge Resection
GI Resection – Large HIS5+HIS2 Oesophagectomy
GI Resection – Large HIS5 Partial Hepatectomy
GI Resection – Large HIS5 Small Bowel Resection – Benign / Malignant
GI Resection – Large HIS5+HIS5 Whipple’s Procedure / Pancreatectoduodenectomy
Gynaecology HIS2 Cervical Biopsy
Gynaecology HIS1 Cervical Polyp
Gynaecology HIS4 Cervix
Gynaecology HIS1 Curettings – Endocervical
Gynaecology HIS1 Curettings – Endometial
Gynaecology HIS2 Endometrial Biopsy
Gynaecology HIS1 Endometrial Pipelle
Gynaecology HIS1 Endometrial Polyp
Gynaecology HIS2 Fallopian Tube
Gynaecology HIS3 Fibroids
Gynaecology HIS2 Fimbrial Cyst
Gynaecology HIS4 LLETZ and / or Cone Biopsy
Gynaecology HIS2 Mastoid
Gynaecology HIS2 Ovarian Biopsy
Gynaecology HIS2 Ovarian Cyst
Gynaecology HIS1 Ovarian Pipelle
Gynaecology HIS5 Ovaries (Bilateral)
Gynaecology HIS3 Ovary (Unilateral)
Gynaecology HIS4 Ovary and Tube (Unilateral)
Gynaecology HIS5 Ovary and Tube (Bilateral)
Gynaecology HIS2 Pelvic Mass
Gynaecology HIS1 Peritoneal Biopsy
Gynaecology HIS5 Placenta
Gynaecology HIS2 Pouch of Douglas
Gynaecology HIS1 Products of Conception
Histopathology
Gynaecology HIS2 Uterine Polyp

Gynaecology HIS4 Uterus
Gynaecology HIS5 Uterus and Cervix
Gynaecology HIS5 Uterus, Tubes and Ovaries
Gynaecology HIS1 Vulval Biopsy
Haemato-Oncology HIS5 Bone Marrow
Haemato-Oncology HIS2 Lymph Node
Haemato-Oncology HIS3 Lymph Node (Lymphoma)
Haemato-Oncology HIS3 Lymph Node (Metastatic Disease)
Haemato-Oncology HIS5 Spleen
Haemato-Oncology HIS5 Thymus
Lung – Biopsy HIS3 Lung Biopsy
Lung – Resections HIS3 Lung Lesion Small Wedge Resection
Lung – Resections HIS5+HIS5 Lung Resection
Lung – Resections HIS5 Lung Tumour Resection +/- Nodes
Neurosurgery HIS3 Brain Biopsy
Neurosurgery HIS3 Brain Resection
Neurosurgery HIS5+HIS5 Muscle Biopsy
Neurosurgery HIS3 Pituitary Gland – Resection
Neurosurgery HIS3 Spinal Tumour Biopsy
Neurosurgery HIS3 Spinal Tumour Resection
Neurosurgery HIS4 Vertebrea
Opthalmic HIS1 Conjunctival Biopsy
Opthalmic HIS1 Cornea
Opthalmic HIS4 Globe / Removal of Eye
Opthalmic HIS2 Lacrimal Gland Biopsy / Excision
Opthalmic HIS1 Orbit Contents of Eye
Orthopaedic HIS1 Bone Biopsy
Orthopaedic HIS2 Bone Currettings
Orthopaedic HIS2 Bursa
Orthopaedic HIS2 Duputrenes Contracture
Orthopaedic HIS3 Femoral Head Resection
Orthopaedic HIS1 Ganglion Cyst
Orthopaedic HIS3 Joint Resurfacing / Redo Prosthesis Capsule
Orthopaedic HIS1 Neuroma
Orthopaedic HIS2 Synovial Biopsy
Orthopaedic HIS3 Tendon
Skin and Soft Tissue HIS2 Abscess
Skin and Soft Tissue HIS3 Alopecia Biopsies
Skin and Soft Tissue HIS1 Cyst Excision
Skin and Soft Tissue HIS1 Fossa
Skin and Soft Tissue HIS1 Granuloma
Skin and Soft Tissue HIS3 Lipoma
Skin and Soft Tissue HIS2 Skin Excision BCC / SCC
Histopathology
Skin and Soft Tissue HIS1 Nail

Skin and Soft Tissue HIS1 Pilonidal Sinus
Skin and Soft Tissue HIS5 Sentinel Nodes in Skin Cancer (Melanoma)
Skin and Soft Tissue 1SK Skin Biopsy (1 specimen)
Skin and Soft Tissue 2SK Skin Biopsy (2 specimens)
Skin and Soft Tissue 11SK Skin Biopsy (11-15 specimens)
Skin and Soft Tissue HIS3 Soft Tissue Tumour Biopsy
Skin and Soft Tissue HIS3 Soft Tissue Tumour Resection
Urology – Biopsy HIS1 Bladder Biopsy
Urology – Biopsy HIS1 Core Biopsy (Urology)
Urology – Biopsy HIS2 Hydrocele
Urology – Biopsy HIS2 Penile Biopsy
Urology – Biopsy HIS1 Prostate Biopsy
Urology – Biopsy 2H1 Prostate Biopsies x 2
Urology – Biopsy 10H1 Prostate Biopsies x 10-12
Urology – Biopsy HIS5 Testicular Biopsy (Bilateral)
Urology – Biopsy HIS4 Testicular Biopsy (Unilateral)
Urology – Biopsy HIS1 Urethral Biopsy
Urology – Biopsy HIS2 Vasectomy
Urology – Resection HIS5+HIS5 Cystoprostatectomy
Urology – Resection HIS3 Epididymis
Urology – Resection HIS1 Foreskin / Circumcision
Urology – Resection HIS5 Nephrectomy / Kidney
Urology – Resection HIS5+HIS5 Prostatectomy
Urology – Resection HIS5+HIS5 Radical Cystectomy
Urology – Resection HIS3 Testis
Urology – Resection HIS3 – HIS5+ TURBT (dependent on number of blocks)
Urology – Resection HIS3 – HIS5 TURP (dependent on number of blocks)
Special instructions for samples
1 Contact the laboratory for special sample tubes/ 20 Sample types: FCRU or PCR swab or TPV
containers/instructions. or Semen.
2 Confirmation of not negative drug screens by 21 Urine cytology container, ideally first catch,
LCMS/MS may take up to 5 days. mid-morning specimen.
3 Clinical history essential and protect from light. 22 Must be fresh.
4 Send to the laboratory without delay. 30 Collect sample at end of exposure.
5 Do not send sample to the laboratory between 33 Sample must be labelled by hand with first
Friday noon and Monday morning. name, family name, gender and date of birth
6 Contact the Referrals Department before taking detailed on sample and form. Do not use labels
and sending sample to the laboratory. other than the tube label.
7 Sample should be separated and frozen if 34 Samples must arrive in the laboratory on the same
sending overnight. day of sample taking or contact the laboratory.
8 DRP Form required. DRP Form can be found 35 Patient should be fasting and resting for 30 mins
at the back of the guide. before sample taking. Samples need handling
urgently.
9 Clinical history must be provided.
36 Renin: Sample collected either upright /active
10 Contact the laboratory for special stability tubes or resting /supine (3 hours lying).
for lymphocyte subsets – or take an EDTA sample
and ensure same day delivery to the laboratory, 37 Provide sample time and date of collection.
Monday to Friday noon (do not send sample 38 EDTA sample should not be separated:
between Friday noon and Monday morning). send whole blood.
11 Patient consent required. Consent Form can 39 Urgent samples have a 3 day TAT if genotype is
be found at the back of this guide. required for prenatal diagnosis or two weeks TAT
12 Please provide one sample for each person if urgent for other factors.
being tested. 40 Informed Consent is required for these tests.
13 Protect from light. 41 Recommendation for patient to attend
14 Provide details of travel history. Patient Reception for sample taking.
15 Ammonia 42 LGV can be added to a positive chlamydia sample
using the same swab if requested within 4 days
Sample: EDTA plasma only. Full tubes and tightly
of receipt of result.
stoppered. On ice, centrifuged and analysed
20-30 mins post venepuncture (or plasma can 43 Please contact [email protected]
be frozen). If haemolysed gives falsely high results. for details for referring samples to the laboratory
Patient: Fasting. Avoid smoking. for sequencing testing.
16 Lactate
Example of profile panel information
Sample: Fluoride oxalate plasma only.
On ice and separate from cells 15-30 mins,
analyse promptly. Handle with care as sweat Profile PRE-TRAVEL SCREEN (DVT)
contains large amounts of lactate. No tourniquet. name
Patient: Rest 30 mins prior to test. FBC
17 Homocysteine Profile Factor II Prothrombin Gene
content Factor V Leiden
Should be spun and separated with 1 hour
Anticardiolipin TAT
of venepuncture.
Turnaround
Antibodies 5
18 Citrate Samples DAYS
time
Samples should be double spun and separated
and frozen within 4-8 hours of sample taking, DVT1
if a delay is expected with transportation to Sample
AAB9 Code
the laboratory, samples must be transported requirements
as frozen. Reference to sample taking and
special handling instructions (see above)
19 Must include patient’s age, height and weight.
Alphabetical test index
TEST CODE SAMPLE REQS TAT PAGE
1,25 Vitamin D D3 B 5-8 days 148

2-Butanone GC BUTA RU 7 days 160
2-Furoic Acid 2FA RU 10 days 160
4th Generation HIV1 & 2 Abs/p24 Ag
THIV B Tiny™ 4 hours 96
(45 days post-contact)*
5 HIAA RU5H PU 1 5 days 29
5’ Nucleotidase 5NT B 5 days 29
6-Thioguanine Nucleotides TGN AA 2 weeks 29
7 STI Profile by PCR 67, 77,
PP12 FCRU / PCR / TPV 2 days
(7 tests from 1 Sample) 164
11 Deoxycorticosterone DEOX B 10 days 51
11 Deoxycortisol 11DC B (Frozen) 10 days 51
16S rRNA Bacterial Gene 16S J 1 week 42
17 Hydroxyprogesterone 17OH B 5 days 51
18S rRNA Fungal Gene 18S J 1 week 42
21 Hydroxylase Ab’s 21HA B (Frozen) 10 days 29
Acetone – Blood ACTB A or H 2 weeks 160
Acetone – Urine ACTU RU 5 days 160
Acetylcholine Receptor Autoantibodies ACRA B4 5 days 29
Acetylcholinesterase Isoenzymes ACEI AF 7 days 29
Acid Phosphatase – Total APT B 5 days 29
ACTH (Adreno Corticotrophic Hormone) ACTH A (Plasma Frozen) 41 1 day 51
Activated Protein C Resistance APCR C (Frozen) 4,18 3 days 39
Acute Viral Hepatitis Screen AHSC B 4 hours 79, 92
ADAMTS-13 Activity CP13 C (Frozen) 3 days 39
ADAMTS-13 Antibody A13A C (Frozen) 1 month 39
Adenosine Deaminase AD A / B / Fluid 3 weeks 29
Adenovirus by PCR ADV A / PCR / VS / SC 7 days 98
Adiponectin ADIP B 2 weeks 29
Adrenal Cortex Antibodies ACTX B 2 days 79
Albumin ALB B 4 hours 29
Alcohol (Medical) [Do not use alcohol
ALCO G1 4 hours 29
swab prior to sample taking]
Alcohol (Urine) UALC RU 4 hours 29
157-158,
160
157-158,
160
Aldolase ALDO B 5 days 29
Aldosterone ALDN A or B 5 days 51
Aldosterone (Urine) UALD PU 5 days 51
Alk Phosphatase lsoenzymes APIE B 5 days 29
Alkaline Phosphatase ALP B 4 hours 29
Allergen Component Profiles 145
Allergy – Individual Allergens

ALLE B 2 days 138
(see list on page 141)
Allergy Profile (Mediterranean) ALMD B 2 days 137-138
Allergy Profile (Middle East) ALME B 2 days 137-138
Allergy Profile (UK) ALUK B 2 days 137-138
Allergy Profile 1 (Food & Inhalants) 1A BB 2 days 138-139
Allergy Profile 2 (Inhalants) 2A B 2 days 138-139
Allergy Profile 3 (Food) 3A B 2 days 138-139
Allergy Profile 4 (Nuts & Seeds) 4A B 2 days 138-139
Allergy Profile 5 (Children’s Panel) 5A B 2 days 138-139
Allergy Profile 6 (Shellfish) 6A B 2 days 138, 140
Allergy Profile 7 (Finfish) 7A B 2 days 138, 140
Allergy Profile 8 (Cereal – singles) 8A B 2 days 138, 140
Allergy Profile 9 (Antibiotics) 9A B 2 days 138, 140
Allergy Profile 10 (Insects) 10A B 2 days 138, 140
Allergy Profile 11 (Combined
11A B 2 days 138, 140
Shellfish/Finfish)
Allergy Profile 12 (Milk & Milk Proteins) 12A B 2 days 138, 140
Allergy Profile 13 (Stone fruit/
13A B 2 days 138, 140
Rosaceae family)
Alpha 1 Antitrypsin (Serum) A1AT B 1 day 29
Alpha 1 Antitrypsin (Stool) A1AF RF 10 days 29
Alpha 1 Antitrypsin Genotype Requires patient informed consent
29
Alpha 1 Glycoprotein OROS B (Frozen) 5 days 29
Alpha 1 Microglobulin A1MG RU 1,22 10 days 29
Alpha 2 Macroglobulins A2MG B 5 days 29
Alpha Feto Protein AFP B 4 hours 51, 101
Alpha Feto Protein (Maternal) AFPM B 4 hours 29
Alpha Gal Components
ZZ37 B 2 days 145
(related to red meat)
ALT (Alanine Aminotransferase) (SGPT) ALT B 4 hours 29
Alternaria Components ZZ1 B 2 days 145
Aluminium (Blood) ALUM K 7 days 29, 159
Aluminium (Urine) ALUU RU 1-2 weeks 160
Amenorrhoea Profile AMEN B 4 hours 51, 57
Amikacin Level (State dose) AMIK B4 4 hours 133
Amino Acid (Serum/Plasma) AMIN B 7 days 29
Amino Acid Quantitative (Urine) UAAQ RU 7 days 29
Amino-Laevulinic Acid (Urine) RUAL 100mls PU 5 days 29
Amitriptyline AMTR A4 5 days 134
AML/ALL Molecular MRD – NPM1,
PML-RARA, CBFB-MYH11, RUNX1- 109
GENE Bone Marrow / A 5 days
RUNX1T1, ETV6-RUNX1
Ammonia AMMO A (Frozen) 15 4 hours 29
Amniocentesis – rapid BOBs aneuploidy

diagnosis for all chromosomes ABK AF 9 5-15 days 109
Amniocentesis – rapid PCR diagnosis
for common aneuploidies (2 days) APCC AF 9 2-15 days 109
Amoebic (E. histolytica) Antibodies AFAT B 2 days 88
Amoebic (E. histolytica) PCR AMAG RF 2 days 88
Amphetamines – Blood AMPB BB 5 days 157
Amylase AMY B 4 hours 29
Amylase (Urine) UAMY CU 4 hours 29
Amylase lsoenzymes AMYI B 5 days 29
Amyloidosis (Amyloid A Protein) SAA B 5 days 29
Anaemia Profile ANAE AAB 2 days 38, 41
Anafranil (Clomipramine) CHLO A 7 days 134
ANCA (Anti-Neutrophil Cytoplasmic Abs) ANCA B 2 days 79
Andropause Profile ANDP BB 8 hours 51, 56
Androstanediolglucoronide ANDG B 3 weeks 29
Androstenedione ANDR B (Frozen) 4 days 51
Angiotensin II ANG2 A (Frozen) 2 weeks 29
Angiotensin Converting Enzyme ACE B 4 hours 29
Angiotensin Converting Enzyme – CSF ACEF CSF (Frozen) 2 weeks 29
Antenatal Profile ANTE A A 33 B B B G 3 days 38, 41
Anti-Actin Antibodies AAA B 5 days 79
Anti-Basal Ganglia Antibodies ABGA B 3 weeks 79
Anti-CCP Antibodies (RF) CCP B 2 days 79
Anti-Liver Cytosol Antibodies ALCA B 5 days 79
Anti-MOG [Myelin Oligodendrocyte
AMOG B 3 weeks 79
Glycoprotein] Antibodies
Anti-MUSK Antibodies MUSK B 2 weeks 79
Anti-Phosphatidylserine Antibodies PHTS B 5 days 79
Anti-Phospholipase A2 Receptor AA2R B 3 weeks 79
Anti-Ri Antibodies RIAB B 3 days 79
Anti-SLA (Soluble Liver Antigen) Abs LSA B 10 days 79
Anti-Xa Apixaban monitoring APIX C (Frozen)* 3 days 39
Anti-Xa Fondapariux Monitoring FOND C (Frozen)* 3 days 39
Anti-Xa LMWH monitoring LMWX C (Frozen)* 3 days 39
Anti-Xa Rivaroxaban monitoring RIVA C (Frozen)* 3 days 39
Antidiuretic Hormone ADH A A (Plasma Frozen) 4 10 days 51
Antimony (Urine) ANTI RU 30 10 days 29
Antimullerian Hormone (AMH Plus) AMH B 4 hours 29, 51, 56
Antinuclear Antibodies (titre & pattern) ANAB B 2 days 79
Antistaphylolysin Titre (SGOT) ASTT B 3 days 79
Antistreptolysin Titre/ASOT ASLT B 2 days 79
Antisulfatide Antibodies ASA B 5 weeks 79

Antithrombin Ill A111 C (Frozen) 4,9,18 3 days 39
AP50 Alternative Hemolytic Complement AP50 B (Frozen) 2 weeks 29
Apolipoprotein A1 APOA B 3 days 29
Apolipoprotein B APOB B 3 days 29
Apolipoprotein C APOC B 3 months 29
Apolipoprotein E (12 hours fasting) APOE B (fasting) 5 days 30
Apolipoprotein E genotype – E2, E3, E4 APEG A9 5 days 110
Apple Components ZZ36 B 2 days 145
APTT/KCCT KCCT C 18 4 hours 38
Aquaporin 4 Antibodies
AQUA B 2 weeks 79
(Neuromyelitis Optica)
Arbovirus Antibodies/Abs ARBO B 9,14 3 weeks 98
Array CGH (Comparative
CGH CVS / AF / A H 9 10 days 110
Genomic Hybridisation)
Arsenic (Blood) ARS A or H 5 days 30, 159
Arsenic (Urine) ARSE RU 30 5 days 30, 160
Arylsulphatase A ARYL H 5,6 8 weeks 30
Ascariasis Serology ASC B 5 days 79
Ashkenazi Jewish Carrier Screen 110
GENE A9 4 weeks
Aspartate Transaminase (AST) (SGOT) AST B 4 hours 30
Aspergillus Components ZZ2 B 2 days 145
Aspergillus Precipitins ASPP B 5 days 42
Atypical Antibody Screen
AASC A 22,33 2 days 38
(handwritten tube label)
Atypical Pneumonia Screen APS B 2 days 98, 100
Autoantibody Profile I AUTO B 2 days 79, 87
Autoantibody Profile II ENDO B 2 days 79, 87
Avian Precipitins (11 Species) AVIA B 5 days 79
Azoospermia – karyotype + cystic fibrosis
GRP AH 9 10-15 days 110
screen + polyT(5T) + Y deletions
Babesia Antibodies BABE B 3 weeks 79
Bancroftia/Oncerciasis/Filarial Antibodies TFIF B 14 2 weeks 98
BCR/ABL Quantitative – fusion
gene sizes p190 + p210 – MUST
BCRA AA 9 10 days 111
arrive in the laboratory within 48
hours, before 12pm on Fridays
Becker Muscular Dystrophy
DMD A9 10 days 111
– deletions/duplications
Behcet’s Disease –
B51 A9 10 days 111
Bence-Jones Protein RBJP 1 x 30mls (RU) 5 days 30
Benzene BENZ J 1,6 3 days 160
Beta 2 Glycoprotein 1 Abs B2GP B 5 days 79
Beta 2 Microglobulin (Serum) B2MG B 2 days 30, 160

Beta 2 Microglobulin (Urine) UB2M RU 3 days 30, 160
Beta Carotene CARO B 5 days 148
Beta D Glucan XBDG B 3 days 42
Beta HCG (Oncology) HCGQ B 4 hours 101
Beta HCG (Quantitative) QHCG B 4 hours 51
Beta-Glucuronidase (Sly Disease) BGLU H H 9,4 8 weeks 30
Bicarbonate HCO3 B 4 hours 30
Bile Acids – Serum BILE B 4 hours 30
Bilharzia (Schistosome) Antibody Screen BILH B 14 10 days 88
Bilharzia (Urine) USCH 1-2 days 88
Bilirubin (Direct/Indirect) DBIL B 4 hours 30
Bilirubin (Total) BILI B 4 hours 30
Bilirubin (Urine) UBIL RU 1 day 30
Biotin BIOS B 5 days 148
Biotinidase BIOT H (Frozen plasma) 4 3 weeks 30
Birch Components ZZ3 B 2 days 145
Bismuth BISM B 5 days 30
BK Polyoma Virus by PCR BKPV A /B /RU 5 days 98
Bleeding and Platelet Gene Panel Requires patient informed consent
111
(known familial variants) – Contact lab GENE AA 6 weeks
Bleeding and Platelet Gene
Panel (unknown familial 111
GENE AA 12 weeks
variants) – Contact lab
Blood Culture# BCUL 2 x BC 4 6 days + 42
Blood Film Examination FILM A 1 day 38
Blood Group † ABO A 22,33 2 days 38
BNP (NT-pro BNP) BNP B 4 hours 30, 51
Bone Alkaline Phosphatase BALP B (Frozen) 2 weeks 30
Bone Marrow (Aspirate) BMAS J1 14 days 40
Bone Marrow (Trephine Biopsy) BMI J1 3 days 40
Bone Screen BONE B CU 4 hours 30, 37
Bone Screen (Bloods only) BON2 B 4 hours 30, 37
Borrelia Antibodies (Lyme
BORR B 9,14 2 days 79, 88
Disease) IgG, IgM
Borrelia Antibodies (Lyme Disease) IgM BORM B 2 days 79, 88
Borrelia Confirmation (Immunoblot) BORC B 9,14 10 days 79, 88
BRAF V600E mutation by PCR Requires patient informed consent
111
for Hairy Cell Leukaemia GENE Bone Marrow / A 5 days
Brazil Components ZZ4 B 2 days 145
Breast Cancer – BRCA1 + BRCA2 only Requires patient informed consent
111
gene sequencing + deletions/duplications GENE A 4 weeks
Breast Cancer NGS Panel – Requires patient informed consent

101
full gene sequencing GENE A A 9,11 4 weeks
Bromide BROM B 3 days 160
Brucella Serology BRUC B9 2-3 weeks 79
BUN (Blood Urea Nitrogen) BUN B 4 hours 30
C-KIT D816V mutation by Requires patient informed consent
111
PCR for Mastocytosis GENE Bone Marrow / A 5 days
C Peptide CPEP B 3 days 51
C Reactive Protein CRP B 4 hours 30
C Reactive Protein (High Sensitivity) HCRP B 4 hours 30
C1 Esterase Inhibitor C1EI B 5 days 79
C1 Esterase: Function & Total FC1E C C (Plasma Frozen) 4,18 10 days 30
C1q Binding Immune Complex IMCP B 5 days 30
C3 Complement C3 B 4 hours 79
C3/C4 Complement COMP B 4 hours 79
C4 Complement C4 B 4 hours 79
CA 15-3 C153 B 4 hours 101
CA 19-9 C199 B 4 hours 101
CA 50 CA50 B 5 days 101
CA 72-4 C724 B 5 days 101
CA 125 C125 B 4 hours 101
Cadmium (Blood) CADM A or H 5 days 30, 159
Cadmium (Urine) URCD RU 30 5 days 30, 160
Calcitonin CATO B (Frozen) 4 1 day 51
Calcium CA B 4 hours 30
Calcium (24 hour Urine) UCA PU 4 hours 30
Calcium/Creatinine Ratio CACR RU B 4 hours 30
Calprotectin CALP RF 5 days 79
Calprotectin/Elastase Profile CEP RF 5 days 79, 87
Campylobacter Jejuni Antibodies CJAB B 5 days 42
Candida (Culture) CANC STM / CS 2-4 days 42
Candida Antibodies CANA B 5 days 42
Candida Antigen CCAG B 5 days 42
Cannabinoids (Urine) Screen CANN RU 1 day 157
Carbamazepine (Tegretol) CARB B 4 hours 134
Carbapenemase producing
MDR STM (rectal) 4-5 days ‡ 42
organism screen
Carbohydrate Deficient Glycoprotein CDG B 2 weeks 30
Carbohydrate Deficient Transferrin (CDT) CDT B4 3 days 30
Carboxyhaemoglobin CBHB A 1 week 38
Carcino Embryonic Antigen CEA B 4 hours 101
Cardiac Enzymes (not chest pain) CENZ B 4 hours 30
Cardiolipin Antibodies (IgG+IgM) ACAB B 2 days 79
Cardiovascular Risk Profile 1 PP10 BB 3 days 30, 37
Cardiovascular Risk Profile 2 PP11 B B B C 34 3 days 30, 37

Carnitine – Free & Total CARN H H (Frozen Plasma) 10 days 30
Carotenes CARO B 13 5 days 148
Carrier Screen (Ashkenazi Jewish) 112, 128
GENE A9 4 weeks
Carrier Screen (Ashkenazi Requires patient informed consent
112, 128
Jewish) – Partnered Report GENE A9 4 weeks
Carrier Screen (Pan-Ethnic) 112, 128
GENE A9 4 weeks
Carrier Screen (Pan-Ethnic) – Requires patient informed consent
112, 128
Partnered Report GENE A9 4 weeks
Cartilage Antibodies ACA B 5 days 79
Cashew Components ZZ35 B 2 days 145
Cat Components ZZ5 B 2 days 145
Cat Scratch Fever (Bartonella IgG+IgM) CAT B 5 days 98
Catecholamines (Plasma) CATE A A (Plasma Frozen) 4 5 days 51
Catecholamines (Urine) UCAT PU 1 5 days 51
CCP Antibodies (RF) CCP B 2 days 79
CD3/CD4/CD8 LYSS A 10 1 day 40, 96, 98
CD16 CD16 A4 1 day 40
CD19 B Cells CD19 A4 1 day 40
CD20 CD20 A 10 2 days 40
CD25 CD25 A 10 2 days 40
CD56 CD56 A4 1 day 40
CD57 CD57 A 1 day 40
Celery Components ZZ6 B 2 days 145
Centromere Autoantibodies CENT B 2 days 79
Ceruloplasmin CERU B 1 day 30, 148
PAPT will
Cervical Cytology include TPV 3 days 166
HPVH
CH50 (Classical pathway) CH50 B (Frozen) 4 4 days 79
Chagas Disease Serology (S.American
CHGA B 9,14 10 days 79
Trypanosomiasis) T. Cruzi
Chest Pain Profile CPP B STAT 30, 37
Chikungunya Virus Abs CHIK B 9,14 10 days 98
Chlamydia (PCR swab) SPCR PCR 2 days 67
Chlamydia (Thin Prep) TPCR TPV 2 days 67, 164
Chlamydia (Urine) CPCR FCRU 2 days 67
Chlamydia Species Specific
CHAB B 2 days 80, 87
(MIF) Ab Screen
Chlamydia/Gonorrhoea (PCR Swab) SCG PCR 2 days 67
Chlamydia/Gonorrhoea (Rectal) RSCG PCR 2 days 67
Chlamydia/Gonorrhoea (Thin Prep) TCG TPV 5 days 67, 164
Chlamydia/Gonorrhoea (Throat) TSCG PCR 2 days 67

Chlamydia/Gonorrhoea (Urine) CCG FCRU 2 days 67
Chlamydia/Gonorrhoea/
CCGT FCRU / PCR / TPV 2 days 67, 77
Trichomonas by PCR
Chloride CL B 4 hours 30
Cholesterol CHO B 4 hours 30
Cholesterol (Familial Requires patient informed consent
30, 116
Hypercholesterolaemia) GENE AA 9 7 weeks
Cholinesterase (Serum/Pseudo) CHPS B 4 hours 30, 160
Chromium (Blood) CHRO A 5 days 31, 159
Chromium (Urine) URCR RU 30 10 days 31, 160
Chromogranin A CGA B 5 days 31
Chromogranin A & B MTAB J1 3 weeks 31
Chromosome Analysis
ACUL AF 9 10-15 days 112
(Amniocentesis) – culture only
Chromosome Analysis (Amniocentesis)
– rapid BOBs aneuploidy diagnosis
ABK AF 9 5-15 days 113
for all chromosomes (5 days)
Chromosome Analysis (Amniocentesis) –
rapid PCR diagnosis for common
APCC AF 9 2-15 days 113
aneuploidies (2 days) + culture
(10-15 days)
Chromosome Analysis (Blood) KARY H9 2-3 weeks 113
Chromosome Analysis (Chorionic Villus)
– rapid BOBs aneuploidy diagnosis for
CBK CVS 9 5-15 days 113
all chromosomes (5 days) + culture
(10-15 days)
Chromosome Analysis
(Chorionic Villus) – rapid PCR
CVPC CVS 1,9 2-15 days 113
diagnosis for common aneuploidies
Chromosome Analysis
CVSC CVS 1,9 10-15 days 113
(Chorionic Villus) – culture only
Conception) – reflex to BOBs testing
PROC Placental Sample 1,9 20-25 days 113
if culture fails to grow – reflex to
BOBs testing if culture fails to grow
Conception) – BOBs rapid aneuploidy
PBK Placental Sample 1,9 5-25 days 113
diagnosis for all chromosomes
Chromosome Analysis (Solid Tissue) PROC Fetal tissue 1,9 4-5 weeks 113
Chromosome Analysis (Stem Cells) STEM/SUSP Culture/Fixed cells Contact lab 113
Chronic Fatigue Syndrome Profile VIP1 A + B 10 5 days 80, 87
Citrate (Blood) CITR B 5 days 31
Citrate (Urine) UCIT CU (Frozen) 5 days 31
CK (MB Fraction) CKMB B 4 hours 31

CK Isoenzymes CKIE B 5 days 31
Clobazam CLOB A 5 days 134
Clomipramine (Anafranil) CHLO A 7 days 134
Clonazepam CLON A 7 days 134
Clostridium Difficile Toxin by PCR CLOS RF* 2 days 42
Coagulation Profile 1 CLPF C 18 4 hours 38, 41
Coagulation Profile 2 CLOT A C 18 4 hours 38, 41
Cobalt (Blood) COB A 5 days 31
Cobalt (Serum) COBB B 5 days 31, 159
Cobalt (Urine) COBA RU 30 5 days 31, 160
Cocaine (Urine) Screen UCOC RU 1 day 157
Coeliac Disease – HLA DQ2/DQ8 Genotype Q2Q8 A9 10 days 80-81
Coeliac/Gluten Profile 2 GSA2 AB 10 days 80-81
Coeliac/Gluten Sensitivity Profile GSA B 2 days 80-81
Coenzyme Q10 CQ10 B 2 weeks 31
Cold Agglutinin CAGG J1 5 days 31
Collagen (Type I, II, IV) Antibodies COAB B 10 days 31
Collagen Type 1 Cross-Linked
NTX 2nd EMU 2 weeks 31
N-Telopeptide – NTX
Colloid Antigen-2 Antibodies CA2A B 2 weeks 80
Colorectal Cancer NGS Panel – full gene Requires patient informed consent
113
Comparative Genomic
CGH CVS / AF / A H 9 10 days 113
Hybridisation (Array CGH)
Complement C1q C1Q B 5 days 31
Complement C2 C2 B 10 days 31
Complement C5 C5A B 2 weeks 31
Complement C6 C6 B (Frozen)* 5 weeks 31
Complement Factor H FACH B 3 weeks 31
Complex PSA (Prostate Specific Ag) CPSA B 3 days 101
Congenital Absence of Vas Deferens
– karyotype + cystic fibrosis screen GRP AH 9 10-15 days 113
+ polyT(5T) + Y deletions
Coombs (Direct Antiglobulin Test) COOM A 2 days 40
31, 148,
159
Copper (Urine) URCU CU 5 days 31, 160
Cortisol CORT B 4 hours 51
Cortisol (Urine) UCOR CU 5 days 51
Cortisol Binding Globulin CBG B (Frozen) 1 month 31
Cotinine (Serum) COT B 4 days 80

Cotinine (Urine) COTT RU 2 days 31
COVID-19 (SARS-CoV-2) SST / Serum B * (Venous
GCOV 24 hours 80
Abbott IgG Antibody only)
COVID-19 (SARS-CoV-2) SST / Serum B * (Venous
MCOV 24 hours 80
Abbott IgM Antibody only)
COVID-19 (SARS-CoV-2) Rapid
RNA Sequencing – Contact Lisa
NEW COSQ RNA or PCR swab 43 48 hours 98
Levett for test requirements: Lisa.
[email protected]
COVID-19 (SARS-CoV-2) RNA by PCR NCOV PCR Swab (nasal/pharyngeal) 24 hours 98
COVID-19 (SARS-CoV-2) Roche Elecsys SST/Serum B (Venous/
NEW SCOV 24 hours 80
Anti-SARS-CoV-2 S (SPIKE) Capillary self-collection*)
COVID-19 (SARS-CoV-2) Roche Elecsys SST / Serum B * (Venous and
TCOV 24 hours 80
Anti-SARS-CoV-2 Total Antibody Capillary self-collection)
NEW COVID-19 (SARS-CoV-2) T-SPOT®.COVID TCEL H *** 3 days 80
COVID-19 / FLU /RSV Screen FLU4 PCR nasopharyngeal 2 days 98, 100
Cow’s Milk Components ZZ7 B 2 days 145
Coxsackie Antibodies (IgM) COXM B 10 days 98
Creatine Kinase (CK, CPK) CKNA B 4 hours 31
Creatinine CREA B 4 hours 31
Creatinine (Urine) UCR CU 4 hours 31
Creatinine Clearance CRCL B CU 4 hours 31
Cri du Chat Syndrome – PBOB,
CVS / AF / A H 9 5-15 days 114
Cri du Chat Syndrome – BOBs only PBOB CVS / AF / A 9 5 days 114
Crosslaps (Serum DPD) SDPD B (Freeze within 24 hours) 4 days 31
Cryoglobulins CRYO J6 10 days 31
Cryptococcal Antigen CRYC Serum or CSF 1 day 42
Cryptosporidium CRPO RF 2 days 42
Cryptosporidium Detection by PCR CRPA RF 2 days 88
CSF for Microscopy and Culture CSF CSF 1-3 days 42
CSF Screen by PCR VPCR CSF 2 days 98, 100
CT/GC/Trichomonas/Mgen (PCR Swab) SGTM PCR Swab 2 days 67, 77
CT/GC/Trichomonas/Mgen (Urine) CGTM FCRU 2 days 67
Culture (Any site) CULT up to 5 days 42
CVS PCR for common aneuploidies
CVPC CVS 1,9 2-15 days 114
CVSBOBs – rapid BOBs aneuploidy
diagnosis for all chromosomes CBK CVS 9 5-15 days 114
(3-5 days) + culture (10-15 days)
CVSBOBs only – rapid aneuploidy
diagnosis for all chromosomes + CBOB CVS 9 5 days 114
Cyclic Amp (Urine) CAMP CU (Frozen) 5 days 31
Cyclosporin (Monoclonal) CYCL A 1 day 31
Cyfra 21-1 CY21 B 4 days 101

CYP450 2D6 Genotyping TGEN A9 10 days 114
Cystatin C CYCC B 5 days 31
Cystic Fibrosis (139 common mutations)
CFS A9 5-7 days 114
– reflex to Poly T when required
Cystine – Quantitative (Beta-CTX) QCYS PU 5 days 31
Cytomegalovirus (CMV-DNA) Amnio CMVD AF 5 days 98
Cytomegalovirus (IgG/IgM) Antibodies CMV B 4 hours 98
Cytomegalovirus (PCR) Semen SCVM Semen 7 days 98
Cytomegalovirus (PCR) Urine CMVU RU 5 days 98
Cytomegalovirus Avidity CMAV B 10 days 98
Cytomegalovirus DNA (PCR) CMVP A 5 days 98
Cytomegalovirus Resistance CMVR A A (2 x 6mls) 21 days 98
D-Dimers (Fibrinogen
DDIT C4 4 hours 38
Degradation Products)
Dengue Fever PCR DPCR A or B 9,14 2 weeks 98
Dengue Virus Serology DENG B 9,14 5 days 88
Deoxypyridinoline (DPD) – Serum SDPD B (Freeze within 24 hours) 4 days 31
Deoxypyridinoline (DPD) – Urine DPD EMU 4 days 31
DHEA DHEX B 7-10 days 51
DHEA – Urine (Dehydroepiandrosterone) UDHE CU 3 weeks 51
DHEA Sulphate DHEA B 4 hours 51
NEW Diabetes – Obesity NGS Panel 114
GENE A 6 weeks
Diabetic Profile 1 DIAB AG 8 hours 31, 37
Diabetic Profile 2 DIA2 A G RU 2 days 32, 37
Diamine Oxidase Activity DIAM B 2 weeks 32
Diazepam (Valium) DIAZ A 7 days 134
DiGeorge Syndrome (22q11 & 10p14
deletion) – BOBs (5 days) DGB, KARY CVS / AF / A H 9 5-15 days 114
DiGeorge Syndrome (22q11
DGB CVS / AF / A 9 5 days 114
& 10p14) – BOBs only
Digoxin DIGO B 4 hours 134
Dihydrotestosterone DHT BB 7 days 51
Diphtheria Antibodies DIPH B 5 days 80
DL1-DL12 Screening Profiles 24-25
DNA (Double Stranded) Antibodies IgG DNAA B 2 days 80
DNA (Single Stranded) Antibodies DNAS B 5 days 80
DNA Extraction & Storage –
XDNA A9 20 days 114
3 years (longer upon request)
DNA Identity Profile – 15 STR markers DNAF A 9,11 10 days 115
Duchenne Muscular Dystrophy
DMD A 9 10 days 115
– deletions/duplications only
Dog Components ZZ8 B 2 days 145
Down Syndrome Risk Bloods only

HCGF/PAPA B 4 hours 51
(Risk to be calculated by clinician)
Down Syndrome Risk Profile
DRP B DRP form 7,8 2 days 51
(2nd trimester) Quad
Down Syndrome Risk Profile with B DRP form + image of
DRP 2 days 51
risk calculation first trimester scan 7,8
Doxepin Level (Sinequan) DOXE A 10 days 160
Drugs of Abuse from Blood
DOAP B 5 days 157-158
without Chain of Custody
2 days (5 days
Drugs of Abuse Profile – Random
DOA RU with LC-MS/MS 157-158
Urine Sample/No Chain of Custody
confirmation)
Drugs of Abuse Profile – Random 2 days (5 days
Urine Sample/No Chain of DOA3 RU with LC-MS/MS 157-158
Custody Plus Alcohol confirmation)
2 days (5 days
Drugs of Abuse Profile – With RU/CoC Collection
DOAL with LC-MS/MS 157-158
Chain of Custody Containers 1,2
confirmation)
2 days (5 days
Drugs of Abuse Profile – Without
DOAN RU 2 with LC-MS/MS 157-158
Chain of Custody
confirmation)
38, 41,
DVT/Pre-travel Screen DVT1 AAB 9 5 days 88-89,
115, 132
Early CDT-Lung CDTL B 10 days 101
A 10mls or 2 x 4mls
Early Detection Screen PCR/NAAT STDX 3 days 67, 77
(Vacutainer only)
Early Detection Screen PCR/
STXX B A 10mls or 2 x 4mls 3 days 67, 77
NAAT with Syphilis
Echinococcus (Hydatid) Antibodies EFAT B 9,14 5 days 80, 88
Eczema Provoking Profile ALEC B 2 days 138
Egg Components ZZ9 B 2 days 145
Ehlers-Danlos Syndrome/Aneurysm/
Connective Tissue Disorders Requires patient informed consent
115
Ehrlichiosis Antibodies EHRL B 9,14 10 days 80
Elastase (Faecal) ELAS RF 5 days 32
Elastase/Calprotectin Profile CEP RF 5 days 80, 87
Electrolytes ELEC B 4 hours 32
Electrolytes (Urine) UELE CU 4 hours 32
ELF/Enhanced Liver Fibrosis ELF B 5-7 days 32
Endometrial Biopsy Immune Profiling 23RF J (Contact Referrals) 2 weeks 54
Endomysial Antibodies (IgA) AEAB B 2 days 80
Enteric Organism Rapid Detection EORD RF 2 days 88-89
Eosinophil Cationic Protein ECP B 7 days 32
Epanutin (Phenytoin) PHEN B 4 hours 134
Epstein-Barr Virus Antibodies IgG/IgM EBVA A or B 2 days 98

Epstein-Barr Virus PCR EBVQ A 5 days 98
Erectile Dysfunction Profile IMPO ABBG 3 days 51, 56
Erythropoietin ERY B 4 days 40, 134
ESR ESR A 4 hours 38
Essential Fatty Acid Profile (Red Cell) EFAR A4 10 days 148
Ethosuximide ETHO A 7 days 134
Extractable Nuclear Antibodies (nRNP,
ENA B 2 days 80
Sm, Ro, La, Jo1, Scl70) CENP-B
Factor II Assay FAC2 C (Frozen) 9,18 5 days 39
Factor II Prothrombin – G20210A mutation FX2 A9 5 days 115
Factor V Assay FAC5 C (Frozen) 9,18 5 days 39
Factor V Leiden – G1691A mutation FX5 A9 5 days 115
Factor VII Assay FAC7 C (Frozen) 9,18 5 days 39
Factor VIII Assay FAC8 C (Frozen) 9,18 5 days 39
Factor VIII Inhibiting Antibody F8IA C C 18 2 weeks 39
Factor IX Assay F1X C (Frozen) 9,18 5 days 39
Factor IX Inhibiting Antibody F9IA C C 18 2 weeks 39
Factor X Assay FX C (Frozen) 9,18 5 days 39
Factor XI Assay FX1 C (Frozen) 9,18 5 days 39
Factor XII Assay FX11 C (Frozen) 9,18 5 days 39
Factor XIII Assay FA13 C (Frozen) 9,18 5 days 39
Faecal Elastase ELAS RF 5 days 32
Faecal Fat (1 Day Collection) TFFA LF 6 5 days 32
Faecal Fat (3 day) FFAT LF 6 5 days 32
Faecal Lactoferrin FLAC RF 5 days 32
Faecal Occult Blood/FOB
QFIT QFIT 1 day 42
(immunochemical/FIT)
Faecal Sugar Chromatography FCRO RF (Frozen) 3 weeks 32
Faecal Urobilinogen FURO RF 5 days 32
Familial Hypercholesterolaemia – LDLR Requires patient informed consent
116
+ APOB + PCSK9 + LDLRAP1 screening GENE AA 9 7 weeks
Farmers Lung Precipitins FARM B 5 days 80
Fasciola Hepatica Antibodies (Liver Fluke) FASC B 2 weeks 80
FASTest Sexual Health Screening Tests 71
Fat Globules in Faeces FGLO RF 1 week 32
Female Hormone Profile FIP B 4 hours 51, 56
Ferritin FERR B 4 hours 32
Fever (Recurrent) Screening 116
GENE AA 10 weeks
Fibrinogen FIB C 4,18 4 hours 38
Fibrotest (Liver Fibrosis) FIBT B 2 weeks 32
Filaria (Lymphatic and Non-

FIFA B 9,14 10 days 88
Lymphatic) Antibodies
First Trimester Antenatal Screen (Risk
HCGF/PAPA B 4 hours 51, 57
to be calculated by requesting clinician)
Fish Components ZZ10 B 2 days 145
FK506 (Tacrolimus/Prograf) FK5 A4 1-2 days 134
Flecainide (Tambocor) FLEC A 5 days 134
Fluid Culture FLUD SC 2-7 days 42
Fluid Cytology CATF Fluid 4 3 days 169
Fluid for Crystals FLU2 SC 1 day 42
Fluoride (Urine) UFL RU 5 days 32
Fluoxetine (Prozac) PROZ A4 5 days 134
Folate (Red Cell) RBCF A 2 days 32, 148
Folate (Serum) FOLA B 1 day 32
Fragile X Syndrome screen – Requires patient informed consent
116
FMR1 repeat analysis PCR GENE AAA 9 3-8 weeks
Free Cortisol (Urine) UCOR CU 5 days 51
Free Fatty Acids FFA B (Frozen) 1 10 days 32
Free T3 FT3 B 4 hours 51
Free T4 FT4 B 4 hours 51
Fructosamine FRUC B 1 day 32
FSH FSH B 4 hours 51
Full Blood Count FBC A 4 hours 38
Fungal ID + Sens FUID Fungal sample / STM 14 days 42
Fungal investigations All specimens other than
FUN From 3 days 42
(non-superficial extended culture) Skin, Hair and Nails
Fungal investigations (superficial/
DERM Skin, Hair, Nails 3-7 days 42
dermatophyte PCR test)
G6PD G6PD A 3 days 40
Gabapentin GABA B4 5 days 134
Galactomanan
SGAL B 2 weeks 42
(Aspergillus Antigen)
Galactose-1-Phosphate Uridyltransferase GAL1 H 5,6 2 weeks 32
Galactosidase – Alpha* GALA J* 6 weeks 32
Gall Stone Analysis RSTA STONE 10 days 32
Gamma GT GGT B 4 hours 32
Ganglionic Acetylcholine
GACA B 1 month 80
Receptor Antibodies
Ganglioside GM1, GD1B, GQ1B Abs GANG B 5 days 80
Gardnerella vaginalis by PCR GVPC FCRU / PCR / TPV 2 days 67, 164
Gastric Parietal Autoantibodies GASP B 2 days 80
Gastrin GAST B (Frozen) 5 days 32
Genetic Reproductive Profile (Male) GRP AH 9 10-15 days 116
GENETICS: TDL Genetics 103-132
Gentamicin Assay GENT B4 4 hours 133
Giardia Serology GIAR B 5 days 80

Gliadin Antibodies (IgG) (deamidated) AGAB B 2 days 80
Globulin GLOB B 4 hours 32
Glomerular Basement Membrane Abs AGBM B 2 days 80
Glucagon GLUG J1 10 days 32
Glucose RBG G 4 hours 32
Glucose Challenge Test / Mini-GTT RBGM G 1 day 133
Glucose Tolerance Test (Extended Plus) GTTX 7x G 7x RU 1 day 133
Glucose Tolerance Test (Extended) GTTE 5 x G 5 x RU 1 day 133
Glucose Tolerance Test (Short) GTTS 2 x G 2 x RU 1 day 133
Glucose Tolerance Test / OGTT GTT 3 x G 3 x RU 1 day 133
Glucose Tolerance with Growth Hormone GTT + GHDF 3 x B 35 3 x G 3 x RU 1 day 133
Glucose Tolerance with Insulin GTTI 3 x B 3 x G 3 x RU 1 day 133
Glutamic Acid Decarboxylase
GAD B 5 days 80
Antibodies (GAD 65)
Glutathione (Red Cell) GLUR H 5 5 days 148
Glutathione Peroxidase GLPX H 5 days 148
80-81,
138
Gluten Sensitivity Evaluation GSA B 2 days 80-81
Gluten/Coeliac Profile 2 GSA2 AB 10 days 80-81
Glycan Determinants ZZ27 B 2 days 145
Gonorrhoea (Culture) GONN CS ‡ ‡ ‡ 2-3 days 42, 67
Gonorrhoea (PCR swab) SGON PCR 2 days 67
Gonorrhoea (Thin Prep) TGON TPV 2 days 67
Gonorrhoea (Urine) CGON FCRU 2 days 67
Granulocyte Immunology GRIM AA 2 weeks 80
Group B Strep GBSX 2 x STM 3-4 days 42
Growth Hormone (Fasting) GH B 7,35 4 hours 51
A A (Frozen within
Gut Hormone Profile GUTP 3 weeks 51
15 minutes) 41
H. pylori Antibodies (IgG) HBPA B 2 days 80
H. pylori Antigen (Breath) HBQT J 5 days 80
H. pylori Antigen (Stool) HBAG RF 3 days 42
H. pylori Culture HPCU J 3 weeks 42
Haematology Profile PP3 A 4 hours 38, 41
HMD A9 3 days 32
Haemoglobin HB A 4 hours 38
Haemoglobin Electrophoresis HBEL A 4 days 40
Haemophilus B Influenzae Antibodies HINF B 5 days 80
Haemophilus ducreyi by PCR DUCR PCR 7 days 67
Haemosiderin (Urine) HSID EMU 2 weeks 32
Hams Test for PNH (CD59) HAMS J 34,5 5 days 40
Hantavirus Serology HANV B9 10 days 98

Haptoglobin HAPT B 5 days 32
Harmony® Prenatal Test (Non-Invasive
Prenatal Testing) – common aneuploidy NIPT J/Special tubes 1 3-5 days 117
screening from maternal blood
Hazelnut Components ZZ11 B 2 days 145
HbA1c GHB A 6 hours 32
HDL Cholesterol HDL B 4 hours 32
HE4 + ROMA (Earlier Detection
HE4 B 1 day 101
of Ovarian Tumour)
Hepatitis (Acute) Screen AHSC B 4 hours 79, 92
Hepatitis A (IgM) HAVM B 4 hours 92
Hepatitis A Immunity (IgG/IgM) HAIM B 4 hours 91-92
Hepatitis A Profile HEPA B 4 hours 67, 92
Hepatitis A RNA by PCR HAVR A or B 3 weeks 92
Hepatitis A, B & C Profile ABC B 4 hours 92
Hepatitis B ‘e’ Antigen and Antibody HEPE B 4 hours 92
Hepatitis B (PCR) Genotype BGEN A 7 days 92
Hepatitis B Core Antibody – IgM HBCM B 4 hours 92
Hepatitis B Core Antibody – Total HBC B 4 hours 92
Hepatitis B DNA (Viral load) DNAB A 5 days 92
Hepatitis B Immunity HBIM B 4 hours 91-92
Hepatitis B Profile HEPB B 4 hours 92
Hepatitis B Resistant Mutation HBRM A or B 7 days 92
Hepatitis B Surface Antigen AUAG B 4 hours 67, 92
Hepatitis C Abs Confirmation (RIBA) RIBA B 5 days 92
Hepatitis C Antibodies HEPC B 4 hours 67, 92
Hepatitis C Antigen (Early detection) HCAG B 4 hours 92
Hepatitis C Genotype CGEN A 5 days 92
Hepatitis C Quantification (Viral Load) QPCR A or B 5 days 92
Hepatitis Delta Antibody HEPD B 5 days 92
Hepatitis Delta Antigen HDAG B 5 days 92
Hepatitis Delta RNA DRNA A (Frozen plasma) 5 days 92
Hepatitis E (PCR) EHEP A 2 weeks 92
Hepatitis E IgG/IgM HBE B 5 days 92
Hepatitis G (PCR) HEPG A (Frozen plasma) 2 weeks 92
Herpes Simplex I/II Antibody Profile (IgG) HERP B 2 days 98
67, 98,
Herpes Simplex I/II by PCR HERD FCRU / PCR / TPV 5 days
164
Herpes Simplex I/II by PCR (Swab) HERS PCR 5 days 67, 98
Herpes Simplex I/II IgM HERM B 2 days 98
HMD A9 3 days 40
Hirsutism Profile HIRP B 4 hours 51, 57
Histamine (Blood) HITT A (Frozen plasma) 5 days 81
Histamine (Urine) HITU RU 5 days 81

Histamine Releasing Urticaria Test CURT B 3 weeks 81, 138
Histone Antibodies HISA B 5 days 81
Histopathology 170-174
Histoplasmosis HISP B 10 days 81
HIV 1 & 2/p24Ag HDUO B 4 hours 67, 96
HIV-1 Genotypic Resistance (Integrase) INTE A A (2 x 6ml whole blood) 21 days 96
HIV-1 Genotypic Resistance
HIVD A A (2 x 6ml whole blood) 21 days 96
(RT & Protease)
HIV-1 Proviral DNA HIVP A Whole blood 7 days 96
HIV-1 RNA Viral Load by PCR HIV1 A A (2 x 6ml whole blood) 3 days 96
HIV-1 Tropism TRPM A A (2 x 6ml whole blood) 28 days 96
HIV-2 RNA by PCR HIV2 A 21 days 96
HIV/HBV/HCV (Early detection by
STXX B A 10mls or 2 x 4mls 3 days 67, 77
PCR/NAAT) with Syphilis
HIV/HBV/HCV Screen by PCR/ A 10mls or 2 x 4mls 67, 77,
STDX 3 days
NAAT (10 days post exposure) (Vacutainer only) 96-98
HIV Confirmation of Positive Screens
HIVC B 1 day 96
(Using 3 methodologies)
HIV Rapid RNA HIV-1 QUALITATIVE LHIV A (Vacutainer only) 4 hours 67, 96-97
HIV Rapid RNA HIV-1 QUANTITATIVE RHIV A (Vacutainer only) 4 hours 67, 96-97
HIV Therapeutic Drug Monitoring TDM J 21 days 96
HLA B*57:01 HL57 A9 10 days 96
HLA B27 HLAB A9 3 days 81
HLA DQ Alpha Antigens 10RF AA 2 weeks 54
HLA DQ Beta Antigens 11RF AA 2 weeks 54
HLA DR Antigens 9RF AA 2 weeks 54
HLA Tissue Typing A HLA A9 10 days 118
HLA Tissue Typing A+B HLBA A9 10 days 118
HLA Tissue Typing A+B+C (Class I) HABC A9 10 days 118
HLA Tissue Typing A/B/DRB1/3/4/5 HLAF A9 10 days 118
HLA Tissue Typing A/B/DRB1/3/4/5/DQB1 HLF A9 10 days 118
HLA Tissue Typing A/B/C/
HLFC A9 10 days 118
DRB1/3/4/5/DQB1 (Class I & II)
HLA Tissue Typing B HLB A9 10 days 118
HLA Tissue Typing B*27 only HLAB A9 3 days 118
B51 A9 10 days 118
(Behcet’s Disease)
HLA Tissue Typing B*57:01
HL57 A9 10 days 118
high resolution
HLA Tissue Typing C HLC A 9 10 days 118
HLA Tissue Typing Coeliac
Q2Q8 A 9 10 days 118
Disease – DQ2/DQ8
HLA Tissue Typing DRB1/3/4/5 DRB1 A 9 10 days 118
HLA Tissue Typing DRB1/3/4/5/

HLDQ A9 10 days 118
DQB1 (Class II)
HLA Tissue Typing Narcolepsy Requires patient informed consent
118
– DQB1*06:02 GENE A9 4 weeks
Homocysteine (Quantitative) HOMO B 17 1 day 32
Homocysteine (Urine) HCYS CU 2 weeks 32
Homovanillic Acid (HVA) HVA PU 5 days 32
House Dust Mite Components ZZ12 B 2 days 145
HPV (DNA and reflexed mRNA) HPVT TPV 3 days 67, 166
HPV (HR mRNA types 16, 18 + others) HPVH TPV 3 days 67, 166
HPV (Individual low & high
HP20 TPV / PCR 3 days 67, 166
risk DNA subtypes)
HPV Individually Typed High
HPVZ Self-collection kit 10 days 167
Risk DNA Subtypes
HPV mRNA (All High Risk Subtypes) HPVY Self-collection kit 3 days 167
HRT Profile 1 HRT B 4 hours 51, 57
HRT Profile 2 HRT2 BG 4 hours 51, 57
HTLV 1 & 2 Abs. (Human T
HTLV B 8 hours 96
Lymphotropic Virus Type I-II)
HTLV by PCR HTLP A Whole blood 21 days 96
Hughes Syndrome LUPA B C 4,18 2 days 39
Human Anti-Mouse Antibodies HAMA B (Frozen) 6 weeks 81
Human Herpes Virus – 6 by PCR HHV6 A 5 days 98
Human Herpes Virus – 8 (IgG) HHV8 B 10 days 98
Human Herpes Virus – 8 by PCR HV8D A 5 days 98
Human Parvovirus B19 – DNA PCRP A 2 weeks 98
HVS HVS STM / CS ‡‡‡‡ 2-4 days 42
Hyaluronic Acid AHT B 1 week 32
Hydroxybutyrate Dehydrogenase HBD B (Frozen) 1 week 32
Hydroxyprolene UHYD CU 2 weeks 32
Identity Profile (DNA) – 15 STR markers DNAF A 9,11 10 days 118
IgE (Total) IGE B 1 day 81
IGF-1 (Somatomedin) SOMA B (Frozen) 4 1 day 52
IGF-BP3 IGF3 B (Frozen) 4 5 days 52
IgG Subclasses IGSC B 4 days 33
Imipramine IMIP A4 4 days 134
Immune Function Evaluation (Total) TIE A + B 5,10 7 days 38
Immune-Complexes IMCP B 5 days 81
Immunoglobulin A IGA B 4 hours 33
Immunoglobulin D IGD B 5 days 33
Immunoglobulin E – Total IGE B 1 day 33
Immunoglobulin G IGG B 4 hours 33
Immunoglobulin M IGM B 4 hours 33
Immunoglobulins (IgG, IgM, IgA) IMM B 4 hours 33, 81
Impotence Profile IMPO ABBG 3 days 52

Individual Semen Parameters*** SPOD Semen 1 1 day 63
Inhibin A INIA B 1 month 52
Inhibin B INIB B (Day 3 of cycle, frozen) 5 days 52
Inner Ear Antigen (Ottoblot) IEA B 3 weeks 81
INR PTIM C 18 4 hours 38
Insect/Worm/Ova/Cysts FLEA Send Specimen 9,14 5 days 88
Insulin INSU B 4 hours 52
Insulin Antibodies INAB B 5 days 81
Insulin Resistance (Fasting) FIRI BG 4 hours 52
Insulin-Like Growth Factor 2 IGF2 B6 1 month 33
Interferon – Alpha IFA B (Frozen) 9 3 weeks 81
Interferon – Gamma IFG A (Frozen) 3 weeks 81
Interleukin 1 Beta ILB B (Frozen) 4,7 1-2 weeks 81
Interleukin 2 IL2 B (Frozen) 4,7 1-2 weeks 81
Interleukin 4 IL4A B (Frozen) 4,7 1-2 weeks 81
Interleukin 28b Genotype IL28 A 2 weeks 81
Intrinsic Factor Antibodies IFAB B 2 days 81
Iodide – Urine UIOD RU 1 week 33
Iodine – Serum IODI B 1 week 33
Ionised Calcium ICPA B 5 days 33
Iron (TIBC included) FE B 4 hours 33
33, 36,
119, 132
Iron Status Profile ISP B 4 hours 33, 36
ISAC Panel ISAC B 3 days 138-139
Islet Cell Antibodies ICAB B 2 days 81
IUCD for Culture IUCD Send Device 11-12 days 42
JC Polyoma Virus by PCR JCPV A /B /CSF 5 days 98
Ketamine Screen KETA RU 7-10 days 157
KIR (Killer-like Immunoglobulin-
17RF AAA 2-3 weeks 54
like Receptors) Genotyping
Kiwi Components ZZ32 B 2 days 145
Lactate (Plasma) LACT G 16 1 day 33
Lactate Dehydrogenase (LDH) LDH B 4 hours 33
Lactate Pyurvate Ratio LPR J1 4-6 weeks 33
Lactose Intolerance Gene LACG A 2 weeks 119
Lactose Tolerance Test LTT By appointment only 1 day 133
Lamotrigine LAMO B4 5 days 134
Langer-Giedion Syndrome – PBOB,
CVS / AF / A H 9 5-15 days 119
Langer-Giedion Syndrome – BOBs only PBOB CVS / AF / A 9 5 days 119

Latex Components ZZ13 B 2 days 145
LDH lsoenzymes ISOL B 5 days 33
LDL7 Subfractions LDL7 B 10 days 33
Lead (Blood) LEAD A 5 days 33, 159
Lead (Urine) URPB RU 5 days 33, 160
Lead Profile (Hb, ZPP, Lead) LEAZ A 13 3-5 days 159
Legionella Antibodies LEGO B 2 days 81
Legionella Urine Antigen LEGA RU 1 day 42, 81
Leishmania Antibodies LEIS B 5 days 88
Leptin LEPT B 19 5 days 33
Leptospirosis (Weil’s Disease) Abs (IgM) LEP B 5 days 81
Leucine Amino Peptidase LAP B 5 days 33
Leucocyte Antibody Detection
8RF B 1 week 54
Panel FEMALE
Leucocyte Antibody Detection Panel MALE 7RF HHH 3,4,6 1 week 54
Leukaemia Immunophenotyping LYPT A 4,5 5 days 40
Leukotriene E4 LTE4 CU (Frozen) 3 weeks 81
Levetiracetam (Keppra) LEVE B4 3 days 134
Lipase LIPA B 4 hours 33
Lipid Profile LIPP B 4 hours 33, 36
Lipid Transfer Proteins ZZ23 B 2 days 145
Lipocalins ZZ28 B 2 days 145
Lipoprotein (a) LPOA B 4 hours 33
Lipoprotein Electrophoresis LEL B 5 days 33
Listeria IgG/IgM Antibody LIST B 1 week 81
Lithium (take 12 hours after dose) LITH B 4 hours 33, 134
Liver Fibrosis (Enhanced
ELF B 5-7 days 33
Liver Fibrosis ELF)
Liver Fibrosis Fibrotest FIBT B 2 weeks 33
Liver Function Tests LFT B 4 hours 33, 36
Liver Immunoblot LIVI B 3 days 81
Liver Kidney Microsomal Antibodies LKM B 2 days 81
Lorazepam LORA A4 10 days 134
Lp-PLA2 (PLAC) Test PLA2 B 2 days 33
LSD LSD RU 5 days 157
Lupus Anticoagulant and
LUPA B C 4,18 2 days 39, 81
Anticardiolipin Abs
Lupus Anticoagulant only LUPC C 18 2 days 39
Lutein LUTE B 13 2 weeks 148
Luteinising Hormone (LH) LH B 4 hours 52
Lycopene LYCO B 2 weeks 148
Lyme Disease (Borrelia Abs) IgG, IgM BORR B 9,14 2 days 81
Lyme Disease (Borrelia Abs) IgM BORM B 2 days 81
Lymphocyte Subsets (CD3/CD4/CD8) LYSS A 10 1 day 38

Lymphogranuloma Venerium (LGV) LGVP PCR* 42 1-2 weeks 67
Lysosomal Enzyme Screen LE HH 6 2 months 33
Lysozyme LYSO B 5 days 33
Macrolide Resistance Test (Mgen) MGR FCRU / PCR 1-2 weeks 67
Macroprolactin PRLD B 4 days 52
Magnesium (Serum) MG B 4 hours 33, 159
Magnesium (Urine) URMG PU 1 day 33, 160
Magnesium (Whole blood) RCMG A or H 4 days 148
Malarial Antibodies (Pl. falciparum) MALA B 9,14 5 days 88
Malarial Antibodies (species specific) MALS B 9,14 10 days 88
Malarial Parasites MALP A 4,9,14 STAT 38
Male Genetic Reproductive Profile GRP AH 9 10-15 days 120, 132
Male Hormone Profile MIPR B 4 hours 52, 56
Manganese (Serum) MANG B 5 days 33, 159
Mannose Binding Lectin MBL B 3 weeks 33
MBOCA in Urine MBOC RU 10 days 160
Mean Cell Volume (MCV) MCV A 4 hours 38
Measles Antibodies (IgG) Immunity MEAS B 1 day 91, 98
Measles Antibodies (IgM) MEAM B9 2 days 91, 98
Measles PCR MEAP Buccal swab 48 hours 98
Measles, Mumps, Rubella (MMR) MMR B 1 day 91
Melanin MELA RU 13 5 days 52
Melatonin (Serum) MEL B (Frozen) 5 days 52
Melatonin (Urine) UMEL CU 13 2 weeks 52
Meningococcal Abs MENI B 2-4 weeks 81
Menopause Profile MENO B 4 hours 52, 57
Mercury (Blood) MERC A or H 5 days 33, 159
Mercury (Urine) URHG RU 1 5 days 33, 160
MERS Coronavirus Test MERS J 1 day 98
Metabolic Syndrome Profile METS ABBG 9 days 52, 57
Metanephrines (Plasma) PMET A (Frozen plasma) 7 days 52
Metanephrines (Urine) UMEX PU 1 5 days 52
Methaemoglobin METH A 3 days 33
Methaqualone METQ RU 5 days 33
Methotrexate METX B 2 days 134
Methylmalonic Acid – Serum MMAS B 5 days 33
Methylmalonic Acid – Urine MMA CU 2 weeks 34
Metronidazole Level METR B4 7 days 133
Microalbumin (Urine) UMA RU 4 hours 34
Microdeletion (common)
PBOB CVS / AF / A 9 5 days 120
Syndromes – BOBs only
Microfilaria Blood Film MICF A STAT 38
Miller-Dieker Syndrome – PBOB,

CVS / AF / A H 9 5-15 days 121
Miller-Dieker Syndrome – BOBs only PBOB CVS / AF / A 9 5 days 121
Mineral Screen MINE BK 5 days 148
Mineral Screen (Whole blood) RMIN HH 5 days 147-148
Mineral Screen and Industrial Heavy
TRAC ABHK 7-10 days 148
Metal Screen (Trace Metals)
39, 125,
Miscarriage/Thrombotic Risk Profile PROP A A B C C C 18 5 days
132
Mitochondrial Antibodies AMIT B 3 days 81
Mitochondrial Antibodies M2 MAM2 B 2 days 81
Molybdenum (Serum) MOLY B 5 days 160
MRSA (Rapid PCR) one swab per site MRSA Blue Micro Swab 4 hours 43
MRSA Culture one swab per site MRSW Blue Micro Swab 2 days 43
Mucopolysaccharides MPS RU (Frozen) 3 weeks 34
Mumps Antibodies (IgG) MUMP B 1 day 91
Mumps Antibodies (IgM) MUMM B 1 day 91, 98
Myasthenia Gravis Evaluation MGE B 5 days 81
Mycology/Skin Scrapings by PCR DERM Submit Sample 3-7 days 43
Mycophenolic Acid (Cellcept) MYCP A 5 days 134
Mycoplasma genitalium by PCR MGEN FCRU / PCR / TPV 2 days 67, 164
Mycoplasma genitalium/
MUPC FCRU / PCR / TPV 2 days 67
Ureaplasma by PCR
Mycoplasma species – DNA MPCR A 5 days 99
Myelin Associated Glycoprotein
MAG B 5 days 81
Antibodies
Myelin Basic Protein Antibodies MBPA B 2 weeks 81
Myeloma Screen MYEL A B G RU 5 days 34, 36
Myeloperoxidase Antibodies MPO B 2 days 81
Myocardial Antibodies MYO B 1 week 81
Myoglobin (Serum) SMYO B 4 hours 34
Myoglobin (Urine) UMYO RU 5-10 days 34
Myositis Panel MYOS B 3 days 81
Mysoline (Primidone) PRIM B4 3 days 134
N. gonorrhoea TGON TPV 2 days 164
Nail Clippings DERM Nail clippings 3-7 days 43
Natural Killer Profile 2 NKP2 A 2 days 38, 41
Needle Stick Injury Profile NSI BB 4 hours 91, 99
Neurological Viral Screen NVIR BB 2 days 99-100
Neuronal Antibody (Hu, Ri, Yo, Cv2, Ma2) NEUR B 10 days 81
Neurone Specific Enolase NSE B 5 days 101
Newborn Screening Panel GUTH J1 2 weeks 34
Nickel (Serum) NICK B 5 days 34, 159
Nickel (Urine) NICU RU 10 days 34, 160
NK (CD69) and NK Cytotoxicity 69C HHH* Send Mon-Thurs only 55
NK (CD69) Cell Assay CD69 H* Send Mon-Thurs only 55

NK Assay Follow-Up Panel 5RF HHH 1 week 54
NK Assay Panel + Intralipids 16RF HHH 1 week 54
NK Assay/Cytotoxicity Panel 4RF HHH 1 week 54
NK Cytotoxicity Assay HSNK HHH* Send Mon-Thurs only 55
NK Cytotoxicity with suppression
with steroid, IVIg and intralipin, 69CI HHH* Send Mon-Thurs only 55
and NK (CD69) cell assay
NK Cytotoxicity with suppression,
NKCY HHH* Send Mon-Thurs only 55
steroid, IVIg & Intralipin
NMDA Receptor Antibodies NMDA B 3 weeks 81
NMP22 (Bladder tumour) NMP J1 4 days 34, 101
Non-Invasive Prenatal Testing – common
NIPT J / Special tubes 1 3-5 days 121
aneuploidy screening from maternal blood
Nucleic Acid Antigen Antibodies DNA B 2 days 82
Oestradiol (E2) OEST B 4 hours 52
Oestriol (Estriol) E3 BB 4 days 52
Oestrone E1 BB 4 days 52
Olanzapine OLAN A4 5 days 134
Oligoclonal Bands CSFO CSF + B 5 days 82
Oligosaccharides UOLI RU 6 weeks 34
Olive Components ZZ14 B 2 days 145
Omega 3/Omega 6 OMG3 A4 4 days 148-149
Opiate Screen (Urine) UOPI RU 2 days 157
Orosomucoid (A1AG – Alpha
OROS B (Frozen) 5 days 34
1 Glycoprotein)
Osmolality (Serum) OSMO B 1 day 34
Osmolality (Urine) ROSM RU 1 day 34
Osteocalcin OST B (Frozen) 4 4 days 52, 101
Osteoporosis Screen OPS BB 4 days 34, 37
Ovarian Autoantibodies OVAB B 2 days 82
Oxalate (Plasma) POXA A (Frozen) 7 days 34
Oxalate (Urine) UOXA PU 5 days 34
Oxidative Stress in Semen
SROS Semen 1 1 day 63
(ROS + MIOXSYS)
P2Y12 Receptor Platelet Function
P2Y C (Whole blood)** 1 day 39
Analysis (Clopidogrel Resistance)
PAI1 4G/5G Polymorphism PAIP A 10 days 38
Pancreatic Peptide PP J 4 weeks 34
PAPT +
PAPT and HPVH TPV 3 days 166
HPVH
Paracetamol PARA B 4 hours 134
Paragomius Serology PRGM B 2 weeks 82
Parathyroid Antibodies PTHA B 1 week 82
Parathyroid Hormone (Whole) PTHI B4 1 day 52
2ml A Plasma frozen

Parathyroid Related Peptide PTRP 2 weeks 34
(Freeze immediately) 1
Parvalbumins ZZ29 B 2 days 145
Parvovirus Antibodies (IgM) PARV B 2 days 99
Parvovirus IgG Antibodies PARG B 2 days 99
Parvovirus IgG/IgM Abs PARP B 2 days 99
Paternity Testing (postnatal and
prenatal) – sample required from PATT A / AF / CVS 9,11,12 Contact lab 5 days 122
each person being tested (3 people)
Paul Bunnell (Monospot) PAUL A or B 8 hours 38
Peach Components ZZ15 B 2 days 145
Peanut Components ZZ16 B 2 days 145
Pemphigus/Pemphigoid Autoantibodies SKAB B 2 days 82
Pertussis (Whooping Cough) Antibodies PERS B 5 days 82, 91
PEth (Phosphatidylethanol) PETH A 38 5-7 days 34, 157
Pethidine – Urine UPET RU 4 weeks 160
Phelan-McDermid Syndrome
KARY, FISH CVS / AF / H 9 12-17 days 122
– karyotype + FISH
Phencyclidine (PCP) DUST RU 5 days 34
Phenobarbitone PHB B 4 hours 134
Phenytoin (Epanutin) PHEN B 4 hours 134
Phosphate PHOS B 4 hours 34
Phosphate (24 hour Urine) UPH PU 4 hours 34
Pituitary Antibodies PITU B4 1 month 82
Pituitary Function Profile PITF BB 1 day 52, 57
PLAC Test (Lp-PLA2) PLA2 B 2 days 34
Plasminogen PLAS C (Frozen plasma) 4 5 days 34
Plasminogen Activator Inhibitor – 1 PAI1 C (Frozen plasma) 2 weeks 34
Platelet Aggregation Studies PLAG J 5,6 3 days 39
Pleural Fluid for Culture FLUP SC 7 days 43
Pneumococcal Antibodies
PASS B 5 weeks 82
– Serotype Specific
Pneumococcal Antibody Screen PNEU B 5 days 82, 91
Pneumococcal Antigen PNAG RU 1 day 43
Pneumocystis Jiroveci (PCP) Examination PCYS BAL ‡‡ 2-3 days 43
Pneumonia (Atypical) Screen APS B 2 days 99-100
Polcalcins ZZ25 B 2 days 145
Polio Virus 1, 2, 3 Antibodies POLO B9 15 days 91
Polycystic Ovary Syndrome Profile PCOP ABBBG 7 5 days 52, 57
Polycystic Ovary Syndrome SHORT PCOS BG 4 hours 52, 57
Porphyrin (Blood) PORP A3 15 days 34
Porphyrins (Faeces) FPOR RF 3 3 weeks 34
Porphyrins Full Screen (Total:
PORS A RU, RF 3 3 weeks 34
Urine, Stool, Blood)
Porphyrins Screen (Urine) RPOR RU 3 3 weeks 34
Postnatal array CGH CGH AH 9 10 days 123

Post-Travel Screen 1 (Prior to 6 weeks) PTS A A B G 14 10 days 88-89
Post-Travel Screen 2 (Prior to 6 weeks) PTS2 A A B B B G 14 10 days 88-89
Potassium K B 4 hours 34
PR-10 Proteins ZZ22 B 2 days 145
Prader-Willi Syndrome
PWAM A9 10 days 123
(Primary Screen) – methylation PCR
Prealbumin PALB B 3 days 138
Pregnancy (Serum) [Quantitative] QHCG B 4 hours 34, 52
Pregnancy Test (Urine) PREG RU 4 hours 34
Pregnanetriol (Urine) UPTR CU (Frozen) 5 days 52
Pregnenolone PREN B 15 days 52
Prenatal array CGH CGH Amniotic fluid or CVS 9 10 days 123
38, 41,
Pre-Travel Screen (DVT) DVT1 AAB 9 5 days 88-89,
123, 132
Primidone (Mysoline) PRIM B4 3 days 134
Procalcitonin PCAL B (Frozen) 4,7 1 day 34
Procollagen 1 Peptide N-Terminal (NTX) P1NP B 5 days 34
Procollagen III Peptide PRCO B 5 days 34
Products of Conception – rapid BOBs
aneuploidy diagnosis for all chromosomes PBK Placental Sample 1,9 5-25 days 123
Products of Conception (BOBs + Culture) PBK Placental Sample 1,9 5-25 days 123
Products of Conception BOBs only – rapid Placental Sample or
KBOB 3-6 days 123
aneuploidy diagnosis for all chromosomes Solid Tissue 1,9
Profilins ZZ24 B 2 days 145
Progesterone PROG B 4 hours 52
Proinsulin PROI A (Frozen plasma) 4 5 days 52
Prolactin PROL B 4 hours 52
Prolactin (Macro) PRLD B 4 days 52
Propanalol PRO B4 7 days 135
Propoxyphene DPRO RU 5 days 34
Prostate Profile (Total & Free PSA) PR2 B 4 hours 101
Prostate Specific Antigen (Total)* PSPA B 4 hours 101
Prostatic Acid Phosphatase PACP B (Frozen) 3 days 34
Prostatitis Screening Panel VB1U + VB2U + EPS or EPSW
NEW PROS 4-5 days 43-44
– see page 44 for sample details + VB3U
Protein (Urine) UPRT CU 4 hours 34
Protein 14.3.3 (Creutzfeldt–
CJD CSF (Frozen) 5 weeks 34
Jakob Disease)
Protein C PRC C (Frozen) 4,9,18 3 days 39
Protein Electrophoresis
PRTE B 2-4 days 34
incl. immunoglobin
Protein S Activity PS1 C (Frozen) 4,9,18 5 days 39
Protein S Free Ag FPRS C (Frozen) 4,9,18 3 days 39

Protein Total (Blood) PROT B 4 hours 34
Protein/Creatinine Ratio (Urine) UCPR RU 4 hours 35
Proteinase 3 Ab PR3 B 2 days 82
Prothrombin Time PTIM C 18 4 hours 38
Prothrombin Time + Dose PT+D C 18 4 hours 38
Purkinje Cell Antibody (Hu and Yo) PURK B 10 days 82
Pyruvate Kinase (M2-PK) M2PK A 5 days 101
Pyruvate Kinase (M2-PK) M2ST RF 4 5 days 101
Q Fever (C Burnetti) Antibodies QFEV B9 10 days 82
QF-PCR rapid common
APC AF / A 9 1-2 days 124
aneuploidy screen
Rabies Antibody RABI B 10 days 91
Rapid Strep (incl. m/c/s) RAPS STM** 1-3 days** 43
Rapid Xpert HIV-1 RNA Qualitative
LHIV A (Vacutainer only) 4 hours 68, 78
– Early Detection from 10 days
Rapid Xpert HIV-1 RNS Viral Load
– Rapid Testing for HIV-Positive
RHIV A (Vacutainer only) 4 hours 68, 78
Patient Prognosis and Response
To Antiretroviral Therapy
Recurrent Fever Screening 123
GENE AA 10 weeks
Recurrent Miscarriage Profile (female) RMP A A B C C C H 9,18 10-15 days 124, 132
Renal Calculi Screen (Metabolic) RSPR J6 5 days 35
Renal Stone Analysis RSTA STONE 10 days 35
Renin RENI A (Frozen plasma) 36 5 days 52
Reproductive Immunophenotype Panel 3RF HHH 1 week 54
Reticulocyte Count RETC A 4 hours 38
Retinol Binding Protein RBP B 3 days 35
Retrograde Ejaculation RTRO Contact lab 2 days 63
Reverse T3 RT3 B 7,37 10 days 52
Rheumatoid Factor (Latex Test) RF B 1 day 82
Rheumatology Profile 1 (Screen) RH AB 2 days 82, 86
Rheumatology Profile 2
RH2 AABB 3 days 82, 86
(Connective tissue)
RH3 AB 2 days 82, 86
(Rheumatoid/Basic)
Rheumatology Profile 4 (Systemic Lupus) RH4 ABB 2 days 82, 86
Rheumatology Profile 5 (Mono Arthritis) RH5 AABB 3 days 82, 86
Rheumatology Profile 6 (Rheumatoid Plus) RH6 B 2 days 82, 86
RH7 B 10 days 82, 86
(Sjogren’s Syndrome)
Rhinitis Provoking Profile ALRN B 2 days 138
Rickettsial Species Antibody Profile RICK B 7 days 82, 88
Risperidone RISP A4 7 days 135
NEW RNA Polymerase Antibodies RNAP B 3 days 82
Rotavirus in Stool by PCR ROTA RF 1 day 99
RPR (VDRL) RPR B 2 days 68, 82
Rubella Antibody (IgG) RUBE B 4 hours 91, 99
Rubella Antibody (IgM) RUBM B 4 hours 91, 99
Rubella Avidity RUAV B 1 week 99
Rubella PCR RUBP A / Amniotic Fluid 5 days 91
S100 Malignant Melanoma S100 B 4 days 101
Saccharomyces Cerevisiae Antibodies ASCA B 2 weeks 82
Salicylates SALI B 4 hours 35
Salivary Duct Antibodies SAB B 12 days 82
Schistosoma (Urine) USCH 1-2 days 43
Schistosome (Bilharzia) Antibodies BILH B 14 10 days 88
Scleroderma Immunoblot SCLI B 3 days 82
Screening Profile 1 – Biochemistry PP1 BG 4 hours 24
Screening Profile 2 – Haematology/
PP2 ABG 4 hours 24
Biochemistry
Screening Profile 3 – Haematology PP3 A 4 hours 24
PP4 ABG 4 hours 24
Biochemistry (Short)
PP5 ABG 4 hours 24
Biochemistry (Postal)
Screening Profile 6 – Well Person PP6 ABG 4 hours 24
Screening Profile 7 – Well Man PP7 ABG 4 hours 25
Screening Profile 8 – Well Person PP8 ABG 2 days 25
Screening Profile 9F – Senior Female PP9F A B B G RU QFIT 4 2 days 25
Screening Profile 9M – Senior Male PP9M A B B G RU QFIT 4 2 days 25
Screening Profile 10 –
PP10 BB 3 days 25
Cardiovascular Risk 1
PP11 B B B C 34 3 days 25
Cardiovascular Risk 2
PP12 FCRU / PCR / TPV 2 days 25
Sexual Health Screen
Seed Storage Proteins ZZ26 B 2 days 145
Selenium (Serum) SELE B 4 days 35, 148
Selenium (Whole Blood) SELR A or H 4 days 35, 148
Sellotape Test SELL Send Sample*** 1 day 43
Semen Analysis, Comprehensive* SPER Semen 1 2 days* 63
Semen Analysis, Post-Vasectomy** PVAS Semen 1 2 days 63
Semen Analysis, Vasectomy Reversal* SPER Semen 1 2 days* 63
Semen Culture SPCU Semen 2-4 days 43, 63
Semen Fructose SPCF Semen 2 days 63
Semen Leucocytes PMNS Semen 2 days 63
Semen Zinc SPCZ Semen up to 10 days 63
Serotonin SERT H (Frozen whole blood) 1 10 days 52

Serotonin (Urine) USER PU 50mls (Frozen) 1 5 days 52
Serum Albumins ZZ30 B 2 days 145
Serum Free Light Chains SLC B 1 week 35
Sex Hormone Binding Globulin SHBG B 4 hours 52
Shrimp Components ZZ17 B 2 days 145
Sickle Solubility SSOL A 4 days 40
Silver (Blood) SILV B 5 days 35, 159
Silver (Urine) USIL RU 5 days 35, 160
Sinequan (Doxepin) DOXE A 10 days 135
Sirolimus SIRO A 3 days 135
Sjogren’s Syndrome RH7 B 10 days 82
Skin (Pemphigus/Pemphigoid)
SKAB B 2 days 82
Autoantibodies
Skin Antibodies by Immunofluorescence STSK B 1 month 82
Skin Scrapings/Mycology by PCR DERM Send Sample 3-7 days 43
Sleeping Sickness Serology
TRYP B9 10 days 82
(African Trypanosomiasis)
Smith-Magenis Syndrome – PBOB,
CVS / AF / A H 9 5-15 days 124
Smith-Magenis Syndrome – BoBs only PBOB CVS / AF / A 9 5 days 124
Smooth Muscle Antibodies ASMO B 2 days 82
Sodium NA B 4 hours 35
Somatomedin (IGF-1) SOMA B (Frozen) 4 1 day 52
Soybean Components ZZ18 B 2 days 145
Specific Gravity (Urine) USG RU 24 hours 43
Sperm Aneuploidy SPPL Semen 1 4 weeks 63
Sperm Antibodies (Serum) ASAB B 5 days 63, 82
Sperm Antibodies/MAR Test (Semen)† ASPA Semen 1 day 63
Sperm Comet® CMET Semen 1-2 weeks 63
Sperm Count (Post-Vasectomy) PVAS Semen 1 2 days 63
Sperm DNA Fragmentation (SCSA) SEXT Semen 1 1-2 weeks 63
Sperm Morphology (Kruger strict criteria) MRPH Semen 1 2 days 63
SMA A9 10 days 124
– SMN1 deletions/duplications
AAABBBB
Sports/Performance Profile SPOR 5 days 147-148
GK 4
Sputum for Routine Culture SPU1 SC 2-4 days 43
Sputum for TB Culture (AFB) SPU2 SC up to 8 weeks 43
Squamous Cell Carcinoma SCC B 4 days 101
STD1 M/F STD Quad (Urine and Serology) STD1 B FCRU 2 days 68, 76
B FCRU (If culture swabs
STD2 M/F STI Profile Plus
STD2 are needed please request 4 days 68, 76
(Urine and Serology)
separately)
STD3 Female STD Quad

STD3 B PCR 2 days 68, 76
B PCR (If culture swabs
STD4 Female STI Profile Plus
STD4 are needed please request 4 days 68, 76
separately)
STD5 Serology only STD5 B 4 hours 68, 76
STD6 Serology only without HIV STD6 B 4 hours 68, 76
STD8 Vaginitis/BV Profile using
STD8 PCR / STM 3 days 68, 77
Culture & PCR Swab
STD9 Symptomatic lesion sample using
STD9 2 x PCR Swab 7 days 68, 77
PCR Swab from lesion & PCR Swab
Steroid Cell Antibody SCA B 2 days 82
B / FCRU / PCR Swab
STI Profile: MSM1 MSM1 2 days 68, 78
B / FCRU / PCR Swab
STI Profile: MSM2 MSM2 3 days 68, 78
Stool for OCP and Culture PENT RF 2-3 days 43
Stool for OVA Cysts & Parasites by PCR OCP RF 1 day 43
Stool Reducing Substances STRS RF 7 5 days 43
Streptomycin Levels STRM F 5 days 135
Striated/Skeletal Muscle Antibody STRA B 2 days 82
Strongyloides Antibodies STGA B 10 days 82
Sulpiride SULP B4 4 days 135
Superoxide Dismutase Inhibitor SODI A/ H 5 days 35
Suppression with steroid, IVIg
and intralipin, NK (CD69) cell NCIT HHH* Send Mon-Thurs only 55
assay, TH1/TH2 cytokines
Swab (Cervical) CERS STM / CS 2-4 days 43
2-4 days (Culture) 8-9
Swab (Ear) EARS STM days (Fungal) – same 43
swab
Swab (Eye) EYES STM 2-4 days 43
Swab (Nasal) NASS STM 2-4 days 44
Swab (Oral) ORSW STM / CS 2-4 days 44
Swab (Penile) PENS STM / CS 2-4 days 44
Swab (Rectal) RECG STM / CS 2-4 days 44
Swab (Skin) SKIS STM 2-4 days 44
Swab (Throat) THRS STM 2-4 days 44
Swab (Urethral) URES STM / CS 2-4 days 44
Swab (Vaginal) VAGS STM / CS 2-4 days 44
Swab (Vulval) VULV STM / CS 2-4 days 44
Swab (Wound) WOUS STM 2-4 days 44
Synacthen Stimulation Test SYNA By appointment only 1 day 133
Synovial Fluid (for microscopy
FLU2 SC ††† 14 days 44
and culture)
Syphilis by PCR (chancre) SYPS PCR 5 days 68

Syphilis IgG/IgM SERJ B 4 hours 68, 82
T Regulatory Cells 25RF H 3 days 54
NEW T-SPOT®.COVID TCEL H *** 3 days 26, 82
T3 T3 B 4 hours 52
T3 (Reverse) RT3 B 7,37 10 days 52
Tacrolimus/Prograf (FK506) FK5 A4 1-2 days 135
Taipan Snake Venom Time TTVT C 18 1 week 39
TB (pleuralfluid) TBCU SC up to 8 weeks 44
TB Culture SPU2 SC up to 8 weeks 44
TB Culture (Urine) TBUR 3 x EMU up to 8 weeks 44
TB Quantiferon®-TB Gold* TBQ4 Special tubes or H 1 3 days 82
TB Slopes – Confirmation and Sensitivity TBSL TB slope (LJ medium-green) 6 up to 8 weeks 44
TDL Tinies™ and Self-collection samples 150-155
Tegretol (Carbamazepine) CARB B 4 hours 135
Teicoplanin Assay TEIC B 5 days 133
Temazepam TEMA B4 4 days 135
Testicular Autoantibodies TAB B 2 days 82
Testicular Tumour Profile TTP B 4 hours 101
Testosterone TEST B 4 hours 52
Testosterone (Bioavailable) BTES B 5 days 52
Testosterone (Free) FTES B 3 days 52
Tetanus Antibody TETA B 5 days 82, 91
TH1/TH2 Cytokine Profile 1TH2 HHH* Send Mon-Thurs only 55
TH1/TH2 Cytokine Ratio 6RF HHH 5 1 week 54
21RF HHH 5 1 week 54
Ratios with IVIG
Ratios with IVIG, Prednisolone
Ratios with Prednisolone
Thalassaemia Screen HBEL A 4 days 40
Thallium (Blood) THAL A/ H 1 week 160
Thallium (Urine) URTH RU 1 week 160
Theophylline THEO B 4 hours 135
Thiopurine Methyl Transferase TPMT A5 5 days 35
Thrombin Time THRO C 18 4 hours 38
39, 41,
125, 132
Thyroglobulin Abs TGAB B 1 day 53
Thyroglobulin Assay TGA B 1 day 53
THAB B 1 day 53, 82
Thyroid Peroxidase Antibodies/Anti TPO TPEX B 1 day 53, 83
Thyroid Profile 1 TF B 4 hours 53, 56

Thyroid Profile 2 TF2 B 2 days 53, 56
Thyroid Profile 3 TF3 B 4 hours 53, 56
Thyroxine (T4) T4 B 4 hours 53
Thyroxine Binding Globulin TBG B (Frozen) 10 days 53
Timothy Grass Components ZZ19 B 2 days 145
Tissue for culture TISS Tissue sample up to 14 days 44
Tissue Polypeptide Antigen TPA B 1 week 35
Tissue Transglutaminase IgA (Coeliac)** TAA B 2 days 83
Tissue Transglutaminase IgG TAAG B 5 days 83
Tobramycin Assay (Provide
TOBR B 3 days 133
Clinical Details)
Toluene (Blood) TOL J 10 days 160
Toluene (Urine) UTOL RU 10 days 160
Topiramate (Topamax) TOPI B4 4 days 135
Torch Screen TORC B 2 days 99-100
Total Acid Phosphatase APT B 5 days 35
Total Bile Acid/Bile Salts BILS B 1 week 35
Total IgE IGE B 1 day 35, 138
Total Immune Function Evaluation TIE A + B 5,10 7 days 83
Total Immunoglobulin E IGE B 1 day 83
Toxocara Antibodies (IgG) TFAT B9 5 days 83
Toxoplasma Antibodies (IgG+IgM) TFAM B9 4 hours 83, 88
Toxoplasma Antibody Full Evaluation
TDYE B9 10 days 83
(IgM, Dye Test, IgG Avidity)
Toxoplasma by PCR TXAG A 5 days 83
TPPA TPPA B 2 days 68, 83
Trace Metal (Blood) Profile TRAC ABHK 7-10 days 159
Transferrin TRAN B 1 day 35
Transferrin Electrophoresis TREL B 2 weeks 35
Trichinella Serology TRIC B 5 days 83
Trichloracetic Acid (Urine) UTCA RU 5 days 160
Trichomonas vaginalis by PCR TVPC FCRU / PCR / TPV 2 days 68, 164
Triglycerides TRI B 4 hours 35
Trimethylaminuria (Fish Odour Syndrome) FOS PU 6 weeks 35
Trimipramine TRIM A 5 days 135
Tropical Screen (from 6
TROP B B 9,14 10 days 88-89
weeks post-travel)
Tropomyosins ZZ31 B 2 days 145
Troponin T (High sensitive) TROT B 4 hours 35
Trypanosome (Chagas) Antibodies CHGA B 9,14 10 days 83
Tryptase STRY B 2 days 35, 138
TSH TSH B 4 hours 53
TSH-Receptor Antibodies TSI B 4 days 53, 83

Tularaemia Antibodies TULA B 14 5 days 83
Tumour Necrosis Factor – Alpha TNF B (Frozen) 4 2 weeks 35
Uni Parental Disomy (UPD) – Specify
A 9,12 5 days 125
parents and child – Specify chromosome type
Urate (Uric acid) UA B 4 hours 35
Urea UREA B 4 hours 35
Urea (Urine) UURE CU 4 hours 35
Urea and Electrolytes U/E B 4 hours 35-36
Urea Electrolytes (Urine) UELE CU 4 hours 35
Ureaplasma urealyticum by PCR UGEN FCRU / PCR / TPV 2 days 68, 164
Uric Acid (Serum) UA B 4 hours 35
Uric Acid (Urine) UURI CU 4 hours 35
Urinary Methyl Histamine UHIT RU (Frozen) 2 weeks 83
Urine (Microscopy Only) UMIC RU 1 day 44
Urine Cytology (Urine cytology containers
URCY Urine (30mls) 21 2 days 169
available from TDL Supplies)
Urine EtG (Ethyl glucuronide) ETG RU 1 week 157
Urine for Extended Culture – Request
NEW UCXD MSU up to 7 days 44
from outset, not as an add on
Urine for Microscopy and Culture UCEM MSU †††† 1-2 days 44
Urine Free Light Chains UFLC RU 1 week 35
Urine Organic Acids UORG RU (Frozen) 3 weeks 35
Urine Steroid Screen (Steroid Hormones) USTE CU or RU 9 2 weeks 35
Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks 35
Urobilinogen (Urine) UURO RU 1 day 35
Urticaria Test (Histamine Releasing) CURT B 3 weeks 83
Vaginitis/BV Profile using
STD8 PCR / STM 3 days 68
Culture & PCR Swab
Valium (Diazepam) DIAZ A 7 days 135
Valproic Acid (Epilim) VALP B 4 hours 135
Vancomycin Hydrochloride VANC B 4 hours 133
Varicella Zoster – DNA VZPC A 5 days 99
Varicella Zoster Antibodies (IgG) VZOS B 1 day 91, 99
Varicella Zoster Antibodies (IgM) VZOM B 1 day 91, 99
Vascular Endothelial Growth Factor VEGF B 14 days 83
VDRL (RPR) RPR B 2 days 83
Venom Components ZZ33 B 2 days 145
Very Long Chain Fatty Acids VLCF A or H (Frozen) 9 4-6 weeks 35
Vigabatrin (Sabril) VIGA A 10 days 135
Viral Antibody Screen VIRA BB 2 days 99-100
Viral Eye by PCR VPE PCR 3 days 99-100
PCR or as specified
Viral Respiratory RNA screen by PCR VPR 2 days 99-100
on the form
Viral Skin/Mucosa by PCR VPSK PCR 2 days 99-100

Viscosity (Plasma) VISC A4 3 days 39
Vitamin A (Retinol) VITA B 5 days 148
Vitamin B (Functional) FUNC A A or H 13 5 days 148
Vitamin B Profile VBP AAB 5 days 147-148
Vitamin B1 (Thiamine) VIT1 A 5 days 148
Vitamin B2 (Riboflavin) VIB2 A 5 days 148
Vitamin B3 (Nicotinamide) VIB3 B 5 days 148
Vitamin B5 (Pantothenic Acid) VB5S B 5 days 148
Vitamin B6 (Pyridoxine) VITB A 5 days 148
Vitamin B8 (Biotin) BIOS B 5 days 148
Vitamin B9 (Folic acid) – Red cell RBCF A 2 days 148
Vitamin B9 (Folic acid) – Serum FOLA B 1 day 148
Vitamin B12 (Active) B12 B 1 day 35, 148
Vitamin B12 (Active)/Red Cell Folate B12F AB 2 days 35, 148
Vitamin B12 (Total) TB12 B 1 day 35
Vitamin C (Active) VITC B (Frozen) 7 5 days 149
Vitamin D (1, 25 Dihydroxy) D3 B 5-8 days 149
Vitamin D (25-OH) VITD B 4 hours 35, 149
Vitamin E (Alpha Tocopherol) VITE B 5 days 149
Vitamin K (Nutritional) VKN B 13 5 days 149
Vitamin K (With PIVKA II) VITK B 13 10 days 38
Vitamin Profile 1 VITS ABB 7 5 days 147, 149
Vitamin Profile 2 VIT2 A A A B B 7,13 5 days 147, 149
VLDL Cholesterol VLDL B 13 1 week 35
VMA UVMA PU 1 5 days 35
Voltage Gated Calcium Channel Antibodies CCAB B 3 weeks 83
Voltage Gated Potassium
VPCA B 3 weeks 83
Channel Antibodies
Von Willebrand Profile FVWF C C C 4,12 5 days 39, 41
Von Willebrands Multimers VWM C C C 18 3 months 39
Wall Pellitory Components ZZ20 B 2 days 145
Walnut Components ZZ34 B 2 days 145
West Nile Virus Abs WNV B 2 weeks 99
Wheat Components ZZ21 B 2 days 145
Whooping Cough (Pertussis) Antibodies PERS B 5 days 83
Prenasal (posterior
Whooping Cough (Pertussis) by PCR PERP 5 days 83
nasopharynx) swab
Wolf-Hirschhorn Syndrome – BOBs PBOB,
CVS / AF / A H 9 5-15 days 126
(5 days) + karyotype (15 days) KARY
Wolf-Hirschhorn Syndrome – BOBs only PBOB CVS / AF / A 9 5 days 126
Xanthine – Blood XANB A 2 weeks 160
Xylene – Urine UXYL RU 30 2 weeks 160
Xylose Tolerance Test XTT J1 7 days 148

Y chromosome microdeletions –
YDEL A9 5 days 126
AZFa + AZFb + AZFc + SRY
Yellow Fever Antibodies YELL B 9,14 10 days 83
Yersinia Antibodies YERS B 4 days 83
ZKAB B Up to 14 days 83, 88, 99
Zika RNA by PCR in Semen ZIKS Semen Up to 14 days 83, 88, 99
ZIKU RU Up to 14 days 83, 88
ZIKA B Up to 14 days 83, 88
Zinc (Serum/Plasma) ZINC K 1 day 148, 159
Zinc (Urine) URZN CU 5 days 148, 160
Zinc (Whole Blood) RBCZ A or H 5 days 148
Zinc Protoporphyrin ZNPR A 13 5 days 160
A (From each twin
Zygosity testing – comparative DNA profile DNAC 5 days 126
and both parents) 9
TDL Referral Laboratories
For certain specialist tests TDL has developed a selected network of TDL Group and Reference
Laboratories. These Group or specialist laboratories can be identified by a code assigned to reports.
The quality of these laboratories is recognised by UKAS, or similar accrediting bodies for the
laboratories outside the UK.
Addenbrooke’s Hospital – BGU and Immunology Guildford RSCH Trace Element Laboratory,
SAS Trace Element Centre
Affinity Biomarker Labs
HCA Healthcare UK – HCA Laboratories
Alder Hey Children’s NHS Foundation
Trust – Biochemistry Department Health & Safety Laboratory
Analytical Services International Ltd, St George’s HFL Sport Science (LGC Group)
University of London – Forensic Toxicology Service
Homerton University Hospital –
Animal and Plant Health Agency – Veterinary labs Department of Clinical Biochemistry
Antenatal Screening Service, Wolfson Institute Igenomix UK
of Preventive Medicine, Barts and The London
Imperial College Healthcare NHS Trust – Charing
School of Medicine and Dentistry
Cross Hospital, Chemical Pathology Department
Bio Predictive
Imperial College Healthcare NHS Trust – Charing Cross
Biodesix, Inc. Hospital, Infection and Immunity Department
Biolab Medical Unit Imperial College Healthcare NHS Trust – Charing
Cross Hospital, Medical Oncology
Bioscientia
Imperial College Healthcare NHS Trust – Hammersmith
Birmingham Children’s Hospital NHS
Hospital, Molecular Endocrinology
Foundation Trust – Clinical Chemistry
Imperial College Healthcare NHS Trust, St Mary’s Hospital
Brucella Reference Unit – Liverpool Clinical Laboratories,
– Virology Department
Royal Liverpool and Broadgreen Hospital
Independent Histopathology Services
Cambridge Clinical Laboratory
Institute of Aquaculture – University of Stirling
Cambridge Life Sciences
Institute of Neurology – Neurogenetics Unit
Cambridge Nutritional Science Ltd
Instituto Bernabeu Biotech
Cardiff and Vale University Health Board
– The Analytical Toxicology Department King’s College Hospital – HMDC Laboratory
for Molecular Haemato-Oncology
Cerba
Labor Augsburg MVZ GmbH
Chelsea and Westminister Hospital NHS Foundation Trust
Latis Scientific
CNC Forensic Toxicology Service Ltd
London School of Hygiene & Tropical Medicine
Douglass Hanly Moir Pathology
– Diagnostic Parasitology Lab
Epsom and St Helier University Hospital NHS
Matrix Diagnostics
Trust – Biochemistry Department
Mayo Clinic Laboratories
Trust – Immunology Department Meningococcal reference unit (Men RU) Manchester
– Manchester Royal Infirmary
Trust – Microbiology Department Micropathology Ltd
Eurofins – Biomnis, France National Blood Service – Colindale, Red Cell
Immuno Haematology Department
Great Ormond Street Hospital –
Department of Chemical Pathology NHS Blood and Transplant – Birmingham
Great Ormond Street Hospital – Enzyme NHS Blood and Transplant – H & I Laboratory
Unit, Chemical Pathology
NHS Blood and Transplant – Tooting
Great Ormond Street Hospital – Immunology Department
Norfolk and Norwich University Hospital NHS
Great Ormond Street Hospital – Neurometabolic Unit Foundation Trust – SAS Metabolic Bone Laboratory
Oxford Immunotec
210
TDL Referral Laboratories
Oxford University Hospital NHS Foundation Trust UCL Great Ormond Street Institute of Child Health
– Churchill Hospital
UCL Queen Square Institute of Neurology –
PHE – Bacteriology Reference Department (BRD), Department of Neuroimmunology
Colindale
University Hospital Birmingham NHS Foundation
PHE – Virus Reference Department (VRD) – Colindale Trust – Heartlands Hospital
PHE Mycology Reference Laboratory – PHE South University Hospital of Wales – Cardiff
West Laboratory, Southmead Hospital, Bristol Medical Immunology Department
PHE National Mycobacterium Reference Service Viapath – Guy’s Hospital, Biochemistry Genetics Laboratory
National Infection Service, Colindale
Viapath – King’s College Hospital, Clinical Biochemistry
PHE Rare and imported pathogens laboratory – Porton Down
Viapath – St Thomas’ Hospital Haemophilia Centre
Queens University Hospital, Belfast
Viapath – St Thomas’ Hospital Immunohistology
– Institute of Clinical Science
Viapath – St Thomas’ Hospital Purine Research Laboratory
Radboud University Nijmegen Medical Center
Randox Health – London
GROUP LABORATORIES
Reflab – Copenhagen
Royal Free London NHS Foundation Trust – Haemostasis
Reproductive Immunology Centre
University College London Hospitals NHS
Rosalind Franklin University
Foundation Trust (UCLH) – Cytology
Royal Berkshire Hospital NHS Foundation Trust
University College London Hospitals NHS Foundation
– Clinical Biochemistry
Trust (UCLH) – Hospital for Tropical disease
Royal Devon and Exeter NHS Foundation Trust
University College London Hospitals NHS Foundation
Royal Surrey County Hospital – SAS Peptide Hormone Section Trust (UCLH) – Molecular Virology
Sandwell and West Birmingham NHS Trust – City Hospital University College London Hospitals NHS Foundation
Birmingham, Clinical Biochemistry Department Trust (UCLH) – Special Chemistry
SCSA Diagnostics
Sheffield Children’s NHS Trust – Clinical Chemistry
Sheffield Teaching Hospital NSH Foundation Trust
– Protein Reference Laboratory Unit
and Immunology Department
Southmead Hospital – Antimicrobial
Reference Laboratory, Bristol
St George’s University Hospital NHS Foundation Trust
– Cell Marker Department
SYNLAB Laboratory Service – Abergavenny
The European Laboratory of Nutrients
The Leeds Teaching Hospital NHS Trust – Endocrinology
Laboratory (including SAS Steroid Centre), Department of
Specialist Laboratory Medicine, St James University Hospital)
The Leeds Teaching Hospitals NHS Trust
– Mycology Reference Centre
The Newcastle upon Tyne Hospitals – Royal Victoria Infirmary
The Royal Marsden Hospital – Department
of Haematology / Oncology
The Royal Marsden Hospital – Department of Pathology
Toxoplasma Reference Unit, Public Health Wales
Microbiology ABM, Singleton Hospital – Swansea
Trace Laboratories Ltd
211
TDL Genetics Referral Laboratories
All Wales Medical Genetics Service Protein Reference Unit & Immunology
Department – Sheffield Protein Unit
Anthony Nolan, Histocompatability and Immunogenetics
Purine Research Laboratory – St Thomas’ Hospital
Asper Biotech
Royal Marsden – Haemato-Oncology Unit
Bioscientia GmBH
Sheffield Diagnostic Genetics Service
Bristol Genetics Laboratory (North Bristol NHS Trust)
SIHMDS – Cytogenetics Laboratory,
CentoGene
Great Ormond Street Hospital
DiaGenom GmbH
South East Scotland Genetics Service (NHS Lothian)
Douglass Hanly Moir Pathology
South West Thames Regional Genetics Service
East Scotland Regional Genetics Service (NHS Tayside)
SYNLAB Budapest Diag Center
Exeter Clinical Laboratory – Department of Molecular Genetics
The Leeds Genetics Laboratory Viapath Analytics LLP
Fulgent Diagnostics
Wessex Region Genetics Service
Institute of Neurology, Queen’s Square
West Midlands Regional Genetics Laboratory
International Blood Group Reference Laboratory
West of Scotland Genetic Service
London South East Genetics Service (NHS Greater Glasgow and Clyde)
Medical Genetics Laboratory – Central Manchester
University Hospitals NHS Foundation Trust
Medical Neurogenetics Laboratory LLC
Micropathology Ltd
Molecular Genetics Laboratory – Liverpool’s
Women NHS Foundation Trust
Molecular Vision Laboratory
Newcastle Mitochondrial NGC Diagnostic Service
North East Thames Regional Genetic Service
North West London Pathology
North West Thames Regional Genetic Service
Northern Genetics Service
Oxford Genetics Laboratory – Oxford University Hospitals
Prevention Genetics
Progenika Biopharma Grifols
212
Terms & Conditions of Business from 1st Jan 2022
The definitions which apply to these Terms 1.7 TDL may destroy or dispose of a Sample after
and Conditions are set out in clause 18. completing the Testing or on termination
of the Agreement, unless otherwise
1 THE SERVICES agreed in writing with the Client.
1.1 These Terms and Conditions will apply to any services 1.8 The Consumables shall remain the property
that TDL provides to the Client, unless those services of TDL at all times, regardless of any use
are the subject of a separate written agreement signed by the Client of the Consumables.
by TDL and the Client. These Terms and Conditions 1.9 In providing the Services, TDL shall comply with
apply to the exclusion of any other terms presented by all Applicable Law relating to anti-bribery and
the Client or implied by custom or course of dealing. anti-corruption, including the Bribery Act 2010.
1.2 By submitting a request for any services described TDL shall not, and shall ensure that its staff do
in the Laboratory Guide or in any other proposal not, engage in any activity which would constitute
provided by TDL (an ‘Order’), the Client offers an offence under the Bribery Act 2010.
to purchase those services on these Terms and 1.10 TDL is committed to trading ethically, with zero
Conditions. A contract between TDL and the Client for tolerance for modern slavery (including forced
the provision of services incorporating these Terms and labour or human trafficking of any kind), human
Conditions (an ‘Agreement’) takes effect when TDL rights violations, and child labour. In performing its
confirms acceptance of the Client’s Order in writing, obligations under this Agreement, TDL will comply
logs the relevant Pathology Request in its laboratory with all Applicable Law and applicable internal policies
information management system, or begins performing relating to anti-slavery and human trafficking.
the Services (whichever occurs first). Any request for 1.11 TDL’s laboratories are operated by members of the
add-on Tests (as described in the Laboratory Guide) TDL Group. TDL uses those laboratories to undertake
constitutes a request for further Services under that the Tests, except where TDL refers the Tests to
Agreement, which TDL may accept or decline. suitably accredited laboratories operated outside
1.3 TDL will provide the Services under the Agreement: the TDL Group. The UKAS accreditation numbers for
1.3.1 in accordance with Good Industry Practice; the TDL Group laboratories in the UK are as follows:
8059 (HSL Analytics LLP) Genetics and Molecular
1.3.2 in accordance with the UKAS medical laboratory
Sciences, 8169 (HSL Analytics LLP) Blood Sciences,
accreditation standard (ISO 15189); and
8860 (HSL Analytics LLP) Infection Sciences, 8812
1.3.3 using suitably skilled and experienced staff. (The Doctors Laboratory Limited) Haematology, Blood
1.4 TDL will use reasonable efforts to achieve the Test Transfusion, Biochemistry, Microbiology, Molecular
turnaround times quoted in the Laboratory Guide, Biology, 10199 (The Doctors Laboratory Limited)
but does not warrant that it will achieve those Andrology, 8511 (HSL Analytics LLP) Cytology, 9706
times in the case of any particular Sample. (The Doctors Laboratory Limited) Urine Cytology.
1.5 The Laboratory Guide sets out Sample rejection criteria.
If the Sample meets those criteria, or if TDL considers 2 PRICE AND PAYMENT TERMS
that the Sample is otherwise unsuitable for Testing or 2.1 The fees payable by the Client for the Services
TDL is unable to conduct the Testing then TDL may will be the most recent price confirmed by TDL
decline to carry out the Testing under the Agreement to the Client in writing or by telephone prior to
and will be entitled to dispose of the Sample. the Client submitting its Order. If TDL has not
1.6 As part of its Services TDL will, on request, arrange for confirmed the price for the Services, the price
collection of Samples from locations within the M25 will be that indicated in the Laboratory Guide.
motorway. Such collection service is included within 2.2 As at the date of these Terms and Conditions many of
the price of the Test unless otherwise specified by TDL. TDL’s services are VAT exempt. All of TDL’s prices are
Collection of Samples from locations outside the M25 stated exclusive of VAT and where VAT is chargeable on
is by special arrangement, and may incur an additional the Services the Client will pay it at the applicable rate.
charge. Where collection by TDL has not been
requested and agreed, the Client will be responsible,
at its own cost, for the transport of Samples to TDL.
Where TDL arranges collection of Samples it will use
reasonable efforts to achieve the timescales it quotes
for collection, but does not warrant that it will achieve
those timescales in the case of any particular collection.
213
2.3 Invoices are normally issued on a monthly basis, but 4.2 Except where TDL agrees to arrange transport
TDL reserves the right to issue them more frequently. of the Sample to TDL’s laboratory, the Client will
The client will pay TDL’s invoices under the Agreement ensure that the Sample is transported to TDL’s
within 30 days of the date of the invoice, without any laboratory in accordance with Applicable Law
deduction or set off. At TDL’s option interest may and good clinical practice. Where TDL agrees to
be charged on late payment at the statutory rate arrange transport of the Sample the Client will
prescribed from time to time by regulations under the ensure that the Samples are ready for collection
Late Payments of Commercial Debts (Interest) Act 1998. by TDL or its carrier at the agreed times.
Invoices paid from outside the UK must be paid by 4.3 The Client will ensure that all necessary consents
either direct bank transfer or by cheque drawn on a UK and permissions are obtained and all necessary
branch. All payments will be made in pounds sterling. information provided to the patient, which is required
2.4 Without affecting any of its other rights, TDL under Applicable Law or good clinical practice in
may suspend provision of the Services if the order to permit the Testing, the performance of and
Client fails to pay an invoice due to TDL. any other Services, and the use of the Protected
Data as contemplated in the Agreement.
3 CONFIDENTIALITY 4.4 The Client will provide TDL with any information
3.1 TDL agrees that it will hold and reasonably necessary for performing the Services,
maintain the confidence of: including by ensuring that the Pathology Request
contains sufficient information regarding the Sample,
3.1.1 all information of a confidential nature which is
the relevant patient, and the persons to whom the Test
received by TDL from the Client or its patients
results are to be reported, and will ensure that any
in connection with the Services; and
information the Client provides to TDL in connection
3.1.2 all Test results, invoices and other information of a with the Services is accurate and complete.
confidential nature issued by TDL to the Client or
4.5 The Client shall ensure that any Consumables provided
its patients in connection with the Services, and,
by TDL are only used by healthcare professionals
save with the Client’s consent or as otherwise
who are appropriately qualified and trained in
permitted under this Agreement, will not disclose
the proper use of such Consumables. The Client
such information other than to its professional staff,
shall ensure the healthcare professionals use the
independent consultants and/or persons to whom
Consumables in accordance with any instructions
it has delegated the performance of the Services
relating to the use of the Consumables provided by
and who require the information for such purpose.
TDL and in any event with the degree of skill and care
Where TDL has been provided with the details of a
reasonably to be expected of a healthcare professional
patient’s private medical insurance in connection
experienced in the use of such Consumables.
with the Services, TDL will be entitled to assume
(and the Client so warrants) that both the Client and
the patient consent to the disclosure of information 5 LIABILITY
relating to that patient to the insurer concerned. 5.1 Nothing in the Agreement will limit or exclude
3.2 The restrictions in clause 3.1 will not apply to liability for death or personal injury caused by
information which: (i) was in TDL’s possession prior negligence or any other liability that cannot be
to disclosure by the Client; or (ii) is now or hereafter limited or excluded under Applicable Law.
comes into the public domain other than by default 5.2 In these Terms and Conditions ‘liability’ means any
of TDL; or (iii) was lawfully received by TDL from a liability whether in contract, tort (including negligence),
third party acting in good faith having a right of further misrepresentation, breach of statutory duty or
disclosure; or (iv) is required by law to be disclosed otherwise, which arises in connection with the Services
by TDL; or (v) which is required by a regulatory or under or in connection with any Agreement.
or accreditation body to be disclosed to it for the 5.3 The liability of TDL and the Client will each
purpose of regulating or accrediting the TDL Group. be limited to £2,000,000 in total. This limit
applies per Agreement and in aggregate for
4 CLIENT RESPONSIBILITIES all Agreements made in a calendar year.
4.1 Except where TDL obtains the Sample directly 5.4 Neither TDL nor the Client will have any liability for:
from the patient during a home visit or at TDL’s 5.4.1 loss of profit or revenue;
patient reception facility, the Client will ensure
that the Sample is obtained from the patient, 5.4.2 loss of anticipated savings;
packaged, and labelled in accordance with 5.4.3 loss of reputation or goodwill; or
Applicable Law and good clinical practice. 5.4.4 indirect, special or consequential loss.
214
5.5 TDL will have no liability for any delay or failure 8 DATA PROCESSING INSTRUCTIONS
in performance of the Services arising from the
8.1 When TDL processes Protected Data as the data
Client’s delay or failure in performing its obligations
processor, TDL will comply with the obligations of
under clause 4 (Client Responsibilities).
data processors under Data Protection Laws.
5.6 All of the warranties which TDL gives in relation
8.2 Unless required to do otherwise by Applicable
to the Services are expressly set out in these
Law, TDL will (and will take steps to ensure each
Terms and Conditions. All other warranties,
person acting under its authority will) process
whether implied or express, are excluded from the
the Protected Data only in accordance with the
Agreement where it is lawful to exclude them.
Client’s documented instructions as set out in the
5.7 In this clause 5 references to TDL include the Order, pursuant to the Terms & Conditions, and
members of TDL’s Group, and for the purpose of the in the Annex (the ‘Processing Instructions’).
limit in clause 5.3 the liabilities of TDL and the TDL
8.3 If Applicable Law requires TDL to process Protected
Group Members will be counted in aggregate. The
Data other than in accordance with the Processing
members of TDL’s Group may enforce this clause 5.
Instructions, TDL will notify the Client of any such
requirement before processing the Protected Data
6 FORCE MAJEURE (unless Applicable Law prohibits TDL from doing so).
If the performance of any obligation under the 8.4 TDL will promptly inform the Client if TDL becomes
Agreement (except for an obligation to pay) is prevented, aware of a Processing Instruction that, in TDL’s
restricted or interfered with by reason of circumstances opinion, infringes Data Protection Laws. TDL will
beyond the reasonable control of that party obliged have no liability for any processing in accordance
to perform it (a ‘Force Majeure Event’), the party so with those Processing Instructions after giving the
affected will be excused from any resulting failure or notice. TDL’s obligations under this clause 8.4 do
delay in performance, and the time for performance not limit the Client’s obligations under clause 7.3.
will be extended by an amount of time equal to the
duration of the Force Majeure Event. The party so
9 DATA SECURITY MEASURES
affected will use reasonable endeavours to mitigate the
effect of the Force Majeure Event on its performance In relation to the processing of the Protected Data,
of its obligations. If the Force Majeure Event delays TDL will implement and maintain, at its cost and
or prevents performance of a party’s obligations for expense, appropriate technical and organisational
more than three months, either party may terminate measures to ensure for the Protected Data a level
the agreement on written notice to the other. of security appropriate to the risks presented by the
processing, taking into account the state of the art,
the cost of implementation and the nature, scope,
7 DATA PROCESSOR
context and purpose of the processing of the Protected
AND DATA CONTROLLER
Data as well as the risk of varying likelihood and
7.1 When TDL processes Protected Data on behalf severity of the rights and freedoms of natural persons.
of the Client in providing the Services the parties
agree that the Client will be the data controller and
10 USING STAFF AND OTHER PROCESSORS
TDL will be the data processor. The Annex to these
Terms and Conditions sets out when TDL processes 10.1 TDL will not engage any data processor to process
Protected Data on behalf of the Client. Clause 16 the Protected Data on the Client’s behalf (a ‘Sub-
describes the circumstances where TDL will use Processor’) without the Client’s authorisation of that
Protected Data on its own behalf as data controller. specific Sub-Processor. The Client will not unreasonably
withhold, condition or delay such consent. By accepting
7.2 When TDL processes Protected Data as the data
these Terms and Conditions the Client authorises the
processor, clauses 8 to 15 will apply in relation to
appointment of the Authorised Sub-Processors.
the Protected Data. Where TDL processes Protected
Data as data controller, clause 16 will apply instead. 10.2 TDL will ensure that each Sub-Processor is appointed
under a written contract containing materially the
7.3 The Client will comply with the Data Protection
same obligations as clauses 8 to 15 (inclusive).
Laws in relation to the Protected Data, and
ensure that all instructions given by it to TDL 10.3 TDL will ensure that all persons authorised to process
in respect of Protected Data will at all times be Protected Data are subject to a binding obligation to
in accordance with Data Protection Laws. keep the Protected Data confidential (except where
disclosure is required in accordance with Applicable
Law, in which case TDL will, where practicable and
not prohibited by Applicable Law, notify the Client
of any such requirement before such disclosure).
215
11 ASSISTANCE WITH THE CLIENT’S 13.2 TDL will, in accordance with Data Protection Laws,
COMPLIANCE AND DATA SUBJECT RIGHTS make available to the Client such information as is
reasonably necessary to demonstrate TDL’s compliance
11.1 Taking into account the nature of the processing,
with its obligations as a data processor under these
TDL will implement and maintain reasonable
Terms and Conditions and the Data Protection Laws,
measures to assist the Client to respond to the
and allow for and contribute to audits, including
Data Subject Requests relating to the Protected
inspections, by the Client (or another auditor mandated
Data that TDL processes on the Client’s behalf.
by the Client) for this purpose, subject to the Client:
TDL will refer such Data Subject Requests it receives
to the Client promptly, and in any event within 13.2.1 giving TDL reasonable prior notice of such information
five Business Days of receipt of the request. request, audit and/or inspection being required
by the Client;
11.2 TDL will provide such assistance as the Client
reasonably requires (taking into account the nature 13.2.2 ensuring that all information obtained or generated
of processing and the information available to by the Client or its auditor(s) in connection with such
TDL) to the Client in ensuring compliance with the information requests, inspections and audits is kept
Client’s obligations under Data Protection Laws strictly confidential (save for disclosure to the relevant
with respect to: (i) security of processing, (ii) data regulator or as otherwise required by Applicable Law);
protection impact assessments (as such term is 13.2.3 ensuring that such audit or inspection is undertaken
defined in Data Protection Laws), (iii) prior consultation during normal business hours, with minimal disruption
with the relevant regulator regarding high risk to TDL’s business, the Sub-Processors’ business
processing, (iv) and notifications to the regulator and/ and the business of other customers of TDL.
or communications to data subjects by the Client in
response to any Personal Data Breach. The Client
14 BREACH NOTIFICATION
will pay TDL’s charges for providing the assistance
in this clause 11, such charges to be calculated TDL will, without undue delay notify the Client
on a time and materials basis at TDL’s applicable of the Personal Data Breach involving the
daily or hourly rates in force from time to time. Protected Data, and provide the Client with
details of the Personal Data Breach.
12 INTERNATIONAL DATA TRANSFERS
15 DELETION OR RETURN OF
The Client agrees that TDL may transfer Protected
PROTECTED DATA AND COPIES
Data to countries outside the United Kingdom for
the purpose of providing the Services, provided all TDL will, at the Client’s written request, either delete
transfers by TDL of Protected Data to such recipients or return all of the Protected Data to the Client in
are in accordance with such safeguards or other such form as the Client reasonably requests within
mechanism(s) for transfers of personal data as may a reasonable time after the end of the provision of
be permitted under Data Protection Laws from time to the relevant Services related to processing, and
time. The Client agrees that TDL may implement such delete existing copies (unless storage of any data is
safeguards by entering into standard data protection required by Applicable Law and, if so, TDL will inform
clauses authorised under the Data Protection Laws, the Client of any such requirement). Where TDL will
which TDL may do as agent on behalf of the Client. process that Protected Data as data controller under
The provisions of clauses 8 to 15 (inclusive) will clause 16, TDL may retain the Protected Data.
constitute the Client’s instructions with respect to
transfers in accordance with clause 8.2. 16 PROTECTED DATA THAT TDL
PROCESSES AS A DATA CONTROLLER
13 RECORDS, INFORMATION AND AUDIT 16.1 TDL may process Protected Data as data controller
13.1 TDL will maintain, in accordance with Data in the circumstances and for the purposes set out
Protection Laws binding on TDL, written in TDL’s Privacy Notice. In particular TDL may:
records of all categories of processing activities 16.1.1 retain and submit Protected Data to a Health
carried out on behalf of the Client. Authority in the United Kingdom for the purposes
of a Public Health Programme operated by that
Health Authority, or to regulator for the purpose
of complying with regulatory obligations; and
216
16.1.2 retain and process Protected Data in its laboratory 17.3 Rights and waiver
records in order to meet the requirements of the All rights granted to either of the parties will be
UKAS medical laboratory accreditation standard cumulative and not exhaustive of any rights and
(ISO 15189) and implement the guidelines of the remedies provided by law. The failure of either
Royal College of Pathologists for the retention and party to enforce (or delay in enforcing) at any time
storage of pathological records and specimens. for any period any one or more of the terms of this
16.3 When TDL processes Protected Data to Agreement will not be a waiver of such term or of
provide Harmony® Non-Invasive Prenatal the right of such party at any time subsequently
Tests, TDL does so as a data controller. to enforce all the terms of this Agreement.
16.4 When TDL processes personal data on its own behalf 17.4 Severability
as data controller, it will do so in accordance with the If any provision of this Agreement is or becomes
obligations of data controllers under Data Protection invalid, illegal or unenforceable in any respect under
Laws and with the applicable terms of the Agreement. any law, the validity, legality and enforceability of the
remaining provisions will not be in any way affected.
17 GENERAL 17.5 Sub-contracting and Assignment
17.1 Dispute resolution TDL may assign or sub-contract the performance
17.1.1 If any dispute arises relating to this Agreement or of this Agreement (in whole or in part) or any one
any breach or alleged breach of this Agreement, or more of the Tests to be performed hereunder to
the parties will make a good faith effort to resolve suitably accredited laboratories including those listed
such dispute without recourse to legal proceedings. in the Laboratory Guide. The Client may not assign
If, notwithstanding such good faith efforts, the this Agreement or any of its rights or obligations
dispute is not resolved either party may submit the hereunder without the prior approval of TDL.
dispute to the jurisdiction of the English Courts. 17.6 Relationship of the parties
17.1.2 Except to the extent clearly prevented by the area It is acknowledged and agreed that TDL and the
of dispute, the parties will continue to perform Client are independent contractors and nothing in this
their respective obligations under this Agreement Agreement will create or be construed as creating a
while such dispute is being resolved. partnership or (except as provided in clause 12 and the
17.2 Variation Annex) a relationship of agent and principal between
17.2.1 TDL may amend these Terms and Conditions by the parties. The Client acknowledges and agrees that, in
updating the Laboratory Guide and providing the requesting Services from TDL, it is not acting as agent
Client with a copy of the update or publishing it on for any patient or patients to which the Services relate.
TDL’s website. Such amendments will only apply 17.7 Notices
to an Order submitted after the date of the update, All notices given under this Agreement will be in
and the Client will be deemed to accept those writing and will be delivered by hand or sent by prepaid
amendments by submitting an Order after that date. first class post or by prepaid first class recorded
17.2.2 Except as set out in clause 17.2.1, any amendments delivery or by email transmission. All notices will be
to this Agreement will not be effective unless in writing delivered at or sent, in the case of TDL, to The Halo
and signed by an authorised signatory on behalf of Building,1 Mabledon Place, London WC1H 9AX, email
each of the parties. The terms of this Agreement [email protected] and, in the case of the Client
may be varied by agreement of the parties but to the address and/or email address set out in the Order
without the consent of any third party whether or not (or such other address as that party will notify in writing
the rights of such third party are affected by such to the other for this purpose). A notice sent by post
variation. The Client will not unreasonably withhold, will be deemed to be served at 9.00 am on the second
delay or condition its agreement to any variation to Business Day following the date of posting; a notice
this Agreement requested by TDL in order to ensure sent by email transmission will (provided the sender
the Services and TDL (and each Sub-Processor) receives no error message indicating that delivery has
can comply with any change in Applicable Laws. been unsuccessful) be deemed to have been served at
the time it is transmitted if transmitted within business
hours (9.00 am to 6.00 pm) on a Business Day or, if
transmitted outside such business hours on a Business
Day or on a day which is not a Business Day as soon
thereafter as such business hours commence.
217
17.8 Entire agreement ‘controller’, ‘data subject’, ‘personal data’,
The Agreement is set out in the Order and these ‘process’ and ‘processor’ have the meanings
Terms and Conditions, which together set out the given to those terms in Data Protection Laws;
entire contract between the Client and TDL relating ‘Consumables’ means any goods provided by TDL
to their subject matter. In the event of a conflict in order for the Client to benefit from the Services;
between the Order and these Terms and Conditions, ‘Data Protection Laws’ means the UK GDPR,
the Terms and Conditions will take priority. Each the Data Protection Act 2018, and any other
party acknowledges that it has not entered into the Applicable Law having effect in the United Kingdom
Agreement in reliance on, and will have no remedies concerning privacy or the use of personal data;
in respect of, any representation or warranty that
is not expressly set out in the Agreement except ‘Data Subject Request’ means a request made
in the case of fraudulent misrepresentation. by a data subject to exercise any rights of
data subjects under Data Protection Laws;
17.9 Third parties
‘Good Industry Practice’ means the standard of
The Agreement is not intended to create any skill and care reasonably to be expected from
rights for, nor be enforceable by, any third a professional provider of the Services;
party except as set out in clause 5.
‘Group’ in respect of any undertaking, means
17.10 Governing law such undertaking and its group undertakings
The Agreement and any dispute arising out (‘undertaking’ and ‘group undertaking’ having the
of or in connection with it (including non- meanings given in the Companies Act 2006);
contractual disputes and claims) will be governed ‘Health Authority’ means (i) a department of the
by and construed in accordance with English UK government or of a devolved administration, (ii)
law and each of the parties submits to the an executive agency of such department, or (iii) a
exclusive jurisdiction of the English Courts. body exercising statutory functions in relation to
public health in the UK or any part of the UK;
18 INTERPRETATION ‘Laboratory Guide’ means TDL’s Laboratory Guide
18.1 In these Terms and Conditions and the Annex:- current at the time the Client submits the Order,
‘Agreement’ has the meaning given in clause 1.2; as supplied to the Client or, if not so supplied,
available on request from TDL, including any
‘Annex’ means the annex to the Terms and Conditions;
updates or supplements issued by TDL;
‘Applicable Law’ means the laws, regulations,
‘Order’ has the meaning given in clause 1.2;
judgments, binding on the relevant party,
as amended from time to time; ‘Pathology Request’ means an Order requesting Testing;
‘Authorised Sub-Processors’ means: ‘Personal Data Breach’ means any breach of

security leading to the accidental or unlawful
a) Health Service Laboratories LLP and
destruction, loss, alteration, unauthorised
any other member of the TDL Group which
disclosure of, or access to, any Protected Data;
provides the applicable Test or Service;
‘Privacy Notice’ means TDL’s detailed Privacy
b) accredited specialist centres for onward
Notice available at tdlpathology.com;
referral of esoteric assays as identified
in the TDL Laboratory Guide; ‘processing’ has the meanings given to that term
in Data Protection Laws (and related terms such
c) persons who provide information
as process have corresponding meanings);
technology services that TDL uses in the
course of providing the Services; and ‘Processing Instructions’ has the meaning given
to that term in paragraph 8.2;
d) any Sub-Processor referred to in the Annex;
‘Protected Data’ means personal data provided
‘Business Day’ means a day other than a
to TDL by the Client or a third party on the
Saturday, Sunday, or public holiday in England;
instructions of the Client, or collected or generated
‘Client’ means the person or organisation requesting by TDL in the course of the Services;
Services from TDL and for whom TDL has agreed to
provide the Services;
218
‘Public Health Programme’ means a programme ANNEX
administered by a Health Authority to monitor
1 Subject matter and nature of processing
or analyse health data for the purpose of
public health or for statistical, scientific or 1.1 TDL processes Protected Data as data processor
research purposes in the public interest; on behalf of the Client:
‘Sample’ means a sample provided by the Client 1.1.1 in the case of Testing, when TDL receives a Pathology
to TDL for Testing; Request and Sample and processes the corresponding
Protected Data to carry out the Test and report
‘Services’ means the services to be
the Test results in accordance with the
provided under the Agreement;
Client’s documented instructions;
‘Sub-Processor’ has the meaning given in clause 10.1;
1.1.2 when TDL carries out the Client’s ‘fee to patient’
‘TDL’ means The Doctors Laboratory Limited instructions, as described below; and
or such other member of the TDL Group as
1.1.3 in the case of any other Services, when TDL is required
has agreed to provide the Services;
to process the Protected Data on the Client’s behalf
‘TDL Group’ means The Doctors Laboratory Limited to fulfil the Client’s instructions.
and its Group and Health Service Laboratories LLP
1.2 The subject matter and nature of TDL’s processing
and its Group;
of the Protected Data are:
‘Test’ means a laboratory test to be carried out by
1.1.1 pathology samples and test results for the purpose
TDL on a Sample, and ‘Testing’ means the process
of providing clinical pathology services;
of conducting that Test and reporting the results;
1.1.2 information about clinicians who order
‘UKAS’ means the United Kingdom Accreditation
pathology tests, for the purposes of
Service, or any successor to it;
reporting the test results to the Client;
‘UK GDPR’ has the same meaning as it does
1.1.3 information about a patient’s health insurance for the
in section 3(10) of the Data Protection Act
purposes of administering payment for the Services; and
2018, read with section 205(4) of that Act.
1.1.4 billing information for a patient where the Client has
18.2 References to the singular include the plural
asked TDL to direct TDL’s invoice to the patient.
and vice versa.
18.3 Clause headings and paragraph headings are for 2 Duration of processing
ease of reference only and are not part of these The duration of the processing is the time necessary
Terms and Conditions for the purpose of construction. to carry out the Services.
18.4 References to paragraphs are to paragraphs 3 Types of personal data
of the Annex.
3.1 The Protected Data comprise the following types
18.5 Words following the terms ‘including’, ‘include’, of personal data:
‘in particular’, ‘for example’ or any similar expression
shall be construed as illustrative and shall not limit 3.1.1 Name
the sense of the words, preceding those terms. 3.1.2 Gender
18.6 The Annex is incorporated into these Terms 3.1.3 Date of birth
and Conditions. 3.1.4 Address
3.1.5 Identity numbers assigned by TDL or the Client
3.1.6 Types of pathology tests conducted
3.1.7 Results of pathology tests
3.1.8 Health insurance policy details
3.1.9 Billing information
3.1.10 The types of data referred to in the
TDL Laboratory Guide
219
4 Categories of data subjects
The Protected Data concerns patients in respect
of whom TDL conducts pathology tests, and
clinicians who request pathology tests.
5 Reporting pathology test results

5.1 TDL will report Test results using the method selected
by the Client from the range of options offered by
TDL or, if no method is selected by the Client, using
a method selected by TDL from that range of options.
5.2 TDL will report the Test results using the contact details
supplied to TDL in the relevant section of the Pathology
Request. The Client will be responsible for ensuring
that those contact details are correct.
5.3 Where TDL supplies Test results electronically it
will ensure that the results are supplied in the format
selected by the Client (from the range of options
offered by TDL) and are supplied to the address
indicated when the Client selects electronic results
reporting. The Client will be responsible for ensuring
that the selected format is compatible with the
Client’s information systems and for making the
results available to the users of those systems.
6 Fee to patient
Where the Client selects the ‘fee to patient’ option in
a Pathology Request Form, the Client instructs TDL to
seek payment from the patient of the fees owed by the
Client in respect of that test. The Client confirms that
the patient has agreed with the Client to pay those fees
to TDL for the Client. The Client instructs TDL to recover
the fees by invoicing the patient using the personal
data provided by the Client. The Client instructs TDL on
the Client’s behalf to appoint debt collectors to recover
the fees from the patient if the patient does not pay
the invoice by the date payment falls due. The Client
authorises TDL to appoint those debt collectors as
Sub-Processors in accordance with clauses 8 to 15.
220
SAMPLE
TYPES
Vacutainer Anticoagulant Capacity
Lavender EDTA 4ml / 10ml* A
Gold SST/Gel 5ml B
Light Blue Citrate 4.5ml C
Red None 6ml F
Grey Fluoride oxalate 2ml, 4ml G
Green Lithium heparin 6ml H
Dark Blue Sodium heparin 7ml K
* 10ml EDTA tubes are used for specific PCR assays
Blood culture bottle: contact laboratory BC

Contact laboratory for advice on sample taking J
Test by appointment X
Random Faeces RF
Faecal Collection LF
Random Urine RU
Mid Stream Urine MSU
First Catch Random Urine (for DL12/Chlamydia, etc.) FCRU
30ml aliquot from a 24 hour urine collection – state total volume CU
30ml aliquot from a 24 hour urine collection with 10ml of
0.1N Hydrochloric Acid added – state total volume PU
Early Morning Urine (1st sample of the day) EMU
60ml container (sterile) SC
Cytyc Thin Prep Vial TPV
Orange/Blue swab for culture – swab in transport medium/Blue microswab STM

Black Charcoal swab CS
Green Viral swab VS
PCR swab for Chlamydia/PCR Infection Screening PCR
Tap/bottled water mouth wash – 20mls MW
Ammotic fluid (5mls PCR – 10mls Karyotype) AF
Chorionic Villus (medium provided by laboratory) CVS
Urine cytology container UCYT
The Doctors Laboratory
The Halo Building, 1 Mabledon Place, London WC1H 9AX
Tel: 020 7307 7373 Email: [email protected]
Web: www.tdlpathology.com
Please recycle responsibly. Printed on FSC accredited Novatech Matt.

Laboratory Guide 2022

Uploaded by

Copyright:

Available Formats

Laboratory Guide 2022

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Laboratory Guide 2022

Uploaded by

Copyright:

Available Formats

Laboratory

We promise to provide easy access to our pathology services

We promise to help you

We promise to support the communities we work in

• Commit to service excellence.

• Be enthusiastic about continuous improvement.

Index of TDL Profiles 2-3

TDL SPECIFIC PROFILES

Selfridges John Lewis

THE DOCTORS LABORATORY Out-of-hours samples

OPENING TIMES Phlebotomy Services

THE DOCTORS LABORATORY

Samples can be dropped

TDL COLLECT: SPECIMEN COLLECTION SERVICES BY COURIER

TDL COLLECT UK: 020 7307 7373

LONDON LABORATORY TIMES: 24 HOURS

MANCHESTER LABORATORY TIMES: 24 HOURS

MANCHESTER TURNAROUND TIMES

PATIENT RECEPTION TIMES

PATIENT REQUEST FORM

PATHOLOGY CONSUMABLES / REQUEST FORMS / POSTAL PACKS

EMAILED RESULTS INCORPORATING YOUR LOGO

TDL PATHOLOGY HANDBOOK

FEES FOR PATHOLOGY

PROTECTION OF PERSONALLY IDENTIFIABLE INFORMATION

HEADS OF SUPPORT DEPARTMENTS

Group Laboratory Operations Manager Lisa Manze [email protected]

HEADS OF LABORATORY DEPARTMENTS (LONDON)

Haem / Bio / Automated Pathology Naina Chavda [email protected]

Operational Site Lead Diane Benson [email protected]

8169 8860 8059 8812 10199 8511 9706

BIOCHEMISTRY: UKNEQAS, WEQAS, RIQAS, BIORAD for Hepatitis A (with B and C)

UKNEQAS: UKNEQAS – Infectious Immunology for:

ENDOCRINOLOGY: UKNEQAS for Information security:

SAMPLE REJECTION CRITERIA

Summary List for Sample Rejection

TDL LEAD CONSULTANTS

Dr Abdel-Razek Abu-Sitta Dr Norbert Blesing Professor Brian Jones

Dr Adrian Bloor Dr Philip Robson Dr Damien Mack

Dr Alex Sternberg Dr Salim Shafeek Dr Emmanuel Wey

Prof Atul Mehta Dr Sreetharan Munisamy Dr Indran Balakrishnan

Dr Gillian Evans Dr Mary Falzon Dr Sophie Collier

Dr Glenn Rainey Dr Stephen Mepham

Urea and Electrolytes HAEMATOLOGY ESR 4

DL2 DL2 DL2

ABG ABG ABBG RU QFIT 4

SENIOR FEMALE CARDIOVASCULAR CARDIOVASCULAR

DL2 Cholesterol Cholesterol

DL9F DL10 DL11

7 STI PROFILE BY PCR

Chlamydia trachomatis Trichomonas vaginalis

FCRU OR PCR Swab OR TPV

Key: See page 23 for sample-taking and special handling instructions. 25

CDC/ Alissa Eckert, MSMI; Dan Higgins, MAMS

There are six human coronaviruses that can infect people:

COVID-19 (SARS-CoV-2) RNA by PCR

COVID-19 (SARS-CoV-2) T-SPOT®.COVID NEW

TEST CODE SAMPLE REQS TAT

Platform Roche e801 Roche e801 Abbott Architect Abbott Architect

Assay Electro- Electro- Chemiluminescent Chemiluminescent